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Abstract
The aim of this project was to explore and refine the conformational rationale for the 
activity of capsazepine (CPZ) as a blocker of the ion channel TRPV1 (transient 
receptor potential vanilloid type 1), by the synthesis and biological evaluation of 
further conformationally constrained capsaicin analogues.
The resolution of the stereoisomers of N-(4-chlorophenethylthiocarb amo y 1) - 6,7 - 
dihydroxy-1 -methyl-1,2,3,4-tetrahydroisoquino-line 29, Af-(4-chlorophenethylthio- 
carbamoyl)-6,7-dihydroxy-3-methyl-l,2,3,4-tetra-hydroisoquinoline 30 and N-(4- 
chlorophenethylthiocarbamoyl)-6,7-dihydroxy-1,3-dimethyl-1,2,3,4-tetrahydroiso- 
quinoline 31 by stereoselective synthetic methodology is described, and some of the 
more unusual and interesting mechanisms are discussed.
The novel asymmetric chemistry described includes the separation of the 
enantiomers of 2-(3,4-dimethoxyphenyl)-l-methylethylamine 38 by crystallisation 
with the enantiomers of mandelic acid, the use of sodium triacetoxyborohydride in 
the stereoselective reduction of 6,7-dimethoxy-1,3-dimethyl-3,4-dihydroiso- 
quinoline 171, to give the c/s-diastereomers of 6,7-dimethoxy-1,3-dimethyl-1,2,3,4- 
tetrahydroisoquinoline 44, and the novel stereoselective route to the trans- 
diastereomers of 6,7-dimethoxy-1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline 44 from 
the enantiomers of 2-(3,4-dimethoxyphenyl)-l-methylethylamine 38 by the Michael 
addition of A-benzyl-2-(3,4-dimethoxyphenyl)-1 -methylethylamine 155 to ethynyl- 
4-tolylsulfone 150, followed by TFA-mediated cyclisation, single electron reductive 
desulfonylation and palladium-catalysed hydrogenolysis.
The results of investigations into the conformational behaviour of the resolved 
stereoisomers of 29, 30 and 31 by techniques of NMR spectroscopy and molecular 
modelling, the evaluation of their biological activity at the rat and human orthologues 
of the ion channel TRPV1, and the attempted correlation of the two sets of data, with 
respect to the published conformational rationale for the activity of CPZ, are also 
described.
The biological evaluation of these compounds has identified one analogue 31(15,31?) 
with a similar activity profile to CPZ, which has allowed a more accurate definition 
of the requirements for biological activity akin to CPZ at the human and rat 
orthologues of TRPV1. In addition, four analogues (295, 301?, 305 and 31(15,35)) 
have been identified with potent antagonism (IC5o<100nM) of capsaicin-induced
2
activation of the human orthologue of TRPV1, and potent agonism (EC5o<60nM) of 
the rat orthologue of TRPV1. Compounds possessing opposing activities for different 
mammalian orthologues of TRPV1 have not been described previously in the 
literature.
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Pain, Capsaicin and TRPV1
Pain is ‘one of the most challenging problems in medicine and biology’ 
Ronald Melzack and Patrick D W alll.
It is ‘a more terrible lord of mankind than even death itself.’ Albert Schweitzer2
‘The conquest of pain remains...the most important task...of every medical man’ 
Cornelius Medvei3
The briefest perusal of the relevant literature from just the past fifty years reveals the 
topic of pain to be of enormous interest and immensely complex, both in the 
proposed biological mechanisms contributing to the sensation of pain, and in the 
proposed means of intervention. Many journal papers, reviews, books and textbooks 
have been written on and around the subject, from a multitude of perspectives. 
Despite the wealth of ongoing research and available information, many aspects of 
the sensation of pain remain unchallenged by current therapies.
As of October 2002, the National Pain Education Council (www.npecweb.org) 
estimated that more than 50million Americans are partially or totally disabled by 
chronic pain, with 7-10million (15-20%) having no treatment for that pain.
An increasingly significant field for both academic and industrial research into 
understanding the underlying mechanisms of the sensation of pain, and developing 
new pain therapies, is the ion channel transient receptor potential, vanilloid type 1 
(TRPV1), also known as the vanilloid receptor, subtype 1 (VR1), or the capsaicin 
receptor. Initially studied indirectly through the effects of its exogenous agonist 
capsaicin, this ion channel has been the focus of a considerable amount of attention 
for over forty years, with fresh research and in depth review articles appearing with 
increasing frequency. So, what is pain, and where does TRPV1 fit in?
The Sensation of Pain
Pain is a general term, covering a broad spectrum of sensation. The International 
Association for the Study of Pain (IASP) has given the concise, generic definition of 
pain as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage”4.
29
Pain has two distinct components: the sensory, and the emotional. At its simplest, a 
potentially damaging noxious stimulus is detected by the pain receptors, or 
nociceptors5, of the peripheral nervous system (PNS), and is communicated to the 
higher brain centres of the central nervous system (CNS). Here it is analysed, 
interpreted and, if categorised as painful, a suitable response is formulated. The 
sensory aspect of pain, i.e. the detection of noxious stimuli and the cascade of 
physiological and biochemical events that this can trigger, are a consistent 
component of the sensation of pain. The emotional aspect of pain, i.e. the 
interpretation of these stimuli as pain, can be highly variable, and specific to the 
individual.
Pain has been categorised in various ways:
• qualitatively, according to severity, from mild discomfort to agony;
• temporally, as transient (accompanying a noxious stimulus), acute 
(accompanying the healing process), and chronic (prolonged, persisting 
beyond the normal time of healing);
• mechanistically, as physiological, or pathological6, and more recently as 
nociceptive, inflammatory and neuropathic7.
The final approach will be followed herein.
While attempting to cover the entire complexity of current pain knowledge would be 
impossible, a brief resume of the more pertinent physiological and biochemical 
principles and mechanisms involved would be appropriate, with much of the basic 
foundations for the preparation of this overview being drawn from the following key 
textbooks:
Biochemistry, 2nd edition, L. Stryer, (1988);
j
Ion Channels in Excitable Membranes, 3 edition, B. Hille (2001);
Molecular Biology o f the Cell, 1st edition, B. Alberts, D. Bray, J. Lewis, M. Raff, 
K. Roberts and J. D. Watson (1983);
Neuroscience: Exploring the Brain, 2nd edition, M. F. Bear, B. W. Connors, and 
M. A. Paradiso (2001);
Sensory Mechanisms o f the Spinal Cord, 2*d edition, W. D. Willis, Jr. and 
R. E. Coggeshall (1991);
Textbook o f Pain, 4th edition, edited by P. D. Wall and R. Melzack (1999).
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Pain in the Periphery - Nociception8
The detection of noxious stimuli is a function of the somatic sensory nervous system, 
a collective term for the parts of the nervous system dedicated to the senses of touch, 
temperature, proprioception and pain. Unlike the other senses, where the receptors 
are concentrated in small, specialised sense organs, the receptors of the 
somatosensory system are distributed throughout the body, being found in skin, 
bone, muscle, most internal organs, blood vessels, and the heart.
Stimulation of the peripheral receptors of the somatic sensory nervous system is 
communicated to the CNS via the sensory primary afferent neurones (PANs). PANs 
have processes, of axons, extending from the receptors in the periphery to the 
superficial layers of the spinal cord, where they terminate within the dorsal horn; 
their cell bodies lie outside the CNS, in the dorsal root ganglia (DRG) (see Figure 1).
Dorsal horn Neuronal cell 
body in the 
dorsal root 
'  ganglion
Peripheral
terminalsIntermediate zone
Axon
Ventral horn
Spinal cord Primary afferent neurone
CNS PNS
Figure 1: A schematic overview of PAN architecture, from the PNS to the CNS.
Subtypes of Primary Afferent Neurones of the Somatic Sensory System8
There are four categories of axon, divided according to diameter. The diameter is a 
function of the degree of myelination an axon has, and the greater the degree of 
myelination of an axon, the faster the speed of conductance of the action potential 
along that axon. The speed of conductance of an axon, and the type of sensory 
receptors they are associated with, are mutually interdependent, and determine the 
sensory function they perform. Three Of the four categories of PAN, as described by 
axon diameter, have been determined to have a role in pain (see Figure 2).
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sheath Axon
A/3-fibres:
heavily myelinated; 
6-12juM diameter; 
conductance: 35-75I11S'1.
A6-fibres:
lightly myelinated; 
l-5pM diameter; 
conductance: 5-30II1S'1.
C-fibres:
C ID unmyelinated;
0.2-1.5 pM diameter; 
conductance: 0.5-2ms '.
Figure 2: Schematic representation of subtypes of primary afferent neurones of the cutaneous somatic 
sensory system.
In addition to characterisation by cross-sectional diameter, the primary afferent 
neurones o f the cutaneous somatic sensory system are also categorised by their 
response to different stimuli, the degree of stimulation (or threshold) necessary to 
cause activation, and thereby their presumed physiological role9. There are 
mechanoreceptors (responding to either innocuous (low threshold) or noxious (high 
threshold) pressure or displacement), thermoreceptors (activated by innocuous 
changes in temperature), and the ‘pain’ receptors. It has been noted that stimulation 
of the pain-sensing apparatus of the somatic sensory system does not itself constitute 
pain. To distinguish this stimulation of the pain-sensing apparatus from the 
emotional perception of pain, the term ‘nociception’ (from the Latin nocere-‘to hurt’) 
was adopted5. Neurones activated by noxious stimuli are therefore described as 
‘nociceptive receptors’, or nociceptors.
The low threshold mechanoreceptors (LTM) and their associated organelles, 
(generally named after histologist who discovered them: e.g. Krause end bulbs, 
Merkel’s discs, Meissner’s corpuscles, Pacinian corpuscles, and Ruffini’s endings) 
are predominantly innervated by Ap-fibres, and, as the name suggests, they have a 
low threshold of activation, responding to non-noxious stimulation of the skin 
(touch)10. However, while not directly involved in the detection of noxious stimuli,
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A/3-PANs have been demonstrated to play a significant role in chronic pain 
conditions (see Pain modulation -  the Gate-Control Theory of Pain).
The thermoreceptors and nociceptors are associated with A8- and C-fibres. The 
sensitive termini of the C-fibre thermoreceptors and nociceptors are free nerve 
endings, without associated organelles; those associated with A5-fibres may have a 
protective covering of Schwann cells11, the non-neuronal glial support cell associated 
with myelination. There are two classes of thermoreceptor responding to innocuous 
temperature changes: warm receptors and cold receptors. The warm receptors are 
mostly innervated by C-fibres, and activate with increasing intensity between 30°C 
and 46°C9;1214. The cold receptors are innervated by A8 - or C-fibres, and respond to 
temperatures between 10°C and 35°C9’14'16.
Capsaicin, an Exogenous Noxious Chemical Stimulus
Noxious stimuli can be broadly sub-divided into:
• mechanical, relating to pressure upon, and displacement of, the receptor;
• thermal, both hot and cold;
• chemical, both endogenous and exogenous in nature.
Of the exogenous chemical mediators of pain and nociception, one of the most 
widely investigated has been capsaicin. It is the principle pungent ingredient of the 
chilli peppers (Capsicum spp.\ and the progenitor of the vanilloids (see Figure 3). 
This family of neuroexcitants is a diverse group of exogenous compounds with 
agonist activity at the capsaicin receptor (VR1/TRPV1). The name ‘vanilloid’ 
derives from the common vanillyl substitution pattern of the aromatic ring seen in the 
original members of the group:
• capsaicin, derived from chilli peppers (Capsicum spp.)\
• pipeline, derived from black pepper;
• zingerone, obtained from ginger; and, more recently,
• resiniferatoxin (RTX), obtained predominantly from the latex of
1 n
Euphorbia resinifera .
RTX has proven itself to be of particular interest; it is frequently described as an 
‘ultrapotent vanilloid’, being anything up to 1 0 ,0 0 0 -fold more potent than capsaicin
• 17*18in some assays ’ .
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Once believed essential for activity, more recently discovered ‘vanilloids’ of fungal 
origin, including isovelleral19 a terpenoid possessing a 1,4-dialdehyde moiety, and 
scutigeral20 a non-pungent triprenyl phenol, demonstrated that the requirement for a 
vanillyl moiety is not absolute.
HO
Capsaicin
HO
Piperine Zingerone
I\0
HO OH
Resiniferatoxin
OHC
CHO HO
ScutigeralIsovelleral
HO OH
Figure 3: Examples of the vanilloids.
Early Vanilloid Pharmacology
Investigations into the isolation, structural elucidation and functional exploration of 
the vanilloid progenitor, capsaicin, began in the latter half of the nineteenth century. 
Derived from cayenne, this ‘pungent principle’ was first crudely isolated as a thick
ired oil, termed ‘capsicol’ (Buchheim, see Thresh ), from which was derived a 
colourless crystalline solid, termed ‘capsaicin’21'24.
During the original isolation of capsaicin, the extreme irritancy caused by exposure 
to the compound was noted. In the case of the mucous membranes, inhalation of the 
volatilised compound caused ‘severe fits of coughing’ and Tong continued fits of
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sneezing’ . In the direct application of a capsaicin solution to the skin, the 
application to the arm of lint soaked in a solution of one part capsaicin to forty parts 
of spirit and glycerine caused ‘an unbearable sensation of warmth and reddened 
inflammation, without blistering’22. The results of the ingestion of one-eighth of a 
grain dose of capsaicin in a coated pill were also reported, and two hours after 
ingestion, the subject experienced violent burning pains in the stomach, assuaged by 
‘copious drafts of demulcents’ .
In 1878, it was reported that the burning sensation experienced when an alcoholic 
solution of the crude isolate capsicol was dropped on the skin was the result of a 
selective activation of sensory neurones (Hogyes25, from Szolcsanyi26), and was 
reported to be accompanied by hyperaemia (an excess of blood at the site) (Hogyes25, 
from Toh et al.21).
These combined experiences illustrated the two aspects of painful sensation caused 
by exposure to capsaicin; firstly, exposure causes an acute nociceptive response, and 
secondly, a neurogenic inflammatory response.
Capsaicin has other in vivo biological effects. It has potent effects upon the 
cardiovascular and respiratory systems. Early experiments showed capsaicin to exert 
a potent hypotensive action in the anaesthetised dog28, with later experiments 
extending these results. The i.v. administration of capsaicin to anaesthetised cats and 
dogs produced a ‘triad’ of hypotension (lowering of blood pressure), bradycardia 
(abnormally low rate of heart contraction) and apnoea (the temporary cessation of 
breathing)27’29’30.
Capsaicin has a profound effect upon thermoregulation. It was reported that, while 
low doses of capsaicin induced a sudden transient drop in the rectal temperature of
<2<j ^  j
mice ’ , rats and guinea pigs {hypothermia) , higher doses of capsaicin actually 
desensitise the warmth response, such that thermoregulation is no longer possible for 
treated animals, even after one year33’34.
Capsaicin and Sensory Neurones
The latter half of the nineteenth century saw the painful burning sensation resulting 
from exposure to capsaicin attributed to the specific actions of capsaicin upon 
sensory neurones25; it wasn’t until the latter half of the twentieth century that further 
detailed explorations were made. The observation that nociceptive nerve endings 
were not only stimulated by capsaicin, but were disabled by high doses of capsaicin
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(Jansco35; see Szolcsanyi26’36) stimulated further exploration into the actions of 
capsaicin. The discovery of capsaicin’s ability to desensitise sensory neurones to 
noxious chemical stimuli formed the basis for much of the later research into 
capsaicin, and analogues of capsaicin, as novel analgesics and 
anti-inflammatories.
Further experimentation demonstrated that parenterally (other than orally/rectally) or 
locally administered applications of high, prolonged or repeated doses of capsaicin 
cause animals to develop long-term, or even permanent, loss of sensitivity to a wide 
range of noxious chemical stimuli37'42, as a result of selective degeneration of the 
capsaicin-sensitive primary afferent sensory neurones. This neurotoxic effect has 
allowed capsaicin to be widely used as a biological tool to investigate the properties 
of this discrete subset of PANs, by selectively damaging this neuronal subset and 
assessing the effects43.
Nociceptor subtypes
As already noted, there are three broad categories of noxious stimuli, and the 
nociceptors are categorised according to the noxious stimuli that activate them. There 
are three main populations of nociceptor:
• those responding to ‘damaging mechanical stimulation of the skin’ only 44; these 
high threshold mechanoreceptors, or HTMs, can be innervated by A5-fibres 
(hence A8 -HTM) 44 45 or C-fibres (C-HTM). Studies using rat skin found 
approximately 20% of A5-fibres, and 10-15% of C-fibres examined were 
HTMs46’47. Although normally insensitive to stimulation by noxious chemical or 
thermal stimulation, it is possible for a sub-population of these receptors to 
become heat sensitive, after repeated application of noxious heat48. These 
nociceptors are unaffected by capsaicin.
• those responding to noxious mechanical, thermal and chemical stimuli. Because 
of their multiple modalities of activation, these nociceptors are termed the 
polymodal nociceptors49, or PMNs. They are predominantly innervated by C- 
fibres, although there is a small and significant sub-population innervated by A8 - 
fibres50’51. The majority of the cutaneous nociceptors are polymodal; the 
polymodal nociceptors are the primary conduit for relaying the detection of 
nociception in the periphery to the CNS.
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• those that are unresponsive to acute noxious stimulation, but can become 
‘sensitised’ to respond to noxious chemical stimulation following tissue injury as 
a result of the inflammatory response (see Peripheral Sensitisation). These are the 
‘silent’ nociceptors52.
During the period that these nociceptors were being defined and described, the 
Hungarian laboratories working with capsaicin had begun to use the term ‘capsaicin- 
sensitive afferents53. Comparative studies in rat51;54, rabbit55 and monkey56 
demonstrated that:
a) the capsaicin-sensitive afferents were comprised of polymodal nociceptors 
and warmth receptors, and
b) all of the polymodal nociceptors are capsaicin-sensitive, so much so that 
sensitivity to capsaicin is recognised as a pharmacological signature of the 
polymodal nociceptors.
For a fuller understanding of the actions of capsaicin, a consideration of the 
molecular components of nervous functioning, with particular reference to pain, is 
required.
Key Features of the Neuronal Membrane
As previously described, the PANs of the somatosensory nervous system, including 
the PMNs, have their cell bodies outside the CNS, in the DRGs. They have 
processes, or axons, extending from the receptors in the periphery to the superficial 
layers of the spinal cord, where they terminate within the dorsal horn (see Figure 1). 
The axons are essentially sealed hollow tubes, with the internal contents of the axon, 
or axoplasm, separated from the extracellular fluid (ECF), by the neuronal 
membrane. This membrane between the two fluids has as its basic structure the
r ' l . r o
phospholipid bilayer ’ . As its name suggests, this barrier is composed of a double 
layer of phospholipids, a category of biological building block which is exemplified 
by the phosphoglycerides (see Figure 4). These molecules have a central glycerol 
molecule, to which is attached a charged functionality, in the form of a 
phosphorylated alcohol, and two long chain fatty acids (usually 14 to 24 carbons 
long), bound to the glycerol as esters. Individual phospholipids are therefore 
amphipathic, having a hydrophilic ‘head’ region and a hydrophobic ‘tail’ region.
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Figure 4: Representation o f the more common components of the phosphoglycerides.
In an aqueous environment, their amphipathic characteristics require such molecules 
to form composite structures that effectively exclude water from the non-polar 
hydrophobic domains, while allowing the polar hydrophilic domain to continue to 
associate with the water. One such composite structure is a sheet, of two molecules 
in thickness, with the hydrophilic heads forming the outer surfaces of the sheet, 
sandwiching the hydrocarbon tails. The hydrophobic interior of this phospholipid 
bilayer makes it effectively impermeable to ions.
Embedded within this phospholipid bilayer are two categories of biological 
macromolecular complex which span the membrane and permit the passage of ions 
across the membrane. These are the ion pumps and the ion channels. These 
membrane proteins are constrained within the plane of the membrane, but are free to 
diffuse laterally within the membrane in a ‘fluid mosaic’59.
Ion Pumps
The hydrophobic interior of the phospholipid bilayer makes it effectively 
impermeable to ions, allowing different concentrations of ions to exist on either side 
of the membrane, resulting in a difference in electrical potential across the 
membrane, which is key to neuronal function. Defined as the inside potential minus 
the outside potential60, this transmembrane voltage potential difference (Vm) can be 
measured by inserting a microelectrode into the neurone. The value in the ‘resting’ 
axon is -65mV57.
While the phospholipid bilayer is essentially impermeable to ions, there is leakage of 
ions in both directions. The resting value of Vm is maintained by the ion pumps, 
constructed from specialised transmembrane proteins that are ‘dissolved’ within the 
plasma membrane. The ion pumps actively carry ions across the membrane, against
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existing gradients, to establish and maintain such gradients, at the expense of 
metabolic energy, generally in the form of adenosine triphosphate (ATP).
There are two ion pumps in particular that are key to neuronal function, These are:
• the sodium-potassium pump (for a review, see Skou61), which exchanges 
internal sodium ions for external potassium ions at the expense of ATP, 
ensures that the resting neurone has a much higher cytosolic than 
extracellular potassium ion concentration, and a much higher extracellular 
than cytosolic sodium ion concentration;
• the ATP-dependent calcium ion/proton exchange pump (for a review, see 
Carafoli62), which actively pumps calcium ions out of the neurone. This and 
other mechanisms responsible for sequestering intracellular calcium within 
calcium-binding proteins and organelles ensure that the level of calcium ions 
within the resting axon is extremely low (<0.2pM), while the extracellular 
concentration might be as high as ImM.
These concentration differences mean that, at rest, the inside of the axon has a 
negative charge with respect to the outside of the cell. It is the function of these ion 
pumps to maintain or, when disrupted, restore the resulting electrical potential 
difference (Vm) to the resting potential of -65mV.
Ion Channels
A typical functional ion channel requires the association of four to six similar 
transmembrane protein subunits, to form a pore between them. Such pores are not 
simply holes in the membrane through which there is free and random movement for 
any passing chemical entity; the nature of the protein subunits determines the nature 
of the pore and its properties. Many ion channels are selectively permeable to a 
particular ion, giving preferential passage to their selected ion through the 
membrane. Also, most ion channels are not permanently open, as the movement of 
ions through ion channels must be a controlled process. The majority of ion channels 
are ‘gated’, opening and closing in response to conformational changes in their 
tertiary and quaternary structure caused by specific changes in their immediate 
microenvironment. When this change is a result of a change in the immediate 
transmembrane potential difference, the channel is said to be voltage-gated. If it is 
the result of interaction with a specific chemical entity, the channel is said to be 
ligand-gated.
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In contrast to the ion pumps, the movement of ions through an open ion channel is 
passive and bidirectional. The net direction of the movement of ions is determined by 
the electrochemical gradient. This gradient is a combination of:
• the concentration gradient, with ions moving from a solution of a higher to a 
lower concentration; and
• the transmembrane voltage potential (V m ) ,  with ions ‘pulled’ to the side of 
the membrane possessing the opposite charge.
Where these two gradients are contradictory, ions move to establish an equilibrium 
that balances these contributory factors, such that the diffusional and electrical forces 
are equal and opposite. For cations such as sodium and, in particular, calcium, where 
there is a steep concentration gradient into the cell and Vm of the resting membrane is 
negative, the driving force for the passive entry of these ions into the cell is 
extremely high.
Generation and Propagation of the Action Potential63;64
The first step in the detection of any stimulus requires the presence of that stimulus 
to be converted into the neuronal common currency of the action potential, by the 
process of transduction. The action potential is a brief, self-propagating 
depolarisation and repolarisation of the axonal membrane, during which Vm rises 
from -65mV, to +40mV (<depolarisation), before dropping back again 
(repolarisation), over approximately 2 milliseconds . The capacity to generate and 
conduct action potentials defines the membranes of neuronal cells as excitable54. The 
modem understanding and interpretation of the events occurring during the 
generation and conductance of an action potential arise from the classical analysis of 
ionic currents in the squid giant axon performed by Hodgkin and Huxley65. They 
were the first to recognise that the observed membrane currents of the excited squid 
giant axon required controlled, separate, voltage-dependent changes in membrane 
permeability toward different ions, specifically sodium and potassium. The agents of 
these permeability changes have been established to be the voltage-gated sodium ion 
channels and the voltage-gated potassium ion channels.
It has been noted that the internal concentration of ions in the resting neurone is 
maintained by ion pumps to ensure that:
■ the concentration of potassium ions is higher internally than externally;
40
■ the concentration of sodium and calcium ions is much lower internally 
than externally.
When an action potential is triggered, the voltage-gated sodium ion channels open, 
allowing a large influx of sodium ions into the cell. These channels are only open for 
approximately one millisecond, but this is long enough for Vm to rise from -40mV to 
+40mV. This change of membrane polarity, or depolarisation of the membrane, then 
inactivates the voltage-gated sodium channels, and stimulates the opening of the 
voltage-gated potassium channels. The resulting large efflux of potassium ions from 
the axon causes a repolarisation of the membrane, with Vm rapidly dropping back to 
below the resting potential of -65mV. This repolarisation closes the potassium 
channels, and is followed by the gradual restoration of Vm to the resting potential by 
the ATP-dependent sodium-potassium ion pumps, which work throughout to restore 
the original ionic concentration gradients.
Once generated, the action potential is communicated from the periphery to the CNS, 
by conductance of the action potential along the axons of the primary afferent 
neurones. The triggering of an action potential causes the opening of the voltage- 
gated sodium channels. The influx of sodium ions depolarises the adjacent section of 
membrane, until that too reaches threshold, and generates its own action potential. In 
this way, the action potential is propagated along the axon, as each action potential 
generates an action potential in the membrane adjacent to it. The direction of 
conductance is orthodromic, or unidirectional, away from the site of stimulation and 
toward the CNS, because the voltage-gated sodium channels at the site of an action 
potential are unable to open again until Vm has returned to the resting value of 
-65mV, resulting in the sodium channels ‘behind’ the action potential being 
inactivated until the local value for Vm has returned to the resting value of-65mV.
It is important that minor fluctuations in Vm either side of the resting potential do not 
stimulate an action potential. Therefore, for an action potential to be generated, it 
must be triggered by a rise in Vm from the resting potential of -65mV to above the 
threshold value of «-40mV. This initial change in the value of Vm requires a 
dedicated influx of cations, and this is the role of transduction. Noxious stimuli, 
whether mechanical, thermal or chemical, act to trigger the action potential by either 
directly or indirectly causing the opening of cation-selective channels in the neuronal 
membrane, resulting in an influx of cations (generally calcium and sodium) into the
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cell, causing the value of Vm rises. A sufficiently large stimulus will cause a large 
enough influx of cations to cause Vm to rise beyond the threshold, and an action 
potential is triggered.
Capsaicin, the Capsaicin Receptor and TRPV1
In vitro mechanistic studies of the capsaicin-induced activation of PMNs, made using 
cultured DRG neurones and isolated PANs, demonstrated that exposure to capsaicin 
initiated an increase in membrane cation permeability, particularly to calcium and 
sodium42;66'68. As described, an increase in the non-selective cation permeability of 
the resting neuronal membrane results in a net movement of cations into the neurone, 
and a sufficiently large influx of cations triggers an action potential.
How does capsaicin do this? The highly selective nature of capsaicin’s activity upon 
sensory neurones, coupled with the strict requirements for analogues of capsaicin to 
retain activity, implied mediation by a specific receptor. The first hypothetical 
pharmacological receptor for capsaicin, based upon SAR studies indicating critical 
moieties for binding, was presented by Szolcsanyi and Jancso-Gabor in 197569 
(see Figure 5).
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Figure 5: Schematic representation o f the hypothetical capsaicin receptor (after Szolcsanyi and 
Jancso-Gabor 69).
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Further evidence for the existence of a specific receptor to capsaicin came with the 
experimental evidence for capsaicin’s activation of polymodal nociceptors occurring 
via the opening of a non-selective cation channel42’66'68’70, and the discovery of the 
competitive antagonist to capsaicin-induced activation of the polymodal nociceptors, 
capsazepine (CPZ; see Figure 6 ) 71’72 (see The Discovery of Capsazepine - the First 
Competitive Antagonist of the Neuroexcitatory Action of Capsaicin).
ho.
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Capsaicin Capsazepine (CPZ)
Figure 6: Capsaicin and the first competitive antagonist of capsaicin-induced activation of the 
polymodal nociceptors, capsazepine (CPZ).
The identity of the capsaicin receptor was determined by using a cDNA library 
constructed from rat DRG-derived mRNA to successfully isolate, clone and express 
a capsaicin-sensitive non-specific cation channel for the rat73. A homology search of 
available protein databases revealed the similarities between this receptor and the 
transient receptor potential (TRP) superfamily of ion channels73. The receptor was 
given the name VR1, for vanilloid receptor subtype 1, and orthologues have been 
identified for human74’75, chick76, guinea pig77, rabbit78 and mouse79. Five closely 
related mammalian homologues have subsequently been discovered (see Table 1), 
and given a variety of names that were eventually successfully standardised under 
the umbrella of the transient receptor potential vanilloid (TRPV) family of the TRP 
superfamily of ion channels, numbered one through six. As the progenitor of this 
branch, VR1 has become the transient receptor potential vanilloid type 1 (TRPV1)
OA
ion channel . Despite the name, none of the other TRPV ion channels are sensitive 
to activation by capsaicin, or any of the vanilloids.
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Unified nomenclature80 Alternative nomenclatures
TRPV1 VR1 7TVanilloid receptor subtype 1
TRPV2 VRL-1 Vanilloid receptor-like l 81
TRPV382 83;84
TRPV4 VR-OAC vanilloid receptor-related osmotically 
activated channel85;
TRP12 Transient receptor potential 1286
OTRPC4 Osm-9-like transient receptor potential 
channel 487
TRPV5 ECaCl Epithelial calcium channel 1
CaT2 Calcium transporter 2
TRPV6 ECaC2 Epithelial calcium channel 2
CaTl Calcium transporter 1
Table 1: Members of the mammalian TRPV subfamily.
The Transient Receptor Potential (TRP) Superfamily of Ion Channels
The TRP superfamily of ion channels have recently been described as ‘the vanguard 
of our sensory systems’88, with individual TRP homologues responding to a range of 
thermal, mechanical and chemical stimuli allowing responses to changes in 
temperature, touch, pain, osmolarity, pheromones and taste88’89. With a couple of 
exceptions, the TRP channels have been found to be non-selective Ca2+ permeable 
cation channels. Many of the TRP channels are found to be expressed in neuronal 
membranes. As already described, the concentration of calcium ions within neurones 
is maintained at an extremely low level, by means of the ATP-dependent calcium 
pump and intracellular calcium sequestering. [Ca2+], can be as much as 20,000 fold 
lower than extracellular concentrations90. This extreme concentration gradient and 
electrical potential difference across the plasma membrane of the resting neurone 
constitute a powerful driving force for calcium ions to enter the cell. When TRP ion 
channels open in response to their respective aforementioned stimuli, the resulting 
influx of calcium ions leads to a sharp and decisive rise in [Ca2+]j, and with it the
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value of Vm. As such, these ion channels are molecular transducers, translating 
changes in the extracellular environment into changes in the value of Vm, thereby 
elevating Vm to beyond the threshold value, ‘kick-starting’ the action potential 
(see Generation and Propagation of the Action Potential).
The existence of the first TRP channel was extrapolated from behavioural studies of 
a Drosophila melanogaster mutant. Despite exhibiting normal behaviour in dim 
light, this mutant strain appeared as though blind in bright light91. 
Electroretinograms, which record the changes in extracellular current flow in the eye 
in response to light, revealed that, while the wild-type fly has a constant change in 
receptor potential as a result of exposure to continuous bright light, the mutant shows 
only a temporary, or transient, change in receptor potential, hence trp mutant91. The 
mutation was deduced to be the result of a gene deletion , coding for a 
transmembrane protein93, which was later demonstrated to be an ion channel94. 
Homologues of this ion channel have been found throughout the animal kingdom. 
The sequencing of entire genomes, coupled with advances in techniques of gene 
isolation and identification, have led to examples of TRP ion channels being 
identified in yeast95'97, nematodes98 and several mammalian species. With the 
identification of the first human homologue of the TRP ion channel (TRPC1) " ;100 
and six TRP-related genes in the mouse genome101 came a deluge of publications 
revealing new mammalian TRP ion channels. At the last count, there are upward of 
twenty eight human genes coding for TRP monomers88’89, organised into six 
families, according to sequence homology.
As the number of recognised human TRP channels has increased, so the requirement 
for a unifying nomenclature for the TRP channels increased. Unlike most other ion 
channels, the TRP channels are not grouped according to their functional roles 
which, where they have been determined, are diverse. These channels are classified 
by identity in homologous regions of their sequence, some of which are highly 
conserved. The first attempt was based upon the 13 TRP channels of the nematode 
Caenorhabditis elegans, and divided the TRP channels into STRPCs (Short), 
LTRPCs (Long) and OTRPCs (Osm-9-like), as all TRPs known at the time could be 
grouped according to these three subfamilies102. As further TRPs were identified, the 
present generally accepted system was proposed and adopted80. The three original 
families of STRPC, OTRPC and LTRPC became TRPC (Canonical, or Classical), 
TRPV (Vanilloid) and TRPM (Melastatin) respectively, and these have been joined
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by the TRPA (Ankyrin transmembrane protein), TRPP (Polycystins) and the TRPML
OQ
(MucoLipins) .
None of the TRP proteins have been crystallised, so no crystal structures exist as yet. 
The currently accepted model for the generic TRP channel architecture has been 
deduced from the derived primary sequences of amino acids encoded for by the TRP 
genes, with regions of hydrophobicity and putative secondary structural organisation, 
as well as other recognised motifs, having been identified. Although the initial 
hydrophobicity analysis of the Drosophila TRP channel predicted eight 
transmembrane domains93, subsequent analyses of the second Drosophila TRP (trpl, 
for trp-\\ke)m  and the first published human TRP channel (TRPC1)99’104 revised the 
number of transmembrane domains to six. The currently accepted model has six 
hydrophobic domains that span the membrane (6TM), with an hydrophobic loop 
between the fifth and sixth transmembrane domains forming a putative pore domain 
(see Figure 7). An apparent lack of cell recognition sequences has led to the 
conclusion that the C and N termini are located intracellularly102’105.
Pore region
Extracellular
Plasma membrane
Intracellular
Figure 7: Diagrammatic representation of the putative architecture of the TRP channels.
The nature o f these cytoplasmic regions is more varied, both in length and 
recognisable motifs. The TRPC and TRPM channels have a proline-rich region 
immediately after the sixth putative transmembrane sequence, and the TRPC, TRPV 
and TRPA channels have varying numbers of ankyrin-like repeats in the N-terminal 
region before the first transmembrane sequence105. The ankyrins are a family of 
proteins that ‘coordinate interactions between various integral membrane proteins 
and cytoskeletal elements’106. Presumably the ankyrin-like repeats of the TRP 
channels fulfil a similar role. Their presence and number is one of the identifying
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markers for characterising members of the TRP subfamilies (TRPC and TRPV have 
three or four; TRPA has fourteen88).
Comparison with the voltage-gated Ca2+ and Na+ ion channel families has also been 
used to predict the active TRP ion channel as homo- or heterotetrameric, comprised 
of four single TRP subunits102.
Pain from the PNS to the CNS - Synaptic Transmission107
The axons of the primary sensory afferent neurones enter the spinal cord, via the 
dorsal root, and terminate within the superficial layers of the dorsal horn of the 
spinal cord. Here apy action potential is relayed to second-order neurones, also 
called projection neurones, because they have axons which project up the 
spinothalamic tract to the higher centres of the CNS.
Amino Acids:
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CO„H
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Peptides:
Adrenaline
Substance P: Arg—Pro—Lys—Pro—Gin—Gin—Phe—Phe—Gly—Leu—Met—NH2 
Figure 8: Some neurotransmitters.
In general, neurones do not actually touch; there is a gap or space maintained 
between them, and communication between neurones across this gap, or synapse, is
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almost exclusively chemical in nature. When an action potential arrives at a synapse, 
it stimulates the opening of voltage-gated calcium ion channels in the membrane. 
The resulting influx of calcium ions from the extracellular fluid stimulates the rapid 
release (within 0 . 2  milliseconds) of neurotransmitters, specialist chemicals which 
cross the synapse and bind to dedicated receptors on the surface of the adjacent 
neurone. These neurotransmitters can be excitatory or inhibitory, and fall into one of 
three chemical classes: amines, amino acids and peptides (for examples, 
see Figure 8 ).
Of these transmitters, the following have all been identified as being located within 
the nociceptors, and have been confirmed as being released from nociceptors 
following activation by capsaicin:
• glutamic acid108' 111 is an excitatory amino acid, generally accepted as the 
principle excitatory neurotransmitter in the spinal cord112'114. It has been 
demonstrated that stimulation by capsaicin causes the release of glutamic acid 
from isolated rat DRG neurones109 and from rat dorsal horn slices115;116.
• substance P is108’117' 122 an 11 amino acid residue peptide of the tachykinin 
group of proteins. There is compelling evidence that substance P is one of the 
key neurotransmitters in central nociceptive signalling and central 
sensitisation. When applied to the dorsal horn, it has been shown to excite 
CNS neurones that respond to noxious peripheral stimuli123’124, with increased 
levels of substance P resulting in increased sensitivity to noxious 
stimuli119’125. In addition, antagonists of the activation of the substance P 
receptor (NK1) are anti-hyperalgesic126’127, and the selective removal of 
spinal neurons expressing NK1 leads to a reduction in responses to noxious 
stimuli128. It has been demonstrated that stimulation by capsaicin causes the 
release of substance P from the hemisected rat spinal cord129 and from slices 
of the spinal cord of the rat130 and the guinea pig131.
• calcitonin gene-related peptide (CGRP) is a 37 amino acid residue 
peptide ’ and has been reported to have a role in the transmission of 
nociceptive information, and central sensitisation134*137. CGRP has been 
reported to potentiate substance P release138 and to attenuate the nociceptive 
actions of substance P and capsaicin139. It has been demonstrated that
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stimulation by capsaicin causes the release of CGRP in slices of the guinea 
pig dorsal spinal cord140.
There are two principle types of receptor for neurotransmitters: the transmitter-gated 
ion channels, and the G protein-coupled receptors (GPCRs). The transmitter-gated 
ion channels are ligand-gated ion channels, and operate as already described (see Ion 
Channels). The GPCRs are much more complex and diverse in function, forming a 
large superfamily of homologous transmembrane proteins found in most cell types. 
They are activated by a variety of different classes of ligand, such as hormones, 
neurotransmitters and calcium ions141;142. GPCRs are formed by a single protein, 
comprising an extracellular N-terminus, a serpentine portion containing seven 
transmembrane helices connected by intracellular and extracellular loops, and an 
intracellular C-terminus. Rather than the ‘simple’ action of directly opening a pore, 
the GPCRs are much more diverse in their effects, mediating their actions via the 
activation of intracellular G proteins. The G-protein is comprised of three non­
identical subunits, a, p and y; when activated, the G-protein splits into two parts, Ga 
and Gpy; these are each capable of activating a third group of effector proteins. These 
effector proteins may be G-protein-gated ion channels in the membrane, or they may 
be G-protein-activated enzymes which can trigger an elaborate cascade of 
biochemical reactions, via second messenger systems. These second messenger 
systems ultimately alter neuronal function, either by the regulation of ion channel 
function, or by altering cellular metabolism. The same G-protein has the potential to 
be activated by any one of several GPCRs; each GPCR is capable of activating 
several G-proteins. This potential is dependent upon gene expression within the cell. 
Hence, the same neurotransmitter can have different effects, in different synapses, 
depending upon the nature of the G-proteins present in the neuronal membrane. Over 
100 GPCRs have thus far been described in the literature. The preferred substance P 
receptor (Neurokinin 1, or NK1) and the CGRP receptor are both GPCRs; their 
location within the superficial dorsal horn has been confirmed by radioactive ligand 
binding experiments143. There are GPCRs for glutamate, the metabotropic glutamate 
receptors (mGluR), and these have also been localised to the superficial dorsal 
horn144.
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Nociceptive Action of Capsaicin - Summarised
The sequence of events by which the nociceptive effects of capsaicin are transmitted 
from the periphery to the neurones of the CNS would appear to be:
• transduction, from noxious chemical to action potential by the activation of 
TRPV1 at the PMN cell surface, causing the opening of the non-specific, 
calcium permeable cation channel, leading to an influx of cations, particularly 
calcium, triggering an action potential;
• conductance of the action potential to the central synapse in the dorsal horn;
• release of excitatory neurotransmitters, such as substance P, CGRP and 
glutamic acid, into the synapse, stimulating the second order neurones of the 
CNS.
Pathological Pain
The information so far summarises the underlying mechanism of nociception, with 
particular reference to the nociceptive action of capsaicin. If this was all there was to 
the sensation of pain, then the same noxious stimulus, applied in the same way, 
would produce the same sensation, every time. This is not the case. When there is 
actual tissue damage, as a result of disease or trauma, the somatosensory system can 
be subject to a host of induced alterations, resulting in either an enhancement or a 
disruption of normal sensory mechanisms. When the responses of the neurones of the 
somatosensory nervous system concerned with pain are altered, the resulting pain 
states have been generally categorised as pathological pain6. Several different 
mechanisms underlie the pathological pain states, which may include any or all of 
the following conditions:
• hyperalgesia, an amplification of responsiveness to noxious stimuli145;
• allodynia, pain resulting from a normally non-noxious stimulus145;
• hyperpathia, an abnormally painful and prolonged reaction to noxious 
stimuli145;
• spontaneous nociceptor activation.
Key pathological pain states are inflammatory and neuropathic pain.
Inflammatory Pain
Actual tissue damage can be accompanied by inflammation (oedema) of the injured 
tissue. This is due to changes in the local blood flow (vasodilatation) and vascular
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permeability, leading to the leakage of plasma into the surrounding tissues 
(iextravasation). These changes also lead to reddening (erythema) of the injured 
tissue and the surrounding area. This is generally accompanied by an increase in pain 
sensitivity (.sensitisation), as a result of the lowering of pain thresholds in the 
nociceptors at the site of injury. This inflammatory hyperalgesia serves a protective 
function, to limit further damage, and is part of the healing process of tissue
• 146:147repair ’ .
Neurogenic Inflammation
In addition to peripheral PMN stimulation causing the central release of excitatory 
neurotransmitters via the generation of an action potential, an accompanying 
peripheral release at the site of tissue damage (linked to increase [Ca2+]i) has been 
reported for glutamic acid148, substance P and CGRP149151. This local release of 
excitatory neurotransmitters is a key component of the inflammatory response to 
tissue damage. The co-release of substance P and CGRP in particular has a co­
operative inflammatory effect. Substance P and particularly CGRP are potent 
vasodilators, increasing blood flow in the site of tissue damage. Substance P also 
causes plasma extravasation, conceivably enhanced by the simultaneous increase in 
blood flow caused by the vasodilation149’150’152'160.
Vasodilatation and plasma extravasation caused by neuropeptide stimulation is 
termed neurogenic inflammation.
Peripheral Sensitisation
In addition to the neurotransmitters already mentioned, a vast array of other 
chemicals are released into the ECF in response to tissue damage, forming an 
‘inflammatory soup’ of endogenous chemical mediators146;161 that serve to sensitise 
the nociceptors and enhance the pain response. As well as their role in neurogenic 
inflammation, substance P and CGRP have also been linked to other aspects of 
inflammatory hyperalgesia146’161’162. Mast cells are stimulated by substance P to 
release histamine and serotonin. Substance P and CGRP attract other inflammatory 
cells (monocytes, neutrophils, basophils) to the site of injury, where they are 
stimulated to release a plethora of peptides and lipids with roles as mediators of 
inflammation146,161’163’164. The peptidic mediators are collectively known as the 
cytokines, and include the interleukins (IL), the interferons (IFN) and tumour
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necrosis factor (TNF). The many lipid mediators of inflammation are predominantly 
the products of the oxidative metabolism of arachidonic acid, itself the product of the 
phospholipase A2 catalysed cleavage of membrane phospholipids, and are 
collectively known as the eicosanoids. There are two main classes of oxidative 
enzymes (oxygenases):
• the cyclooxygenases, which give rise to the prostanoids (particularly 
prostaglandins E2 (PGE2) and I2 (PGI2)); and
• the lipoxygenases, which produce the hydroperoxyeicosatetraenoic acids 
(HPETE), the hydroxyeicosatetraenoic acids (HETE), the hepoxilins, the 
lipoxins and the leukotrienes.
In addition, damaged cells release their intracellular contents, including 
inflammatory mediators that have an identified role in pain and hyperalgesia, 
including protons165’166, potassium ions and adenosine triphosphate (ATP). 
Bradykinin (BK), a potent pain-producing and pro-inflammatory substance, is 
produced by the cleavage of high molecular weight kininogens by proteases at the 
site of tissue injury167.
Many of these inflammatory mediators act to either excite or sensitise nociceptors, 
either by direct interaction (opening ion channels to boost the nociceptive signal), or 
by acting via GPCR-mediated second messenger systems to release other mediators 
which act directly upon the nociceptors161;163;168. They are also responsible for 
recruiting the ‘silent’ nociceptors52;169;170, neurones which, under normal 
circumstances, do not respond to noxious stimuli, but under inflammatory conditions, 
respond to chemical mediators such as BK169, thereby magnifying the nociceptive 
signal.
This is peripheral sensitisation, the activation of the local somatosensory afferents, 
including the nociceptive pathways, in such a way as to generate an abnormal 
response to both noxious and non-noxious stimuli.
TRPV1 in Inflammatory Pain
As already described (see Early Vanilloid Pharmacology), accompanying the
‘unbearable sensation of warmth’ of the topical application of capsaicin was
00‘reddened inflammation, without blistering’ , and when an alcoholic solution of the 
crude isolate capsicol was dropped on the skin, the pain was accompanied by an 
excess of blood at the site25. These early experiments clearly demonstrated a
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capsaicin-induced neurogenic inflammation. In the classical afferent nociceptive 
action of capsaicin already described, the capsaicin-induced increase in [Ca2+]i in the 
peripheral termini of the PMN triggers an action potential, ultimately causing a 
central release of the excitatory neurotransmitters substance P, CGRP and glutamic 
acid in the CNS. The rise in [Ca2+]i also causes the local release of the same 
neurotransmitters from the peripheral termini of the PMNs171. Implicit in these 
actions of capsaicin is a major role in inflammatory pain for TRPV1, both as the 
initiator of neurogenic inflammation, and a key target for peripheral sensitisation, 
and this has been demonstrated in vivo for inflammatory hyperalgesia, where 
TRPVl 7 knockout mice demonstrate a severely impaired response to in vivo models
1 7 0 * 1  7 1of thermal inflammatory hyperalgesia ’ .
Many of the inflammatory mediators already described have been demonstrated to 
have an effect upon the activation of TRPV1, either by direct excitation or indirectly, 
by sensitisation, lowering the threshold of TRPV1 to direct activation.
Protons
Extracellular acidosis is a feature of inflamed tissues, with damaged cells releasing 
protons into the ECF, thereby reducing the extracellular pH to below the normal 
physiological level. Prior to the cloning of TRPV1, protons were identified as 
activating capsaicin-sensitive DRG neurones isolated from the rat174;175, and the 
human176. Protons and capsaicin have also been demonstrated to share a common 
mechanism of neuronal activation177. The sensitivity of the capsaicin receptor to 
activation by protons was used in the original characterisation of the TRPV1 ion 
channel73, where, in addition to activation by capsaicin, TRPV1 was shown to be 
activated in the absence of capsaicin by a reduction in extracellular pH, from 7.6 to 
5.5.
Low pH has also been shown to facilitate responses to capsaicin in isolated rat DRG 
neurones73,178'180. In addition to the direct stimulation of PMNs, it has been 
demonstrated that decreasing pH, from 7.3 to 6.3, enhanced the capsaicin-induced 
current in rat DRG neurones by 7-fold178. A reduction in pH, from 7.6 to 6.3, 
potentiates the response to a submaximal dose of capsaicin73; these results suggest 
that protons have an allosteric effect, lowering the threshold of activation of the 
channel, presumably by protonation of the ion channel. An extracellular Glu residue 
within the putative TRPV1 pore region has been demonstrated to be key to these pH- 
mediated effects181.
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Lipid mediators
Several of the lipid mediators of inflammation derived from the lipoxygenase- 
mediated metabolism of arachidonic acid (see Figure 9) have been demonstrated to 
be weak agonists at TRPV1182. The potency and efficacy of these compounds are 
such that each is unlikely to activate TRPV1 in isolation, but might act 
synergistically to enhance activation of the ion channel.
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Figure 9: Arachidonic acid and the lipoxygenase-mediated metabolites with TRPV1 agonist 
activity182.
Other endogenous arachidonic acid derivatives have also been demonstrated to have 
agonist activity at TRPV1 (see Figure 10). The endogenous cannabinoid receptor
agonists AT-arachidonoylethanolamide (anandamide) 183 and AT-arachidonoyl-
dopamine184 are also full agonists
1 100vasodilatory/vasorelaxant activity ' .
at TRPV1 185-187 with potent
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Anandamide
OH
OH
NAOA
Figure 10: Other derivatives of arachidonic acid with full agonist activity at TRPV1: 
jV-arachidonoylethanolamine (Anandamide) and A-arachidonoyldopamine (NAD A)
Bradykinin, Serotonin and PGE2
Other inflammatory mediators, such as BK, PGE2 and serotonin (5-HT) have been
shown to act in concert to facilitate activation of the TRPV1 ion channel at acidic
pjji9i;i92 5_jjt may act independently of the TRPV1 channel, via its own 5 -HT3 ion
channel193. BK does not act directly upon TRPV1, but binds to its own bradykinin B2
receptor. This receptor is a GPCR, and BK’s sensitisation of the TRPV1 ion channel
is achieved via second messenger signalling within the neurone194’195. PGE2 has also
been identified as acting upon TRPV1 via a GPCR-mediated second messenger 
1signalling cascade .
TRPV1 and Noxious Heat
As already described, the PMNs respond to noxious mechanical, thermal and 
chemical stimuli. Further studies have demonstrated the sensitivity of a sub­
population of freshly dissociated196 and cultured197 rat DRG neurones to both 
noxious heat and capsaicin, with the activation by noxious heat being significantly 
reduced in the presence of the competitive antagonist of capsaicin-mediated PMN 
stimulation, capsazepine198.
Not surprisingly therefore, in addition to the ligand-induced activation already 
described, TRPV1 is also sensitive to noxious heat, being activated by an increase in 
temperature into the noxious range (>43°C)73. TRPV1 is therefore capable of 
transducing both noxious chemical and noxious thermal stimuli (two of the three 
categories of stimulation that activate PMNs). Consequentially, TRPV1 has been
described as a molecular integrator of chemical and physical stimuli that elicit
• 180 pain .
Some of the chemical activators of TRPV1 have been demonstrated to effect the 
activation of the ion channel by temperature. Capsaicin has been demonstrated to 
enhance the heat response in rat DRG neurones196. Acidosis can lower the threshold 
of TRPV1 to temperatures as low as 35°C180, potentially resulting in the TRPV1 ion 
channel being continually opened in inflamed tissue.
Pain in the CNS -  Centra! Sensitisation
What happens after the nociceptive signal has been passed on to the neurones of the 
CNS? The perception of pain is a highly variable, complex and subtle process, with 
the same level of nociceptor activity producing quite different individual pain states. 
This process has been attributed to neuronal plasticity, the ability of neurones to 
change their function down to the metabolic level in response to external influence. 
Excitatory examples include wind up and secondary hyperalgesia.
Secondary Hyperalgesia
The peripheral sensitisation described so far does not explain the full extent of 
changes occurring in inflammatory pain. The phenomenon of hyperalgesia has two 
components. There is primary hyperalgesia, where increased responsiveness to heat 
and mechanical stimuli occurs at the site of injury. This is adequately explained by 
peripheral sensitisation. There is also the mechanical allodynia displayed by 
surrounding uninjured tissue, termed secondary hyperalgesia, which peripheral 
sensitisation does not explain6’199’200. This secondary hyperalgesia has been attributed 
to changes within the CNS, that result in the input from A/3 primary afferent fibres 
responding to normally innocuous stimuli being interpreted as nociceptive201’203. This 
central sensitisation is probably mediated by excitatory amino acids acting at the 
NMDA receptor204.
Capsaicin has been used to explore this phenomenon; intradermal injections of 
capsaicin produces an intense, but transient, pain, followed by heightened sensitivity 
outside the region of the capsaicin injection to pinprick (secondary hyperalgesia) and 
brush (secondary allodynia)205;206.
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Wind-up
Wind up was first described in the mid-1960s as a frequency-dependent facilitation
00*7of spinal cord neuronal responses mediated by afferent C-fibres , but not A/3- 
fibres208. The repeated stimulation of a C-fibre, at an identical intensity, induces a 
sudden marked increase in the response from the second-order neurones, which 
persists beyond the cessation of the initial C-fibre stimulus. The most widely 
accepted hypothesis for wind-up209 relies upon the neurotransmitter glutamic acid, its 
function as a substrate for both the a-amino-3-hydroxy-5-methyl-4- 
isoxazoleproprionate (AMPA) and N-methyl-D-aspartate (NMDA) receptors, and the 
connectivity of the second-order neurones that bear them.
While the AMPA receptor ion channels are free to open in response to the presence 
of glutamic acid, the NMDA receptor ion channels are not. Under normal
o i nphysiological conditions, the ion channel is blocked by magnesium ions . This 
blockade is voltage-dependent209. When the Ap-fibres are activated by low- 
threshold, innocuous stimulation, the glutamic acid released acts upon second-order 
neurones of the CNS with AMPA receptors, the stimulation of which is registered as 
‘innocuous’. PMNs contain glutamic acid and substance P108, and release both in 
response to noxious stimulation109;115;116;129;131;2n. Wind up is the result of repeated 
PMN stimulation, with each stimulation causing the release of glutamic acid and 
substance P. With the repeated release of substance P comes a gradual, cumulative 
depolarisation of the plasma membrane in the second-order neurone, mediated via 
the NK1 tachykinin receptor. The voltage-dependent affinity of magnesium ions for 
the NMDA receptor gradually lessens, until the ion channel is no longer blocked. 
Glutamic acid can now open the ion channel, and sodium and calcium ions flood into 
the neurone, resulting in a high firing frequency of action potentials. In addition, the 
originally innocuous Ap-fibre-mediated release of glutamic acid now registers as 
noxious, with the net result that a prolonged painful stimulus can become more 
painful over time.
This phenomenon has been simulated by repeated exposure to noxious heat212. 
Neuropathic Pain
Neuropathic pain is a generic term, defined by the LASP as ‘pain initiated or caused 
by a primary lesion or dysfunction in the nervous system’145. In contrast to 
nociceptive and inflammatory pain, neuropathic pain and suffering are the result of
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ongoing nervous system dysfunction that serves no apparent biological purpose . 
The sensation of pain has been described as alternately burning, aching, throbbing, 
shooting, and stabbing. The sources of potentially painful neuropathies are manifold; 
some examples are:
• direct injury to the nerves, by trauma or avulsion;
• indirect injury to the nerves, by compression or entrapment;
• ischaemia;
• metabolic (e.g. diabetes);
• vitamin deficiency (Bi, B6, B12, E);
• infectious pathogens (e.g. herpes zoster, HIV);
• neurodegeneration (e.g. multiple sclerosis);
• stroke.
The mechanisms of these associated neuropathic pain conditions, where established, 
are equally as varied, but all involve damage to the tissues of nervous system. The 
normally long term nature of this category of pain defines it as chronic pain. 
Neuropathic pain is the least understood, and as a result, the least amenable to 
current pharmaceutical intervention. In particular, painful diabetic neuropathy 
(PDN), post-herpetic neuralgia (PHN) and painful HIV-associated neuropathy are all 
considered to be insensitive to current therapies.
Endogenous pain modulation and analgesia
The perception of pain is a highly variable, complex and subtle process. The same 
level of nociceptor activity is capable of producing quite different individual pain 
states. In addition to the enhanced and exaggerated pain states already described, the 
reverse is also seen, with the nervous system able to moderate the sensation of pain 
and, in extreme cases, disregard it altogether. There must be considerable modulation 
and regulation of the nociceptive information both prior to and post its ascension of 
the spinothalamic tract.
The most successful hypothesis for this regulation came with the gate-control theory 
of pain, proposed in 1965 by Ronald Melzack and Patrick D. Wall1’214; its success 
lies in its emphasis of the mechanisms of the CNS that control the perception of a 
noxious stimulus. While subsequent research has filled in many of the gaps and 
modified the details, it has yet to be seriously contradicted.
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Pain modulation -  the Gate-Control Theory of Pain1;214
In summary, nociceptive information is relayed from the periphery to the spinal cord 
by the small diameter A<5- and C-fibre nociceptors, which transmit this information, 
via chemical synapse, to the second-order neurones of the CNS. The nociceptive 
information is transmitted onward to the higher centres of the brain, for interpretation 
and response, but not without first being ‘tweaked’ by other parts of the nervous 
system. In the gate-control theory of pain, Melzack and Wall hypothesised that, in 
addition to the primary nociceptors, and the second-order neurones, there are 
intemeurones, which serve as a focus for modulation of the nociceptive message 
within the CNS (see figure 11). The intemeurones have synapses with the second- 
order neurone and, when stimulated, inhibit the stimulation of the second order 
neurone by the nociceptors. The nociceptors also synapse to the intemeurone, and 
can in turn inhibit the stimulation of the intemeurone, and thereby inhibit the 
inhibition of the second-order neurone by the intemeurone.
The stimulation of the inhibitory intemeurones comes from two sources:
• afferent regulation. The simultaneous stimulation of nociceptive fibres and 
the low-threshold A/3-fibre mechanoreceptors of the peripheral nervous 
system can reduce the pain that would be evoked by the sole stimulation of 
nociceptors (for a practical example, consider the relief associated with 
rubbing a pinch). The A/3-fibres conceivably synapse to the intemeurone, and 
stimulation of the A/3-fibres causes excitation of the intemeurone, with 
subsequent inhibition of the second-order neurone.
• descending regulation. Electrical stimulation of areas of the midbrain can 
lead to the successful suppression of nociceptive signalling and behavioural 
analgesia in a variety of mammalian species215'218. This analgesia is the result 
of the stimulation of neuronal filaments found to extend from the midbrain to 
the areas of the dorsal horn associated with nociception, and the secretion of 
serotonin (5-hydroxytryptamine, or 5-HT)219'222, and noradrenaline219’220, 
from these descending neuronal filaments. The secretion of these 
neurotransmitters causes neurones within the dorsal horn to secrete further 
inhibitory neurotransmitters, with the subsequent inhibition of the responses 
within the dorsal horn to noxious stimuli.
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Serotonin has quite a broad range of effects within the CNS, probably due to the 
many different receptor subtypes distributed throughout the CNS ’
r
Brain
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Figure 11: A schematic representation of Melzack and Wall’s gate-control theory of pain (D = dorsal 
root ganglion; I = intemeurone; S = second-order neurone).
Inhibitory Neurotransmitters
Many neurotransmitters have been found to have an inhibitory effect upon 
nociceptive transmission (for reviews, see Fiirst (1999)225 and Millan (2002)226). The 
receptors for these neurotransmitters are widely distributed throughout the CNS, but 
are concentrated in regions associated with pain perception . The receptors are 
found both presynaptically, where they inhibit the release of excitatory 
neurotransmitters, and post-synaptically, where they inhibit the generation of action 
potentials in the second-order neurone.
The more common inhibitory neurotransmitters found in nociception include:
1. the inhibitory amino acids gamma-aminobutyric acid (GABA) and glycine228. 
GABA is the main inhibitory transmitter in the CNS229; GABA secreting 
neurones have been found throughout the dorsal horn of rats230 and 
monkeys231;232. Two receptor subtypes that bind GABA have been described 
in the rat dorsal horn. The GABAa receptor is a transmitter-gated ion 
channel, comprised of four different subunits that combine to form a chloride 
permeable ion channel; the GABAb receptor is a GPCR.233'235. Glycine acts 
via a post-synaptic transmitter-gated chloride ion-permeable channel (the
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glycine receptor, GlyR)227’236. It has been found to be co-localised with 
GABA in primary afferents237;238; GlyR and the GABAa receptor have also 
been found co-localised in the rat spinal cord239, implying some form of co­
operative inhibition.
2. the endogenous opioids. Four opioid receptors and their endogenous ligands 
have been identified. The p opioid receptor is activated by /3-endorphin, the 
8  opioid receptor responds to enkephalins, the k opioid receptor binds 
dynorphins, and the most recently recognised member of the group, the 
opioid orphan receptor (ORL-1) binds nociceptin (also known as 
orphaninFQ)240"246. Opioid receptors are predominantly present on the 
presynaptic terminals; their activation either causes potassium channels to 
open (p, 6 , and ORL-1) or calcium channels to close (k);
3. adenosine. Adenosine has both inhibitory and facilitatory effects upon the 
transmission of nociceptive stimuli247. Of the four recognised neuronal 
adenosine receptors (Ai, A2A, A2B and A3)248’249, the adenosine Ai receptor 
has been localised to the dorsal hom250;251, and identified as mediating the 
antinociceptive effects252’253;
4. somatostatin. Somatostatin is released by primary afferent neurones in the 
dorsal horn in response to noxious thermal stimulation254’255; the somatostatin 
receptors (SSTR1-5) are GPCRs coupled to inhibitory cellular signalling 
systems. The conclusion is that this sub-population of C-fibres containing 
somatostatin have an inhibitory effect upon thermal nociception;
5. acetylcholine (ACh)227. Both nicotinic acetylcholine receptors (nAChR) 256;257 
and muscarinic acetylcholine receptors (mAChR) have been shown to have 
antinociceptive involvement.
As with the excitatory neurotransmitters, neurones are frequently found to contain 
more than one inhibitory neurotransmitter, leading to the supposition that the 
modulation of nociception is the result of several neurotransmitters working in 
concert to achieve the desired effect.
The antinociceptive effect of the activation of inhibitory receptors is produced by the 
hyperpolarisation of the neuronal membrane, i.e. the value of Vm is lowered, to 
below -65mV, either by opening chloride permeable channels, thus allowing 
chloride to enter the neurone, closing calcium channels, thereby preventing calcium
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ions from entering the cell, or opening potassium channels, thus allowing potassium 
ions to leave the neurone.
Contemporary Pharmaceutical Analgesia
So far, this brief description of the best understood mechanisms of the nervous 
system and their involvement in the complexity of the sensation of pain has 
described some of the myriad of transmitters and receptors that have been shown to 
have a role in the sensation of pain. This section should have served to introduce the 
sensation of pain as an incredibly complex area of study, which continues to expand. 
There are many potential ‘points of intervention’ that might offer opportunities for 
the design of new analgesics. Despite this, current drug therapies are largely reliant 
upon the development of therapies that have been in place for thousands of years, 
namely the non-steroidal anti-inflammatory drugs (NSAIDs) and the opioids.
The NSAIDs
The use of proto-NSAIDs has its origins in the writings of the Assyrians and ancient 
Egyptians, with evidence of the use of infusions of myrtle and willow leaves for joint 
pain259, and Hippocrates is frequently cited as recommending the use of the leaves of 
willow trees and the juice of poplar trees for eye diseases and in childbirth259'261.
Figure 12: Some examples of the chemically diverse non-steroidal anti-inflammatory drugs.
The analgesic activity of this broad class of chemical structures (see Figure 12), 
stems primarily from their disruption of the biosynthesis of the prostanoids, via the 
inhibition of the enzyme cyclooxygenase (COX)260;262. As described in the section on
A
(Aspirin) Indomethacin
Ibuprofen Cl Diclofenac
62
Peripheral Sensitisation, there are two principle pathways of arachidonic acid 
metabolism by which lipid mediators of inflammation are biosynthesised. In addition 
to the lipoxygenase based metabolism, and the TRPV1 agonists already described182 
(seeTRPVl in Inflammatory Pain), the cyclooxygenase-mediated metabolism of 
arachidonic acid produces the prostanoids. Many of these (thromboxane (TXA2), 
prostaglandin D2, (PGD2), E2 (PGE2), F2a (PGF2a) and prostacyclin (prostaglandin I2; 
PGI2)) have been identified as present in the inflammatory soup of chemical 
mediators released or produced in the periphery as a result of tissue damage. PGE2 in 
particular is prevalent as the major metabolite of arachidonic acid146.
PGEj
Figure 13: Arachidonic acid, and the principle inflammatory COX metabolite, PGE2.
Unfortunately for the NSAIDs, the prostanoids are found throughout the body, 
fulfilling several biological functions beyond their role in inflammatory pain. COX is 
the first enzyme in the biosynthetic pathway from arachidonic acid, so the inhibition 
of COX has resulted in the classical NSAIDs having a range of well known adverse 
effects263. TXA2 is a thrombotic agent and a vasoconstrictor; PGD2 is an inhibitor of 
platelet aggregation and a vasodilator; PGF2a is a bronchoconstrictor and a mediator 
of myometrial contraction; and PGI2 is an inhibitor of platelet aggregation, a 
vasodilator and a hyperalgesic264. The most abundant inflammatory prostanoid, PGE2 
also has a range of other effects, including the contraction of bronchial and 
gastrointestinal smooth muscle, the stimulation of intestinal fluid secretion, the 
stimulation of gastric mucus secretion, and the inhibition of gastric acid secretion. In 
addition to the inhibition of inflammation and pain, some normal tissue function can 
also be compromised, leading to the recognized side effects of gastrointestinal 
bleeding and ulcers, renal impairment, and platelet function abnormalities263.
More recently, the search for new, side-effect free NSAIDs received a boost with the 
discovery that COX has two isoforms (COX-1 and COX-2)265'268. COX-2 was 
reported to be an inducible isoform of COX expressed by macrophages and other
o
Arachidonic acid OH
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9AQ ')7')cells at sites of inflammation ' , with little expression elsewhere. The assumption 
that selectivity for COX-2 will only inhibit prostanoid synthesis at the site of 
inflammation, thereby minimising the inhibition of prostanoid activity outside the 
site of inflammation and significantly reducing adverse side effects , has led to the 
search for COX-2 selective NSAIDs. Although there are differences in the binding 
pocket when compared with COX-1274'276, the classical NSAIDs have been shown to 
be fairly non-specific between COX-1 and COX-2. Subsequent drug discovery 
programs have given rise to a new generation of COX-2 selective NSAIDs, such as 
celecoxib277 (Celebrex®, Searle), rofecoxib278 (Vioxx®, Merck) and lumiracoxib279 
(Prexige®, Novartis) (see Figure 14), with much improved side effect profiles 
reported . The sudden withdrawal of Vioxx® (as of September 2004), citing 
increased risk of stroke and heart attack in long term users, has put a significant dent 
in the confidence of the market in this drug class281'283.
rofecoxibcelecoxib
OH
lumiracoxib
Figure 14: Some COX-2 inhibitors.
One very popular analgesic frequently included within the NSAIDs is the antipyretic 
analgesic acetaminophen (paracetamol; see Figure 15), although there is still some 
debate over its mechanism of action. Despite some in vivo inhibition of PG synthesis 
being reported, the analgesic mechanism of action of acetaminophen is unclear284, as 
acetaminophen does not exhibit anti-inflammatory or anticoagulant activity. While it 
does exhibit weak inhibition of COX-1 and COX-2 in vitro2*5, there is also literature 
evidence for the presence of inducible, acetaminophen-sensitive variants of both 
COX-1 (called COX-3286) and COX-2287.
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Paracetamol
Figure 15: The structure of paracetamol.
The Opioids
Awareness of the opioids can be traced back to the Babylonians, the ancient 
Egyptians, even to the Sumerian culture of 3000 B.C.288. The earliest documented 
medical use for opium comes from the Ebers papyrus (1550 B.C.), where it is 
recommended for calming crying children1! Opium itself is obtained from the opium 
poppy Papaver somniferum, and three active components have been isolated: 
morphine, codeine and thebaine (see Figure 16).
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Figure 16: Structures of the opioid analgesics isolated from opium.
As already described, there have so far been four opioid receptors identified: the p-, 
8 - and K-opioid receptors, and ORL-l241 244;246. While all have been reported as 
having a role in the inhibition of nociception, experiments with p-opioid receptor 
knockout mice have shown that morphine and its analogues mediate their analgesic 
effect via the p-opioid receptor289. However, as with the NSAIDs, a diverse range of 
adverse side effects are found with opioid usage, as the opioid receptors occur 
throughout the CNS, serving to modulate synaptic transmission in a variety of 
neuronal pathways other than nociception. Side effects include euphoria, sedation, 
respiratory depression and constipation, with the additional complications of 
addiction and tolerance. Numerous attempts have been made to isolate receptor 
subtypes, and synthesise analogues to separate the analgesic effects from the adverse 
effects, with little success.
Analgesic Adjuvants
Neither of the two classical classes of analgesic are particularly effective against 
neuropathic pain. However, several other diverse medicines are in widespread use as 
analgesics. This group of largely unrelated compounds are drugs with a primary 
therapeutic indication other than analgesia, that have been found to be effective 
against neuropathic pain conditions, particularly PDN and PHN290"293. Since 
analgesia is a secondary indication for these drugs, side effects can be anticipated. 
These analgesic adjuvants (see Figure 17) include selected tricyclic antidepressants 
such as amitryptiline and desipramine294'298 and antiepileptic/anticonvulsant
*}Q Q  -1/VV
medicines, including carbamazepine and gabapentin . Pfizer’s follow up to 
gabapentin, pregabalin301, is in phase III trials in fibromyalgia, a condition typified 
by non-specific pain in the soft fibrous tissues of the body, the muscles, ligaments, 
and tendons.
Tricyclic antidepressants:
Amitriptyline Desipramine
Antiepileptics/anticonvulsants:
N^H,
NH2
-c o 2h
Carbamazepine Gabapentin
Figure 17: Some examples of analgesic adjuvants.
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Capsaicin, TRPV1 and Agonist Analgesia
Current drug therapies are largely reliant upon the developments of therapies that 
have been in place for thousands of years, despite the myriad of transmitters and 
receptors that have been shown to have a potential role in the sensation of pain. This 
is not for lack of effort, with both industry and academia exploring the many 
potential ‘points of intervention’ that offer opportunities for pharmaceutical-based 
analgesia. Of the modulatory neurotransmitters and inflammatory mediators already
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described, most have been the target for exploration toward analgesic exploitation at 
some time, and the more successful approaches have been reviewed extensively 
elsewhere290;29U29W02;303.
Of particular relevance to this thesis is the TRPV1 ion channel, and its role in 
nociception. Over the last forty years, the effects of capsaicin have been used 
extensively to investigate aspects of acute and chronic pain sensation. TRPV1 
appears to occupy a significant role in peripheral nociception and neurogenic 
inflammation. Exposure to capsaicin is painful, it’s activation of the TRPV1 ion 
channel provokes nociception, peripheral sensitisation via neurogenic inflammation, 
central sensitisation and wind-up. The development of TRPVl"' knockout mice has 
confirmed that the ion channel is essential for the development of some pathological 
pain conditions172;173. As has already been touched upon (see Early Vanilloid 
Pharmacology), the seed for the eventual appreciation of the importance of the 
TRPVl ion channel was sown in the mid-nineteenth century, with the works of 
Hogyes26;27;304 and Thresh21'24, since when capsaicin and its actions, both in 
nociception and as an instigator of neurogenic inflammation, have continued to 
intrigue.
Structural Elucidation of Capsaicin
After the successful isolation of capsaicin by Thresh21*24, initial attempts at deducing 
the composition by elemental analysis failed to detect the presence of nitrogen within 
the atomic composition and gave capsaicin the erroneous empirical formula C 9 H 1 4 O 2 .  
Later structural analyses established the presence of nitrogen in the molecule, as well 
as one hydroxyl substituent and one methoxy substituent. Thermal decomposition of 
capsaicin yielded a vanilla-like odour, and it was concluded that capsaicin was a 
derivative of vanillin (4-hydroxy-3-methoxybenzaldehyde). After further elemental 
analysis, capsaicin was given the impossible empirical formula of C18H28NO3305’306, 
which was later corrected to C18H27NO3 by Nelson307.
The isolation of 50g of capsaicin from 501bs of ‘very hot’ cayenne pepper, and 
subsequent chemical degradation, revealed capsaicin as an amide of vanillylamine
• • 1A7and a decenoic acid . In an attempt to ascertain the geometry of the decenoic acid, 
several analogues were synthesised308; unfortunately, their similar potency (by taste!) 
shed no light on the nature of the decenoic acid. The first partial synthesis of 
capsaicin was from synthetic vanillylamine and the decenoyl chloride derived from
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the hydrolysis of capsaicin309; the decenoic acid was eventually correctly identified 
as 8 -methylnon-6 -enoic acid of unspecified geometry310.
The first complete synthesis of capsaicin, of undefined alkene geometry, was 
published by Spath and Darling311, with the final piece of the jigsaw, the nature of 
the geometrical isomerism, being resolved in 1955. The information was published,
o i 9
along with a selective total synthesis of the correct isomer, by Crombie et al. .
SAR Studies of Capsaicin Analogues
To facilitate the consideration of capsaicin analogue SAR, it is useful to adopt a 
modular consideration of the molecule, dividing it into three regions: A, B and C313' 
315 (see Figure 18).
HO
Aromatic Amide Hydrophobic
A-region B-region C-region
Figure 18: A modular consideration of capsaicin substructure313'315
Interest in capsaicin and its inherent pungency led to the publication of several SAR 
studies, where analogues of capsaicin were synthesised and tested to determine the 
structural requirements for pungency. The earliest, while initiated to determine the 
exact geometry of the decenoic acid portion of capsaicin308;316, established the
0 1 7  0 9 7
optimal unbranched chain length for pungency of 9 carbons. Further studies 
proposed the following requirements as optimal for pungency.
For the aromatic A-region:
• the parent vanillyl substitution pattern for the aromatic ring, with any 
substitution of the 4-hydroxyl eliminating pungency (the aromatic ring can be 
replaced by a n-propyl chain, with some loss of pungency);
• the number of methylenes between the aromatic ring and the amide must be 0  
or 1 ;
For the amide B-region/ hydrophobic C-region:
• a free NH is required;
• C9 -  Ci 1 straight chain carboxamides are the most pungent.
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Antinociceptive Action of Capsaicin
Rather than becoming a pharmacological footnote, capsaicin’s potential began to 
blossom from the mid-twentieth century onwards with the serendipitous discovery 
that it also has an antinociceptive effect. Large, repeat doses of topically or 
systemically applied capsaicin proved to be ultimately analgesic in rodents ' . This 
capsaicin-evoked desensitisation of the animals to noxious stimulation was seen as a 
result of chronic exposure to capsaicin over several days, with chronic dosing of 
experimental animals with capsaicin causing the loss of response to noxious thermal 
and chemical stimuli. This was manifested as raised thresholds to stimulation by 
noxious chemicals and nociceptive pressure, long after dosing with capsaicin had 
ceased41. Studies have shown that the repeated in vivo application of capsaicin over a 
period of days by subcutaneous injection depletes the nociceptive neurones of 
substance P328, and has been ascribed to the blockade of ‘axoplasmic transport’329. 
Primary afferent neurones have their cell bodies located in the DRG, with axonal 
processes extending to the periphery and into the dorsal horn. Axons and the axonal 
termini cannot construct the biomolecules necessary for their function. Biosynthesis 
of the cellular macromolecules of neuronal function, such as substance P, occurs in 
the cell body, and the products of biosynthesis are transported from the cell body 
within the axon to the axonal termini. When the axoplasmic transport is interrupted, 
presynaptic stocks of neurotransmitter are not replenished330.
However, in vitro studies of the effects of capsaicin on isolated rat sciatic nerve 
demonstrated rapid desensitisation with repeated application331, and the acute in vivo 
dosing of rats with capsaicin has also been shown to be antinociceptive for a few 
hours ’ . It is this acute desensitisation that is reported to be responsible for 
capsaicin’s analgesic and anti-inflammatory effects334. Some early studies on the 
acute desensitising action of capsaicin indicated the site of action to be at the 
peripheral nerve endings335. Studies on isolated DRG neurones have demonstrated 
this acute desensitisation to be in response to the capsaicin-induced increase in the 
concentration of intracellular calcium ([Ca2+]i), resulting from the influx of calcium 
ions from the extracellular fluid336’337. One effect of the increase in [Ca2+]i is to 
promote the activity of the calcium-dependent cytosolic phophatase 2B (calcineurin). 
Specific inhibition of calcineurin has been shown to inhibit capsaicin-evoked 
desensitisation , implying that the capsaicin-evoked desensitisation of polymodal
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nociceptors to noxious stimuli is, at least in part, a result of the dephosphorylation of 
the capsaicin receptor-gated calcium-selective cation channel by calcineurin. A more 
recent study has confirmed the desensitisation of the capsaicin receptor in cultured 
rat DRG neurones by calcineurin, and reported that the desensitisation can be 
reversed while the [Ca2+]i is still high, by phosphorylation of the capsaicin receptor 
by Ca2+/calmodulin-dependent kinase II (CaMKII)339. Despite the identification, 
cloning and successful expression of a functional capsaicin-sensitive ion channel , 
the precise molecular mechanism for capsaicin-evoked desensitisation still remains 
elusive. TRPVl activation does appear to be under exquisitely fine control via 
mechanisms of [Ca2+]i dependent phosphorylation and dephosphorylation, with 
sequences corresponding to active sites of phosphorylation for protein kinase A 
(PKA)340, protein kinase C (PKC) 341 and Ca2+/calmodulin-dependent kinase II 
(CaMKII) 339 having been identified.
So, capsaicin has a diverse range of effects, mediated via activation of the polymodal 
nociceptors. Depending upon dose, frequency of exposure and age of the animal at 
exposure, capsaicin can be:
• excitatory, (algesic/ algogenic/ nociceptive);
• desensitising (analgesic/ antihyperalgesic/ antinociceptive);
• neurotoxic (neuronal cell death; see Capsaicin and Sensory 
Neurones).
Capsaicin and Agonist Analogues as Analgesics
TRPVl has a central role in peripheral nociception and neurogenic inflammation. It 
has a highly specific distribution, being predominantly associated with the PMNs, 
and is an appropriate target for analgesic intervention, with minimal foreseeable side- 
effects. The phenomenon of the capsaicin-induced desensitisation/antinociception of 
TRPVl has great potential for analgesia, and topical creams containing capsaicin 
have been used in the treatment of PHN and PDN, as well as psoriasis, osteoarthritis 
and rheumatoid arthritis ’ . Unfortunately, repeated applications are usually 
required to achieve analgesia, and the initial excitatory effects of burning pain and 
reddening of the skin inherent in the topical application of capsaicin22’25 are often too 
great, with patients frequently abandoning treatment before analgesia is achieved. 
Some effect has been achieved with co-administration of a local anaesthetic with
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large doses of capsaicin344, however. Although the antinociceptive actions of 
capsaicin has great appeal as a putative analgesic with a novel mode of action, the 
intensely painful response to initial exposure makes capsaicin itself unattractive, 
except in the most extreme cases.
A successful analgesic based upon capsaicin’s mechanism of action would need to 
minimise the acute excitatory effects, while promoting the desensitisation of the 
sensory neurone. In addition, other biological effects, such as apnoea, bradycardia, 
hypotension and hypothermia (see Early Vanilloid Pharmacology) would all have to 
be addressed. Capsaicin’s actions upon the polymodal nociceptors have promoted 
decades of research into understanding the mechanisms behind the two physiological 
actions of the initial acute excitatory and algesic effect, and the subsequent analgesic 
effect of desensitisation to noxious stimuli. The pharmaceutical industry has focussed 
upon attempts to separate these two effects and exploit the beneficial analgesia.
Of the other vanilloids, the ultrapotent capsaicin analogue RTX has provoked some 
pharmaceutical interest. While in vivo measures of acute nociception have revealed 
RTX to have a similar potency to capsaicin17, the potency of RTX with respect to 
other aspects of vanilloid pharmacology, such as hypothermia, neurogenic 
inflammation and desensitisation of PMNs, is several orders of magnitude higher 
than capsaicin17;18;345. Unfortunately, detailed investigations have been hampered by 
the limited availability of RTX, which can only be obtained either via purification 
from natural sources, or via a low-yielding 26 step synthesis346. However, RTX 
pharmacology has demonstrated that the separation of nociception and 
desensitisation is possible.
Several attempts to separate the antinociceptive effects of synthetic capsaicin 
analogues from their nociceptive and other biological actions have been published. 
Of these structure-activity relationship (SAR) studies69;313'315;347"350, while some 
divergence in the structural requirements for pungency and desensitisation was 
achieved, none achieved total separation. One attempt to separate capsaicin’s 
antinociceptive properties from its hypothermic properties , also failed. It was only 
when very specific changes to the 4-substituent of the A-ring were made that a 
significant reduction in pungency was achieved351'354. The A-region 4-hydroxyl 
substituent has been repeatedly demonstrated as pivotal for pungency69; its 
modification was essential to the amelioration of pungency351. Procter & 
Gamble353;354, and the Novartis Institute for Biomedical Research, London (formerly
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the Sandoz Institute of Medical Research) 313'315’352 both discovered analogues with 
reduced pungency, yet with sufficient in vivo analgesic activity to enter development. 
The common feature of both strategies was to replace the 4-hydroxy substituent of 
pungent analogues with a 2-aminoethoxy moiety (see Figure 19); neither of these 
compounds have survived the rigours of subsequent drug development. A Korean 
academic group have followed a similar route, patenting an assortment of N- 
arylalkylphenylacetamides possessing excellent analgesic and anti-inflammatory 
activities, and a greatly reduced level of skin irritation and toxicity355’356. The lead 
compound, DA-5018 (see Figure 19), has been taken into clinical trials by Dong-A 
Pharmaceutical of South Korea.
Novartis (Sandoz) Procter and Gamble
RO
R = H; NE19550; olvanil.
R = CH2CH2NH2; NE21610; nuvanil.
NH2
SDZ 249-482.
Korea Research Institute o f Chemical Technology
NH2.HCI
DA-5018
Figure 19: Capsaicin analogues entering clinical development3525354
Lastly, a second Korean group have focussed upon increasing the potency of 
capsaicin analogues such as SDZ 249-482 and DA 5018 by introducing structural 
features to mimic key potential pharmacophores from the tricyclic diterpene 
C-region of RTX357'361, with some success (see Figure 20). Of the compounds 
shown, A-(3-/er/-butanoyloxy-2-(3,4-dimethylbenzyl)propyl)-A’-(4-hydroxy-3- 
methoxybenzyl) thiourea (1) and N-(3-tert-butmoy\oxy-2-(4-tert- 
butylbenzyl)propyl)-A’-(4-hydroxy-3-methoxybenzyl) thiourea (2) are respectively 
reported as 280- and 480-fold more potent than capsaicin in a [3H]RTX binding 
assay, while A-(3-te/T-butanoyloxy-2-(3,4-dimethylbenzyl)propyl)-A’-(4-(2-
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aminoethoxy)-3-methoxybenzyl) thiourea (3) is described as a ‘potent analgesic’, 
based upon results from the acetic acid-induced writhing test in mice.
HOI
o'o,
HO
Resiniferatoxin
HOHO
3
Figure 20: Potent synthetic capsaicin analogues, derived from modelling of the putative 
pharmacophores of RTX357'361.
The Discovery of Capsazepine - the First Competitive Antagonist of the 
Neuroexcitatory Action of Capsaicin71572
HO,
NH
HO
Figure 21: The competitive capsaicin antagonist, capsazepine (CPZ).
First synthesised in 1988 at the Sandoz Institute for Medical Research (now the 
Novartis Institute for Biomedical Research, London), capsazepine (CPZ, 
see Figure 21) was synthesised as part of the ongoing drug discovery project to 
produce agonist analogues of capsaicin with antinociceptive activity. Prior to the
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successful identification, cloning and expression of the TRPV1 ion channel73, 
various in vitro and in vivo assays had been employed at various times to assess the 
activity of capsaicin analogues, including the evaluation of capsaicin-like pungency 
by taste! With respect to the published SAR studies of capsaicin analogues at the 
Sandoz Institute for Medical Research from the early i9 9 0 s 72;313'315;352, the primary 
screen for analogue activity required the monitoring of the analogue-induced influx 
of radioactive 45Ca2+ ions into cultured, isolated neonatal rat DRG neurones66.
During the project, a short series of capsaicin analogues were synthesised and tested 
in which a conformational constraint was introduced to assess the effect upon 
activity that controlling the orientation of the A- and B-regions of the molecule with 
respect to each other would have. In addition to the conformational tether, there are 
other structural differences between these compounds and capsaicin. Rather than 
using capsaicin as the parent, parallel investigations had produced a synthetically 
more accessible, slightly more potent progenitor. The key structural stepping stones 
on the way from capsaicin to the constrained analogues, complete with their 
activities in the calcium efflux assay, are illustrated in Figure 22.
5: EC,o 0.55 1 0.08pM
O
Capsaicin: ECM 0 .3 1 0.04pM
Figure 22: Key steps in development, from capsaicin to CPZ.
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To summarise, the drug discovery project had produced JV-(2-(4-chlorophenyl)ethyl)- 
Ar’-(4-hydroxy-3-methoxybenzyl) thiourea (4) as the lead compound, with a 6 -fold 
greater agonist potency than capsaicin . It retained the optimal A-nng vamllyl 
substitution pattern313, but had replaced the B-region amide with a thiourea314, and 
the C-region aliphatic chain with the 2-(4-chlorophenyl)ethyl moiety315. Parallel 
investigations had also demonstrated that the replacement of the 4-hydroxy-3- 
methoxy substitution pattern of the vanillyl ring in an analogue with the 3,4-catechol 
produced an analogue of similar potency, as exemplified by comparison of N-(4- 
hydroxy-3-methoxybenzyl)nonanoyl amide (5) and N-(3,4-dihydroxy
' inbenzyl)nonanoyl amide (6 ) . This substitution pattern for the A-ring was adopted
for synthetic expediency in the constrained molecules. To incorporate a degree of 
conformational constraint into the molecules, a tether of 1 to 3 methylenes between 
the benzylic nitrogen and the 6 -position of the vanillyl ring was introduced, to give 
A-(5,6-dihydroxy-l,3-dihydroisoindole-2-thiocarboxy)-2-(4-chlorophenyl)ethyl- 
amine (7), A-(6 ,7-dihydroxy-3,4-dihydro-1 H-isoquinoline-2-thiocarboxy)-2-(4-
chlorophenyl)ethylamine (8 ) and A-(7,8 -dihydroxy-1,3,4,5-tetrahydrobenzo[c]- 
azepine-2-thiocarboxy)-2-(4-chlorophenyl)ethylamine (capsazepine, CPZ). Of the 
conformationally restrained compounds, the isoindoline (7) and the 
tetrahydroisoquinoline (8 ) showed agonist potency of the same order of magnitude as 
capsaicin, whereas the tetrahydrobenzazepine (CPZ) was totally inactive as an 
agonist (see Table 2). However, further testing revealed CPZ to be a moderately 
potent, competitive antagonist of the capsaicin-induced 45Ca2+ influx, with an I C 5 0  of 
0.420 ± 0.046 pM (see Table 2)71.
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Compound 45Ca2+ influx 
EC50 (pM)
Inhibition of 
capsaicin 
(500nM)-induced 
45Ca2+influx 
IC50 (pM)
0
/  n
Capsaicin
0.3 ± 0.04 NT
JOO^-O^
7
0.55 ± 0.08 NT
“ ,  J.....-XXJCO ■
8
0.29 ±0.04 NT
H O ^ ^ —  Cl
Capsazepine, CPZ
> 1 0 0 0.42 ± 046
Table 2: Primary biological data for the conformationally constrained capsaicin analogues 
(NT = not tested)71;72.
The magnitude of this discovery, and its contribution to the field of vanilloid and 
vanilloid receptor research cannot be overestimated. Ruthenium red, an inorganic 
microscopic stain , had been demonstrated to have functional antagonism of
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capsaicin activity as an inhibitor of both capsaicin-evoked stimulation and 
desensitisation of sensory neurones363.3645365 This action had been determined to be 
wow-competitive ’ , and was deemed a result of ruthenium red’s general actions as 
a blocker of calcium ion channels, rather than a specific interaction with the 
capsaicin receptor.
As the first competitive antagonist of capsaicin-evoked activation of polymodal 
nociceptors, CPZ has been used widely as a pharmacological tool to investigate PMN 
functionality, with respect to the actions of capsaicin. Using SciFinder to search the 
CAplus database for references to ‘capsazepine’ produced 400 hits.
As a pharmacological tool, CPZ has proven a little promiscuous in its actions, having 
some activity at other ion channels. These include the blockade of voltage-activated
' l f . n
calcium channels in sensory neurones and of cold and menthol-activated channels 
(probably TRPM8) in rat DRG neurones368, the inhibition of nicotinic acetylcholine 
receptors (nAChR)369 and of human hyperpolarization-activated cyclic nucleotide- 
gated 1 (HCN1) channel , and the activation of the 8-subunit of the human 
amiloride-sensitive epithelial Na+ channel (ENaC)371, albeit at multiple millimolar 
concentrations. Despite this, antagonism by CPZ continues to be a standard by which 
potential ligands for the TRPV1 ion channel are measured and defined.
Conformational Hypothesis for the Activity of Capsazepine
If we refer back to the original paper in the Journal of Medicinal Chemistry that 
described the discovery of CPZ72 and the section entitled The Discovery o f 
Capsazepine - the First Competitive Antagonist o f the Neuroexcitatory Action o f 
Capsaicin, the three constrained analogues 7, 8 and CPZ, while at first glance are 
structurally very similar, have very different activities. To reiterate, 7 and 8 are 
agonists of a similar potency to capsaicin, whereas CPZ is an antagonist. The 
techniques of NMR spectroscopy, X-ray crystallographic analysis, and molecular 
modelling were used to study, compare and contrast the conformational behaviour of 
CPZ with respect to 8 as the agonist exemplar, and a rationale for the difference in 
activity was proposed. By considering the aromatic ring of the A-region and the 
thiourea of the B-region as each being planar, and the angle between these planes as 
a  (see Figure 23), it is possible to envisage the length of the conformational tether as 
determining the value of a  for each of the analogues.
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Figure 23: Definition of the angle a 72
For 8, the heterocyclic ring displays some degree of flexibility, which is reflected in 
the NMR spectra, with no single favoured conformation. Even so, the A/B-region of 
the molecule maintains an extended conformation, with a  held at 180°±30°. The 
heterocyclic ring of CPZ, on the other hand, adopts four discrete and quite rigid 
conformations, with 92% of the conformations populating one of two ‘pseudochair ’ 
forms. These serve to hold the two planes almost orthogonal to one another, with a  
at ~±90°. As a result, it was postulated that, while both compounds possess the 
pharmacophores for activity, CPZ was unable to attain the necessary conformation 
for agonism. The antagonist activity was envisaged as resulting from the different 
disposition of the pharmacophores utilising a different binding mode to the agonist, 
but with some overlap in the binding motifs of the receptor ensuring antagonism. The 
distinctive orientation of the pharmacophores in CPZ might provide a template for 
the design of a second generation of antagonists. The accessible low energy 
conformations from the molecular dynamics simulations performed at the time for 
each of 8 and CPZ are reproduced in Figure 24, by kind permission of the authors.
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Figure 24: Accessible low energy conformations of 8 (top) and CPZ (bottom), as described by 
Walpole et al, with the C-region side chains omitted for clarity72
CPZ as an Analgesic
Consideration of the mechanism of the activation of TRPV1 by capsaicin, with the 
central role TRPV1 appears to have in peripheral nociception and neurogenic 
inflammation, would suggest that antagonists of such activation would be efficient 
analgesics. As such, they would be preferable to the desensitisation of the agonists, 
as an antagonist would not have the acute excitatory effects associated with agonism. 
Rather tragically, early studies on capsazepine concluded that capsaicin antagonists 
would be unlikely to be useful as analgesics, as early experimental pharmacology 
demonstrated that CPZ lacked any antihyperalgesic activity in in vivo models of 
acute and chronic pain in the rat372. It wasn’t until subsequent studies showed CPZ to 
have an antinociceptive effect in inflammatory pain models in the mouse373 374, and 
that CPZ could effect reversal of mechanical hyperalgesia in models of inflammatory 
and neuropathic pain in the guinea pig375 that interest in the potential for TRPV1 
antagonists as analgesics was renewed. This begs the question; why is CPZ analgesia 
species specific?
The most likely answer came as the identification, cloning and expression of various 
orthologues for mammalian TRPV1, particularly the rat73, the human74 75 and the
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guinea pig77, occurred, allowing CPZ’s behaviour in each of these species to be 
explored. CPZ was demonstrated to inhibit the capsaicin-induced activation of them 
all, with higher potency in the human75 (see Table 3). However, TRPV1 is not only 
activated by chemical mediators such as the vanilloids, it is also activated by acidic 
pH (~5.5)73 and noxious heat (>43°C)73. It has been demonstrated that, while CPZ 
successfully blocks the opening of TRPV1 by capsaicin, protons and noxious heat in 
the guinea pig77 and the human75, CPZ does not block the proton-induced activation 
of the rat orthologue of TRPV175 (see Table 4) and is much less effective at 
inhibiting the noxious heat-induced activation of TRPV1 in the rat75 (data not 
shown). This would seem to imply that the inhibition of capsaicin-induced activation 
of TRPV1 alone is not sufficient for analgesia. The determinants of this variance in 
activity between species appears to be the responsibility of only a few amino acid 
residues, as demonstrated by the ability to confer human-like activity on the rat 
orthologue of TRPV1 by point mutation of only three amino acid residues to the 
human orthologue equivalent376. Since the inhibitory action of CPZ in the human 
orthologue more closely resembles that seen in the guinea pig over the rat, might 
CPZ, or close analogues, be analgesic in the human?
IC50 (pM) for CPZ vs. capsaicin-induced activation of orthologues of TRPV1
Rat75 Guinea pig77 Human75
0.478 0.324 0.186
Table 3: IC50 values for CPZ vs. capsaicin-induced activation of TRPV1 orthologues.
IC50 (pM) for CPZ vs. activation of orthologues of TRPV1 by low pH.
Rat75 Guinea pig77 Human75
>10 0.355 0.180
Table 4: IC50 values for the inhibition by CPZ of the activation of orthologues o f TRPV1 by low pH.
Further Vanilloid-derived Analogues with Antagonist Activity at TRPV1
Other vanilloid-derived antagonists of the capsaicin-induced activation of TRPV1 
have been published. After CPZ, the next to be reported as a potential antagonist of 
capsaicin activity was capsazocaine377, and only antagonism of capsaicin-induced
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activity was reported. Described as a ‘molecular fusion product of irritant synthetic
capsaicin and the local anaesthetic benzocaine’, capsazocaine incorporates structural 
features of benzocaine and synthetic capsaicin, a synthetically more amenable, yet 
equipotent, analogue of capsaicin, in which the branched and unsaturated aliphatic C- 
region sidechain of capsaicin has been replaced with an n-octyl chain. The synthesis 
and similar potency of this simplified capsaicin analogue were first reported in 
1925317; and has more recently appeared in other SAR studies315 (see Figure 25).
w v/
Figure 25: Capsazocaine377
Simple iodination appears to convert specific agonists to antagonists (see Figure 26). 
RTX is an ultrapotent vanilloid17, with in excess of 6500-fold greater potency than
antagonist, at least 40-fold more potent CPZ against capsaicin-induced currents in 
Xenopus laevis oocytes expressing the rat orthologue of TRPV1378 and 800-fold 
more potent than CPZ when assayed against capsaicin-induced currents in human 
embryonic kidney cells (HEK) expressing rat TRPV1379. I-RTX also inhibited both 
proton-induced and heat-induced currents in rat TRPV1-HEK cells379, and intrathecal 
administration of I-RTX blocked pain responses induced by the injection of capsaicin 
into the paw of the mouse378. However, the local sub-cutaneous injection of I-RTX 
did not inhibit the capsaicin-induced nociceptive response of the rat, as modelled by 
capsaicin-induced paw flinching379.
o A
Benzocaine Synthetic capsaicin (nonivamide)
O
capsaicin in a given assay378. The 5-iodo analogue (I-RTX) is a highly potent
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Similarly, N-(4-chlorobenzyl)-N'-(4-hydroxy-3-methoxybenzyl)thiourea (9)352 is an
approximately 5-fold more potent TRPV1 agonist than capsaicin, as assessed by 
influx of radioactive 45Ca2+ ions into cultured, isolated neonatal rat DRG neurones66. 
The similar addition of an iodo-substituent to the compound produced N-(4- 
chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl)thiourea (IBTU), a 5-fold 
more potent antagonist than CPZ, as assessed by the inhibition of capsaicin-induced 
uptake of 45Ca2+ ions by Chinese hamster ovary (CHO) cells heterologously 
expressing the rat orthologue of TRPV1380. IBTU was not tested against other 
modalities ofTRPVl activation.
Agonist Antagonist
[>0
HO .OH
RTX
[\0
HO OH
I-RTX
HO
X
H H
Cl
H
ClHO
IBTU
Figure 26: Iodinated vanilloid analogues with antagonism of capsaicin-induced activation ofTRPVl, 
and their agonist progenitors.
In addition to increasing the potency of capsaicin analogues such as SDZ 249-482 
and DA 5018 by introducing structural features to mimic key potential 
pharmacophores from the tricyclic diterpene C-region of RTX (see Capsaicin and 
Agonist Analogues as Analgesics), Lee and co-workers at the Seoul National 
University have also explored several other approaches to synthesising antagonists of 
capsaicin-induced activation of the rat TRPV1 ion channel. Their first approach 
explored the effect of combining their modified 3-acyloxy-2-benzylpropyl C-regions 
with the conformationally constrained A/B-regions of 8 and CPZ381. Intriguingly, 
both the tetrahydrobenzazepine analogue (10) and the tetrahydroisoquinoline
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analogue (11) are antagonists of similar potency to CPZ, while minor structural 
changes to the C-region substitution produced full agonists of submicromolar 
potency. Clearly, the requirements for agonism vs. antagonism are finely balanced in 
this series.
Figure 27: Some vanilloid-derived TRPV1 antagonists of similar potency to CPZ.
The second approach explored the potential in opening the tetrahydrobenzazepine 
ring of CPZ between the benzene ring and the benzylic methylene, then re­
micromolar antagonists, or in the form of steric bulk (e.g. 14) to produce antagonists 
of submicromolar potency, similar to that of CPZ383 (see Figure 27).
A third approach was discovered during investigations into the effect of varying the 
substitutents of the A-region away from the parent vanillylamine upon already potent 
agonists such as 1 and 2, and included the isosteric replacement of the phenolic 
oxygen beyond the 2-aminoethoxy alternative already seen in PKF249-482 and 3 
(see Capsaicin and Agonist Analogues as Analgesics). This approach ultimately 
yielded antagonists with nanomolar activity (see Figure 28), with 15384 clearly
introducing constraint in the form of a pyrrolidine (12 and 13) to produce
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derived from 1 (see Figure 20) and SC0030385"389 clearly derived from Novartis’s 
PKF249-482 (see Figure 19).
i—N
s—N SC0030
Figure 28: Nanomolar antagonists ofTRPVl activation.
Of the vanilloid-derived antagonists 10-15 and SC0030, only SC0030 was reported 
to also inhibit activation by acidic pH and noxious heat in the rat orthologue of 
TRPV1386;387, and to exhibit analgesia in the parabenzoquinone-induced writhing test
• 7 0 0
in mice of similar potency to the COX inhibitor indomethacin . Although the 
antagonist activity of 15 was only reported for capsaicin-induced activation of the rat 
orthologue of TRPV1, it was reported to have dramatically enhanced analgesic 
potency over ketorolac (another COX inhibitor) in the acetic acid-induced writhing
384test in mice .
Non-Vanilloid-derived Antagonists ofTRPVl Activation
With the demonstration that TRPV1 antagonists can be analgesic in rodents came a 
change in the drug discovery approach to analgesics acting via the capsaicin receptor, 
from partial agonist desensitisers to antagonists. Initial research centred around 
antagonists based upon capsaicin and other vanilloids. The subsequent successful 
identification, cloning and expression of assorted mammalian orthologues ofTRPVl, 
particularly the rat and the human ’ , coupled with advances in high throughput 
screening (HTS) technologies and assay development, has allowed companies to 
exploit both their in-house and commercially available compound collections, using 
such technologies to identify structurally novel antagonists of TRPV1 activation. 
Most pharmaceutical companies have or have had projects devoted to developing 
TRPV1 channel blockers as analgesics, and the last few years have seen numerous 
publications to this effect. The ‘building block’ nature of such compound libraries 
has resulted in some recurring structural motifs. In particular, compounds featuring a
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central piperazine with pendant aryl groups plus linkers have been patented or 
published by Purdue Pharma (4-(3-chloropyridin-2-yl)piperazine-l-carboxylic acid 
(4-tert-butyl-phenyl)amide, BCTC, 16)390;391, Neurogen ((R)-4-(3-chloro-pyridin-2- 
yl)-2-methylpiperazine-l-carboxylic acid (4-trifluoromethyl-phenyl)amide, 17)392, 
Euro-Celtique (//-(4-tert-butylphenyl)-Ar’-cyano-4-(3-chloropyridin-2-yl)piperazine-
1-carboxamidine, 18)393, Amgen (2-[4-(3-chloro-pyridin-2-yl)piperazin-l-yl]-6- 
trifluoromethyl-lH-benzoimidazole, 19)394 and Johnson and Johnson (4-(3- 
trifluoromethylpyridin-2-yl)piperazine-1 -carboxylic acid (5-trifluoromethylpyridin-
2-yl)amide, 20)395 (see Figure 29).
Figure 29: Diarylpiperazine antagonists ofTRPVl.
SmithKlineBeecham, now GlaxoSmithKline (GSK), have patented/published on a 
series of N,N’-substituted ureas (see Figure 30), exemplified by compounds 2 1396’397, 
22398 and 23399'401. These compounds are clearly related to the diarylpiperazines 
described above.
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Figure 30: N,N’-substituted ureas antagonists ofTRPVl from GSK.
Quinazoline cores have also appeared as a common structural motif, as exemplified 
by 3-[4-[(4-trifluoromethylphenyl)amino]-7-(3-trifluoromethylpyridin-2-yl)quinazo- 
lin-2-yl]propionic acid (24) from Neurogen402-404, and 6-(4-Chloro-3-cyclopropyl-
Figure 31: Quinazoline-derivedTRPVl antagonists.
Amgen and GSK have both described A-aryl cinnamides (see Figure 32), with 
Amgen publishing a detailed SAR study406’407, featuring (£)-A-quinolin-7-yl-3-(6- 
trifluoromethyl-2-(piperidin-l-yl)pyridin-3-yl)acrylamide (26) and (is)-Ar-quinolin-7- 
yl-3-(6-trifluoromethyl-2-(morpholin-4-yl)pyridin-3-yl)acrylamide (27) as their most 
potent antagonists ofTRPVl activation, and GSK reporting the discovery of {E)-N- 
(3-methoxyphenyl)-3-(4-chlorophenyl)acrylamide (SB-366791)408;409.
methoxyphenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one (25) from Novartis405 
(see Figure 31)
F
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26: X = CH2 | \ p  U
27: X = O F SB-366791 Cl
Figure 32: N-aryl cinnamide-derived TRPV1 antagonists
Finally, Purdue Pharma have improved upon the pharmaceutical and 
pharmacological profile of 16, with the recent disclosure of (R)-4-(6-Chloro-4- 
methylpyridazin-3-yl)-2-methylpiperazine-l -carboxylic acid (6-fluorobenzothiazol- 
2-yl)amide (28)410 (see Figure 33).
28
Figure 33: (/?)-4-(6-Chloro-4-methylpyridazin-3-yl)-1 -(6-fluoro-benzothiazol-2-yl)carbamoyl-2- 
methylpiperazine 28410.
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Further Conformationally Constrained Antagonists
During the drug discovery phase that produced CPZ, several other conformationally 
constrained analogues were also synthesised. In particular, three analogues (29, 30 
and 31) of the tetrahydroisoquinoline derivative 8 were synthesised and tested 
(see Table 5).
Compound Ca -influx assay (pM)
agonist EC50 antagonist IC50
n x A - ^ . 0.29 ± 0.04 NT
CPZ >100 0.420 ±0.046
N N
29
>100 1.07
|| H
30 >100 0.18
hoA A A  31 >100 0.63
Table 5: Biological activities of 1-, 3- and 1,3- substituted analogues of 8.
Interestingly, 29, 30 and 31 were found to be totally inactive as agonists, at 
concentrations up to lOOpM, as determined by the stimulation of uptake of 45Ca2+ 
ions by neonatal rat DRGs, while 8 was already established as an agonist of similar 
potency to capsaicin. Further investigation revealed these compounds to act as 
antagonists of the capsaicin-induced uptake of 45Ca2+ ions by neonatal rat DRGs, 
with potencies of a similar magnitude to CPZ (see Table 5).
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Stereoisomerism
Marked with a * in Table 5, 29, 30 and 31 each possess one or more tetrahedral 
carbon atom(s), to which four different substituents are attached. These chiral 
centres411 allow each analogue to exhibit stereoisomerism, i.e. each has non- 
superimposable isomers of identical constitution, which differ in their conformation 
and/or configuration (the arrangement of their atoms in space)411 (see Figure 34). 
Compounds with one chiral centre, such as 29 and 30, have two possible 
stereoisomers; these are mirror images of each other, and are referred to as 
enantiomers. For compounds with more than one chiral centre such as 31, the 
situation is more complex. While some pairs of stereoisomers are mirror images of 
one another, and hence are still termed enantiomers, others are not mirror images of 
one another; these are referred to as diastereomers.
a a
I
C'"»lc clii"C N^  
b v d /  ^ b
Figure 34: Illustration of the non-superimposability of tetrahedral chiral centres (Cabcd).
To distinguish between these stereoisomers and others throughout this thesis, the 
author has employed the commonly used Cahn-Ingold-Prelog (CIP) system for the 
specification of absolute molecular configuration. This system uses the chiral 
descriptors R and S to denote the absolute configuration at a chiral centre412"414. 
Briefly, to assign the correct descriptor, the four substituents at the chiral centre are 
ranked, or prioritised, from highest to lowest, according to rules based upon the 
material properties (atomic number and mass number) and the structural properties of 
topology and geometry, as described in the cited references412"414.
Once ranked, it is necessary to then consider the chiral centre and its substituents 3- 
dimensionally. The molecule is oriented such that it is possible to look down the 
bond between the central atom and the lowest priority ligand, with the lowest priority 
ligand ‘behind’ the central atom. The remaining three ligands form a triangular array, 
with two possible directions of rotation when moving from highest to lowest priority. 
If the direction is clockwise, the descriptor used is R; if anticlockwise, then S is used 
(see Figure 35).
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Ligand priority, from highest to lowest: a>b>c>d
The direction of rotation from a to c 
is clockwise, therefore the descriptor 
of absolute configuration is R
The direction of rotation from a to c 
is anticlockwise, therefore the descriptor 
of absolute configuration is S
Figure 35: Chiral descriptors of absolute configuration, as defined by the CIP system412-414.
Further points of relevance:
• When there is a mixture of stereoisomers, and both configurations at a chiral
centre are present, both descriptors are used i.e. when both enantiomers of 29 are
present in a mixture, the material would be more accurately labelled as 29RS.
• When more than one chiral centre exists in a molecule, each is identified by
positional numbering (see Figure 36) i.e. the mixture of stereoisomers comprising 
31 is more accurately described by the identifier 31(1RS,3RS).
5 4
Figure 36: Numbering of the isoquinoline ring system 
Aims
For reasons of synthetic expediency, 29, 30 and 31 were originally synthesised 
without regard to stereoisomerism, and were subsequently tested as mixtures of 
stereoisomers (i.e. as 29RS, 30RS and 31(1 RS93RS)). The aim of this research 
project was to develop enantio- and diastereoselective synthetic routes to each 
stereoisomer of 29, 30 and 31 (see Figure 37), to investigate their in vitro biological 
activity at the TRPV1 ion channel, to explore their conformational behaviour, and 
possibly extrapolate these findings to the activity of CPZ.
8 1
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Figure 37: The desired stereoisomers of 29,30 and 31.
31(1/?,3S)
31(1/?,3/?)
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RESULTS AND DISCUSSION
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Chemistry
Synthesis of the Stereoisomeric Mixtures of 29125, 30RS  and 31(1125,3125)
The common final step in the established achiral routes to 29RS, 30125 and 
31(1125,3125) was the formation of the thiourea moiety by the coupling of an 
unresolved tetrahydroisoquinoline precursor (33RS, 34RS or 35(1125,3125)) with the 
the commercially available 2-(4-chlorophenyl)ethyl isothiocyanate 32 
(see Figure 38).
32 33RS :R1 = Me, R2 = H 29RS :R1 = Me, R2 = H ^  J )
34RS  :R1 = H, R2 = Me 30RS :R1 =H, R2 = Me
35(1RS,3/?S):R1 = Me, R2 = Me 31(1RS,3RS):R1 = Me, R2 = Me ICl
Figure 38: The generic final step in the synthesis of analogues of 8.
The synthesis of 29RS  had been simplified by the commercial availability of the 
racemate of 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline 33RS (known 
trivially as (±)-salsolinol), allowing the synthesis of 29RS  to be achieved in one step 
(see Figure 39).
NCS EtjN, THF HO.HO.
NH
HOHO
NH HBr +
33 RS 32 29RS
Figure 39: The synthesis of 29RS.
By comparison, neither 34RS, the 3-methyl analogue tetrahydroisoquinoline 
precursor to 30125, nor 35(1125,3125), the 1,3-dimethyl tetrahydroisoquinoline 
precursor to 31(1125,3125), were commercially available. Each was synthesised from 
the commercially available 3,4-dimethoxyphenylacetone 36 (see Figure 40). 
Reaction of ketone 36 with methoxylamine hydrochloride gave the O-methyl oxime 
37, the reduction of which with borane-tetrahydrofuran complex gave the racemic 
amine 38125. Cleavage of the methyl ethers with refluxing hydrobromic acid gave the 
racemic hydrobromide salt of 2-(3,4-dihydroxyphenyl)-l-methylethylamine 39125,
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and the tetrahydroisoquinolines 34RS  and 35(1RS,3RS) were formed by reaction of 
39RS with either formaldehyde or acetaldehyde, using classical Pictet-Spengler 
tetrahydroisoquinoline synthesis methodology415. The final products 30RS  and 
31(1RS,3RS) were synthesised by coupling these unresolved tetrahydroisoquinolines 
with the isothiocyanate 32 (see Figure 40).
MeONH2.HCI, < ,
NaOAc, MeOH
92% yield
1. BHj.THF,
THF, reflux;
2. NaOH, H20/MeOH
O—  42% yieldr
HO OH
36 37 38 RS
48%HBr(aq)>
reflux
96% yield
NH2HBr
HO.
Formaldehyde/H20 NH HBr THF
Quantitative yield
HO HO
34 RS 30 RS
Z9RS
Acetaldehyde/H20
Quantitative yield
HO HO
NH HBr thf
Figure 40: Syntheses of SOILS' and 31(1RS,3RS), and the tetrahydroisoquinoline precursors 34RS and 
35(lJLS',3iLS).
Retrosynthesis Common to 29,30 and 31
The initial retrosynthetic analysis for each of the target full structures confirmed the 
most appropriate first disconnection to be of the carbon-nitrogen bond between the
2-position tetrahydroisoquinoline nitrogen and the thiocarbonyl carbon of the 
thiourea (see Figure 41; see Figure 36 for numbering of the tetrahydroisoquinoline 
ring). In addition to its commercial availability, the isothiocyanate 32 could be 
readily synthesised from 2-(4-chlorophenyl) ethylamine 40 and thiophosgene 41, and 
a large batch was prepared in this way.
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HO
HO
NCS
+
HO
HO
R1
R2
29RS :R1 ■ Me, R2 * H
30RS :R1 = H, R2 = Me
31(1RS,3RS):R1 ■ Me, R2 = Me
33RS :R1 = Me, R2 = H
34RS :R1 = H, R2 = Me
35(1RS,3/?S):R1 = Me, R2 = Me
V R1
R2Cl 40 41 42RS  :R1 = Me, R2 -  H
43RS :R1 ■ H, R2 -  Me
44(1RS,3RS):R1 = Me, R2 = Me
Figure 41: The initial retrosynthesis of the full structure targets:
Catechols are quite reactive, and can be difficult to store. Their reactivity in 
particular can impose limitations for many potential synthetic manipulations, due to 
putative side reactions. While determining asymmetric syntheses for the each of the 
stereoisomers of the tetrahydroisoquinolines 33, 34 and 35 and their appropriate 
precursors, it was decided to perform the bulk of the synthetic work with the 
catechols protected as the methyl ethers, with deprotection as the penultimate step, 
prior to coupling with the isothiocyanate (see Figure 41).
The investigative synthetic work therefore concentrated upon routes to 
synthesise/resolve the pure (R)- and (5)-enantiomers of tetrahydroisoquinoline 42, 
the pure (R)- and (<S)-enantiomers of tetrahydroisoquinoline 43, the pure (\R,3S)~ and 
(15,3i?)-diastereomers of the cis-isomer of tetrahydroisoquinoline 44, and the pure 
(IR,3R)~ and (lS,3S)-diastereomers of the trans-isomers of tetrahydroisoquinoline 
44, as key intermediates. Through the exploitation and the modification of literature 
precedent, and the development of new methodology, the synthesis of each of these 
key intermediates, and hence each of the eight target full structures, was achieved.
Approaches to the Synthesis of Tetrahydroisoquinolines
There are traditionally three approaches to the synthesis of isoquinolines, each of 
which have proven amenable to enantioselective modification, much of which has 
been reviewed elsewhere416*17. Each approach requires an appropriately substituted 
benzene ring, from which the heterocycle is formed by means of a cyclisation step. 
They are respectively the Pictet-Spengler synthesis415, which gives the 1,2,3,4-
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tetrahydroisoquinoline directly, the Bischler-Napieralski synthesis418, which gives 
the generally isolable 3,4-dihydroisoquinoline, and requires a subsequent reduction 
to the 1,2,3,4-tetrahydroisoquinoline, and the Pomeranz-Fritsch synthesis419"423, 
which gives the fully aromatic isoquinoline, but which, via the Bobbitt 
modification424, gives the 1,2,3,4-tetrahydroisoquinoline via the in situ reduction of a 
generally unstable 1,2-dihydroisoquinoline.
These classical approaches to isoquinoline synthesis were comprehensively reviewed 
in separate chapters in the 1951 edition of Organic Reactions425"427.
Pictet-Spengler Tetrahydroisoquinoline Synthesis415
R
.R  H+ rf' ^NHT
45 46 47
Figure 42: Pictet-Spengler tetrahydroisoquinoline synthesis415.
The classical Pictet-Spengler reaction (see Figure 42) has been comprehensively 
reviewed elsewhere426. The tetrahydroisoquinoline 47 is formed by the condensation 
of a 2-phenylethylamine 45 with an aldehyde 46, and can be considered to be a 
special example of the Mannich reaction (see Figure 43).
\ h  + Y  + + H*°
/  O O |
48 49 50 51
Figure 43: Comparison of the Mannich and Pictet-Spengler reactions.
These reactions are generally carried out in acidic media (e.g. hydrochloric acid, 
acetic acid), and are considered to occur in two steps:
1. the amine (45/48) reacts with the aldehyde (46/49) to form an iminium ion,
2. the iminium ion is then susceptible to attack by a carbon nucleophile to form 
a new carbon-carbon bond.
For the generic Mannich reaction shown, the carbon nucleophile is the ketone 50, 
and the product is a 4-aminobutan-2-one 51; for the Pictet-Spengler reaction, this 
second step occurs intramolecularly, with the new bond formation occurring between 
the iminium carbon and the ring carbon ortho to the ethyl chain, to join carbon-1 and
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carbon-8a of the newly formed tetrahydroisoquinoline 47 (see Figure 36 for the 
numbering of the tetrahydroisoquinoline ring).
The mechanism of the Pictet-Spengler reaction is detailed in Figure 44 and 
Figure 45. In Figure 44, the mechanism of imine formation is described. Both 45 and 
46 exist in equilibrium between their protonated and unprotonated forms. The 
formation of the imine 52 requires the nucleophilic attack of the lone pair of the 
neutral amine nitrogen onto the carbonyl carbon of the protonated aldehyde. The 
carbon-oxygen bond of the aldehyde is polarised, due to the greater electronegativity 
of the oxygen atom; the carbonyl carbon is therefore suited to nucleophilic addition. 
Protonation of the carbonyl oxygen increases the positive character of the carbon 
atom, facilitating nucleophilic attack. The neutrality of the nitrogen is restored by the 
loss of a proton. This is repeated; protonation of the hydroxyl induces the loss of the 
remaining proton from the nitrogen atom, and a transfer of electrons to form the 
imine. The imine itself is readily protonated, and the resulting iminium ion is highly 
reactive to nucleophiles.
In Figure 45 the mechanism of ring closure is described. The cyclisation step with an 
unactivated aromatic ring can be slow and require forcing conditions; it can be 
facilitated by increased electron density at the point of ring closure, and most 
literature examples have an electron-donating substituent, such as an alkoxyl or 
hydroxyl moiety, para to the point of ring closure. Therefore, for exemplification 
purposes, an appropriately placed methoxy group is included in Figure 45. 
Protonation of the nitrogen of imine 53, to form the iminium ion, also facilitates 
nucleophilic attack on the iminium carbon atom. The oxygen donates a lone pair of 
electrons into conjugation with the aromatic ring, increasing the electron density at 
the point of ring closure; nucleophilic attack on the iminium carbon restores the 
neutrality of the nitrogen, with the loss of a proton restoring both the aromaticity of 
the benzene portion of the tetrahydroisoquinoline core and the neutrality of the 
oxygen substituent, to give the neutral product 54.
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Equilibrium between protonated 
and unprotonated amine
H+
K *. « H+ H
Equilibrium between protonated \<H- 6- H* \
> °  ^and unprotonated aldehyde , „
R R
46
Mechanism o f imine formation
OH
H
v . k R
,N  OH
Oh
-H
H
H
Figure 44: The mechanism of imine formation in the Pictet-Spengler tetrahydroisoquinoline synthesis.
R
I k +H+ £?l^H
53
NH -H +
54
Figure 45: The mechanism of ring closure in the Pictet-Spengler tetrahydroisoquinoline synthesis.
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Bischler-Napieralski Tetrahydroisoquinoline Synthesis418
45
cyclodehydration \ \  / /
55
reduction A  / /
R
47
Figure 46: The Bischler-Napieralski tetrahydroisoquinoline synthesis
The classical Bischler-Napieralski reaction (see Figure 46) has been 
comprehensively reviewed elsewhere425. As in the Pictet-Spengler synthesis of
1.2.3.4-tetrahydroisoquinolines, the Bischler-Napieralski synthesis requires a 2- 
phenylethylamine 45 as its starting point. Rather than making an imine and cyclising 
the iminium salt, the amine 45 is acylated to an amide 55, and cyclised in anhydrous 
solvent in the presence of a dehydrating agent, such as phosphorus pentoxide, 
anhydrous zinc chloride or, more commonly, phosphorus oxychloride. As before, 
carbon-carbon bond formation occurs between a ring carbon ortho to the ethyl chain, 
and the activated electrophilic carbon alpha to the nitrogen, to join carbon-1 and 
carbon-8a of the newly formed tetrahydroisoquinoline 47 (see Figure 36 for the 
numbering of the tetrahydroisoquinoline ring). The product of the ring closure is the
3.4-dihydroisoquinoline 56, and a subsequent reduction is required to give the 
desired 1,2,3,4-tetrahydroisoquinoline 47, with sodium borohydride in methanol a 
popular choice.
ci—p—ci
Figure 47: The accepted mechanism of the cyclodehydration step o f the Bischler-Napieralski synthesis 
of 3,4-dihydroisoquinolines 56.
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The probable mechanism of the cyclodehydration step is represented in Figure 47. 
The amide can be considered as having two tautomeric forms, the amide 55 and the 
imidic acid 57. The oxygen of the imidate 57 performs a nucleophilic attack upon the 
phosphorus atom, with the formation of a new phosphorus-oxygen bond at the 
expense of cleavage of a phosphorus-chorine bond as the driving force. The 
dichlorophosphinyl group formed is an excellent leaving group; the imide carbon is 
susceptible to nucleophilic attack. The liberated chloride ion returns to attack this 
carbon, and release the dichlorophosphinic acid. The imidoyl chloride 58 is the 
accepted reactive precursor for the ring closure step of the Bischler-Napieralski
t
isoquinoline synthesis . The electron rich carbon in the ortho-position of the 
benzene ring attacks the carbon of the imidoyl chloride 58, and displaces the chloride 
ion, to form a new six-membered heterocyclic ring. The loss of the proton from the 
ortho carbon restores aromaticity to the benzene ring portion of the molecule.
Pomeranz-Fritsch Tetrahydroisoquinoline Synthesis419"423
59 60 61 62
Figure 48: The Pomeranz-Fritsch isoquinoline synthesis.
The classical Pomeranz-Fritsch isoquinoline synthesis (see Figure 48) has been 
comprehensively reviewed elsewhere427. In contrast to the two approaches already 
discussed, this synthesis does not involve the use of 2-phenylethylamine 45 as the 
starting point; rather, the carbon-carbon bond formation occurs between carbon-4 
and carbon-4a of the newly formed isoquinoline ring. The original synthesis required 
the condensation of a benzaldehyde 59 and an aminoacetal 60, to give an imine 61, 
the sulphuric acid-catalysed cyclisation of which gave the fully aromatic isoquinoline 
62 (see Figure 48). In the Schlittler-Muller modification429, an alternative imine 65 
can be obtained from the condensation of a benzylamine 63 and 
dimethoxyacetaldehyde 64, and cyclised under identical conditions, to give the same 
fully aromatic isoquinoline 62 (see Figure 49).
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-h2o f.H2S 0 4
63 64 65 62
Figure 49: The Schlittler-Muller modification o f the Pomeranz-Fritsch isoquinoline synthesis.
To obtain the 1,2,3,4-tetrahydroisoquinoline 47 requires the utilisation of the Bobbitt 
modification424’430 of these isoquinoline syntheses, in which the imines 61/65 are 
reduced to the secondary amine 66 prior to cyclisation. The resulting 1,2- 
dihydroisoquinolines 67 are inherently unstable, with disproportionation to a mixture 
of the fully aromatic isoquinoline 62 and the tetrahydroisoquinoline 47 frequently 
seen. This is resolved by utilisation of an in situ reduction of the 1,2- 
dihydroisoquinoline 67 with hydrogen over palladium on carbon, to give the 1,2,3,4- 
tetrahydroisoquinoline 47 (see Figure 50).
H2i P t02l EtOH
H2> PtO,, EtOH
Figure 50: The Bobbitt modification of the Pomeranz-Fritsch/Schlittler-Muller isoquinoline syntheses, 
to obtain 1,2,3,4-tetrahydroisoquinolines, such as 47.
Stereogenic Synthesis
The synthetic approaches to each of the requisite stereoisomers of the 
tetrahydroisoquinoline cores requires at least one stereogenic step. There are three 
general approaches to obtaining pure stereoisomers.
• Utilise an appropriate isomerically pure stereogenic starting material from the 
‘chiral pool’, such as an amino acid.
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• Introduce the new stereogenic centre into your target compound non- 
selectively, to form a mixture, then separate the stereoisomers. When forming 
a new stereogenic centre in a molecule that already contains one or more 
stereogenic centres, this separation may occur readily, as the diastereomers 
produced will have different physical properties and can normally be 
separated based upon these properties. For a racemic mixture of enantiomers, 
the standard approach is to use a resolving agent, i.e. one enantiomer of a 
chiral compound that can be combined with the racemate, to form a mixture 
of diastereomers. Once separation of the diastereomers is achieved, the 
resolving agent can be removed to leave the resolved enantiomers. Two 
examples of this approach were used in the course of this research.
• Form the new stereogenic centre stereoselectively. This may involve the use 
of a chiral catalyst to bias the formation of the new stereogenic centre to the 
required asymmetry. More usually for enantiomers, a chiral auxiliary or 
adjuvant is used. This is temporarily covalently bound to the achiral starting 
material and used to guide the formation of the new stereogenic centre of the 
target compound, ideally to the exclusion of the undesired stereoisomer. The 
auxiliary is then removed to leave the desired enantiomer with a high degree 
of enantiopurity. For diastereomers, the same approach may be taken, or a 
more ‘atom efficient’ and elegant approach will utilise the existing 
stereogenic centre(s) within the starting material to guide the stereogenicity 
of the new centre. Two examples of this approach were used in the course of 
this research.
Naturally Occurring Tetrahydroisoquinolines
The 1-substituted- and 1,3-disubstituted-1,2,3,4-tetrahydroisoquinoline cores occur 
widely within the realm of the plant alkaloids431-433. It has also been proposed that 
tetrahydroisoquinolines may form in trace amounts in mammalian tissues, via Pictet- 
Spengler-like cyclisation415 of the products of the direct, non-enzymatic 
condensation of endogenous amines and amino acids, such as dopamine, adrenaline, 
noradrenaline, tryptamine, serotonin, L-DOPA, tryptophan and 5-hydroxytryptophan, 
with metabolic or exogenous carbonyl compounds, such as acetaldehyde and a-keto 
acids. The putative existence of these ‘mammalian alkaloids’434-438 and their potential 
pharmacological activity, has encouraged detailed research into their synthesis, first
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as racemates, then as enantiomers. Of particular interest to this thesis are the 
synthetic approaches made to the plant alkaloids shown in Figure 51, which is 
discussed in detail below.
HO HO.
NH NH NH NH
HO HO
Salsolinol Salsoline Isosalsoline Salsolidine
33 42
Caraegine
NH
HOHO
Andstrodadine Andstrodine
Figure 51: Some tetrahydroisoquinoline-containing plant alkaloids.
Investigations into the Synthesis of the Enantiomers of 6,7-Dimethoxy-l-methyl-
1,2,3,4-tetrahydroisoquinoline (42)
42R  42S
Figure 52: The desired enantiomers o f 6,7-dimethoxy-l-methyl-1,2,3,4-tetrahydroisoquinoline (42R 
and 42 S).
When this project commenced, while the racemic 6,7-dihydroxy-l-methyl-l,2,3,4- 
tetrahydroisoquinoline 33 ((±)-salsolinol) was commercially available, the 
enantiomers were not. We therefore required a protocol for the synthesis/resolution, 
of either 33, or of an appropriate 6,7-dioxygenated precursor, such as 42 
(see Figure 53).
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HO. HO.
NH NHNH NH
HO HO
Salsolinol Salsoline Isosalsoline Salsolidine
33 42
Figure 53: Some 6,7-dioxygenated-l-methyl-l,2,3,4-tetrahydroisoquinoline cactus alkaloids.
These and other l-substituted-6,7-dialkoxy/dihydroxy-l,2,3,4-tetrahydroiso- 
quinolines have been the subject of chemical and pharmacological interest for several 
years, as:
• potential metabolites of biogenic primary amines, such as L-tryptophan, L-5- 
hydroxytryptophan, dopamine and L-DOPA434-437, with pharmacological 
significance as neurotoxins;
• inhibitors of human monoamine oxidases439; and
• bronchodilators440.
As a result, several literature approaches to producing the desired enantiomers of 33 
have been reported, and these have recently been reviewed441. Although the 
resolution of suitable racemic precursors to 33R  and 335 by recrystallisation with 
chiral acids has been reported442, these were generally low yielding. More attractive 
were two routes to the enantiomers of 6,7-dimethoxy-l-methyl-1,2,3,4- 
tetrahydroisoquinoline 42 (see Figure 52).
The first offered an enantioselective route to 425 from 3,4-dimethoxyphenyl acetic 
acid 6S443 (see Figure 54). The route used (5)-l-(2,6-dichlorophenyl)ethylamine 695 
as a chiral auxiliary, and the reaction of 68 with 695 to form amide 70 as the first 
step. Reduction of the carbonyl of 70 gave the secondary amine 71, and acetylation 
with acetic anhydride gave a chiral tertiary amide 72. Cyclodehydration under 
Bischler-Napieralski conditions gave a chiral iminium ion 73 which, when reduced 
with sodium borohydride, was capable of inducing stereoselectivity in the new 
stereogenic centre of the 1-methyl tetrahydroisoquinoline 74. The auxiliary was 
removed by hydrogenation over palladium on carbon, to give 425. Presumably the 
enantiomer of the chiral auxiliary 69R  could be used to acquire 42R. This approach 
was rejected in favour of the route chosen, because it required the synthesis of the 
chiral auxiliaries 69R  and 695.
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68
NH.
+
69S
, I HN Ar
70
Ar
iv Hi HNAr
—O 7173 72
X .
ViAr NH
74 42S
Ar = 2,6 dichlorophenyl
i. 1.2 eq. 1,1 '•carbonyldiimidazole, THF, 0°C to r.t;ii. 2.5 eq. BH,-THF. 0.4eq B F j ^ O , THF, reflux; 
Hi. 1.5 eq. Ac^O, 0.1 eq DMAP, 1.2 eq Et,N, CH2CI2; iv. 2:1 benzene-POCI3,90°C; 
v. 4-5 eq. NaBH^ added in portions, -78°C; vi. H2, 10% Pd/C, EtOH-EtOAc, 10% HCI.
Figure 54: An enantioselective synthesis o f (-)-42443
Synthesis of the Enantiomers of 42
The route chosen followed an elegant literature synthesis444, with the key resolution 
of racemic 42, to the pure enantiomers 42R  and 425  being performed by reaction of 
the racemic 42 with the chiral auxiliary (/?)-( 1 -phenylethyl)isocyanate 751?, thereby 
creating a diastereomeric mixture of (5)-2-((/?)-l-phenylethyl)carbamoyl-6,7- 
dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline 76(15,aR) and (7?)-2-((7?)-1 - 
phenylethyl)carbamoyl-6,7-dimethoxy-1 -methyl-1,2,3,4-tetrahydroisoquinoline 
76(1/?,a/?). This route had the advantage over the route using the enantiomers of the 
chiral auxiliary 69, in that:
a. both enantiomers of 42 were reported as resolved by using the one 
enantiomer of 75,
b. the pure enantiomers of 75 were commercially available.
The creation of diastereomers frequently allows enantiomers with identical physical 
properties to be separated as diastereomers with differing physical properties. In this 
case444, separation was achieved by recrystallisation of the diastereomeric 
mixture444. 76(15,a/?) was reported as being readily obtained as a crystalline solid,
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and repeated recrystallisation of the residue from the mother liquor removed all trace 
of 76(15,clR), to leave the pure, non-crystalline 76(11?,a/?). The enantiomers of 42 
were reported to be obtained by the thermal decomposition of each urea in refluxing 
2M sodium butoxide in butan-l-ol444, with no loss of enantiopurity (see Figure 55).
non-crystalline diastereomer
76(1/?,oU) 42 S
I. NaBH^ MeOH, 0*C • r.t.; II. (/?)-(1 -phenylethy1)isocyanate (75/?), Et,N, CH2CI2; III. 2M NaOBu/BuOH, reflux
Figure 55: Selected literature resolution o f 41444.
Although eventually successful, some modification proved necessary during the 
synthesis. Reduction of the commercially available achiral 6,7-dimethoxy-l-methyl-
3,4-dihydroisoquinoline 77 with sodium borohydride gave racemic AIRS, which was 
characterised as the hydrochloride salt. Subsequent reaction with 751? gave the 
diastereomeric mixture of 76(ll?5,a!?). It was not possible to distinguish between 
these diastereomers by analytical HPLC using the conditions detailed in the 
literature444; baseline separation was eventually achieved using a chiral stationary 
phase (Anachem CHI-D-PGC-250A (250 x 4.6mm)) and isocratic elution (20% 
propan-2-ol in n-hexane; 210nm). In addition, the diastereomers were clearly 
distinguishable by ]H- and 13C-NMR, with 13C-NMR becoming the method of choice 
for determining diastereomeric purity (see Figure 56, spectrum A). Repeated 
recrystallisation of the mixture of diastereomers, once from ethyl acetate, then 
dichloromethane/ propan-2-ol, gave the crystalline 76(15,al?) to analytical purity 
(see Figure 56, spectrum B). As a point of interest, the optical rotation of the 
diastereomer thus obtained ([a]D20 +75.0° (c 0.7, chloroform)) was consistently 
higher than that given in the literature (c.f [a]or t +48.0° (c 0.7, chloroform)444).
crystalline diastereomer 
76(1 S,aR)
42 RS
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Unfortunately444, it was not possible to purify the non-crystalline 76(11?,al?) beyond 
a d.e. of -90% by HPLC, despite repeated recrystallisation, with the 13C-NMR 
spectrum confirming the presence of residual 76(15,a/?) (see Figure 56, spectrum C).
B 76(15, aR)
76(1/?,a/?) (plus residual 76(15, aR))
D
i ' i ■ i 1 i ■ i ■ r  ----- 1-----   1-----•
2 2 . 8  2 2 . 6  2 2 . 4  2 2 . 2  2 2 . 0  2 1 . 8  ppm
Figure 56: Expansions from the ,3C-NMR spectra o f diastereomers of 76, showing the peaks 
corresponding to the methyl groups attached to each o f the stereogenic centres.
The commercial availability of the enantiomer of the chiral auxiliary 755 meant that 
this complication was readily overcome. Thermal decomposition of the enriched 
mixture of 95% 76(11?,al?), plus 5% residual 76(15,aR), by refluxing in 2M sodium 
butoxide in butan-l-ol444, gave an enriched mixture of 95% 42R, plus 5% 425. 
Reaction with 755 gave a mixture of 95% 76(11?,a5), contaminated with 5% of the 
76(15,a5). As 76(11?,a5) is the enantiomer of the crystalline 76(15,al?), it was 
readily purified to analytical purity (for 13C-NMR spectroscopy;
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see Figure 56 spectrum D) ( [ « ] d 22 -75.1° (c 0.7, chloroform)) by recrystallisation 
from dichloromethane/ propan-2-ol. The absolute stereochemistry o f 76(1/?,aS) was 
confirmed by X-ray crystallography (for a representation of the X-ray 
crystallographic image of 76(1/?,aS), see Figure 57; for the crystal co-ordinates, 
see Appendix 1).
Figure 57: An X-ray crystallographic image o f 76(1/?,clS).
The pure enantiomers of 42R  and 42*5 were obtained by thermal decomposition of 
the analytically pure, crystalline diastereomers 76(1/?,cl5) and 76(1*5,a/?) in 
refluxing 2M sodium butoxide in butan-l-ol444; the product tetrahydroisoquinolines 
(42R  and 42*5 respectively) were purified and characterised as the recrystallised 
hydrochloride salts. The full synthetic route, from commercially available achiral 77 
to enantiopure 42R and 42*5 is shown in Figure 58.
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77, ex-Maybridge 42 RS
X
76(1 S,aA) - crystalline; pure
ill, iv
NH HCI
42S
76(1 R,aR) - non-crystalline; 90% d.e. 
ill, v.
76(1 R,aS) - crystalline; pure
III, iv.
NH HCI
42 R
i. NaBH4, MeOH, 0°C - r.t.; ii. (/?)-(1 -phenylethyl)isocyanate 75R, EtgN, CH2CI2; 
iii. 2M NaOBu/BuOH, reflux; iv. hydrogen chloride, 1,4-dioxane/methanol; 
v.(S)-(1-phenylethyl)isocyanate 75S, EtaN, CH2CI2.
Figure 58: Synthetic route to the pure (R)- and (^-enantiomers o f 42.
Investigations into the Synthesis of the Enantiomers of 6,7-Dimethoxy-3-methyl-
1,2,3,4-tetrahydroisoquinoline (43)
43/? 43 S
Figure 59: The desired enantiomers o f 6,7-dihydroxy-3-methyl-1,2,3,4-tetrahydroisoquinoline (431? 
and 435)
When this project commenced, neither the enantiomers nor the racemate of 43 were 
commercially available. While there were numerous approaches in the literature 
toward the synthesis of the enantiomers of the 1-methyl tetrahydroisoquinoline 42, 
this was not the case for the enantiomers of the 3-methyl regioisomer 43. 
Retrosynthetic analysis of 43 (see Figure 60) suggested two possible routes:
1. via a Pomeranz-Fritsch-Bobbitt type synthetic approach, using 3,4- 
dimethoxybenzaldehyde 79 (veratraldehyde) and either the racemate or the 
enantiomers of an appropriate 2,2-dialkoxy-l-methylethylamine 80;
2. via a Pictet-Spengler type of synthetic approach, from either the racemate or 
the enantiomers of 2-(3,4-dimethoxyphenyl)-l-methylethylamine 38.
Pictet-Spengler ^ O .Pomeranz-Fritsch
79 80
Figure 60: Retrosynthesis of 6,7-dimethoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline 43.
Neither of the required chiral starting materials were commercially available, so 
either the resolution of 43, or the resolution/ enantioselective synthesis of either 80 or 
38 was required.
With respect to the synthesis of the enantiomers of 80, literature precedent445 
describes how to prepare these useful reagents from l,l-dialkoxy-2-propanones 81, 
by the asymmetric reduction of the chiral imines 83, formed by condensation of 81 
with the enantiomers of 1-phenylethylamine SIR  and 8IS, to give the diastereomeric 
secondary amines 84. The benzyl group from the chiral auxiliary can then be cleaved 
by palladium-catalysed transfer hydrogenation, to give 80 (see Figure 61).
The desired enantiomers of 43 could then be accessed by the reductive alkylation of 
80 with 79 and sodium borohydride in methanol, followed by cyclisation in 6M 
hydrochloric acid, and in situ reduction with hydrogen over 5% palladium on carbon 
(see Figure 62).
I l l
OR
OR
81
R=Me, Et, -CH2-
*
Toluene,
reflux
82S
H.N
HCO2NH4/10% Pd-C, 
0R  MeOH, reflux
OR
80S  
(>95% 0.0.)
Figure 61: Synthesis o f (5)-1,1 -dialkoxy-2-propanamines 80S445
,OR
OR
83S
Raney-Ni/H2 (5bar), 
EtOH, r.t., 24hours
84S
OR
OR
79 80S
1. MeOH
2. NaBH4
0 R  1 .6M HCI(>q)
2. Hj/ 5% Pd-C /
78S 43S
Figure 62: Putative Pomeranz-Fritsch-Bobbitt route to (5)-6,7-dimethoxy-3-methyl-l,2,3,4-tetra- 
hydroisoquinoline (435).
The alternative approach to the enantiomers of 43, via a Pictet-Spengler cyclisation 
of the pure enantiomers of amine 38, was given priority as, once in hand, the 
enantiomers of 38 would not only give access to the desired enantiomers of 43, but 
were also envisaged as a useful starting point to gain access to the four diastereomers 
of the 1,3-dimethyl analogue 44 (see Figure 63).
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43 trans-44 c/s-44
Figure 63: 38 as a common intermediate to 43 and 44.
Investigations into the Synthesis of the Enantiomers of 2-(3,4- 
Dimethoxy phenyl)-!-methylethylamine (38)
38R  38S
Figure 64: Key intermediates 38R  and 38S.
The literature offered four approaches to the desired enantiomers of the stereogenic 
amine 38, although three were unsatisfactory for various reasons (see below). The 
one attractive approach utilised commercially available starting materials from the 
chiral pool, namely the enantiomers of alanine 85R  and 85-S446. The use of such 
starting materials to provide the stereogenic centre of the enantiomers of 38 would 
provide products of known absolute configuration. The reaction scheme for this 
approach is illustrated in Figure 65.
The first step required the synthesis of Af-trifluoroacetyl-(L)-alanine 865, and this 
was achieved in good yield by the literature reaction of ethyl trifluoroacetate with 
85S447. The next sequence of reactions were carried out in one pot. Firstly, the 
conversion of 865 to iV-trifluoroacetyl alaninoyl chloride 875, by reaction with 
oxaloyl chloride in dichloromethane with a catalytic amount of N,N-DMF, followed 
by the in situ Friedel-Crafts acylation of 1,2-dimethoxybenzene 88, to give (S)-N- 
trifluoroacetyl-l-(3,4-dimethoxybenzoyl)ethylamine 895. Had this step proven 
reproducible, all that would be required to obtain the key stereogenic intermediate 
385 would be the triethylsilane-mediated reduction of the carbonyl group448 to give
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(*S)-7V-trifluoroacetyl-2-(3,4-dimethoxyphenyl)-l-methylethylamine 905, followed by 
basic hydrolysis of the amide.
OH OH
h2n
o
85S
F O
86S
(COCI)2, N.N-DMF, 
CH2CL, 0°C to r . t .
HN
CH2CI2, 0#C to r.t 
2. A1CI,, CH-CL, r.t.
87S
89S
NH2HN
38S90S
Figure 65: Proposed route to the enantiomers o f amine 38 from alanine 85, as exemplified for 38S  
from 85S446,449
Unfortunately, despite scrupulously following the literature procedure446’449, the 
conversion of 865 to 895 proved unreliable and highly variable, with only a small 
amount of the desired product formed from four attempts at the reaction and total 
consumption o f865 seen each time. The most likely side reaction is that of formation 
of the oxazolone 91450(see Figure 66). The reactive polarised complex intermediate 
formed between the acid chloride 875 and the Lewis acid catalyst451 would 
conceivably facilitate this reaction. This side reaction is suppressed with carbamate 
protecting groups, but these do not lend themselves to Friedel-Crafts reactions, with 
decarbamoylation readily occurring452. Of the two published carbamate-protected 
alanine derivatives used to successfully acylate aromatic systems via a Friedel-Crafts 
reaction, iV-methoxycarbonylalanine453 was only tried for benzene, and N- 
ethoxycarbonylalanine452 did not work with methoxybenzene, and would not, 
therefore, be anticipated to work with 88.
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Figure 66: Side reaction of amino acid chlorides.
Of the three alternative literature procedures, one utilised the asymmetric reductive 
animation of ketone 36 with amine 825 under an atmosphere of hydrogen over 
Raney nickel at 100 atmospheres pressure to give [(5)-2-(3,4-dimethoxy-phenyl)-l- 
methylethyl]-((£)-l-phenylethyl)amine 92(15,1 \S), followed by cleavage of the 
benzyl group by palladium-catalysed hydrogenolysis. While this approach appeared 
highly efficient, no facilities to achieve the required pressure were available to us at 
the time (see Figure 67)454.
H,N
36 82S
Hj/Raney Ni, EtOH, 100atm 
2 hours at 85°C, than 15 hours at rt.
H^PdClj, MeOH
92(1S,1'S)
Figure 67: The Weinges and Graab synthesis o f 38S454.
38S
The remaining literature routes, while unattractive, were useful in that they provided 
evidence for the absolute configuration of the product amines 38i? and 385. The 
earliest route was rejected, as it required the synthesis and enantiomeric resolution of 
3-(3,4-dimethoxyphenyl)-2-methylpropionic acid 93455. The procedure isolated (+)- 
93 as diastereomeric salt by recrystallisation of the racemate 93RS  with quinine 94, 
with subsequent isolation of (-)-93 from the enriched mixture of enantiomers 
obtained from the mother liquor using a diastereomeric salt of the popular chiral 
auxiliary amine 825. The pure (-)-93 thus obtained was reported as being readily 
converted to (-)-38 via a Curtius rearrangement, and hence with retention of 
configuration (see Figure 68)455.
Resolution of 
(+)-enantiomer as  
the salt of quinine
CO.H
Resolution of (-)-enantiomer 
from enriched mixture derived 
from mother liquor, a s salt of 
(-)-1 -phenylethylamine
CO.H
(+)-93 H -9 3
1. (COCI)2, reflux, one hour
2. NaNj, acetone, ~10°C
3. Heated in benzene
NH,
H -3 8
HO
CH.O. NH.
82 S
quinine
Figure 68: Schrecker’s synthesis o f (-)-38455.
The absolute configuration of (-)-38 was demonstrated in a companion paper456, in 
which the tosylation of the (-)-38 gave (-)-Af-tosyl-2-(3,4-dimethoxyphenyl)-l- 
methylethylamine (-)-95. (*S)-3,4-dihydroxyphenylalanine 96S, a natural amino acid 
of established absolute configuration, can also be converted, via intermediates 97,98, 
99 and 100 and with retention of configuration, to (-)-95, thereby establishing the 
absolute configuration of (-)-95, and of (-)-38, as R  (see Figure 69).
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—o
NHLiAIH.,0
0 \NH
S — O
95 R 100S
LiAIH.
—O O-
,NH TsCI
NH.
HO
99S
TsCI
95R = H-95 => H-38 = 38/?
NH,
■ ' ' ' / /
38 R
Figure 69: Literature route to establish the absolute configuration of (—)-38 as R, by the synthesis of 
965" from chiral starting materials of known absolute configuration456.
The final literature route also utilised the available chiral pool of starting materials, 
synthesising (-)-38 from (Z)-alanine 85R  (see Figure 70). However, some 
racemisation was reported in the product of the Friedel-Crafts acylation to give 
ketone 101/? and the reduction with aluminium isopropoxide to give the 
diastereomeric alcohol 102/?457. Although these impurities were crystallised out, it 
was felt that this was undesirable in our synthetic route. However, by synthesising 
(-)-38 from 85/?, via a series of transformations that left the stereogenic centre 
largely unaffected, (-)-38 was again confirmed as having the (J?)-configuration457.
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H,N
Dimethoxybenzene, 
AICL, CS,P reflux N
Cl O
O
Prepared according to the method of 
AH Beckett and AF Casy JCS  (1955) 900-904 Al(OlPr)3, toluene, reflux
N2H4.H20 , EtOH 
reflux
H,N
HO
O—
102/?
O HO
H/I0%  Pd-Ba2S 0 4 
AcOH/HCI0 4, 
24hours @ 80°C
(-)-38 = 38/?
Figure 70: Literature route to (-)-38 from S5R, establishing the absolute configuration as i?457;458. 
Synthesis of the Enantiomers of 38
The enantiomers of our key intermediate amine 38 were eventually obtained, albeit 
in low yields, via a classical resolution of the racemate 38RS  (see Figure 73), using 
one enantiomer of a chiral acid to form a diastereomeric salt mixture, and separating 
the diastereomers based upon differences in solubility459. The racemic amine 3SRS 
was synthesised as described previously (see Figure 40) from ketone 36; the racemic 
amine 3SRS was purified and characterised as the hydrochloride salt.
When resolving enantiomers, it is necessary to be able to follow the success, or 
otherwise, of the resolution. A widely used method for establishing the degree of 
enantiomeric purity of amines, and particularly amino acids, employs the reaction of 
the amine with A-a-(2,4-dinitro-5-fluorophenyl)-(L)-alaninamide 1045 (Marfey’s 
reagent, see Figure 71)460’461. The diastereomers generated can then be analysed for 
analytical differences, with reverse-phase analytical HPLC normally adequate462.
To establish whether this method could be used for following the resolution of 
amine 38, a sample of the racemate 38RS was reacted with an excess of 1045, to 
form 105(/?,5-ala) and 105(5,5-ala) as a mixture of diastereomers. This mixture was 
analysed by reverse-phase analytical HPLC at 340nm, as Marfey’s reagent and the
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product diastereomers are bright yellow. 105(jR,5-ala) and 105(£,5-ala) were 
separated at the baseline (see Figure 72B), therefore Marfey’s reagent 104S was 
demonstrated as suitable for following the attempted resolution of amine 38.
=°2N\ ^ / N 0 2
o
H
104S 
Marfey's reagent
Z8RS
1.NaHCO, ^ ,, acetone, 40°C, one hour
2.HCI(aq)
H,N
0,N
H,N
105<R,S-ala) w 105{SfS-ala)
The product diastereom ers are separable by reverse phase analytical HPLC
Figure 71: Scheme to show the diastereomers produced by the reaction of racemic 38 and Marfey’s 
reagent 10451.
Resolution of 38S  was achieved by combining the free base of 38RS  with a 
stoichiometric amount of (R)-mandelic acid 1031? in boiling propan-2-ol, which 
crystallised as the diastereomeric salt mixture upon cooling. Repeated 
recrystallisation of this mixture from ethyl acetate/methanol 2:1 eventually gave one 
enantiomer of 38 to enantiomeric purity, as the salt of 1031? (see Figure 73). 
Enantiomeric enrichment at each stage of recrystallisation, as well as the eventual 
enantiomeric purity of the resolved amine, was determined by the method of 
Marfey460;461 (for a comparison of the HPLC traces, see Figure 72).
Once the pure enantiomer was obtained as the salt of 1031?, a sample was converted 
to the free base and crystallised from n-pentane as waxy low melting point solid. The 
value for the standardised optical rotation of plane polarised light by the amine was 
recorded, and the absolute configuration was assigned by comparison with the 
literature values ([a]D22 +32.5 (c4.02, EtOH); c.f. [a]D21 +32.1 (c3.98, EtOH)455). 
This established that the enantiomer of 38 resolved by crystallisation with 1031? was 
(+)-38, with the absolute configuration S.
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Figure 72: HPLC confirmation of the successful resolution of the enantiomers o f 38. 
A shows the trace for 1045 alone;
B shows the trace after the reaction of 38RS and 1045;
C shows the trace after the reaction of resolved 385 and 1045;
D shows the trace after the reaction of resolved 38J? and 1045.
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The enantiomer 38R was obtained by combining the mother liquors from the 
recrystallisations performed to obtain 385, and removing the solvents under reduced 
pressure to yield a colourless crystalline mixture of 381? and 385 salts of 1031?. This 
mixture was dissolved in water, and the (R)-enriched amine 38 was liberated as the 
free-base by basification of the aqueous solution with sodium hydroxide, and 
extraction into dichloromethane. Removal of the dichloromethane under reduced 
pressure gave a colourless syrup; combination with stoichiometric (5)-mandelic acid 
1035 in boiling propan-2-ol yielded the diastereomeric salt mixture as a colourless 
crystalline solid upon cooling. Repeated recrystallisation of the colourless crystalline 
mixture of salts from ethyl acetate/methanol 2:1 gave the pure colourless 
diastereomeric salt 381?+1035, with the enantiomeric enrichment of 38 established 
after each recrystallisation by reaction of the free amine with 1045 as already 
described, until enantiomeric purity, to the limit of detection, was achieved (for the 
HPLC trace, see Figure 72).
As for 385, a sample of the resolved 381? was converted to the free base and 
crystallised from n-pentane as waxy low melting point solid. The optical rotation was 
recorded, and compared with the literature value ([oc]d21 -32.8 (c 4.00, EtOH); c.f 
[<x]D21 -32.1 (c 4.00, EtOH), -31.8 (c 3.80, EtOH)455). The resolution of 38* and 385 
is summarised in Figure 73.
Figure 73: Synthesis and resolution o f the enantiomers of the key intermediates 38J? and 385.
Repeat recrystallisation from 
EtOAc/MeOH as the (R)-mandelate
Repeat recrystallisation from 
EtOAc/MeOH as the (S)-mandelate
38S 103S
Freebase Freebase
(dissolve in water, 
basify with NaOH, 
extract into CH2CI2).
(dissolve In water, 
basify with NaOH, 
extract into CH2CI2).
38S
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Synthesis of the Enantiomers of 43
With the resolved enantiomers of amine 38 in hand, the enantiomers of 
tetrahydroisoquinoline 43 were readily synthesised by a variation of the Pictet- 
Spengler tetrahydroisoquinoline synthesis415. The reaction of each enantiomer of 
amine 38 with paraformaldehyde in glacial acetic acid and purification by 
recrystallisation from n-hexane gave the desired enantiomers of 43 as a cream 
coloured crystalline solid (see Figure 74).
(CH20 )n, AcOH, 40°C
(CH20 )n, AcOH, 40°C
38S 43S
Figure 74: Synthesis o f the enantiomers of 43 from the enantiomers of 38.
Establishing the Enantiopurity of 43R and 435
Although racemisation was not anticipated during ring closure, it was considered 
prudent to confirm that no racemisation had occurred during the cyclisation step of 
the tetrahydroisoquinoline synthesis. The high .enantiopurity of the 
tetrahydroisoquinoline enantiomers 43/? and 435 was confirmed by !H-NMR 
spectroscopy, using a chiral solvating agent463. The 'H-NMR spectra were recorded 
for each enantiomer, and a racemic mixture, in the absence and the presence of 2 
equivalents of the chiral solvating agent (5)-(+)-l-(9-anthryl)-2,2,2-trifluoroethanol 
1065 ((5)-TFAE; see Figure 75)463;464.
HO,
106S, (S)-TFAE
Figure 75: Structure o f (£)-(+)-1 -(9-anthryl)-2,2,2-trifluoroethanol 1065 ((^-TFAE)464.
While some resolution of the separate enantiomers was seen with one equivalent of 
1065, the incomplete separation apparent for most of the substituted 
tetrahydroisoquinoline signals necessitated the addition of two equivalents,
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whereupon baseline separation for most of the signals of interest was observed. In 
particular, the doublets corresponding to the methyl group attached to the stereogenic 
carbon, the doublet of doublets corresponding to each of the protons of the adjacent 
methylene, and the singlets corresponding to the aromatic protons of the 
tetrahydroisoquinoline were clearly realised for each enantiomers (see Figure 76).
A J j l
B
.a L l
ULLJL  aA_aAVw _ jv \*_
.A aL—Wl JL
E
J U
6 .5  ppm 3 .0
1r~ T     i '
2 . 5  2 . 0  1 .5 ppm
Figure 76: Comparative ‘H-NMR spectra, confirming the enantiopurity o f the enantiomers o f 43: 
A. 43RS; B. 43RS + 1 eq. 1065; C. 43RS + 2 eq. 1065; D. 435 + 2 eq. 1065; E. 43R + 2 eq. 1065.
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Investigations into the Synthesis of the Enantiomers of the cis- and the trans- 
diastereomers of 6,7-dimethoxy-l ,3-dimethyl-1,2,3,4-tetrahydro-isoquinoline 
(44)
c/s-44CI/?,3S) c/s-44(1 S,3R)
trans-44(\R,3R) trans-44('\S,3S)
Figure 77: The four desired diastereomers o f 6,7-dimethoxy-1,3-dimethyl-1,2,3,4-
tetrahydroisoquinoline (c/s-40(l/?,35), cis-40(1»S,,3^0j trans-40(lR£R) and ^ra/is-40(liS',3iS))
Figure 77 shows the four possible diastereomers of the key intermediate 
tetrahydroisoquinoline 44, the enantio- and diastereoselective syntheses of which 
was a key objective of this thesis. Ideally, and with the resolved enantiomers of 
amine 38 as a starting point, the synthesis of each pair of diastereomers was to be 
achieved by the stereoselective insertion of a 2-carbon unit to form the ring and the 
methyl group of the 1-position. Direct stereoselective insertion required an 
asymmetric Pictet-Spengler synthesis of the tetrahydroisoquinoline, while an indirect 
approach, via acetylation to give the amide 107 and ring closure under Bischler- 
Napieralski conditions to give the 3,4-dihydroisoquinoline intermediate 108, 
followed by a stereoselective reduction, offered a viable synthetic alternative 
(see Figure 78). Given that we could start from 38R  and 385, the use of a Pomeranz- 
Fritsch-Bobbitt approach to tetrahydroisoquinoline synthesis was not considered.
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Pictet-Spengler
HN ^  Bischler-Napieralski
107
Figure 78: Retrosynthetic analysis o f approaches to 44 form 38.
NH
44
108
Investigations into the Synthesis of the Stereoisomers of 44, via Modification of 
the Bischler-Napieralski Tetrahydroisoquinoline Synthesis418
At the commencement of this project, few diastereoselective synthetic approaches to 
1,3-dimethyl-1,2,3,4-tetrahydroisoquinolines had been published, and none contained 
the desired 6,7-dioxygenated substitution pattern; a recent review has confirmed that 
this is still the case417. However, the requisite cis- and trans- 1,3-dimethyl-1,2,3,4- 
tetrahydroisoquinoline cores are found in the naturally occurring 
naphthylisoquinoline alkaloids433, with representatives being isolated from tropical 
lianas of the families Ancistrocladaceae and Dionchophyllaceae. These include
(-)-ancistrocladine 
(see Figure 79).
109(15,35)465 and (+)-isoancistrocladine 110(1«,35)466
NH
HO
NH
HO
109(1S,3S)
(-)-Ancistrocladine
110(1/?,3S)
(+)-lsoancistrocladine
Figure 79: Some examples o f naturally occurring alkaloids containing 1,3-dimethyl-1,2,3,4- 
tetrahydroisoquinoline cores (in red).
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Included in the first published total synthesis of 109(15,35)467 was a 
diastereoselective synthesis of (1S, 3-S)-6,8-dimethoxy-1,3 -dimethyl-1,2,3,4- 
tetrahydroisoquinoline 114(15,3-5). Acetylation of (<S)-2-(3,5 -dimethoxyphenyl)-1 - 
methylethylamine 1115 gave the acetamide 1125, the ring closure of which under 
Bischler-Napieralski conditions gave the 3,4-dihydroisoquinoline 1135. Reduction of 
the imine with UAIH4 in the presence of AlMe3 gave the desired 114(15,35) with 
92% d.e. (see Figure 80).
o—
o —
/ \  / = \
/ = (
D
h2n — (
*
0
111S 112S
NH
113 S  114(1S,3S)
R eagents and conditions: i. H,CCOCI, Et,N, CH2CI2; ii. POCI,, MeCN, reflux; iii. LiAIH^AIMe,, THF, -78°C to  0°C
Figure 80: Diastereoselective synthesis o f 114(153<S)467.
Interestingly, this synthesis required the synthesis of the pure enantiomer 1115, 
which was obtained by the stereoselective two step reductive animation of 
3,5-dimethoxyacetophenone 115 with 825 to give the diastereomeric amine 
117(15,1’5), via the imine 1165. Hydrogenolysis of the benzylamine of 117(15,1’5) 
gave 1115 (see Figure 81). This synthesis is directly comparable to the route to the 
enantiomers of 38 published by Weinges and Graab already discussed 
(see Figure 67). However, whereas the reduction of imine formed between 36 and 
825 was reported as requiring 100 atmospheres of pressure454, the reduction of the 
imine 1165 was reported as requiring only 5 atmospheres of pressure. If we had not 
been able to resolve 38/? and 385 as diastereomeric salt mixtures of 103/? and 1035, 
we would have investigated the reductive animation of 36 with 825 under similar 
conditions.
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5 bar Hj/Raney Ni W2, 
EtOH, 80 hours.
82S
Toluene,
reflux
117(1Sf1'S;
Figure 81: Stereoselective synthesis of 11 IS467
116S
5 bar H/IO%Pd-C, 
MeOH NH2
O
111S
Seven years after the publication of the total synthesis of 109(15',3S)467, a subsequent 
publication from the same group gave synthetic approaches to all four diastereomers 
of 114468. The key synthetic revelation of the paper was that, while confirming that 
the use of Li AlFLj/AlMes in the reduction of 113 gave trans-114 to greater than 90% 
d.s., the use of sodium borohydride in the same step gave predominantly cis-114, to 
greater than 95% d.s. (see Figure 82).
NH
>95% d.s.
C/S-114
113
NH
frans-114
Figure 82: Diastereodivergent stereoselective synthesis of cis- and trans-114468
When the same methodology was applied in the literature to the synthesis of the 
5,6,7,8-unsubstituted-1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline 119469 however, 
some problems arose. While the enantiomers of cis-119 could be successfully 
obtained by the reduction of the enantiomers of 1,3-dimethyl-3,4- 
dihydroisoquinoline 118 with NaBFU, the reduction of the enantiomers of 118 with 
LiAlHVAlMea not only gave a mixture of cis-119 and trans-119, but also caused the 
loss of chiral integrity at the 3-position (see Figure 83). The diastereomers cis-119
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and trans-119 were separated by column chromatography, and the enantiomers of 
trans-119 by recrystallisation as diastereomeric salts with the enantiomers of 
dibenzoyl tartaric acid469. It was postulated that the oxygen moiety at the 8-position
in the synthesis of 114467 was essential for both the stereoselectivity, and lack of 
racemisation seen in the LiAlHVAlMea reduction step.
NaBH.
NH
119(1S,3R)
NH ih nh
119(1S,3R) 119(1/?,3/?) 119(1S,3S)
Figure 83: The effects o f using different reducing agents upon the diastereoselectivity o f the reduction 
of 118J?469.
Our 3,4-dihydroisoquinoline 108 does not have the apparently requisite oxygen 
moiety at the 8-position. Rather than explore the diverse range of available reducing 
agents for /raws-diastereoselectivity, we decided to explore the potential for using a 
chiral auxiliary to introduce the 1-position methyl group asymmetrically by the most 
direct route, via a Pictet-Spengler type reaction with the enantiomers of 38. By using 
each enantiomer of the chiral auxiliary, it would be possible to selectively insert the 
2-carbon subunit into the 1-position of the tetrahydroisoquinoline in either the R  or S  
absolute configuration. In conjunction with the enantiomers of 38, this would give 
access to all four diastereomers of 44, ideally with a high degree of 
diastereoselectivity.
Stereoisomerism (2)
It is perhaps worth emphasising at this point that the capacity to act as a chiral centre 
is not confined to tetrahedral carbon atoms; the appropriate substitution of any 
quadriligant (four-coordinate) and sexiligant (six-coordinate) atom, as well as the 
pyramidal triligant (three-coordinate) atoms, such as N and P, can produce 
chirality412;414. The stability and potential for isolation of these putative stereoisomers 
is dependent upon any barrier to rotation; frequently the barrier is too low for the 
existence of such stereoisomers to be anything other than hypothetical.
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Suitably substituted triligant sulfur compounds having pyramidal structure, such as 
sulfonium salts, sulfoxides and sulfinate esters, contain a chiral sulfur atom470. In 
particular, sulfoxides can have three sterically and stereoelectronically different types 
of substituent pendant to the chiral sulfur: the lone pair of electrons, the oxygen 
atom, and two alkyl/aryl groups. As such, sulfoxides are frequently stable to thermal 
racemisation to beyond 200°C470, and the use of the enantiomers of chiral sulfoxides 
in asymmetric carbon-carbon bond formation is well established470.
For the purposes of the CIP-system descriptor assignment, the three ligands of 
sulfoxides (and other triligant centres) are prioritised according to the established 
rules412"414, as touched upon briefly in the section entitled ‘Stereoisomerism’. The 
fourth “absent” ligand in these pyramidal triligant systems, usually a lone pair of 
electrons, is considered to have atomic number zero, and therefore lowest prioritised 
rank414. It is this ligand that is therefore projected away from the viewer when 
assigning the CIP-descriptor. Finally, for clarity, especially with multiple chiral 
centres of more than one atom type, it has proven useful to subscript the descriptors 
for atoms other than carbon with the appropriate atomic symbol. This is summarised 
for the enantiomers of 4-tolylmethylsulfoxide 120 in Figure 84.
120Ss 120Rs
Figure 84: Illustrating the application o f the CIP-system descriptors to sulfoxides.
Investigations into the Synthesis of the Stereoisomers of 44, via Modification of 
the Pictet-Spengler Tetrahydroisoquinoline Synthesis415
The published synthesis of (l?)-(+)-camegine 1251? (A-methylated-421?)471 included 
the enantioselective insertion of the desired 2-carbon unit into the 1-position of the 
tetrahydroisoquinoline, by the reaction of the (l?s)-enantiomer of the chiral acetylenic 
sulfoxide 121 with 2-(3,4-dimethoxyphenyl)ethylamine 122 (see Figure 85). This 
appeared472 to be an attractive starting point in the search for an appropriate chiral 
auxiliary to introduce the 1-position methyl group asymmetrically via a Pictet- 
Spengler type reaction with the enantiomers of 38.
129
NO. O
NH.
CHCI,, 2 hours
121RS 122
NO.
TFA, 0°C, 
4 hours
1. HCHO, NaCNBHj, / °  
CHjCN
2. Raney Nl, 1hr \ O
124(1R,RS) 124(1S,Rs)
Figure 85: Total synthesis of 125/?, using the chiral acetylenic sulfoxide 121/?s471’472
In the published synthesis of 125U471, the Michael addition of 2-(3,4- 
dimethoxyphenyl)ethylamine 122 to (7?s)-ethynyl-2-nitrophenylsulfoxide 121/?s 
formed the p-aminovinylsulfoxide 123/?s, the acid-mediated ring closure of which 
gave only one diastereomer of the product 1-substituted tetrahydroisoquinoline 
124(l/?,/?s). The reaction was repeated with an alternative chiral acetylenic sulfoxide 
((Ss)-ethynyl-4-tolylsulfoxide), and a 2:1 mixture of diastereomers was formed472. 
Methylation of the tetrahydroisoquinoline nitrogen, and subsequent reductive 
cleavage of the sulfur-carbon bond, gave the desired alkaloid 125R412.. The 
rationalisation for the diastereoselectivity ring closure reaction proposed the acid- 
mediated formation of a conformationally constrained iminium intermediate 126i?s, 
stabilised by hydrogen bond formation between the sulfoxide oxygen and the 
iminium hydrogen, to form a six-membered ring (see Figure 86). This intermediate 
determines the orientation of the ring closure. The presence of the 2-nitro substituent 
enhances the diastereoselectivity by stabilising the hydrogen bond472.
130
NH
At
Figure 86: The reactive intermediates of the acid-mediated cyclisation of 123/?s> with the iminium 
intermediate 126i?s proposed as the predominant species. The conformationally constrained, hydrogen 
bond containing six-membered ring was speculated to determine the orientation of the ring closure4 2.
To investigate the applicability of using the (Rs)- and (iSs)-enantiomers of 121472 in 
the synthesis of the enantiomers of cis-44 and trans-44, a synthetic approach to the 
pure (Rs)~ and (Ss)-enantiomers of 121472 was required. Attempts to reproduce the 
stereoselective synthesis and purification of 121J?s472 described in the literature471 
(see Figure 87) proved highly variable, and not without complication.
Step 1:
N 02 (MeO),P, Et,N, 
CH,CI„ reflux
// HO.
128
'a K >
N 02
ICl
Ar<S"0""
127(1 R,2S,5R) 129 130Ss 1.6:1
Ar = 2-nitrophenyl
130/?,
Step 2:
130Ss
*
-MgBr
Toluene, -20°C \  _  //
— SI = = — S NO.
/  V 7
131 132S,
 SI
132S,
N 02
Figure 87: Literature synthetic route to 121J?/71 472
In the literature approach to 125i?472, the pure enantiomer of the chiral sulfoxide 
121 Us was synthesised via resolution of the menthyl sulfinate ester 1305s, following 
the classical route developed by Andersen473 (see Figure 87). Firstly, trimethyl 
phosphite was used to reduce 2-nitrobenzenesulfonyl chloride 128 to 2- 
nitrobenzenesulfinyl chloride 129, using methodology developed by Klunder and
131
Sharpless474, whereupon 129 was trapped in situ by reaction with (IR,2S,5R)~ 
menthol 12 7(1/?,25,5/?), to give the menthyl sulfinate ester 130i?s5s as a mixture of 
diastereomers. 472Some degree of stereoselectivity was reported in the formation of 
the diastereomers of the menthyl sulfinate ester 130471, with 1305s and 130/?s being 
produced as either a 1.6:1 mixture, separable by column chromatography472, or a 3:1 
mixture, resolved by crystallisation from ethanol471.
Presumably the presence of 127(11?,25,5R) created a chiral environment that, during 
the formation of 129, introduced some asymmetry into the reduction of 128, prior to 
ester formation between 129 and 127(11?,25,51?). The small degree of 
diastereoselectivity and reported ‘ease’ of separation were attractive as, in order to 
obtain both enantiomers at the tetrahydroisoquinoline 1-position (and thereby the 
four diastereomers of 44), both 1211?s and 1215s would be required.
In step two, the Grignard reagent trimethylsilylethynylmagnesium bromide 131 was 
generated in situ from trimethylsilylacetylene and ethylmagnesium bromide475, and 
reacted with the purified diastereomer of 1305s, to give the acetylenated sulfoxide 
1325s. This reaction proceeded with total inversion at the sulfur atom, ensuring 
retention of optical purity and absolute configuration. The final step saw the removal 
of the trimethylsilyl group from 1325s by hydrolytic cleavage, reportedly achieved 
during column chromatography, to give the desired chiral acetylenic sulfoxide 
121J?S.
Some subtleties of the CIP system, and the care that must be taken when assigning 
descriptors are apparent from this reaction sequence. Despite the conversion of 
producing inversion at the chiral sulfur atom, the chiral descriptor remained 5s for 
both 130 and 132, as the menthyl group, of higher priority than the sulfoxide oxygen, 
was replaced with an acetylene, of lower priority than the sulfoxide oxygen. In 
contrast, despite no change in the configuration at the chiral sulfur atom in the 
conversion of 132 to 121, the chiral descriptor changed, from 5s to J?s, because the 
loss of the silicon atom altered the priority of the acetylenic substituent with respect 
to the aryl substituent. This is illustrated in Figure 88.
132
Direction o f rotation, from highest (1) to lowest (3) ranking substituent:
anticlockwise anticlockwise anticlockwise
CIP descriptor = Ss CIP descriptor = Ss CIP descriptor = Rs
—Si
2
Figure 88: Absolute configuration, substituent prioritisation and CIP descriptors4125413.
However, following the literature procedure471’472 to the pure enantiomers of 121 
proved problematical. While the addition o f a mixture of trimethyl phosphite and 
triethylamine to a solution of 127 and 128 in dichloromethane yielded the predicted 
diastereomeric mixture of 130/?s and 1305s, neither diastereomer o f 130 could be 
isolated to the necessary degree of diastereomeric purity. Repeated attempts at 
purification by flash column chromatography and preparative HPLC were 
unsuccessful. The similarity of Rf values and HPLC retention times for each of the 
diastereomers led only to incomplete separation, although some enriched fractions 
for each diastereomer were obtained. Repeated recrystallisations also failed to 
significantly increase the d.e.. To test the applicability of the chiral acetylenic 
sulfoxides to the planned synthesis, we decided to push through material of a 
sufficiently high d.e. and react it with the Grignard reagent 131. However, the 
reaction between 130 and 131 also proved low yielding, with significant quantities of 
unreacted 130 recovered.
To improve these aspects o f the synthesis, alternative chiral auxiliaries were sought. 
One literature source described the use of separate 7V-sulfinyloxazolidinones 
135(4/?,55,/?s) and 138(45,5s) as chiral sulfinyl transfer reagents to obtain the 
opposite enantiomers o f synthetically useful arylsulfoxides476. Originally derived 
from (15,2/?)-2-amino-l-phenylpropan-l-ol 133(15,2/?) ((15,2/?)-norephedrine)477, 
the now commercially available (4/?,55)-4-methyl-5-phenyloxazolidin-2-one 
134(4/?,55) can be readily converted to the Af-sulfinyloxazolidinones 135(4/?,55,/?s), 
from which (5s)-enantiomers of arylsulfoxides can be synthesised (see Figure 89). 
Similarly, the commercially available (S)-4-benzyl-oxazolidin-2-one 1375, itself 
originally derived from (5)-phenylalanine 1365478, can be readily converted to the TV-
133
sulfinyloxazolidinones 138(45,5s) which can be converted into the (i?s)-enantiomers 
of arylsulfoxides (see Figure 90).
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Figure 89: Synthesis o f (^-sulfoxides from ( 15,2/?)-norephedrine 133(15,2/?)476;477.
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Figure 90: Synthesis o f (/?s)-sulfoxides from (5)-phenylalanine 1365476:478.
The reported advantages in using the oxazolidinones 134(41?,55) and 1375 included 
greater ease of diastereomeric resolution, either by recrystallisation or 
chromatographic separation, and a 100-fold increased reactivity with Grignard 
reagents over the menthyl sulfmates such as 130476. The synthesis of (5)-4-benzyl-3- 
((5)-2-nitrobenzenesulfinyl)oxazolidin-2-one 140(45,5s) from 1375 required the 
generation of 2-nitrophenylsulfinyl chloride 129. Two approaches were taken: the 
previously employed in situ reduction of 2-nitrophenylsulfonyl chloride 128 with
134
trimethyl phosphite474, and an alternative literature preparation from 2-
nitrophenyldisulflde 139, using sulfuryl chloride in acetic acid479. Reaction of either 
preparation of the 129 with the lithiated 1375 gave multiple products, with no useful 
quantities of either 140(45,5s) or 140(4R^Ss) being isolated. This may be a reflection 
of the inherent instability o f the anticipated products, as described in a footnote in the 
original protocol476.
Anticipated as the major 
diastereomer of the product
Figure 91: The unsuccessful route to 140(45,5s)-
The difficulty in obtaining the pure (Rs)- and (^^-enantiomers of 121472 was proving 
to be a detrimental to the synthetic effort, necessitating a reappraisal of the synthetic 
approach to the pure diastereomers o f 44. Rather than using an additional stereogenic 
centre to induce stereoselectivity at the 1-position, a search of the literature provided 
ample evidence that the existing 3-position stereogenic centre could exert some 
degree of stereoselective induction at the 1-position (see Figure 92). The cyclisation 
of L-DOPA 141 with acetaldehyde in the presence of a mineral acid was reported to 
give the 1-methyl-3-carboxylic acid tetrahydroisoquinoline product 142 in a 95:5 
ratio of the cis-\42(15,35) to the trans-142(1 /?,35)434. The same authors reported 
similar results with Pictet-Spengler cyclisations of acetaldehyde with 
L-tryptophan 143 to give tetrahydroisoquinoline 145 and of acetaldehyde with L-5- 
hydroxytryptophan 144 to give tetrahydroisoquinoline 146, with both producing the 
c/s-analogues as the major diastereomer436. It has also been reported that the
Lithiated 137S, 
THF, -78°C
140(4S,Ss) 140(4 R,Ss)
135
formation of l-substituted-3-aryltetrahydrosioquinolines 148 by the classical Pictet- 
Spengler cyclisation415 of l,2-bis(3,4-dimethoxyphenyl)ethylamine 147 with 
acetaldehyde gave the c/s-products as the major diastereomer480.
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Figure 92: Literature examples o f diastereoselective Pictet-Spengler cyclisations o f 1-substituted 2- 
arylethylamines with acetaldehyde434:436;480.
A review of the !H-NMR spectrum of 31(1RS,3RS) revealed that the original full 
structure mixture of diastereomers, rather than an equal 1:1:1:1 mixture of 
31(11?,31?), 31(15,35), 31(11?,35) and 31(15,31?), was a 6:1 mixture of cis and trans 
diastereomers, as seen from the peaks corresponding to the 1- and 3-methyl 
substituents (see Figure 93).
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a .
JU
7 6 5 4 3 2 1 ppm
1 .4 1 .3 1 . 2 1.1 1 . 0 0 .9 0 . 8 0 .7 0 .6  ppm
Figure 93: a. 'H-NMR spectrum of the racemic mixture of diastereomers of 31(llW,31ifcS); 
b. Expansion of the region 0.5-1.5ppm, showing the doublets corresponding to the 1- and 3-methyl 
groups, with a diastereomeric ratio o f approximately 6:1 (plus a triplet corresponding to the CH3 of 
diethyl ether).
In the synthesis of 31(lJW,31fcS), the 1-position stereogenic centre was introduced via 
a Pictet-Spengler cyclisation415 of amine 39RS  and acetaldehyde in water to give 
tetrahydroisoquinoline 35(1RS,3RS) (see Figure 40). The existing 3-position 
stereogenic centre must exert some degree of chiral induction at this point.
For comparative purposes, a trial reaction was carried out between amine 38RS  and 
acetaldehyde in hydrochloric acid under reflux. The 1 H-NMR spectrum of the crude 
product 44(1125',3RS) confirmed the tetrahydroisoquinoline product mixture to be 
formed with a degree of diastereoselectivity, in an approximately 3:1 mixture of 
diastereomers (see Figure 94).
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Figure 94: Trial synthesis o f 44 as a mixture o f diastereomers from 38RS and acetaldehyde under 
Pictet-Spengler conditions, with expansions from lH-NMR spectra to show the doublets 
corresponding to the aliphatic methyl groups o f a. 38RS, and b. the crude product.
Consideration of the reaction mechanism from a 3-dimensional perspective should 
allow the rationalisation of the indicated diastereoselectivity (see Figure 95). The key 
step of the synthesis, in which the orientation of the substituent at position 1 of the 
tetrahydroisoquinoline is determined, is when the electrons from the electron-rich 
carbon at position 6 of the benzene ring attack the electron-poor carbon of the 
iminium ion 149. The iminium precursor would be expected to have the 
thermodynamically more stable (^-configuration about the C=N bond. As the 
electrons from C-6 carbon attack the electron-poor carbon of the iminium ion, the 
carbon-nitrogen double bond will become increasingly single bond in character, with 
both atoms undergoing a transformation from a planar s/?2-hybridised centre, to a 
tetrahedral s/?3-hybridised centre. As the new carbon-carbon bond is formed, the 
transition state for forming the new ring would be required to adopt a half-chair 
conformation (c.f. cyclohexene481). There are two such transition state conformations 
available to the molecule, with the methyl group of the existing stereogenic centre 
lying either pseudoaxially or pseudoequatorially. With the methyl group in the 
pseudoequatorial position, the formation of the new carbon-carbon bond would lead
138
to the cw-diastereomer; with the methyl group in the pseudoaxial position, the trans- 
diastereomer would form. The preferred conformation has the methyl group held in 
the pseudoequatorial conformation (c .f 4-substituted cyclohexenes481), although not 
exclusively, as some of the /ra/zs-diastereomer is formed.
149 44
NH
H
atoms and existing bonds
atoms and existing bonds, removed for clarity
bond to be made
NH
' ' ' ' i
c/s-44
3-methyl group is equatorial and sterically favoured; the c/s-diastereomer is formed
H
H
trans-44
3-methyl group is axial and sterically disfavoured; the frans-diastereomer is formed
Figure 95: Diagrammatical representation o f the conformations available during the heterocyclic ring 
formation of tetrahydroisoquinoline 44, from the Pictet-Spengler cyclisation of 38 with acetaldehyde.
A similar rationalisation was proposed by Dominguez et al for the 
diastereoselectivity seen in the Pictet-Spengler cyclisation o f 147 with acetaldehyde, 
to form 148 (see Figure 9 2 )480;482. As expected, the steric effect o f having a larger 
aryl substituent in the 3-position disfavours the transition state conformation with the 
axial disposition, thereby enhancing the stereoselectivity of the ring closure. In the 
cited example480, having a 3,4-dimethoxybenzyl substituent in the 3 position resulted 
in an 8:1 ratio of cis.trans diastereomers.
In our example, the cis- and /raws-diastereomers of 44 proved inseparable by either 
reverse-phase analytical HPLC or normal phase TLC. The derivatised BOC- 
protected amine was no better, and accessing the separate pairs of diastereomers via 
this route was not feasible.
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Using Ethynyl-4-tolylsulfone (150) to Introduce the C l-C l9 Subunit.
150
Figure 96: Ethynyl-4-tolylsulfone 150.
Rather than introducing the C l-C l’ subunit by using acetaldehyde, the possibility of 
combining the two approaches explored so far and increasing the stereoselectivity of 
the ring closure reaction by temporarily increasing the steric bulk of the C l-C l’ 
subunit was investigated. It was hoped that the introduction of the required two 
carbon subunit into the ring as a bulky achiral substituted acetylene, in conjunction 
with the potential for chiral induction by the existing stereogenic centre, would 
provide a sufficiently large improvement in diastereoselectivity to be useful. With 
the chiral sulfoxides of Lee et al. still in mind, we chose to investigate the validity of 
this approach by using the commercially available, and readily synthesised483, 
ethynyl-4-tolyl sulfone 150 (see Figure 96), which has been used as both a Michael 
acceptor484 and a Diels-Alder dienophile485.
A further potentially useful investigative aspect to the synthesis was included at this 
point. In addition to the published synthesis of 125/?, using the primary amine 122 
and 121J?s (see Figure 85), a route to the enantiomer 1255 has also been published 
by the same group486. Using the same enantiomer of the acetylenic sulfoxide 121/?s, 
but this time with a range of A-substituted analogues of 122, there was an effective 
reversal of stereoselectivity seen in the ring closure step (see Figure 97).
It was hoped these observations might be used to good effect in this latest approach 
to the stereoisomers of 44. To this end, the synthetic work now focussed upon the use 
of both the primary amine 38 and the A-benzylated secondary analogue 155 (for the 
initial routes investigated, see Figure 98). The Michael addition of the amines 38 and 
155 to the alkyne 150 was anticipated to give the P-aminovinylsulfones 156 and 157 
respectively. The acid-mediated ring closure of 156 should provide the desired 1,3- 
disubstituted-l,2,3,4-tetrahydroisoquinoline 159 directly, while the transformation of 
157 to 159 would occur via 158, with an extra deprotection/cleavage step required. 
The subsequent reductive cleavage of the sulfone should yield the desired 
tetrahydroisoquinoline 44.
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Figure 97: Literature investigations into the reaction of secondary amines 151a-e with 121i?s, and the 
effects upon the stereoselectivity o f the subsequent cyclisation472;486.
The pure enantiomer 38S  was used as the starting point throughout, as the use of 
X-ray crystallographic methods was anticipated in the determination of the absolute 
stereochemistry of the products. Such determinations are facilitated when the 
absolute stereochemistry of one chiral centre is known.
141
Route 1
Route 2
NH
156
NH
15938
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44
Figure 98: Proposed alternative routes to the isomers of tetrahydroisoquinoline 44 from the 
enantiomers o f 38, using 150 to introduce the C l-C l’ subunit.
Exploring the potential of Route 1, and Its Application to the Synthesis of the 
fra/is-Diastereomers of 44
The first route investigated (route 1, see Figure 98), from 38 to 44 via the secondary 
amine, became the route o f choice for the synthesis of the fra«s-diastereomers of 44 
(see Figure 99).
142
44(1 44(1 S,3S)
Figure 99: The desired enantiomers o f the frans-diastereomers of 6,7-dimethoxy-l,3-dimethyl-l,2,3,4- 
tetrahydroisoquinoline 44(1U!,3R) and 44(15,35).
Although a range of secondary amines were used in the synthesis of 1255 
(see Figure 97)486, we chose to investigate the utility of a substituent not published in 
this work. The A-benzylation of 385, to give (-S)-A-benzyl-2-(3,4-dimethoxyphenyl)- 
1-methylethylamine 1555, was chosen not only for its steric bulk, but also for its 
ease of preparation and removal. The A-benzylation of 385 was achieved by the 
reductive animation of benzaldehyde with sodium borohydride in methanol. The 
Michael addition of 1555 to 150 in dichloromethane gave (5)-A-benzyl-A-[2- 
(toluene-4-sulfonyl)-vinyl]-2-(3,4-dimethoxy-phenyl)-l -methylethylamine 1575 in 
good yield (see Figure 100). 1 H-NMR {J= 12.7Hz)487 and X-ray crystallographic 
structure analysis of the recrystallised product confirmed 1575 to be exclusively the 
(2s)-isomer (see Figure 101).
m9 — . -4
92% yield
38S 15SS
150, CH2CI2 
89% yield
157S
Figure 100: Route 1, from 385 to 1575.
Figure 101: Stereo plot o f the X-ray crystallographic structure analysis o f 1575, confirming the 
geometry of the p-aminovinylsulfone as (E).
The cyclisation protocol described for the syntheses of the enantiomers of J25472'486 
was successfully employed for the cyclisation of the Michael adduct 1575. When 
dissolved in dichloromethane and chilled to -15°C, cyclisation of 1575 to the desired
l,3-disubstituted-l,2,3,4-tetrahydroisoquinoline 158 was achieved in good yield by 
the addition of a large excess o f similarly chilled trifluoroacetic acid, with only one 
diastereomer evident, to the limit of NMR detection. It was hoped that NMR 
studies exploiting Nuclear Overhauser Effect (NOE) differences would indicate 
which diastereomer had been formed, but these were inconclusive. The non­
crystalline nature of 158 did not allow for the determination of the absolute 
configuration of the newly formed stereogenic centre at C-l by X-ray 
crystallographic structure analysis.
157S
H2> 10% Pd/C, 
MeOH
NH
158(1R,3S) 159(1K,3S)
Figure 102: Synthesis o f the fra«s-diastereomer 159(1/?,35), from 1575.
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Fortunately, the subsequent removal o f the benzyl group by palladium-catalysed 
hydrogenolysis gave one diastereomer by 'H-NMR spectroscopy of the highly 
crystalline 6,7-dimethoxy-3-methyl-1 -(toluene-4-sulfonylmethyl)-1,2,3,4-tetrahydro- 
isoquinoline 159 (see Figure 102). Slow crystallisation of this product from ethanol 
yielded crystals suitable for X-ray crystallographic structure analysis. This identified 
the product as the /ra/is-diastereomer, and by correlation to the known chirality at the 
3-position, established the absolute configuration of these stereoisomers o f 158 and 
159 as (l/?,35) (see Figure 103).
Figure 103: Stereo plot of the X-ray crystal structure analysis of 159(1/?,35), confirming the trans 
relationship between the 1- and 3- substituents o f the tetrahydroisoquinoline.
Mechanism
One putative mechanism for the ring closure of 157 to 158 can be envisaged as 
following a Pictet-Spengler-like process (see Figure 104). In the first part of the 
reaction, the nitrogen lone pair feeds into the p-aminovinylsulfone to create an 
iminium ion 1605, as the p-carbon picks up a proton from the acidic reaction 
medium. The iminium carbon atom is highly vulnerable to nucleophilic attack from 
the electron-rich carbon in the 6-position of the 3,4-dimethoxybenzene ring; the 
donation of electrons from the oxygen of the 3-methoxy group enhances the 
nucleophilicity o f this carbon atom. Attack from the carbon is matched by the return 
of the electrons from the iminium bond to the positively charged nitrogen atom, 
restoring this atom’s neutrality. This is the key carbon-carbon bond forming step. 
With only the loss o f the proton from carbon-8a o f the tetrahydroisoquinoline ring 
needed to allow the benzene ring to rearomatise and the methoxy oxygen to return to
145
neutral, it is the step in which the diastereoselectivity of the reaction is determined by 
the 3-dimensional conformation of the intermediate.
157S
S(0)2tol
160S
S(0)2tol
R = Bn
Figure 104:
To determine this 3-dimensional conformation, it was assumed the iminium bond has 
full double bond character, with the bond and its connected atoms coplanar. This 
bond will therefore adopt either the (E)- and/or the generally less-favoured 
(Z)-configuration (see Figure 105).
(£)-160S (Z)-160S
Figure 105: Formation and potential configurations o f the iminium bond.
158(1R,3S)
Proposed mechanism for the TFA-mediated cyclisation step, from 1575 to 158(1/?,35).
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This assumption allows for four possible conformations for the ring closure 
intermediate (see Figure 106). Of the four, only A and D will give the correct
1,3-trans substituent configuration in the product, with B and C giving the cis, which 
is not seen experimentally. Presumably the problem with B is the potential for steric 
clash between the a-methyl group and the benzyl group, which are eclipsed, and the 
problem with C is that the iminium double bond is in the less favoured (Z)- 
configuration. Since intermediate A has both of these conformational drawbacks, and 
is therefore doubly disfavoured, the intermediate D is the favoured conformation.
,SO,tol
TFA, CH2CI2, -1S°C
O
157S 158(1/?,3S)
Figure 106:
Of course, this mechanism ignores any potential participation from the sulfone, other 
than the simple contribution of inert steric bulk. This may be naive, given that the 
vinyl sulfone is a good Michael acceptor, in a similar way to 150. An alternative 
mechanism of ring closure can be envisaged for the key diastereomer determining 
step of carbon-carbon bond formation (see Figure 107). The p-carbon of the vinyl 
sulfone is vulnerable to nucleophilic attack from the electron-rich carbon in the 6-
c D
Potential intermediates for the acid-mediated ring closure of 157S  to 158(1/?,35).
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position of the 3,4-dimethoxybenzene ring. Again, the donation of electrons from the 
oxygen of the 3-methoxy group enhances the nucleophilicity of this C-6 carbon 
atom. Attack from the C-6 carbon is further facilitated by the favourable process of 
the movement of electrons into the carbon-sulfur bond, and from either of the sulfur- 
oxygen bonds onto the oxygen atom.
Once the new ring has formed, a return to neutrality within the molecule is realised 
by:
• the loss of the proton from carbon-8a of the tetrahydroisoquinoline ring, 
allowing the benzene ring to rearomatise and the methoxy oxygen to return to 
neutral;
• the return of the electrons from the sulfone oxygen into the sulfur-oxygen 
bond, and from the sulfur to the a-carbon, which picks up a proton.
o H
157S
R = Bn
N
Figure 107: An alternative mechanism for the TFA-mediated cyclisation o f 1575, to give 158(1/?,35).
Completing the Synthesis
The final step required the cleavage of the tolylsulfone from the methylene of 
159(1 R,35), to leave the desired methyl group in the 1-position of the 
tetrahydroisoquinoline, and thereby obtain the key intermediate 44(15,35). Literature 
methods for the desulfonylation of sulfones abound, and are generally via the 
reductive cleavage of the alkyl sulfone bond by a single electron transfer reagent.
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The most frequently used reagent is sodium-mercury amalgam, usually buffered in 
alcohol with disodium hydrogen phosphate and sodium dihydrogen phosphate488"490 
491. Several other electron transfer reagents have been used, including magnesium in 
ethanol, with a catalytic amount of mercuric chloride492, aluminium amalgam493, 
lithium in ethylamine488 sodium dithionite494 and samarium diiodide495. Electrolytic 
reductive cleavage has also been used496.
Trial reactions with commercially available sodium-mercury amalgams (5%, 10% 
and 20%) were low-yielding, slow and with multiple products. Of the alternative 
single electron transfer reagents available, lithium naphthalenide was investigated 
next, due to its stability and ease of preparation497. This reagent worked well, with 
rapid consumption of the starting material 159(11?,35). Unfortunately, the reaction 
gave two products, with the desired 1,3-dimethyl tetrahydroisoquinoline 44(15',35) 
formed as the minor product. The major product was identified as 6,7-dimethoxy-3- 
methyl-3,4-dihydroisoquinoline 1615, and confirmed as such by the comparison of 
!H-NMR spectral data with the commercially available racemate of 161 
(see Figure 108).
y/s\ 1. Lithium naphthalenide, 
n  ^  X  THF, -78°C 0
^  2. HCI(aq) /
159(1/?,3S) 44(1 S,3S)
minor product
Figure 108: Desulfonylation o f 159(11^,35) with lithium naphthalenide.
161S 
major product
Consideration of the reaction mechanism suggests the initial steps toward both 
products share a common mechanism (see Figure 109). The addition of the first 
electron from the napthalenide anion reduces the alkyl sulfone 159 to the 
intermediate radical anion 162(1/?,35).
°\\ / t ° i
I| = °  Lithium naphthalenide
O.. / v  (+ e-, -  naphthalene)
NH ---------------------------- --
159(1R,3S)
Li*0"\ /tol
A
"XXX
162(1 R,3S)
Figure 109: Mechanism for the formation of the intermediate 162(11?,35) common to the synthesis 
from 159(11?,35) of both 44(15,35) and 1615.
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To form the desired product 44(15,35) requires the homolytic cleavage of the sulfur- 
alkyl bond to give the alkyl radical 163(15,35) and the lithium tolylsulfinate 164 as 
shown, with the valency of the sulfur reducing from (VI) to (IV). The addition of a 
second electron to 163(15,35) gives the alkyl anion 165(15,35), with lithium as the 
counter ion. Quenching with hydrochloric acid gives the desired methyl substituent 
at the 1-position, and 44(15,35) (see Figure 110).
oII
162(1/?, 3S) 163(1S,3S)
Lithium naphthalenide 
(+ er, -  naphthalene)
Li C“
Protic quench
165(1S,3S)
44(1 S,3S)
Figure 110: Putative mechanism for the conversion of 162(1/?,35) to 44(15,35).
O, O,\ \ / to1
b  V
' \162(1/?, 3S) 161S
Li
OH
Lithium naphthalenide V 
(*er, -naphthalene) LiOH+ -
O|| HCI(a4) quench
LiCI
166
Figure 111: Putative mechanism for the conversion of 162(1/? ,35) to 1615.
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The competing mechanism (seeFigure 111) sees the charged oxygen atom of 
162(1 R,35) able to deprotonate the nitrogen of the tetrahydroisoquinoline, via a six- 
membered cyclic movement of electrons. This would give the identified side-product 
1615, and, although not isolated, a second single electron transfer could give 
tolylmethylsulfoxide 166.
With this proposed mechanism of by-product formation in mind, replacing the amine 
hydrogen with an appropriate protecting group should eliminate this side reaction. A 
simple yet effective solution to this problem was offered by revising the sequence of 
reactions from 158(1/?,35) to 44(15,35) (see Figure 112). By not removing the N- 
benzyl group until after the desulfonylation step, the side reaction to give 1615 was 
successfully eliminated. Desulfonylation of 158(1/?,35) gave the iV-benzyl-6,7- 
dimethoxy-1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline 167(15,35) in moderate 
yield. This material showed some degree of instability, with some brown 
discolouration of the colourless syrup soon apparent. Subsequent removal of the 
benzyl group by catalytic hydrogenolysis gave the desired fraws-diastereomer of the 
intermediate tetrahydroisoquinoline 44(15,35).
1. lithium naphthalenide, 
THF, -78°C;
2-HCI (aq).
158(1/?,3S) 167(1S,3S)
H2, 10% Pd on C, 
MeOH.
44(1 S,3S)
Figure 112: The synthetic route of choice, from 158(1 i f ,35) to 44(15,35), avoiding the production of 
1615.
Of note here is the potential to vary substituents at the 1-position; quenching the 
reductive desulfonylation with electrophiles other than protons would afford access
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to a range of potential functionality at this position (e.g. quenching with alkyl halides 
for chain extension, or aldehydes to introduce an alcohol moiety, etc.)498,499.
Synthesis of the trans-Diastereomers of 44
With the diastereospecific route to the resolved and enantiopure /ra«.s-diastereoniers 
of 44 from the resolved enantiomers of 38 now successfully determined, it was 
possible to obtain gram quantities of 44(1/?,3/?) and 44(15,35) in a reproducible 
fashion. For each enantiomer of 38, the primary amine was benzylated via a two- 
step, one-pot reductive alkylation reaction. Imine formation with a stoichiometric 
amount of benzaldehyde in methanol at -10°C (salt/ice bath) was followed by 
reduction with an excess of sodium borohydride, to give the enantiomers of the 
secondary amine 155 as colourless oils. Preliminary characterisation of the oils of 
155 was followed by full characterisation of a small sample of each enantiomer as 
the hydrochloride salt. The next step required the formation of the (3- 
aminovinylsulfone (/s)-157 by the addition of acetylene 150 to an ice cold solution of 
the free amine of 155 in dichloromethane on an ice/water bath. The enantiomers of 
(E)-151 were isolated in good yield as colourless crystalline solids.
Formation of the tetrahydroisoquinoline core was achieved by the addition of a large 
excess of chilled TFA (~15°C, salt/ice bath) to a similarly chilled solution (-15°C, 
salt/ice bath) of (is)-157 in dichloromethane. The cyclisation of the enantiomers of 
(E)-157 gave the fra/w-diastereomers of tetrahydroisoquinoline 158 exclusively, 
which were isolated in good yield as colourless expanded foams. Desulfonylation 
with two equivalents of lithium naphthalenide in THF at -78°C and quenching with 
aqueous hydrochloric acid gave the fraws-diastereomers of tetrahydroisoquinoline 
167 as colourless syrups. These compounds proved to be moderately unstable, 
quickly discolouring to brown, and not surviving prolonged storage; characterisation 
was confined to NMR, accurate mass and the measurement of optical rotation. The 
removal of the benzyl groups by palladium-catalysed hydrogenolysis gave the target 
tetrahydroisoquinoline intermediates 44(1/?,3/?) and 44(15,35) as pale yellow syrups, 
with final purification and full characterisation achieved by conversion to, and 
recrystallisation of, the hydrochloride salts. Diastereomeric purity was confirmed by 
the absence of any peaks in the 1H- and 13C-NMR spectra, to the limit of detection, 
corresponding to the subsequently synthesised c/s-diastereomers of 44. Only the
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desulfonylation step had a moderate yield (45%), with every other step yielding 89% 
or better.
The final synthetic reaction sequence, as applied to each enantiomer of 38, is 
described for 38R  to 44(1/?,3/?) in Figure 113.
1. MeOH, -10°C;
NH
2 + o  2. NaBH4, -10°C. 
98% yield
38/? 155 R
158(15,3/?)
89% yield
TFA, CH2CIj, -15°C
92% yield
1. lithium naphthalenide, 
THF, -7 8 #C;
2.HCI(aq).
45% isolated yield
H2, 10% Pd on C, MeOH. 
Quantitative yield
167(1/?,3/?) 44(1/?, 3/?)
Figure 113: Route to the /rans-diastereomers o f 6,7-dimethoxy-1,3-dimethyl-1,2,3,4-tetrahydro- 
isoquinoline 44, from the resolved enantiomers of 38, as exemplified for 44(111,31?) from 381?.
Exploring the potential of Route 2, and Its Application to the Synthesis of the 
cis-Diastereomers of 44
Although a successful and, to the limits of detection, stereospecific route to the trans- 
diastereomers of 44 had been established, a route to the m-diastereomers had still to 
be determined. It was hoped that the effective reversal of the stereoselectivity 
reported for the syntheses of both enantiomers of camegine 125472’486, when 
secondary (151 a-e) rather than primary (122) phenylethylamines were used 
(see Figure 85 and Figure 97), could be repeated here with the enantiomers of 38 and 
the ethynylsulfone 150 (route 2, see Figure 98). As for route 1, one enantiomer of 38 
was used to facilitate any X-ray crystal structure analysis.
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The Michael addition of 38S  to 150, to form (S)-[2-(3,4-dimethoxy-phenyl)-l- 
methyl-ethyl]-[2-(toluene-4-sulfonyl)-vinyl]amine 1565, occurred readily at ambient 
temperature in dichloromethane, with removal of the volatiles under reduced 
pressure giving the desired product in good yield. In contrast to the product of the 
reaction of 155 with 150, the product was quite clearly a mixture of (E)- and (Z)- 
isomers, as determined by !H-NMR spectroscopy. Comparison of the integrations 
and coupling constants of the signals corresponding to the vinyllic protons showed 
the ratio of E:Z to be -10:1 (see Figure 114).
H NHR Tosyl NHR
H  H
Tosyl H’ H H*
trans or E cis or Z
7 . 5  7 . 0  6 . 5  6 . 0  5 . 5  5 . 0  4 . 5  ppm
Isomer Proton 8h in CDC13 Multiplicity J tw  (Hz)*
E H 5.12 d 13.0
H’ 7.31 dd 13.0
Z H 4.49 d 8.5
H’ 6.28 dd 8.5
Figure 114: Identification o f key 'H-NMR signals in the determination of the ratio of E:Z isomers in 
1565. * Reference values for aliphatic cis and trans vicinal coupling constants are in the range 0-12Hz 
for cis (typically 8Hz) and 12-18Hz for trans (typically 15Hz)4 7
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Recrystallisation of this crude product gave the (E)-isomer of 1565 as a colourless 
waxy crystalline solid. While recording the NMR spectrum of 1565 it was noted that 
it began to isomerise immediately, eventually equilibrating to a 3:1 mixture of E:Z 
within hours. Isomerisation of this double bond can be envisaged as occurring via an 
enamine-imine tautomerisation, with accompanying bond rotation (see Figure 115).
H H
R— N -  R— N R— NV S(0)2tol  ^R—  ^S(0)atol
S (0)2tol
(E)-enamine (mine A imine B (Z)-enamine
~N. \ - N ^ y j ( 0 2i
S (0)2tol
i
III III
R£ n / h
R S (0)2to.
r hI k ' h
| S (0),to l |
H H
antiperiplanar synperiplanar, 
or 'eclipsed'
Figure 115: Proposed mechanism for the equilibration of (£)- and (^-configurations of 1565.
At first glance, the conversion of the thermodynamically more stable (£)-1565 to the 
(Z)-1565 was surprising. Although the tautomerisation of the (£)-enamine to 
imine A would allow free rotation about the carbon-carbon bond, such free rotation 
would be hindered by imine A having the sterically more favoured antiperiplanar
fAA
conformation . The tautomerisation of the (Z)-enamine would give imine B, with 
the sterically more hindered, and hence less favoured, synperiplanar500, or eclipsed, 
conformation (see Figure 115). For -25% of molecules to adopt the synperiplanar 
conformation, from which the (Z)-enamine is derived, there must be a significant 
external factor influencing the equilibrium, with the energy difference between the 
synperiplanar and antiperiplanar conformations of the imine being less than 
anticipated.
A closer examination of the (Z)-enamine reveals a possible explanation in the 
potential for the atoms of the amino-vinyl-sulfone moiety to adopt the 
conformational equivalent of an almost planar six membered ring, with either of the 
sulfone oxygens linking to the amine hydrogen via a hydrogen bonding interaction 
(see Figure 116). Such a hydrogen bond would serve to stabilise the (Z)-enamine, 
and would be anticipated to significantly reduce any conformational energy 
difference, with respect to the (iT)-enamine.
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Figure 116: Proposed stabilising hydrogen bond of the (Z)-enamine o f 1565.
To explore this equilibrium, the reaction o f 38S  with 150 was performed on an NMR 
scale in deuterated dichloromethane. The 'H-NMR spectrum for each of the starting 
materials was recorded, the samples were combined, and immediately returned to the 
spectrometer. In the time taken to load, tune the instrument and run the sample (less 
than ten minutes) the reaction had gone to completion. The 1 H-NMR spectrum 
revealed that the bond formed in the reaction was exclusively Z (literature precedent 
reports the nucleophilic addition of secondary amines to such electron deficient 
acetylenes as generally giving the (£)-conformer484). Further spectra were recorded 
at ten minute intervals, and isomerisation of this bond was seen to commence 
immediately; the ratio of E:Z reached 1:2 within 30 minutes, 1.25:1 within 100 
minutes, and had achieved an equilibrium ratio of 3:1 E:Z. within 16 hours 
(see Figure 117). Some slight differences in chemical shift meant that the vinyllic 
proton a  to the amine was not visible for the (E)-isomer, as it was overlapped by the 
peaks of the tosyl aromatic protons. However, the other vinyllic proton was clearly 
visible for both isomers, and was used to determine the isomeric ratio, in conjunction 
with the doublet corresponding to the aliphatic methyl group (8h 1.25 (Z) and 1.14 
(£)), and the multiplet corresponding to the methine (SH 3.46-3.51 (Z) and 3.35-3.40
m
As in the isomerisation of the NMR sample of the crystallised (£)-isomer, the 
equilibrium did not proceed beyond the 3:1 ratio of E:Z, in contrast to the 10:1 ratio 
of the dried residue from the crude reaction. Since the standard conditions for 
removal of the reaction solvent under reduced pressure include the use of elevated 
temperature (40°C water bath), this may have influenced the isomeric ratio of the 
crude reaction residue. However, the effect of temperature upon the isomeric 
equilibrium was not investigated.
156
B. 30 minutes
D. 16 hours
7.0 6.5 5.5 5.0 2.53.5 2 . 0 1.0 ppm
Figure 117: 'H-NMR spectra, showing the isomerism of 1565, from 2-(3,4-dimethoxyphenyl)-l- 
methylethyl]-[2-(toluene-4-sulfonyl)vinyl]amine over time
The spectra from this NMR experiment illustrate other potentially important 
differences between the two isomers (the regions of particular interest in this 
sequence of spectra are expanded in Figure 118).
a) The difference between the respective chemical shifts of the broad peaks 
corresponding to the proton of the amine is striking and informative. In 
(J5)-156£, it appears at 4.5-4.6ppm; in (Z)-156S, it is 2.3ppm downfield, at
6.8-6.9ppm. This is consistent with the extensive deshielding of an 
intramolecular hydrogen bond501, and constitutes direct experimental 
evidence for the existence of the proposed hydrogen-bonded stabilisation of 
the (Z)-enamine.
b) The peaks corresponding to the benzylic methylene (shown in the expansion 
2.45 to 2.85ppm) show that the two protons in (Z)-156S are quite clearly 
non-equivalent, having the complex coupling pattern of an ABX system, 
with the protons coupled to each other, and to the proton of the adjacent 
methine. In (Zs)-1565, they are equivalent, with only the coupling to the 
proton of the adjacent methine apparent. This would appear to indicate that
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the (^-configuration is conformationally constrained and comparatively 
inflexible.
A.10 minutes
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C. 90 minutes
D. 16 hours
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Figure 118: Expansion o f the more interesting parts of the !H-NMR spectra of 1565, showing the 
evidence for the stabilising hydrogen bond and comparative rigidity of the (Z)-isomer.
This S=0'"H-N hydrogen bond would also account for the (Z)-isomer being formed 
initially. As illustrated in Figure 119, the mechanism of this reaction requires the 
lone pair of electrons from the nitrogen of 385 to attack the electropositive carbon of 
the primary acetylene of 150, forming an ammonium ion. This is facilitated by the 
ability to push electrons from the alkyne into the carbon-sulfur bond and onto one of 
the oxygens, creating an intermediate vinylidene 1685. The electrons from this 
unstable intermediate return into the oxygen-sulfur bond and on to the alpha carbon, 
which picks up a proton. Concurrently, the ammonium nitrogen loses a proton, and 
returns to neutrality. In this example, the potential for the formation of a hydrogen 
bond between a sulfone oxygen and the amine hydrogen atom serves to direct the 
conformation of the intermediate vinylidene as the electrons return to the alpha 
carbon, forcing the reaction product into the (^-conformation. Once formed, the 
conformational equilibrium already postulated (see Figure 115) would allow the 
observed isomerisation.
This would make the (Z)-isomer the kinetic product of the reaction, and the {E)~ 
isomer the thermodynamic product.
158
38S 150 168S
.0
HN
thermodynamic product kinetic product
(£)-156S (Z)-156S
Figure 119: Mechanism for (Z)-1565 as the kinetic product of the reaction o f 385 with 150.
The TFA-mediated cyclisation of 1565 gave a good yield of the desired 
tetrahydroisoquinoline 159, but as a 3:1 mixture of diastereomers. Although a 
mixture, some separation on TLC could be seen. Pure samples o f each 
tetrahydroisoquinoline product diastereomer were obtained by column 
chromatography, although the majority of fractions still contained both. Of the pure 
samples, the major product was crystallised and characterised as the hydrochloride 
salt, while the inherently crystalline nature of the minor diastereomer allowed 
crystallisation and characterisation as the free base. Comparison of the 1 H-NMR 
spectra of these two products with the 1 H-NMR spectrum of the established trans- 
diastereomer 159(1/?,35) confirmed this to be the minor product of the reaction. The 
major product o f the TFA-induced cyclisation of 1565 was therefore the cis- 
diastereomer (see Figure 120).
159
NH 1.150, CH2CI2, 0°C;
2 2. TFA, -15°C NH NH
38S 159(1S,3S) 3:1 159(1/?, 3S)
cis:trans
Figure 120: Summary of route 2, from 38S  to the (IS, 35)- and ( l/?,3S)-diastereomers o f 159.
Why does this ring closure reaction yield the observed mixture of diastereomers, of 
reversed diastereoselectivity, to the diastereospecific route to the fraws-diastereomers 
already described? It has already been stated that, in these asymmetric Pictet- 
Spengler tetrahydroisoquinoline syntheses, the conformation of the iminium ion 
formed immediately prior to ring closure determines the orientation of the 
tetrahydroisoquinoline product. The key difference between the iminium ions of 
routes 1 and 2 is the potential for the iminium ion of route 2 to have a hydrogen 
bonding interaction between either of the sulfone oxygens and the amine hydrogen, 
similar to that already noted in the (Z)-isomer of 156 (see Figure 116). In route 1, the 
presence of the N-benzyl substituent precludes any such hydrogen bond formation. 
This potential hydrogen bond can therefore be assumed to have a key role in the 
diastereoselectivity of the cyclisation reaction.
The existence of a similar hydrogen bond was proposed in the literature synthesis of
125J?471’472 to explain the diastereoselectivity of the acid-mediated cyclisation of
123/?s- The formation of a conformationally constrained iminium intermediate 169J?s
was proposed, with a hydrogen bond between the sulfoxide oxygen and the iminium
hydrogen forming a six-membered ring (see Figure 121).
«
The diastereospecific nature of the reaction was ascribed to the stabilisation of the 
H-bond by the ortho-nitro substituent, as when the same reaction sequence was 
performed with (SsJ-ethynyl-p-tolylsulfoxide, a 2:1 ratio of product diastereomers 
was observed. This would imply that perhaps a greater degree of diastereoselectivity 
could have been achieved in this section of our work, by the use of ethynyl-2- 
nitrophenylsulfone to supply the 2-carbon unit. This reagent appears to be novel; it is 
neither commercially available, nor found in the literature.
160
TFA, OeC, 4 hours
NO.
123 Rs 124(1 A?,A?s)
169 Rs
Figure 121: Hydrogen-bonded intermediate proposed by Lee et al472.471
The isolated yield of 159(15,35) was low. As for 159(1 R,35), attempts to cleave the 
tosyl group with lithium naphthalenide gave the undesired 3,4-dihydroisoquinoline 
1615 as the major product, with the desired tetrahydroisoquinoline 44(1 R,35) formed 
as the minor product (see Figure 122).
Figure 122: Route 2, from 385 to 44(11?,3<S), one m-diastereomer of the key intermediate 
tetrahydroisoquinoline 44.
38S 150
1. CHCIj, 2hr;
2. TFA, 0°C, 4hr
Lithium naphthalenide, 
THF, -78°C
159(1S,3S) 44(1 R.3S) 161S 
major product
161
In the same way that this side reaction was overcome for the synthesis of the trans- 
diastereomers, it was hoped to eliminate this by-product by Af-benzylation of the 
nitrogen atom of 159(15,3-5)- Despite numerous attempts and reagent variation, all 
attempts to benzylate 159(15,35) failed. At this point, the decision was taken to 
abandon this approach to the c/s-diastereomers, and to return to the literature to seek 
an alternative, higher yielding and more diastereoselective route.
Investigations into the Synthesis of the cis-Diastereomers of 44, via Modification 
of the Bischler-Napieralski Tetrahydroisoquinoline Synthesis418
44(1 S,3f?) 44(1 R 3S)
Figure 123: The desired enantiomers of the cw-diastereomers o f 6,7-dimethoxy-1,3-dimethyl-1,2,3,4- 
tetrahydroisoquinoline 44(15,31?) and 44(11?,35).
There are several literature examples of synthetic approaches to compounds with cis-
1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline cores; some have already been touched 
upon. These have generally employed asymmetric reductions of 1,3-dimethyl-3,4- 
dihydroisoquinoline products of the Bischler-Napieralski isoquinoline synthesis418, 
and include:
a. the reduction of the cyclic imine 6,8-dimethoxy-1,3-dimethyl-3,4- 
dihydroisoquinoline 1135 with sodium borohydride, which was reported to 
give the cis-6,8-dimethoxy-1,3 -dimethyl-1,2,3,4-tetrahydroisoquinoline 
114(15,35) with a diastereoselectivity of greater than 95%468;
b. the reduction of the parent l,3-dimethyl-3,4-dihydroisoquinoline 118/? with 
sodium borohydride, which was reported to give a similar result, with a single 
recrystallisation of the hydrobromide salt giving the cw-1,3-dimethyl-1,2,3,4- 
tetrahydroisoquinoline 119(15,3/?) exclusively469;
c. catalytic hydrogenation of the l,3-dimethyl-3,4-dihydroisoquinoline on 10% 
palladium on carbon was also reported to give the cis product exclusively by 
‘H-NMR502.
162
38RS 170 RS
Figure 124: The synthesis o f racemic 171115 from 38RS.
171 RS
To explore the application of this approach to the synthesis of the cfs-diastereomers 
of 44, racemic 6,7-dimethoxy-1,3-dimethyl-3,4-dihydroisoquinoline 111RS was 
synthesised over two steps from 385 in modest yield. Acetylation with acetyl 
bromide gave the acetamide 170i?5, which was cyclised by dehydration using 
Bischler-Napieralski conditions of phosphorus oxychloride in toluene425 
(see Figure 124).
A trial reduction of 111RS with sodium borohydride in methanol gave 44 in a 6:1 
ratio of cis'.trans, as determined by 1 H-NMR spectroscopy (see Figure 125). The 3- 
methyl group is exerting some stereofacial selectivity, by sterically hindering the 
approach of the borohydride moiety to the cis face of the dihydroisoquinoline 111RS, 
and thereby impeding the delivery of the hydride. The use of a hydride reducing 
agent of increased steric bulk would be anticipated to increase the degree of 
stereoselectivity. A trial reaction with sodium triacetoxyborohydride, following a 
literature protocol for reductive animations with this reagent , gave a much 
improved ratio of 19:1 cis'.trans (95% d.s.) by 1 H-NMR spectroscopy 
(see Figure 125). The successful utilisation of sodium triacetoxyborohydride to 
reduce 6,7-dimethoxy-3-aryl-l-methyl-3,4-dihydroisoquinolines to cis-6,7- 
dimethoxy-3-aryl-1-methyl-1,2,3,4-tetrahydroisoquinolines with a high degree of 
diastereoselectivity (95:5 cis'.trans) has been published simultaneously to this 
investigation482.
163
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NH, CH,CHO
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Figure 125: Comparison of expanded regions of 1 H-NMR spectra, demonstrating the contrasting 
diastereoselectivities o f comparative synthetic routes from 3SRS to 44:
a) 44(1R,3R), a pure fraws-diastereomer;
b) crude product of the Pictet-Spengler reaction of 38RS with acetaldehyde;
c) the reduction of 111RS with sodium borohydride;
d) the reduction of 111RS with sodium triacetoxyborohydride;
e) 44(1J?,3.S), a pure cis-diastereomer.
Synthesis of the cis-Diastereomers of 44
Given the high diastereoselectivity seen with sodium triacetoxyborohydride, this 
protocol was chosen for the synthesis of the separate (IR,3S)~ and (15,37?)- 
stereoisomers of 44. When repeated with the pure enantiomers of 38, recrystallisation 
of the products as the hydrochloride salt gave the c/s-diastereomers as the only 
diastereomers detectable by 1 H-NMR spectroscopy (see Figure 125), and it was 
possible to obtain gram quantities of 44(11?,35) and 44(15,31?) in a reproducible 
fashion.
For each enantiomer 38, a solution in dichloromethane with triethylamine was 
chilled to -15°C on a salt/ice bath, before acetyl bromide was added. The resulting
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acetamides 170 were isolated in very good yield. Cyclisation to the enantiomers of 
171 was accomplished under Bischler-Napieralski conditions, using phosphorus 
oxychloride in toluene at reflux. Reduction of the 3,4-dihydroisoquinolines with 
sodium triacetoxyborohydride gave the desired (\R,3S)~ and (15,3/?)-enantiomers of 
44; the final route is illustrated for 44(15,3/?) from 38R  (see Figure 126).
The Final Steps in the Synthesis of the Full Structure Conformationally 
Constrained Analogues Of Capsaicin 29,30 and 31
With each of the stereoisomers of the key tetrahydroisoquinoline intermediates 42, 
43 and 44 in hand, it was possible to access the full structure thioureas 29, 30 and 31 
by following a more generic route over two steps. The first step required the removal 
of the methyl groups protecting the catechol moiety. This was achieved by dissolving 
the compounds in refluxing 48% aqueous hydrobromic acid435, usually overnight. 
The resulting catechols were all characterised as the hydrobromide salts 
(see Figure 127).
AcBr, Et3N, CH2CI2
96% yield
POCI3, PhMe, 
reflux, 5 hours
71% yield
NaBH(OAc)3> AcOH, 
1,2-dichloroethane
44(1 S,3R) 19:1 44(1/7,3R)
cls-.trans 
b y 1 H-NMR
Recrystallised from  
HCI in dioxan/MeOH.
48% isolated  yield
O.
44(1 S.3R) 
enantio- and diastereopure  
to  analytical lim its
Figure 126: Route to 44(15,31?) hydrochloride from 3SR.
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NH
R2
A
HO.
NH HBr
HO R2
B
Compound A R1 R2 Compound B Yield after 
crystallisation*
42R Me H 331? quantitative**
425 Me H 335 59%
431? H Me 341? 4%
435 H Me 345 16%
44(11?,31?) Me Me 35(11?,31?) 55%
44(15,35) Me Me 35(15,35) 50%
44(11?,35) Me Me 35(11?,35) 84%
44(15,31?) Me Me 35(15,31?) 72%
Figure 127: Demethylation of the catechols (* the yield for this reaction was quantitative, with 
crystallisation of the product catechols performed for characterisation purposes; ** 33R  was not 
recrystallised, but was rather triturated from diethyl ether).
The final step of coupling the tetrahydroisoquinolines with the isothiocyanate 32 to 
give the desired thioureas, was achieved by reaction in the presence of triethylamine 
in a dry, aprotic solvent (see Figure 128).
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HO.
NHHBr
NCS
R2HO
32
EtjN,
aprotic solvent
HO.
R2HO
Compound C R1 R2 Solvent Yield
29R Me H THF 89%
295 Me H THF 80%
30R H Me A^V-DMF 58%
305 H Me DCM 64%
31(11?,31?) Me Me N^N-DMF 82%
31(15,35) Me Me A^V-DMF 73%
31 (11?,35) Me Me A^V-DMF 67%
31(15,31?) Me Me NJV-DMF 72%
Figure 128: Final steps to the resolved stereoisomers of 29,30 and 31.
Assessing the Purity of Final Products
Despite many of the intermediate compounds being crystalline, all of the final 
compounds resolutely defied every attempt to induce crystallisation. Each full 
structure was found to be a low melting amorphous solid and some residual solvent 
was found to be present in several of the final compounds. Where necessary, solvent 
impurities have been identified by comparative 1H- and 13C-NMR spectroscopy504, 
and quantified by comparative integrations, as observed by 1 H-NMR spectroscopy. 
While successful elemental analyses were obtained for the 1-methyl and 3-methyl 
analogues, this was not possible for any of the dimethylated analogues, and the 
alternative option of using high resolution mass spectrometry to obtain an accurate 
mass value, in conjunction with the use of two separate analytical HPLC systems to 
assess compound purity, was used.
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Determining the Optical Activity and the Optical Purity of Final Products 29,30 
and 31
The determination of the optical activity of the final products was confined to the 
measurement of optical rotation, i.e. with respect to this thesis, the ability of a 
solution of an optically active substance to rotate plane polarised light, as measured 
in a polarimeter. The observed angle of rotation is generally represented by the 
symbol ct It was determined in the early nineteenth century that the value of a  for a 
given compound is proportional to:
a) the concentration c (measured in grams lOOmL1);
b) the path length / (measured in dm).
This was summarised as Biot’s law505:
1 0 0 a =  [a]cl
with the value of the compound-specific proportionality constant [a] generally cited, 
as the compound’s specific rotation. This value was later determined to be dependent 
upon wavelength (normally the sodium D-line of 589nm is used), temperature, 
concentration and solvent, all of which should be quoted with [a]. Optical activity, in 
the form of calculated values for [a], was demonstrated for each of the final products 
(see Table 6 ).
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Compound Optical rotation
29/? [a]D24-124.8 (c 1.0, CHC13)
295
J C O  H
[a] D24 +122.7 (c 1.0, CHCI3)
30/?
H0 I X a  h
[a]D25+113.0 (c 1.05, CHCI3)
305 [a] D25 -114.5 (c 1.04, CHCI3)
31(1/?,35)
hoX ^ O > ^
[a] D23 - 6 8 . 2  (c 1.00, CH2C12)
31(15,3/?) H° ^ r ^ NA N^ X T  
HOI X x H
[a] D23 +60.5 (c 1.01, CHjCb)
31(15,35)
H0I X ^ h
[a] D21 -114.4 (c 0.52, CH2C12)
31(1J?,3/?)
J X x H
[a] D21 +114.1 (c 0.54, CH2CI2)
Table 6: Measured optical rotations for the enantiomers of 29 and 30, and the diastereomers of 31.
While the four pairs of enantiomers have similar rotations of opposing sign, the 
enantiomers of the cw-diastereomers 31(1/?,3*9) and 31(15,3/?) demonstrated a 
potentially significant difference in the numerical values of their respective rotations.
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Rather than the result of stereomeric impurity, both enantiomers were seen to have 
differing amounts of cyclohexane present, as a result of the final steps taken in their 
purification. This could be seen in the !H- and 13C-NMR spectra for each compound, 
with quantification possible from the 1 H-NMR. Compound 31(1/?,35) still contained 
~0.15 equivalents of cyclohexane, while compound 31(15,3/?) had retained ~0.5 
equivalents of cyclohexane. The calculation of the specific rotation [a] does not 
account for this, relying as it does upon the absolute weight of material used (c). 
Unfortunately, any attempt to further reduce the amount of trapped solvent by oven 
drying, even at low temperatures, led to decomposition. However, this inequality in 
effective molecular weight can be compensated for by calculating the molar 
rotation [O]:
[d>] = tol.Effective molecular weight 
100
The resulting values, while not equal and opposite, are within 5% (see Table 7).
Compound Molar rotation
31(1/?,35) ....
J J X "
[<D]d23 -275.2 (c 1.00, CH2C12)
31(15,3/?)
.......O '
J L A A  ”
[ < D ] d 2 3  +262.0 (c 1.01, CH2C12)
Table 7: Calculated values o f molar rotation [O] for 31(l/?,35) and 31(15,3!?).
While useful as an indicator of chirality in the product molecules; there are 
limitations with the use of optical rotation as a measure of optical purity. 
Enantiomers do not have to be pure for a solution to be optically active; any mixture 
of enantiomers will give a value for cl While the preparation of both enantiomers of 
a given compound should give equal values of opposing rotation, without pure 
samples for comparison, the measurement of optical rotation does not allow for the
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possibility that each compound is similarly contaminated with its enantiomer i.e. 
samples of pure (R)- and pure (5)-enantiomers will give equal and opposite rotations, 
but so will e.g. 4:1 mixtures of (R):(S) and (S):(R) enantiomers.
An unequivocal measure of optical purity was therefore required for the final 
products. Analytical HPLC with a chiral column does not have the limitations of 
optical rotation. A chiral HPLC column has an optically active material covalently 
bound to the stationary phase. When passing through the column, each enantiomer of 
a pair can interact with this chiral stationary phase (CSP) to a greater or lesser extent, 
to be retarded to a greater or lesser extent, and therefore eluted from the column 
separately from its enantiomer. The quantity of each enantiomer can therefore be 
readily assessed. However, each compound class may also interact with the many 
and varied CSPs to a greater or lesser extent, requiring a sample of racemic material 
to be tried for enantiomeric separation against a range of analytical columns and 
CSPs. Of the available chiral HPLC columns, the Daicel Chemical Industries 
Chiralpak AD-H column (250 x 4.6mm) was found to successfully separate each of 
the synthesised pairs of enantiomers, by isocratic elution with mixtures of n- 
hexane/propan-2-ol containing 0.1% TFA and 0.1% diethylamine by volume.
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Confirmation of the Enantiomeric Purity of 29R and 29S
The enantiomers of 29 were successfully resolved on the specified column (see the 
section entitled Determining the Optical Activity and the Optical Purity o f Final 
Products 29, 30 and 31) by elution with a 3:1 mixture of n-hexane/propan-2-ol 
containing 0.1% TFA and 0.1 % diethylamine by volume (see Figure 129).
29/? + 295
29S
29R
1.40-
HO.
NO'
MO,
MO'
Si - , , , m | mi i  I I I ( I  I i I I ' l ' i r i  I r4.00 0.00 0.00 10.00 1241 14*00 10.00 10.00 9040 22.00 24.00
Unutw
NO,
1.00- HO'
0.40-
2.00 4.00 22.00 24.00
NO,
0.00
1 "|— i 1 • I r-i— | t t > f  r i i | ■ > n - r r r -; i r i p i  'i  i t- f -v - f- r
10.00 12.00 14.00 10.00 10.00 20.00 22:00 24*00 2o!o0 20.00
Figure 129: Chiral HPLC separation of the enantiomers o f 29.
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Confirmation of the Enantiomeric Purity of 30R and 305
The enantiomers of 30 were also successfully resolved on the specified column (see 
the section entitled Determining the Optical Activity and the Optical Purity o f Final 
Products 29, 30 and 31) by elution with a 3:1 mixture of n-hexane/propan-2-ol 
containing 0.1% TFA and 0.1% diethylamine by volume (see Figure 130).
4.00
30 R .ci
XCt
305
cj 4
i ! i iI
11i
8
I  ______
i
i _________________
A. ---
2.00 4.00 e.oo a.oo io.'oo 12.'oO u.oo
M nutM
Figure 130: Chiral HPLC separation of the enantiomers o f 30.
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Confirmation of the Enantiomeric and Diastereomeric Purity of the
Stereoisomers of 31
The four stereoisomers of 31 were found to separate on the chosen chiral analytical 
HPLC column (see the section entitled Determining the Optical Activity and the 
Optical Purity o f Final Products 29, 30 and 31). A sample containing an equal 
amount of each isomer gave baseline separation when eluted isocratically with a 4:1 
mixture of n-hexane/propan-2-ol containing 0.1% TFA and 0.1% diethylamine by 
volume (see Figure 131). When run individually in the same system, each sample 
was shown to be enantiomerically and diastereomerically pure (see Figure 132 and 
Figure 133).
0.55-
HO.
0.45:
HO'
0.40-
0.35-
0.30:
0.25:
0-20-
0.15-
0.10:
0.05-
o.oo-
Figure 131: Chiral HPLC separation o f the stereoisomers of 31.
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31(15,31?)
0.40-
0.10-
240 4.00 OW LOO' 10.00 12.00 14.00 10LOO ' 10.00 sa w  22.00 24.00 20.00 20.00 30.00
31(15,35)
0.22-
HO'
0.0*-
0.00 MlW 12.00 14.W
Figure 132: Chiral HPLC traces, demonstrating the enantiopurity o f 31(15,35) and 31(15,31?).
175
31(15,35)
31(11?, 31?)
0.**-
0.4*-
12fr
0.1*-
\ ■ ■ - I 'i'" ■' 'i"-i y  i '"t vT " '  ■ • I ■' t~ -~-T" r v i ' , i ■ ) , ■ i i | i . r | ' i . i | >■ r v  | r i .
2.00 4.00 *.0* 0.00 10.00 12.00 14.00 10.00 10.0* 20.00 22.00 24.0* 2100 2100 30.00
■1 I '"l' 1 -I—I "I * 1 1  I I 1 I ' l l  I" I ' T T 'I "J . 1 .  I I t  I I • t I ( I i I [ ) I T - f - r  I f  I T ' f T -1 I ' I r  "1
100 4.00 0.00 0.00 1&00 12.00 14.00 10.00 10.00 20.00 2100 MO* 2U 0 2100
Figure 133: Chiral HPLC traces, demonstrating the enantiopurity of 31(1/?,3/?) and 31(15,35).
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In addition to analytical HPLC, the different physical properties of diastereomers 
allows diastereomeric purity to also be measured by NMR spectroscopy. 
Examination of the !H-NMR and 13C-NMR spectra of the trans- and cis- 
diastereomers of N-(4 ’-chlorophenethylthiocarbamoyl)-6,7-dihydroxy-1,3 -dimethyl- 
1,2,3,4-tetrahydroisoquinoline revealed several signals appropriate for comparative 
purposes as a measure of diastereomeric purity (see Table 8). None of the four 
compounds showed any of the opposing diastereomer, to the limit of detection 
(see Figure 134 and Figure 135).
!h -n m r 13c -n m r
8 h ,  multiplicity 8 c
trans cis trans cis
3 -CH3 0.77, d 1.14, d 18.43 20.37
1 -CH3 1.34, d 1.38, d 23.32 21.65
AtC H aCHbCH 2.42, dd 2.55, dd
AtCHaC H bCH 3.15, dd 2.81, dd
3-H 50.63 49.27
1-H 55.45 53.52
CatH-5 6.69, s 6.55, s 113.44 115.12
CatH-8 6.71, s 6.57, s 115.86 112.97
Table 8: Comparison of *H- and ,3C-NMR peaks for the cis and trans diastereomers of 31.
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31(1/?,35)
31(15,3/?)
31(15,35)
31(1/?,3/?)
1 L
TI
3.0 2.5 ppmppm
Figure 134: Comparison of 'H-NMR spectra for the resolved diastereomers of 31.
31(1/?,35)
31(15,3/?)
31(15,35)
31(1/?,3/?;
X 1
- | , . | , , . | . | , [-
118 116 ppm
_ j   ,  ---------1
54 52 50 ppm 24 22 20 ppm
Figure 135: Comparison of the 13C-NMR spectra for the resolved diastereomers of 31.
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Conformational Analyses - Background
To recap, the conformational rationale for CPZ’s antagonism of the capsaicin- 
induced activation of the TRPV1 ion channel was based upon a comparison between 
the conformational behaviour of CPZ with that of the constrained agonist 8 
(see Figure 136) as determined by NMR spectroscopy, X-ray crystallographic
79structure analysis and molecular modelling techniques (see the section entitled 
Conformational Hypothesis for the Activity o f Capsazepine). Although the C-region 
sidechain remained flexible, the effect of the aliphatic ‘tether’ in each compound was 
to restrict the conformational space accessible to the A- and B-region 
pharmacophores.
Figure 136: The model agonist 8 and antagonist CPZ.
It was postulated that, while both compounds possessed the pharmacophores for 
binding to the receptor, the relative disposition of these pharmacophores imposed by 
the conformational constraint was such that CPZ was able to bind to the receptor site, 
but unable to attain the necessary conformation for activation of the ion channel.
For comparative purposes, a measure of the imposed conformational restriction for 
each molecule was required, and the angle a, defined as the angle of intersection of 
the planes formed by the aromatic ring of the A-region and the B-region thiourea 
(see Figure 137), was used. The values of a  accessible to each compound were 
determined by X-ray crystal structure analysis and molecular modelling, and the 
conformational rationale evolved from this comparison.
8 CPZ
ci
Figure 137: Definition of the angle a 72
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For 8, the molecular modelling suggested the heterocyclic ring was flexible, with no 
particular conformation preferred, and a  held within ±30° of co-planarity 
(see Figure 138). In comparison, molecular modelling gave four discrete and quite 
rigid conformations for the heterocyclic ring of CPZ, with 92% of the conformations 
populating one of two ‘pseudochair’ forms. These two conformations hold the two 
planes almost orthogonal to one another, with a  at ~±90°. The X-ray crystal structure 
of CPZ gave a conformation with a  equal to +93.5°.
Figure 138: Accessible low energy conformations of 8 (top) and CPZ (bottom), reproduced from 
Walpole et al11, with the C-region side chains omitted for clarity
Although the NMR spectroscopy experiments described in the original paper72 were 
primarily for analysing the tautomeric ratio of two possible orientations of the 
thiourea, the anticipated rigidity o f the seven-membered ring of CPZ was supported 
by NMR spectra from the low temperature experiment. While at room temperature 
the protons of each methylene of the conformational tether were magnetically 
equivalent and coincident; at 173K each proton gave rise to distinct signals, implying 
conformational rigidity. Similar experiments for 8 showed no distinction between 
these protons, and this was taken to confirm the highly flexible nature of the 
‘saturated’ ring.
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Conformational Analyses of the Stereoisomers of 29,30 and 31.
HO
HO
Tetrahydroisoquinolines
(8 ,2 9 ,3 0  and 31) CPZ
Figure 139: Atomic numbering for CPZ and the tetrahydroisoquinoline analogues 8, 29,30 and 31. 
NMR Spectroscopy
The principle use of NMR spectroscopy was for structural characterisation and 
confirmation; the assignment of NMR signals for every new chemical entity included 
in this thesis was made after analysis by ID ^H-, 13C- and 13C-DEPT) and 2D 
(COSY, HMBC and HMQC) experiments (for definitions, see Experimental section). 
Some conformational information was also obtained from these experiments, 
primarily as a result of increased complexity of some signals in the !H-NMR spectra 
beyond first-order approximation, in particular of the signals corresponding to the 
protons of the methylenes and methines of the bicyclic ring systems, and the 
methylenes of the C-region sidechain (for the full !H- and 13C-spectra of each 
stereoisomer of 29, 30 and 31, see Appendix 2).
For example, in the !H-NMR spectra of the enantiomers of 29, if the protons of the 
methylenes at C-3 and C-4 (see Figure 139 for numbering) were magnetically 
equivalent, first order approximation would dictate that the corresponding signals of 
the ]H-NMR spectrum would be predicted to be triplets, and the methine at C-l 
would be a doublet. Further, the methylene at C-l 1 would be a doublet of triplets. 
This was not the case (see Figure 140). While C-4 was a triplet, the others were more 
complex. C-l and one of the two protons at C-3 were broad with no splitting 
apparent, while the second proton at C-3 and the protons at C -ll had complex, 
second order splitting patterns.
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C-l 2 C-4
C-l C-ll
5.5 5.0 4.5 4.0 3.5 3.0 ppm
Figure 140: Region of the *H-NMR spectrum of 29S, showing the complexity beyond first order 
approximations of the signals corresponding to the protons of the methylenes at C-3 and C -ll, and the 
methine at C-l.
O
u
'N 
I H
S
Figure 141: Resonance forms for the thiourea moiety.
There are two possible contributory factors487. One arises from the proximity of these 
protons to the thiourea moiety. As a result of the delocalisation of ra-electrons within 
the moiety, each of the bonds between the carbon atom of the thiocarbonyl and the 
nitrogen atoms has a degree of double bond character (see Figure 141), leading to 
slow rotation about these two bonds. This would give rise to four slowly 
interconverting conformers (see Figure 142), with different magnetic environments 
for the protons concerned. Depending upon the rate of interconversion, these 
conformers may be observable within the NMR timeframe as increased complexity 
of the signal and possible line broadening. This phenomenon is known as
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environmental exchange. Variable temperature NMR experiments (not available at 
NIMS beyond a narrow temperature range) would confirm this analysis.
R3
HO.
S
HO HO R2
29: R1=Me; R2=H 
30: R1=H; R2=Me 
31: R1=Me; R2=Me
I
R3=2-(4-chlorophenyl)ethyl
HO
HO
NH
R3
HO
HO
S
Figure 142: The four possible orientations of the thiourea moiety of 29, 30 and 31..
A second phenomenon of efficient relaxation, whereby protons that are close in 
space to one another can facilitate the relaxation from the high energy state to the 
low energy state of the NMR experiment, can also lead to line broadening. The 
presence of two such broad signals would lend credence to this explanation, and by 
extrapolation imply that the conformation of the constrained portion of the molecule 
is such as to hold these protons in the correct orientation and proximity to one 
another.
For the enantiomers of 30, similarly complex signals were seen (see Figure 143). 
Rather than the signal corresponding to the methylene protons at C-l appearing as a 
singlet, the protons were non-equivalent (A8 = 0.37), and a coupled pair of doublets 
were seen. The protons of the C-4 methylene were also non-equivalent (A8 = 0.51),
Aon
and exhibited the classical ABX splitting pattern , coupled as they were with each 
other and with the proton of the methine at C-3. The geminal coupling between the 
two protons of C-l, and between the two protons of C-4, was a result of the 
conformational influence of the methyl group of the chiral centre at C-3. The 
methylene protons were magnetically non-equivalent, or diastereotopic%1.
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C-3 C-ll
5.2 4.8 4.6 4.45.0 4.2 4.0 3.8 3.6 3.4 3.2 3.0 2 . 8 2 . 6 2.4 ppm
Figure 143: Region of the !H-NMR spectrum of 30/?, showing the complexity beyond first order 
approximations of the signals corresponding to the protons of the methylenes at C-l and C -ll, and the 
methine at C-3.
In addition, the signals corresponding to the protons at C-l and the methine proton at 
C-3 were broad, and the signal corresponding to protons of the methylene at C -ll 
was considerably more complex than a first order approximation would predict. The 
likely cause is aforementioned restricted rotation of the carbon-nitrogen bonds of the 
thiourea, with the four possible slowly interconverting conformers (see Figure 142), 
causing environmental exchange.
For the /raws-diastereomers of 31 (see Figure 144), the supposed restricted rotation 
of the thiourea (see Figure 141) produced broadening of the signals corresponding to 
the C-l and C-3 methine protons, and complexity beyond first order approximation 
to the methylenes at C -ll and C-l 2. In addition, the protons of the C-4 methylene 
were diastereotopic and magnetically non-equivalent (A8 = 0.74), due to one or both 
of the stereogenic centres at C-l and C-3. They also had the classical ABX pattern in 
the !H-NMR spectrum, arising from the geminal coupling of the two protons at C-4 
with each other, and vicinal coupling with the adjacent proton at C-3.
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C-l
N-10
C-3 C-ll
Plan
Figure 144: Region of the ‘H-NMR spectrum of the tows-diastereomer 31(15'3*S), showing the 
complexity beyond first order approximations of the signals corresponding to the protons o f the 
methylenes at C -ll and C -l2, the broadening of the signals corresponding to the protons of the 
methines at C-l and C-3, and the non-equivalence and ABX splitting pattern of the signals 
corresponding to the methylene at C-4.
For the c/s-diastereomers of 31 (see Figure 145), the supposed restricted rotation of 
the thiourea (see Figure 141) only produced broadening of the signals corresponding 
to the C-l and C-3 methine protons. There was no apparent complication of the 
signals corresponding to the methylenes at C -ll and C-l2 beyond the first order 
approximation of the splitting pattern. The protons of the C-4 methylene were also 
diastereotopic and magnetically non-equivalent (A8 = 0.27), and exhibited the 
classical ABX pattern in the !H-NMR spectrum seen in other analogues.
N-li C-ll C-l 2
C-l C-4//,
5 .5 5 .0 4 .5 4 .0 3 .5 3 .0
Figure 145: !H-NMR spectrum of the cis-diastereomer 31(15,3^), showing the comparative simplicity 
of the signals corresponding to the protons o f the methylenes at C-l 1 and C -l2, the broadening o f the 
signals corresponding to the protons of the methines at C-l and C-3, and the non-equivalence and 
ABX splitting pattern of the signals corresponding to the protons of the methylene at C-4.
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X-ray Crystallographic Structure Analysis
Unfortunately, the final products resisted all efforts at crystallisation, and this 
prevented any structural analysis via this technique.
Molecular Modelling
The principle basis for the conformational rationale was molecular modelling. 
Walpole et al. used molecular dynamics simulations to study the preferred 
conformations of 8 and CPZ from 251 energy minimised structures, and a 
measurement for a  was taken for each72. A similar analysis was pursued for the new 
analogues, using the desktop molecular modelling package Spartan’02 
(Wavefunction, Inc., Irvine, CA) to generate 100 conformers within lOkcal/mol of 
the lowest energy conformer.
It is important to recognise that, while such a modelling exercise can only give an 
indication of the range of possible conformations accessible by a compound, it 
should be possible to identify the nature of the molecule, its rigidity, and the major 
conformational classes available.
Figure 146: A representation o f the conformations accessible to 8, as determined by molecular 
modelling using Spartan’02.
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Figure 147: Figure 146, minus the C-region sidechains.
The portion of interest for each molecule in this exercise was the tethered and 
conformationally constrained A- and B-regions. In keeping with the original work72, 
while the modelling was performed upon the intact molecule, the flexible 2-(4- 
chlorophenyl)ethyl C-region sidechains were removed when viewing the overlaid 
conformers, as their presence made examination of the conformer overlay difficult 
(compare the results for 8 in Figure 146 with Figure 147). For clarity, subsequent 
representations of accessible conformations are presented minus the C-region 
sidechains.
One key assumption was made when constructing the molecules. It is generally 
accepted that there is delocalisation of 7i-electrons within the thiourea moiety 
(see Figure 141), and that each of the carbon-nitrogen bonds and the carbon-sulfur 
bond of the thiourea must therefore possess a degree of double bond character. To 
accommodate this in to the model, the trigonal planar nitrogen atoms were used 
when building the molecule. Despite this, many of the low energy conformers 
demonstrated deformation of the planarity of the ring nitrogen atom, and frequent 
rotation about the bond between this nitrogen atom and the carbon atom of the 
thiocarbonyl moiety beyond the anticipated 0° and 180°. This in turn introduced
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variation into the measured values of a , as the line of coincidence between the two 
planes was altered. To accommodate this variation, it proved necessary to define an 
alternative angle to a , independent of this bond rotation, by using an alternative 
plane to that defined by the thiourea (see Figure 148). The incorporation of two 
points common to both planes (i.e. the two carbon atoms of the heterocyclic ring 
alpha to the aromatic ring) eliminated any possible distortion in the line of 
intersection between the planes. Using the thiocarbonyl carbon atom as the third
TOpoint to define the plane allowed comparison with the original work .
Figure 148: Revised planes to be used as a measure of conformational variation.
With the planes defined, the angle formed between these planes was defined as 0. 
When the thiocarbonyl carbon was in the plane of the aromatic ring, the value for 0 
was 0°. To distinguish between opposite sides of the molecule, with respect to the 
plane formed by the aromatic A-ring, it was necessary to define positive and negative 
values of 0. If the aromatic ring was held horizontally, with the catechol to the left, 
the heterocyclic ring to the right, and the benzylic carbon of C-l on the far side of the 
molecule, anything above the plane of the aromatic ring was declared to have a 
positive value for 0 and anything below the plane had a negative value for 0. The 
molecule in Figure 148 therefore had a positive value for 0.
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Comparing 8 and CPZ
As an initial exercise, and to demonstrate the suitability o f this approach, the 
modelling experiments for 8 and CPZ were reproduced.
Compound 8
s
HO
N
H
HO
vS
-50.5° < e < -14.5°; 14.8° < 0 < 47.6°
M
-------^
r
-26.8° < 0 < -16.0°; 15.8° < 0 < 16.6°
Figure 149: A tabular representation o f the conformations accessible to 8 (minus the C-region 
sidechain), as determined by molecular modelling using Spartan’02.
The molecular modelling experiment for 8 appeared to confirm the inherent 
flexibility of the aliphatic portion of the tetrahydroisoquinoline bi-cycle 
(see Figure 149). For approximately 90% of the generated conformers, the 
heterocyclic ring adopted the half-chair shape of A, as described by Olefirowicz and 
Eliel in their conformational analysis of C-methyl-l,2,3,4-tetrahydroisoquinolines506. 
This configuration placed the C-3 carbon atom and the N-2 nitrogen on opposite 
sides of the molecule, although there was also a significant minority (-10%) with 
these atoms on the same side of the molecule. Measured values for 0 were between
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-50.0° < 0 < -15.1° and 14.8° < 0 < 47.4° either side o f coplanarity, with no one 
conformation appearing preferred.
CPZ
s
A,HO N
H
HO
CPZ
A: 56.0° < 0 < 79.4° A’: -79.8° < 0  <-54.2°
m
B: 47.5° < 0 <  64.5°
h i
B’: -64.6° < 0 < -44.6°
C: 7 .3°< 0 <  11.3° C ’: -10.5° < 0  < -6 .8°
Figure 150: A tabular representation o f the conformational classes accessible to CPZ (minus the C- 
region sidechain), as determined by molecular modelling using Spartan’02.
In comparison, CPZ had three quite distinct pairs of conformers (see Figure 150). 
The most populated (-60%) conformational class was the published72 ‘orthogonal’
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conformation of A/A’ with the atoms of the saturated tether positioned on the same 
face of the molecule, as defined by the A-region aromatic ring. In addition, there 
were two other conformations: B/B’ (-35%) and C/C’ (-5%). The B/B’ 
conformation had the tether ‘straddling’ the two sides of the molecule, as defined by 
the plane of the aromatic ring. This also produced a ‘bent’ configuration, although 
not as extreme as A/A’. C/C’ produced a much more elongated structure, with 0 
between -7° and 11° either side of coplanarity.
Comparison of the Accessible Values of 0 for 8 and CPZ
The accessible values of 0 for 8 and CPZ are summarised in Figure 151, with the 
accessible ranges in black. By including every available low energy conformation for 
CPZ, rather than only the most populated72, this broadened the accessible range of 
measured values for 0. Even so, it was gratifying to see that, in keeping with the 
general requirements of the conformational hypothesis, there was almost no overlap 
between 8 and CPZ.
e°
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Figure 151: A summary of the accessible values (in black) of 0 for 8 and CPZ, as determined by 
molecular modelling using Spartan’02.
Compounds 29R  and 295
The conformers generated in the molecular modelling of the enantiomers of 29 
(see Figure 152) gave conformers with only negative values of 0 for 29R and 
positive values of 0 for 295. Each conformer was found to hold the methyl group of 
the stereogenic centre at C-l pseudoaxially and on the opposite side of the molecule 
to the thiourea moiety, with respect to the plane of the A-region aromatic ring. The 
most abundant pair of A conformers (-90%) adopted the half-chair shape, and had 
the C-3 methylene on the same side of the molecule as the methyl group. A few of 
the generated conformers had the C-3 methylene on the opposite side of the 
molecule to the methyl group, giving rise to more extended conformations. The 
measured values for 0 for these conformers fell into three discrete groupings (B, C 
and D; see Figure 152), although examples for all three were not seen for both 
enantiomers.
8
CPZ
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N f  V  N NH
X X jHO
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29 S
17.0° < e  <45.0°^ 1 .8 ° < e < - 1 7 .9 <
B
-35.1° < 0  < -31 .3°
C
-20.6° < 0  < -18 .0°
D
32.6° < 0 < 35.2°
9.2° < 0 <  10.9°
Figure 152: A tabular representation of the classes of conformation accessible to 29R and 29S  (minus 
the C-region sidechain), as determined by molecular modelling using Spartan’02.
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Compounds 30/? and 305
A: 43.9° < 0  <47.8° B: 11.7° < 0 <  38.4°
C : -5.3° < 0  < -7 .8°
D2: -39.3° < 0  <-33.7°D l:-21.2° < 0  < -16 .9°
Figure 153: A representation o f the conformations accessible to 30R (minus the C-region sidechain), 
as determined by molecular modelling using Spartan’02.
193
HO.
NH
HO
30 S
A: -46.7° < 0 < -39.4° B: -38.8° < 0 <-9.4°
C: 7 .9°< 0 <  10.1°
D l: 10.8° < 0 <  21.2° D2: 36.7° < 0 < 47.2°
Figure 154: A representation of the conformations accessible to 30S1 (minus the C-region sidechain), 
as determined by molecular modelling using Spartan’02.
The generated conformers o f 30R  and 305 gave a wide range of calculated values for 
0, and four associated conformational classes (see Figure 153 and Figure 154).
The most populated class of conformers was B (-65%). These conformers also 
adopted the half-chair shape, and had the methyl group of the stereogenic centre in a 
axial orientation, and the C-3 carbon and ring nitrogen atoms on the opposite side of 
the molecule. The remaining conformers were evenly distributed between:
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• A: those with the methyl group of the stereogenic centre in an equatorial 
orientation and the C-3 carbon and ring nitrogen atoms on the same side 
of the molecule;
• C: those with the methyl group of the stereogenic centre in a axial 
orientation, but with the C-3 carbon and ring nitrogen atoms on the same 
side of the molecule, resulting in a more extended conformation;
• D: those with the methyl group of the stereogenic centre in an equatorial 
orientation and the C-3 carbon and ring nitrogen atoms on the opposite 
side of the molecule. This class was subdivided into D1 and D2, as 
disposition of the bicycle gave two narrow ranges of values for 0, 
according to the disposition of the thiourea.
Compound 31 (fra/is-diastereomers)
For each of the fraws-diastereomers of 31, the heterocyclic ring of every
conformational class adopted the half-chair configuration (see Figure 155 and 
Figure 156). One conformational class (A) dominated, with >90% of the conformers 
generated holding the two methyl groups of the stereogenic centres at C-l and C-3 
on opposite sides of the molecule and in pseudoaxial/axial orientations. 
Conformational class A gave values for 0 of between -36.6° and -8.8° for 31(11?,31?) 
and between 8.1° and 37.0° for 31(15,35).
In comparison, the minor conformational class B had the two methyl groups on the 
same side of the molecule and, while the C-l methyl group was still pseudoaxial, 
the C-3 methyl group was now equatorial.
A single example of a third conformational class C was generated for 31 (11?,31?), and 
had the C-l methyl with a pseudoequatorial disposition, and the C-3 methyl 
oriented axially, again placing the methyl groups on opposite sides of the molecule. 
Presumably 31(15,35) would also access this conformation.
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31(1/?,3/?)
-36.6° <  0 < - 8 . 8°
I
-40.6° < 0 < -23.0°
C
0 = 47.5
Figure 155: A representation o f the three conformational classes o f conformation generated for 
31(1/?,3/?) (minus the C-region sidechain), as determined by molecular modelling using Spartan’02.
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31(1S,3S)
26.7° < 0 < 40.6°
Figure 156: A representation of the two conformational classes of conformation generated for 
31 (15,35) (minus the C-region sidechain), as determined by molecular modelling using Spartan’02.
Compound 31 (m-diastereomers)
Of the generated minimum energy conformers of the c/s-diastereomers of 31, 
approximately 75% were seen to adopt conformations within class A with the 
heterocyclic ring adopting the half-chair configuration (see Figure 157 and 
Figure 158). As in the /ra«s-diastereomers, the methyl group at C-l was held in a 
pseudoaxial orientation, while the methyl group at C-3 was held in a genuinely axial 
orientation, but this time the methyl groups were held on the same side of the 
molecule, and the measured values for 0 were between -10° and 28° (negative for 
31(1/?,35), positive for 31(15,3/?)).
By comparison, the heterocyclic ring of the conformers in class B (20-25% of the 
generated conformations) appeared to be boat-shaped, with the two methyl groups of 
the stereogenic centres at C-l and C-3 held on opposite sides of the molecule; with 
C-l adopting an pseudoaxial orientation, and C-3 an equatorial one. Three
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examples of a third conformational class C were generated for 31 (IS,3/?); while 
these retained the pseudoaxial orientation of the C-l methyl group and the 
equatorial orientation of the C-3 methyl, the ring adopted the now familiar half­
chair, placing the methyl groups on opposite sides of the molecule. Presumably 
31(1/?,35) would also access this conformation.
HO
NH
HO
A
-28.3° < 0  < -9 .8°
B
-62.3° < 0  < -36 .0°
Figure 157: A representation of the two classes of conformation generated for 31(1/?,35) (minus the 
C-region sidechain), as determined by molecular modelling using Spartan’02.
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HO
NH
HO
A
9.8° < 0 < 27.2°
B
l !
i  * n M
42.9° < 0 < 60.0°
C
h
Figure 158: A representation o f the three classes of conformation generated for 31(1 S,3R) (minus the 
C-region sidechain), as determined by molecular modelling using Spartan’02.
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Can 0 be Used to Predict Activity at TRPV1?
e°
Compound -90 -80 -70 -60 - 50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90
8
31(1/? ,3k )
31(1S,3S)
31(1/?,3S)
31(1S,3/?)
Accessible values for 0
Figure 159: Graphic summation of the accessible ranges of measured values of 0 for the low energy 
conformers generated for each of 8, CPZ, and the stereoisomers of 29, 30 and 31.
Figure 159 summarises the range of measured values of 0 for the generated 
conformers of each compound, with the accessible ranges in black. If 0 could be used 
to predict activity, only the c/s-diastereomers of 31 had the potential to be active as 
antagonists, as only they had a significant overlap with CPZ while failing to overlap 
significantly with all of the values accessible to 8. This was already in contrast to the 
original biological data for the racemates of 29 and 30, and the mixture of 
stereoisomers of 31, which indicated that all three mixtures were antagonists of the 
capsaicin-induced uptake of 45Ca2+ by neonatal rat DRG neurons, with no agonist 
activity. The biological activity of each stereoisomer of 29, 30 and 31 was assessed 
to explore this contradiction.
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Biology
Introduction
The primary assays for determining the activities of test compounds against TRPV1 
were performed by the Biology Department of the Novartis Institute for Medical 
Sciences (NIMS) in London.
Key points:
• the opening of the TRPV1 ion channel causes changes in [Ca ]\. This 
allows the activation of TRPV1, and inhibition of any such activation, to 
be followed by monitoring changes in [Ca ]*;
• when testing compounds for antagonism, it is possible for potent agonist 
compounds to gave false readings as potent antagonists, through 
desensitisation of the TRPV1 ion channel (see Antinociceptive Action o f 
Capsaicin). It was therefore necessary to initially test the synthesised
stereoisomers of 29, 30 and 31 for any agonism at TRPV1, before
entering them into the antagonist assays.
The decision to resolve by synthesis the stereoisomers of 29, 30 and 31 was made 
based upon the biological activity of the unresolved mixtures of stereoisomers as 
antagonists of the capsaicin-induced influx of 45Ca2+ ions into cultured neonatal rat 
DRG neurones66 (see the section entitled Further conformationally constrained 
antagonists). The commencement of the synthetic phase of this research project was 
accompanied by a number of key advances in the study of the biological actions of 
capsaicin, including:
• the identification of the capsaicin receptor as TRP V173;
• the successful cloning and stable expression of TRPV1 orthologues for,
amongst others, rat73, guinea pig77 and human74;75.
• the identification of other activators of TRPV1, such as low pH and
noxious heat73.
These key advances resulted in the replacement at NIMS of the isolated, cultured 
DRG neurone with Chinese hamster ovary (CHO) cells expressing the required
nc
orthologue of TRPV1, cloned from DRG derived cDNA libraries . Each cell line 
was fully characterised and validated as representative for native TRPV1 activity, 
using capsaicin, low pH and noxious heat75.
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While having the advantage of accurately representing the native state, the 
harvesting, isolation and culturing of DRG neurones from neonatal rats is time 
consuming, labour intensive and comparatively low yielding. CHO cells stably 
transfected with cDNA for TRPV1 orthologues are more stable, more robust and are 
amenable to being grown in culture, hence are ethically preferable.
In addition to changes in cells, the development of fluorimetric techniques to 
measure [Ca2+]i, have removed the requirement to use the radioactive isotope 45 of 
calcium in cell-based functional assays. The cytosolic concentration of calcium ions
9+[Ca ]i can now be measured by using any one of a number of commercially 
available fluorimetric dyes. Generally, each dye incorporates a fluorophore, and 
selectively chelates calcium ions. The chelation of a calcium ion causes both a shift 
in the wavelength and an increase in the intensity of the fluorescence. The change in 
fluorescence is proportional to [Ca2+]i, thereby the measurement of changes in 
fluorescence allows the measurement of changes in [Ca2+]i. Two fluorimetric dyes 
were used for the assays at NIMS; the dye used in the agonist assay was fluo-4507 
(see Figure 160), and the dye used in the antagonist assays was fura-2508 
(see Figure 161). Each dye was loaded into intact cells by incubation with the 
membrane-soluble acetoxymethyl (AM) ester form (see Figure 160 and Figure 161); 
once incorporated into the cell, cytosolic esterases hydrolyse the ester groups, to 
leave the membrane-impermeable form of the dye ‘trapped’ within the cell.
HO
OH
OH
'cytosolic esterases'
HO
HO
Fluo-4-AM Fluo-4
Figure 160: Structure o f the fluorimetric dye fluo-4 and its membrane-permeable precursor fluo-4- 
AM507.
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Fura-2-AM
OH
OH
'cytoso lic  esterases'
HO
OH
Fura-2
Figure 161: Structure of the fluorimetric dye fura-2 and its membrane-permeable precursor fura-2 - 
AM508.
Biological Assay Strategy and Data
Given the advances made since the original mixtures of stereoisomers of 29, 30 and 
31 were assayed, it was no longer possible have the resolved stereoisomers tested 
against neonatal rat DRG neurones. Instead, these compounds were initially tested as 
potential agonists at CHO cells expressing either rTRPVl or hTRPVl, with the 1,3- 
unsubstituted analogue 8  included for comparison (see Table 9), and only 
compounds showing no, or very weak, agonist activity were subsequently tested as 
antagonists of both capsaicin-mediated and low pH-mediated activation of rTRPVl 
and hTRPVl, with CPZ included for comparison (see Table 10).
As already described, CPZ is an antagonist of the capsaicin-induced activation of the 
rat73, guinea pig77 and human75 orthologues of TRPV1. However, while CPZ also 
successfully blocks the opening of TRPV1 by protons and noxious heat in the guinea 
pig77 and the human75, CPZ does not block the proton-induced activation of TRPV1 
in the rat75, and is much less effective at inhibiting the noxious heat-induced 
activation of the same75 (see section entitled CPZ as an Analgesic).
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Agonist assay data; EC50 in pM. 
(percentage of maximal capsaicin response)
Compound rTRPVl hTRPVl
Capsaicin 0.0043±0.0003 0.0075±0.0005
8 0.0026±0.0008
(109.4±1.7)
0.0265±0.0121
(71.7±9.2)
CPZ Not active @ 30pM Not active @ 30pM
29R 0.1344±0.078
(109.0±5.5)
> 2 1
(34.8±9.8)
29S 0 .0 1 2 2 ±0 . 0 1 1
(89.4±3.1)
Not active @ 30pM
301? 0.0505±0.0055
(77.7±4.4)
Not active @ 30pM
305 0.0097±0.0036
(84.0±2.7)
Not active @ 30pM
31(11?,31?) 1.086±0.3129
(103.6±2.5)
13.34±3.62
(59.7±9.1)
31(15,35) 0.0452±0.0187
(58.9±2.5)
Not active @ 30pM
31(11?,35) 13.93±6.7225
(72.6±3.3)
Not active @ 30pM
31(15,31?) Not active @ 30pM Not active @ 30pM
Table 9: In vitro data for the resolved stereoisomers o f 29, 30 and 31 as agonists at hTRPVl and 
rTRPVl.
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Antagonist assay data; I C 5 0  in pM
rTRPVl hTRPVl
Compound vs. pH vs. capsaicin vs. pH vs. capsaicin
CPZ > 1 0 0.640±0.04 0.103±0.02 0.093±0.018
29R Agonist, so not tested >30 2.012±0.28
295 Agonist, so not tested >30 0.055±0.013
301? Agonist, so not tested >30 0.079±0.011
305 Agonist, so not tested 0.166±0.045 0.017±0.0031
31 (11?,31?) Agonist, so not tested >30 4.20±0.73
31(15,35) Agonist, so not tested No fit 0 .0 2 1 ±0 . 0 1 0
31(11?,35) Agonist, so not tested >30 0.767±0.133
31(15,31?) >30 0.161±0.014 0.390±0.085 0.045±0.0051
Table 10: In vitro data for the resolved stereoisomers o f 29, 30 and 31 as antagonists of capsaicin- and 
pH-induced activation of the rat (rTRPVl) and the human (hTRPVl) orthologues of TRPV1.
What was immediately apparent from the agonist data in Table 9 was that, despite 
the original 45Ca2+/DRG assay identifying the racemates of 29 and 30 as having no 
agonist activity in the rat at up to lOOpM (see the section entitled Further 
Conformationally Constrained Antagonists), the current protocol has identified the 
resolved enantiomers of each as moderate to potent agonists at rTRPVl. This was 
most unexpected, as the activities of capsaicin, 8  and CPZ were consistent across the 
agonist and antagonist assays (see Figure 162).
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agonist EC50(|xM) antagonist vs. capsaicin IC50(|xM)
DRG/45Ca2+ CHO-rTRPVl
Fluo-4
DRG/45Ca2+ CHO-rTRPVl
Fura-2
Capsaicin 0.30±0.01 0.0043±0.0003 NT NT
8 0.29 ±0.04 0.0026±0.0008 NT NT
CPZ >100 >30 0.420 ± 0.046 0.640±0.04
Figure 162: Comparison of capsaicin, 8 and CPZ as agonists of rat DRG neurones and rTRPVl 
expressed in CHO cells, and CPZ as an antagonist of the capsaicin-induced activation of rat DRG 
neurones and rTRPVl expressed in CHO cells.
These contradictory data could not be reconciled with one another. Unfortunately, it 
was not possible to assay either the original mixtures of stereoisomers of 29, 30 and 
31 in the CHO cell-based functional assays, or the resolved stereoisomers as agonists 
of the capsaicin receptor in isolated, cultured neonatal rat DRG neurones, as the 
running of these assays has been discontinued at NIMS. One plausible explanation 
stems from the fact that ion channels such as TRPV1 do not work in isolation, but in 
conjunction with many accessory proteins that modulate the function of the ion 
channel. In the assays using CHO cells and recombinant DNA, although the cloned 
and expressed orthologue of TRPV1 is from the rat, the full complement of 
accessory proteins in CHO cells are the hamster equivalent. While this is 
unimportant for capsaicin, 8 and CPZ, it is enough to alter the functionality of the 
receptor complex, with respect to the resolved enantiomers of 29 and 30, and 
possibly 31(15,35).
Whatever the reason, this difference in activity between the ‘wild’ type TRPV1 of 
the rat DRG neurone and the recombinant rat orthologue in CHO cells requires 
investigation.
Interestingly, the resolved diastereomers of 31 feature both a potent agonist of 
rTRPVl in 31(15,35), and a potent capsaicin antagonist in 31(15,31?). The mixture 
of stereoisomers of 31 also showed no agonist activity in the original 45Ca2+/DRG 
assay, but this could be explained by the relative potencies and diastereomeric ratio 
in the mixture (6:1, cis:trans; see Figure 93).
What is also apparent from considering the agonist data from Table 9 and the 
antagonist data from Table 10 is there is a profound species difference in the activity 
of almost every one of the resolved compounds. Given that the only difference
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between the two cell lines is the origin of the TRPV1 DNA, this must be the reason 
for the difference. Although there is some evidence for species selectivity in the 
activity of some compounds at these two orthologues of TRPV 1 (e.g. phorbol-12- 
phenylacetate-13-acetate-20-homo-vanillate (PPAHV) shows some agonism of 
ratTRPVl, but is virtually inactive at human TRPV l 75, and CPZ is a more potent 
blocker of the capsaicin-induced activation of human TRPV1 than rat TRPV l 75) 
these are the first compounds to show agonism at one orthologue of TRPV1 and 
antagonism at another. Such compounds could prove highly useful in the 
exploration of the functional differences between the active sites of rat TRPV1 and 
human TRPV1.
Analysis of the Biological Data, and its Comparison with 0
Rather than a direct comparison with the conformational rationale of Walpole et 
al. , is it possible to formulate a similar hypothesis for the resolved stereoisomers of 
29, 30 and 31 at the recombinant rat and human orthologues of TRPV1 in CHO 
cells?
Does 0 predict biological activity in the rat?
By taking the conformational summary table of Figure 159, and colour coding each 
compound for biological activity at rTRPVl (see Figure 163), patterns do emerge, 
and a conformational hypothesis formulated that 0 does appear predictive. The 
comparatively low potency of CPZ against capsaicin at rTRPVl might also be 
explained.
0°
Compound - 9 0 - 8 0 - 7 0 - 6 0 - 5 0 ^ 0 - 3 0 - 2 0 - 1 0  0 10 20 30 40 50 60 70 80 90
inactive'
agonist EC50<60nM 
antagonist vs. capsaicin IC50<1pM
Figure 163: Figure 159, incorporating biological activity at rTRPVl.
207
• There is extensive overlap between the potent agonist analogues and 8.
• For biological activity at rTRPVl {i.e., be it agonist EC50 <60nM, or
antagonist IC50 <lpM), an analogue must be able to access 
conformations where 0 is positive; all of the black ‘inactive’ compounds
{i.e. 29R, 31(1/?,3/?) and 31(1/?,35)) have almost exclusively negative
values for 0.
• Since half of the conformations of CPZ have values of 0 < 0°, and the 
rigidity of the molecule described in the literature72 would indicate the 
requirement of a high input of energy to flip the ring from a 
conformation with a negative values of 0 to one with a positive values, 
would suggest that at any one time half of the molecules of CPZ are 
‘stuck’ in an inactive conformation.
• Assuming neither CPZ nor 31(15,3/?) can attain the necessary 
conformation for agonism, a comparison of 8 with 31(15,3/?) indicates 
that a potent agonist must be able to access conformations such that 
25° < 0 < 43°, the only values of 0 accessible to 8, but not accessed by 
31(15,3/?).
• Consideration of the values of 0 accessed by the newly discovered 
agonists 295, 30/?, 305 and 31(15,35) narrows down this range to 37° < 
0 < 38°, although as stated earlier, 100 conformations is by no means an 
exhaustive and complete picture of the accessible conformations, and the 
agonism of 29R (EC50 135nM) appears anomalous.
• The comparison of CPZ with 31(15,3/?) indicates that a potent antagonist 
of capsaicin at rat TRPV1 must be able to access 47° < 0 < 60°.
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Does 0 predict biological activity in the human?
Compound -90 -80 -70  -60  - 50 -40  -30  -20  -10  0 10 20 30 40 50 60 70 80 90
8
CPZ 
29 R
29 S
30 R 
30 S
31(1/? ,3/?)
31(1S,3S)
31(1/?,3S)
31(1S,3/?)
|  'inactive'
^ ■ ■ a g o n i s t  EC50<50nM
■  antagonist vs. capsaicin IC50<100nM
■  antagonist vs. capsaicin IC50<100nM & vs. low pH
Figure 164: Figure 159, incorporating biological activity at hTRPVl, including data vs. low pH.
As for the rat data, the human data was plotted against 0 by colour-coding the 
conformational summary table (Figure 159) for biological activity (see Figure 164).
• Biological activity (i.e., be it agonist EC50 <50nM or antagonist IC50  
<100nM) was confined to the same molecules that displayed biological 
activity in the rat orthologue assays.
• Of the four novel rat agonists (295, 30/?, 305 and 31(15,35)), all were 
antagonists of capsaicin induced activity in the human. As a result, there was 
complete overlap between the values for 0 accredited to the model agonist 8, 
and compounds with potent antagonism, as represented by 295, 30/? and 
31(15,35); 0 could not therefore be used to distinguish between agonism and 
antagonism in human TRPV 1.
• Two of the new compounds, 305 and 31(15,3/?), were antagonists of both 
capsaicin and low pH (c.f. CPZ) It was not possible to identify values of 0 
unique to these molecules that did not overlap with agonist 8. Again, while 
the 100 conformations generated in the molecular modelling experiment were 
in no way an exhaustive and complete picture of the accessible 
conformations, and 305 may access conformers with values of 0>47° not 
generated by the molecular modelling experiment, this experiment indicated
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that 0 could not be used to predict whether a compound would be a combined 
antagonist of capsaicin and low pH in human TRPV1.
Other determinants must therefore be responsible for fine-tuning the biological 
activity of these analogues at the human orthologue of TRPV 1.
CPZ and 31(15,31?)
HO.
HO
CPZ
= s
HO^ ^  ^Cl
Cl
Figure 165: Reminder o f the structures CPZ and 31(15,31?)
Only one of the resolved conformationally constrained stereoisomers (31(15,31?)) 
had a similar activity profile to CPZ, although the potencies differed (see Table 11). 
By comparing the accessible values of 0 for CPZ and 31(15,31?) against each other 
and compound 8, it was possible to identify the range of values of 0 the active 
conformation of each of CPZ and 31(15,31?) must access as 47° < 0 < 60° 
(see Figure 166). By comparing this range of values for 0 with the conformational 
classes generated for each compound (for CPZ, see Figure 150; for 31(15,31?), 
see Figure 158), it was possible to identify the active conformation of CPZ as BCpz, 
and the active conformation of 31(15,31?) as B3i(i5 /^?) (see Figure 167).
I C 5 0  in pM
rTRPVl hTRPVl
Compound vs pH vs. capsaicin vs pH vs. capsaicin
CPZ >10 0.640±0.04 0.103±0.02 0.093±0.018
31(15,31?) >30 0.161±0.014 0.390±0.085 0.045±0.0051
Table 11: In vitro data for CPZ and 31(15,3R) as antagonists o f capsaicin- and pH-induced activation 
of the rat (rTRPVl) and the human (hTRPVl) orthologues of TRPV1.
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8
CPZ
31(1S,3fl) H + m  o w n
Accessible values for 0
Figure 166: Comparison of the accessible values of 0 for the low energy conformers generated for 
each of 8, CPZ and 31(153/?).
CPZ 31(15,3/?)
Figure 167: The active conformations o f CPZ and 31(15,3/?) as generated by Spartan’02.
Since B c p z  forms only 19% of the generated conformers for CPZ, and 8 3 1 (1 5 ,3/?) 
forms only 25% of the generated conformers for 31(15,3/?), it would be interesting to 
identify, synthesise and test a more conformationally constrained analogue.
211
CONCLUSION
212
In conclusion, this thesis describes the successful stereoselective syntheses of the 
stereoisomers of iV-(4-chlorophenethylthiocarbamoyl)-6,7-dihydroxy-1 -methyl-
1.2.3.4-tetrahydro-isoquinoline 29, TV-(4-chlorophenethylthio-carbamoyl)-6,7-dihyd- 
roxy-3-methyl-l,2,3,4-tetrahydroisoquinoline 30 and 7V-(4-chlorophenethylthio- 
carbamoyl)-6,7-dihydroxy-1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline 31, via the 
development of successful stereoselective routes to the intermediate 6,7-dimethoxy-
1.2.3.4-tetrahydroisoquinoline precursors 42, 43 and 44.
The enantiomers of 6,7-dimethoxy-l-methyl-l,2,3,4-tetrahydroisoquinoline 42 were 
obtained by the modification of a literature route, employing the enantiomers of (1- 
phenylethyl)isocyanate as resolving agents (see Figure 168).
77, ex-M aybridge 42 RS
ii
0
X
oA
76(1 S,aR) - c ry s ta llin e ; p u re 76(1 R,aJR) - non-crysta lline ; 90% d.e.
ill, v.
Hi, iv
76(1 R,aS) - cry sta lline; p u re
iii, iv.
.0
4 2S 42 R
i. NaBH4, MeOH, 0°C - r.t.; ii. (R)-(1-phenylethyl)isocyanate 75R, Et3N, CH2CI2; 
iii. 2M NaOBu/BuOH, reflux; iv. hydrogen chloride, 1,4-dioxane/methanol; 
v.(S)-(1-phenylethyl)isocyanate 75S, EtgN, CH2CI2.
Figure 168: Synthetic route to the pure (/?)- and (5)-enantiomers of 42.
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The resolution of the stereogenic centre in the enantiomers of 6,7-dimethoxy-3- 
methyl-1,2,3,4-tetrahydroisoquinoline 43 was achieved by the separation of the 
enantiomers of 2-(3,4-dimethoxyphenyl)-l-methylethylamine 38 by crystallisation 
with the enantiomers of mandelic acid, and subsequent methylene insertion and ring 
closure under the conditions of the Pictet-Spengler tetrahydroisoquinoline 
synthesis415’426 (see Figure 169).
38 RS
Repeat recrystallisation from 
EtOAc/MeOH a s the (R)-mandelate
OH
NH,
+
38S
Freebase 
(dissolve in water, 
baslfy with NaOH, 
extract into CH2CI2).
38S
(CH20 )n, AcOH, 40°C
° W ^ nh
43S
Repeat recrystallisation from 
EtOAc/MeOH as the (S)-mandelate
OH
nh;
38 R 103S
Freebase 
(dissolve in water, 
basify with NaOH, 
extract into CH2CI2).
NH2
38R
(CH20 )n, AcOH, 40°C
43 R
Figure 169: Synthesis o f the enantiomers o f 43 via the resolution of the enantiomers 38.
The enantiomers of the c/s-diastereomer of 6,7-dimethoxy-l,3-dimethyl-l,2,3,4- 
tetrahydroisoquinoline 44 were synthesised by the stereoselective reduction of the 
enantiomers of 6,7-dimethoxy-l,3-dimethyl-3,4-dihydroisoquinoline 171 with 
sodium triacetoxyborohydride. The enantiomers of 171 were synthesised from the 
resolved enantiomers of 38 via acetylation and cyclisation under Bischler- 
Napieralski conditions418;425 (see Figure 170).
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NH,
'''/
AcBr, Et3N, CH2CI2 
96% yield
38#?
HN
170#?
POCI3, PhMe, 
reflux, 5 hours
71% yield
171#?
NaBH(OAc)3> AcOH, 
1 ,2 -dichloroethane
/ 0 Y V ^ nh +
44(1 S,3#?) 19:1
cis:trans 
by 1H-NMR
44(1#?,3#?)
Recrystallised from 
HCI in dioxan/MeOH.
48% isolated yield
/ ° W V nhhci
44(1 S.3R) 
enantio- and diastereopure 
to analytical limits
Figure 170: Route to 44(15’,3/?), one enantiomer of the ds-diastereomer of 44, from 38J?.
The enantiomers of the /ra«s-diastereomer of 44 were also synthesised from the 
enantiomers of 38, via a novel, efficient and highly stereoselective route. The 
enantiomers of Ar-benzyl-2-(3,4-dimethoxyphenyl)-1 -methylethylamine 155 were 
formed by reductive benzylation of the resolved enantiomers of 38 with 
benzaldehyde and sodium borohydride. Michael addition of 155 to ethynyl-4- 
tolylsulfone 150, followed by TFA-mediated cyclisation, single electron reductive 
desulfonylation and palladium-catalysed hydrogenolysis, gave the desired 
enantiomers of the fraws-diastereomers of 6,7-dimethoxy-1,3-dimethyl-1,2,3,4- 
tetrahydroisoquinoline 44 (see Figure 171).
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158(1S,3/?)
89% yield
TFA, CH2CI2, -15°C
92% yield
1. lithium naphthalenide, 
THF, -78°C;
2.HCI(aq).
45% isolated yield
H2, 10% Pd on C, MeOH.
Quantitative yield
NH
O' ^  ^  °'/
44(1 R.3R)167(1/7,3/?)
Figure 171: Route to the 44(11?,3U), one enantiomer of the /rans-diastereomer of 44, from 38R.
The results of investigations into the conformational behaviour of the resolved 
stereoisomers of 29, 30 and 31 by techniques of NMR spectroscopy and molecular 
modelling, the evaluation of their biological activity at the rat and human orthologues 
of the ion channel TRPV1, and the attempted correlation of the two sets of data, with 
respect to the published conformational rationale for the activity of CPZ, are also 
described.
The use of the original conformational parameter a  of Walpole et al. {Walpole, 
Bevan, et al. 1994 635 /id} proved to give variable results with the different 
molecular modelling software. This variability was overcome by defining a new 
parameter 0, and revising the conformational hypothesis accordingly.
The comparison of 0 with the biological activity data demonstrated a general 
correlation between 0 and the activity of the compounds tested for the rat orthologue 
of TRPV 1, but not for the human orthologue. Of the compounds tested, 31(15,31?) 
had a similar activity profile to CPZ, and a comparison of the values of 0 available to
each of 31(15,31?), CPZ and 8 has suggested a target set of values of 0 when aiming 
for future conformationally constrained capsaicin analogues with an activity profile 
akin to CPZ.
Finally, no less than four of the eight analogues (295, 301?, 305 and 31(15,35)) have 
been identified as potent antagonists (IC5o<100nM) of the capsaicin-induced 
activation of the human orthologue of TRPV1, while being potent agonists 
(EC5o<60nM) of the rat orthologue of TRPV1. Compounds possessing opposing 
activities for different mammalian orthologues of TRPV1 have not been previously 
described in the literature.
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EXPERIMENTAL PROCEDURES
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Instrumentation and methods 
NMR:
*H-NMR were measured at 400MHz, and recorded on a Bruker DPX400 
spectrometer.
13C-NMR were measured at 100MHz on the same instrument.
For samples in CDCI3, CD2CI2 and DMSO-ck, tetramethylsilane was used as an 
internal reference to 80.00, unless otherwise stated.
For samples in D2O, the sodium salt of 3 -(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d4  acid 
was used as an internal reference to 80.00, unless otherwise stated.
In addition to the usual 1-dimensional lR- and 13C-NMR experiments, spectroscopic 
interpretation was facilitated by performing the following series of experiments for 
the majority of compounds synthesised:
13C DEPT (Distortionless Enhancement by Polarisation Transfer) is an experiment 
which uses polarisation transfer from protons to the 13C nuclei to enhance signal 
strength. This experiment can also distinguish whether there are an odd or even 
number of protons attached to each carbon atom, and can separate CH and CH3 peaks 
form CH2 . Peaks due to quaternary carbons do not appear;
H,H-COSY (Correlation SpectroscopY) is a 2D experiment to identify coupled 
pairs of protons;
HMQC (Heteronuclear Multiple Quantum Coherence) is a 2D experiment which 
correlates the signals from the 13C-NMR spectrum with those of the ]H-NMR 
spectrum, to determine which carbons are directly bonded to which protons ( lJcu)- 
HMBC (Heteronuclear Multiple Bond Correlation) is a 2D experiment to determine 
long range couplings between carbon atoms, and the protons attached via two (V c h )  
or three (3*/ch) bonds. Of note here is the observation that, particularly in aromatic 
systems, Vch can be considerably stronger than 2J c h , as there is no simple 
relationship between the size of "Jch and the number of intervening bonds This can 
lead to some confusion for the uninitiated, and accurate interpretation requires 
careful analysis of the spectrum in combination with other data509.
IR:
IR spectra were recorded either at NIMS on a Nicolet Avatar 360 FT-IR 
spectrometer as a film (neat), or by Analytical Services at Novartis Pharma, Basle on 
a Bruker IFS 6 6  FT-IR spectrometer, either as KBr pellets or telquel film.
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All values are given in cm'1.
MS:
Mass spectral data were recorded at Novartis Pharma, Basle.
Electron impact ionisation mass spectra (El) were recorded, using a Finnigan MAT 
8430 spectrometer (acceleration voltage 3000V).
Electron spray ionisation mass spectra (ESI) were recorded on a Fisons VG Platform 
II (capillary voltage 3000V).
High resolution electron spray ionisation mass spectra (HRMS) were recorded as an 
average of 10 measurements, on a Finnigan MAT 900 S spectrometer (capillary 
voltage 4700V), against PEG 400 as the standard.
X-rav crystallography:
X-ray crystallography was performed at Novartis Pharma AG Basle. Data was 
collected using a Nonius CAD4 diffractometer, with the structures solved using 
SHELXS-86 and SHELXL-93.
Elemental analysis:
Elemental analyses were obtained from Solvias AG in Basle, and are within ±0.4% 
of calculated values.
Optical rotations:
Optical rotations were measured on an Optical Activity AA-100 polarimeter.
Melting points:
Melting points were recorded on a Thermovar Hot Stage microscope, and are 
uncorrected.
Thin layer chromatography (TLC):
Analytical TLC was performed on either Merck or Whatman 0.25mm silica gel 60-F 
plates.
Column chromatography:
Flash column chromatography was performed using the Biotage FLASH 12i or 40i 
systems.
Analytical high performance liquid chromatography (HPLC):
Reverse phase analytical HPLC was performed using either the Waters 600E system 
controller, 717 autosampler and 996 photodiode array detector and analysed using 
Waters Millennium software, or the Waters Alliance HPLC system, plus 2996 
photodiode array, and analysed using Waters Empower software.
Analytical systems employed were:
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Column Elution conditions Wavelength
Svstem 1 Phenomenex 
Luna 3p C l8 
(30 x 4.6mm)
Gradient, from 10-100% 
acetonitrile in 0.08% aqueous 
formic acid at 3.0 ml/min over 
10 minutes
254nm
Svstem 2 Phenomenex 
Synergi 4p MAX-RP 
(50 x 4.6mm)
Gradient, from 10-100% 
methanol in 0.1% aqueous TFA 
at 2.0 ml/min over 10 minutes
254nm
Svstem 3 Hichrom Ltd 
Nucleosil 
120-5C18-250A 
(250 x 4.6mm)
Gradient, from 10-100% 
acetonitrile in 0.1% aqueous 
TFA at 1.5 ml/min over 38 
minutes
340nm
Svstem 4 Phenomenex 
Kingsorb 3\i C l8 
(30 x 4.6mm)
Gradient, from 10-100% 
acetonitrile in 0.1% aqueous 
TFA at 3.0 ml/min over 10 
minutes
340nm
All reactions were stirred by magnetic hotplate and follower under an atmosphere of 
either dry nitrogen or dry argon at room temperature, unless otherwise stated.
Molecular Modelling
Studies on the compounds 8, CPZ, 29R, 295, 30R, 305, 31(1/?,3/?), 31(15,35), 
31(1/?,35) and 31(15,3/?) were performed, using the desktop molecular modelling 
package Spartan’02 (Wavefunction, Inc., Irvine, CA). The molecules were 
constructed using the build element of Spartan’02, and a local minimum energy 
conformation generated using Molecular Mechanics Force Fields (MMFF94 -  Merck 
Pharmaceuticals). A representative sample of the conformer distribution available to 
each compound was generated by applying the same force fields to the local 
minimum energy conformation to generate a 100 low energy conformers within 
lOkcal/mol of the lowest energy conformer. These were sorted into groups of similar 
conformation, overlaid and the C-region sidechains deleted for clarity. The parameter 
0 was measured for each, using Spartan’02 (for the definition of 0, see the section 
entitled Molecular Modelling within the section entitled Conformational Analyses o f 
the Stereoisomers o f29, 30 and 31.).
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Enantiomers of iV-(4-chlorophenethylthiocarbamoyl)-6,7-dihydroxy-l-methyl-
1,2,3,4-tetrahydroisoquinoline analogues (29R and 29S)
6,7-Dimethoxy-l-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (42RS)
3,4-Dihydro-6,7-dimethoxy-l-methylisoquinoline 77 (ex-Maybridge Chemicals; lOg,
0.0488mol) was dissolved in methanol and cooled on an ice/water bath. Sodium 
borohydride (ex-Lancaster Synthesis; 5.54g, 0.1463mol, 3 equivalents) was added 
portionwise over fifteen minutes. Once addition was complete, the reaction was left 
to slowly come to room temperature overnight, when it was poured into 0.5M 
aqueous sodium hydroxide (500mL) and the product extracted into dichloromethane 
(2 x 250mL). The combined extractions were washed with brine (lOOmL), and dried 
over dried magnesium sulfate. Filtration, and the removal of solvent under reduced 
pressure, gave an orange syrup (lOg). The residue was dissolved in dioxan (80mL); 
4.0M hydrogen chloride in dioxan (20mL) was added with stirring. The resultant 
suspension was heated to boiling, and sufficient methanol (~25mL) was added to 
dissolve the precipitate; the solution was hot-filtered, and left to cool to room 
temperature overnight. Crystallisation was induced by sonication; the precipitate was 
filtered and washed with diethyl ether, to give a colourless crystalline solid (1 0 . lg, 
85%). Despite attempts to dry the compound (18hours/0.1mmHg/100°C), 
characterisation ^H-NMR, IR and elemental analysis) revealed the presence of -0.17 
equivalents of water, assumed to be solvent of crystallisation from ‘wet’ methanol: 
Characterisation:
TLC: R f 0.23 (dichloromethane/ methanol/ 32% AcOH(aq.) 90:9:1);
Melting point: 194-5°C (literature 196-197°C {Spath & Dengel 1938 8  /id});
1H-NMR(DMSO-d6): dH 1.61 (3H, d, J = 6 .8 Hz, CHCtf3), 2.86-2.92 (1H, m,
ArC//AHBCH2), 2.96-3.02 (1H, m, ArCHA/T„CH2), 3.16-3.23 
(1H, m, CH2C7yACHBN) 3.30-3.39 (1H, m, CH2CHAC//BN),
3.47 (H20), 3.73 (3H, s, ArOC//3), 3.74 (3H, s, ArOC/y3),
4.41 (1H, quartet,V= 6 .8 Hz, C#CH3), 6.77 (1H, s, AiH-5),
6.84 (1H, s, Ar/f-8 ), 9.75 (2H, br, N/72+);
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ru C-NMR(DMSO-d«): 6 C 19.11 (CHCH3), 24.47 (ArCH2CH2), 38.16 (CH2CH2N),
49.75 (CHCH3), 55.41 (ArOCH3), 55.61 (ArOCH3), 109.41 
(CatH-8), 111.53 (CatH-5), 123.62 (CAr-4a), 125.75 (CAr-8a),
147.56 (CArOMe), 147.97 (CArOMe);
MS (El) m/z: M+ 207(21), [M-CH3]+ 192(100), [M-OCH3]+ 176(18);
IR (KBr) jVcm: 3430 (H20), 2543 (N^-H), 1516 (CAr=CAr), 1226 (CAr-OMe);
Microanalysis (C,H,N): Calculated for Ci2Hi8NO2Cl(+0.17 H20): 58.42,7.49,5.68;
Found: 58.39/58.41,7.33/7.36,5.72/5.82
2-((/?)-l-Phenylethyl)carbamoyl-6,7-dimethoxy-l-methyl-l,2,3,4-tetrahydroiso- 
quinoline (76(l«5,aB))444
Racemic 42RS  (11.5g, 0.0472mol) was dissolved in dry dichloromethane (lOOmL) 
with triethylamine (7.23mL, 5.26g, 0.0520mol, 1.1 equivalents) and stirred under 
nitrogen. After cooling on an ice/water bath, (R)-(l-phenylethyl)isocyanate 15R 
(6.62mL, 6.95g, 0.0472mol) was added, and the reaction was stirred at room 
temperature overnight.
The reaction was diluted to 500mL with dichloromethane, and washed consecutively 
with 2.0M hydrochloric acid (2 x 100mL), water (lOOmL) and brine (50mL), before 
drying over dried magnesium sulfate. Filtration and the removal of solvent under 
reduced pressure gave a brown foam (~17.0g, quantitative). Separation of the 
mixture of diastereomers formed was not apparent by TLC (one spot) or reverse 
phase HPLC (system 1: a single peak, with a retention time of 5.1 minutes). The 
separate diastereomers were visualised by:
1. an alternative normal phase analytical HPLC method (Anachem CHI-D- 
PGC-250A (250 x 4.6mm) column; isocratic elution 20% propan-2-ol in n- 
hexane; 2 1 0 nm),
2. ]H-NMR spectral analysis at each of the two aliphatic methyl signals, and
3. 13C-NMR spectral analysis at the peaks corresponding to the racemic 
stereogenic carbon, the attached methyl group, and the tetrahydroisoquinoline 
ring methylenes.
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Characterisation:
TLC: R/0.46 (cyclohexane/ethyl acetate 1:1)
^-NM R (CDCI3): 5h 1.43-1.46 (3H, 2 x d  overlapping, y=6.7Hz,
tetrahydroisoquinoline CHC//3), 1.49-1.52 (3H, 2 x d
overlapping, J=6.9Hz, PhCHCtf3), 2.67-2.73 (1H, m, 
ArGHTAHBCH2), 2.79-2.88 (1H, m, ArCHAtfBCH2), 3.23-3.30 
(1H, m, CH2CtfAHBN), 3.83 (3H, s, ArOCJT3), 3.84 (3H, s, 
ArOC//3), 3.91-3.97 (1 H, m, CH2CHA/ / BN), 4.71-4.77 (1 H, 
m, N//), 4.99-5.09 (2H, m, overlapping
tetrahydroisoquinoline C//CH3 and PhC//CH3), 6.57-6.60 
(2H, br, ArH-5, -8 ), 7.21-7.26 (1H, m, Phtf-4’), 7.30-7.36 
(4H, m, Phff-2’, -3’, -5’, -6 ’); 
i3C-NMR (CDCI3): Sc 21.99, 22.09 (tetrahydroisoquinoline CHCH3), 22.63
(PhCHCH3), 28.35, 28.41 (tetrahydroisoquinoline
ArCH2CH2), 37.80, 37.84 (tetrahydroisoquinoline
CH2CH2N), 49.99, 50.04 (tetrahydroisoquinoline CHCH3), 
50.17 (PhCHCH3), 55.93, 56.03 (2xArOCH3), 109.85 
(CatH-8 ), 111.36 (CatH-5), 126.12 (C^H-2’, C^H-6 ’), 
126.16 (CAr-4a), 127.04 (CArH-4’), 128.58 (CatH-3’, C^H- 
5’), 130.71 (CAr-8 a), 144.70 (C ^-l’), 147.64 (C^OMe), 
147.69 (CArOMe), 156.14 (C=0);
(5)-2-((l?)-l -Phenylethyl)carbamoyi-6,7-dimethoxy-l -methyl-1,2,3,4-tetrahydro- 
isoquinoline (76(15', ai?))444
Initial separation of the diastereomers of 76(l/?5,a/?) (~17.0g), was achieved by 
trituration of the foam with hot ethyl acetate (40mL); the suspension was alternately 
sonicated and heated, until a fine precipitate was apparent. Filtration gave a 
colourless powdered solid (8.3g, 50% from 42RS), which was seen to be 
predominantly one diastereomer of 76 by lH-NMR. The removal of solvent from the 
filtrate under reduced pressure gave a beige foam (8.2g, 49%); !H-NMR confirmed
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this foam to be predominantly the other diastereomer of 76. The precipitate was 
suspended in hot propan-2-ol (50mL); dichloromethane was added until everything 
was in solution (~85mL). The solution was cooled to room temperature, then 
refrigerated overnight. It was necessary to remove much of the dichloromethane 
under reduced pressure to induce crystallisation. Filtration gave a colourless 
crystalline solid (5.50g, 33% of a maximum possible 50%), confirmed as one 
diastereomer (d.e. 100% by HPLC, rH- and 13C-NMR):
Characterisation:
TLC: R f 0.46 (cyclohexane/ethyl acetate 1:1);
Melting point: 210°C;
Optical rotation [ck]d20: +75.0 (c 0.7, chloroform) (lit. +48.0 (c 0.7, chloroform)444;
^-NM R (CDCI3): SH 1.44 (3H, d, J=6.7Hz, tetrahydroisoquinoline CHCtf3),
1.50 (3H, d, J=  6.9Hz, PhCHC//3), 2.67-2.73 (1H, m, 
ArCtfAHBCH2), 2.79-2.88 (1H, m, ArCHA/ / BCH2), 3.23-3.30 
(1H, m, CH2CtfAHBN), 3.83 (3H, s, ArOCtf3), 3.84 (3H, s, 
ArOCtf3), 3.91-3.97 (1H, m, CH2CHAtfBN), 4.75 (1H, d, 
J=  7.1Hz, NH), 4.99-5.09 (2H, m, overlapping
tetrahydroisoquinoline C//CH3 and PhC//CH3), 6.57 (1H, s, 
Ar/7-8), 6.59 (1 H, s, ArfT-5), 7.21-7.26 (1H, m, Phtf-4’),
7.30-7.36 (4H, m, Phff-2’, -3’, -5’, -6 ’); 
i3C-NMR (CDCI3): Sc 22.09 (tetrahydroisoquinoline CHCHj), 22.63 (PhCHCH3),
28.41 (ArCH2CH2), 37.84 (CH2CH2N), 50.04 
(tetrahydroisoquinoline CHCH3), 50.17 (PhCHCH3), 55.93,
56.03 (2 x ArOCH3), 109.85 (C^H-8 ), 111.36 (C^H-5),
126.12 (CArH-2’, CArH-6 ’), 126.16 ( C ^ a ) ,  127.04 (CatH- 
4’), 128.58 (CatH-3’, CatH-5’), 130.71 (C^-Sa), 144.70 (Cat 
1’), 147.64 (CArOMe), 147.69 (CArOMe), 156.14 (C=0);
MS (ESI positive) m/z: MH+ 355(35), [M+Na]+ 377(100);
IR (KBr) v/cm: 3422 (NH), 1642 (C=0), 1519 (Cat^at), 1252 (CAr-OMe);
Microanalysis (C,H,N): Calculated for C2 iH26N20 3 71.16, 7.39, 7.90;
Found 70.91, 7.47, 7.84.
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(i?)-2-((i?)-l-Phenylethyl)carbamoyl-6,7-dimethoxy-l-methyl-l,2,3,4-tetrahydro- 
isoquinoline (76(1/?,a/?))444
The mother liquors from the repeat recrystallisations to resolve the pure 76(15',aR) 
were combined, and the solvents were removed under reduced pressure, to give a 
beige foam; !H-NMR confirmed this to be predominantly 76(1/?,a/?), with a small 
amount of residual 76(15,a/?). Attempts to remove the residual 76(15,a/?) by 
fractional crystallisation were unsuccessful. Despite repeated recrystallisations, a 
trace of the crystalline diastereomer was always apparent, both in the HPLC traces 
and the NMR spectra. NMR data for the major diastereomer, the non-crystalline 
76(1/?,aR) is given:
Characterisation:
!H-NMR (CDC13): 8 h 1.46 (3H, d, J = 6 .7Hz, tetrahydroisoquinoline CHC//3),
1.52 (3H, d, J=  6.8Hz, PhCHCZ/3), 2.67-2.73 (1H, m, 
ArC/yAHBCH2), 2.79-2.88 (1H, m, ArCHA/ / BCH2), 3.23-3.30 
(1 H, m, CH2C//AHBN), 3.83 (3H, s, A1OC//3), 3.84 (3H, s, 
ArOCJ/3), 3.91-3.97 (1 H, m, CH2CHA/ /BN), 4.75 (1H, d, 
J=  7.1Hz, NH), 4.98-5.01 (1H, m, C//CH3) 5.06-5.11 (1H, 
m, C//CH3), 6.59-6.60 (2H, 2 x overlapping s, AiH-5, ArH- 
8 ), 7.21-7.26 (1H, m, Phtf-4’), 7.30-7.36 (4H, m, Ph//-2\ - 
3’, -5’, -6 ’);
UC-NMR (CDCI3): 5c 21.96 (tetrahydroisoquinoline CHCH3), 22.62 (PhCHCH3),
28.32 (ArCH2CH2), 37.71 (CH2 CH2N), 49.95 
(tetrahydroisoquinoline CHCH3), 50.10 (PhCHCHs), 55.88, 
55.97 (2 x ArOCH3), 109.71 (C^H-8 ), 111.25 (C^H-5), 
126.09 (CArH-2’, CArH-6 ’), 126.16 ( C ^ a ) ,  127.03 (CArH- 
4’), 128.54 (C^H-3’, C^H-5’), 130.60 (Cm-8 a), 144.49 (Cm~ 
1’), 147.52 (CArOMe), 147.64 (CArOMe), 156.14 (C=0).
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(/?)-2-((5)-l-Phenylethyl)carbamoyl-6,7-dimethoxy-l-methyl-l,2,3,4-tetrahydro- 
isoquinoline (76(1/?,a5))
This material was synthesised in two steps from the impure 
76(1/?,a/?) (+ 76(15,a/?)), obtained from the mother liquors of the resolution of the 
pure diastereomer 76(15,aR).
i) Sodium spheres (3.45g, 0.15mol) were dissolved in dry butan-l-ol (75mL), in a 
flame-dried round-bottomed flask, under argon. The impure 
76(1/?,aR) (+ 76(15,a/?)) (lOg, 0.0282mol) was dissolved in hot butan-l-ol (35mL), 
and added to the sodium butoxide solution. The resultant solution was stirred at 
reflux for six hours, cooled to room temperature, and poured into 2.0M aqueous 
hydrochloric acid (300mL) to quench residual sodium butoxide. The solution was 
washed with ether (2 x lOOmL); the combined ether washes were washed with fresh 
2.0M aqueous hydrochloric acid (lOOmL), then discarded. The aqueous layers were 
combined, basified by the addition of 5.0M aqueous sodium hydroxide (25GmL), and 
the desired product was extracted into dichloromethane (3 x lOOmL). The combined 
dichloromethane extractions were washed with brine (50mL), and dried over dried 
magnesium sulfate. The filtration and removal of solvent under reduced pressure 
gave a yellow syrup (6 .2 g, > 1 0 0 %).
The residue was purified by being dissolved in dioxan (30mL), to which 
concentrated hydrochloric acid (7.5mL, ~3 equivalents) was added. After 24 hours, 
crystallisation had to be induced by sonication for a few seconds in the sonic bath, 
whereupon an immediate dense colourless precipitate was produced. Filtration of the 
precipitate, washing with diethyl ether and drying gave a colourless powdered solid 
(4.15g, 60%), which ^-N M R  confirmed as the pure hydrochloride salt of 42. 
Removal of the solvents from the mother liquor under reduced pressure gave a 
further 4.0g of material as a brown syrup; ^-N M R confirmed this syrup to contain 
the desired hydrochloride salt of 42 (maximum 2.73g, 0.01 lmol), contaminated with 
dioxan and minor unidentified impurities.
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iia) The pure hydrochloride salt of 42 (4.0g, 0.0164mol) was suspended in dry 
dichloromethane with stirring, and 1.1 equivalents of triethylamine (2.5mL, 1.82g, 
0.0180mol) were added. The mixture was stirred for ten minutes, after which time 
(£)-( 1 -phenylethyl) isocyanate 755 (2.3mL, 2.41g, 0.0164mol) was added in dry 
dichloromethane (lOmL) dropwise over five minutes. After three hours, the reaction 
was washed with dilute aqueous hydrochloric acid (2 x 50mL) and brine (50mL), and 
dried over dried magnesium sulfate. The filtration and removal of volatile 
components under reduced pressure gave a colourless foam (5.5g). !H-NMR 
confirmed this crude material to be predominantly the desired 76(1/?,a5) (by 
comparison with spectral details for 76(15,a/?)).
iib) The impure residue was assumed to contain 0.01 lmol of the hydrochloride salt 
of 42, and was dissolved in dry dichloromethane (lOOmL) with triethylamine (1.70g, 
0.0168mol, 1.5 equivalents). A solution of 755 (1.55mL, 1.61g, 0.01 lmol) in dry 
dichloromethane (lOmL) was added. After eighteen hours, the solution was washed 
with dilute aqueous hydrochloric acid (2 x 50mL) and brine (50mL), and dried over 
dried magnesium sulfate. The filtration, and removal of solvent under reduced 
pressure gave an orange solid. The residue was sonicated in hot ethyl acetate (20mL), 
left to cool to room temperature and filtered. The solid was washed with fresh ethyl 
acetate, and dried by suction; this gave a colourless powdered solid (1.55g, 40%) 
which ^-N M R confirmed as predominantly the desired 76(1/?,a5) (by comparison 
with spectral details for 76(15,a/?)).
On the basis of comparing the !H-NMR spectra of the crude products from iia) and 
iib), the two were combined, to give a total of 7g of impure 76(1/?,a5).
The combined material was suspended in boiling propan-2-ol (50mL) and sufficient 
dichloromethane (lOOmL) was added to achieve dissolution. The solution was left 
loosely covered overnight, to cool slowly to room temperature, while allowing some 
of the more volatile dichloromethane to evaporate. Filtration gave the pure 
76(1/?,a5) as a colourless crystalline solid (4.1g, 42%), with diastereomeric purity 
being established by !H- and 13C-NMR analysis. Several crystals were sent for X-ray 
analysis, to confirm the assigned stereochemistry of the tetrahydroisoquinoline as 
(l/?,o5).
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Characterisation:
TLC:
Melting point:
Optical rotation [ajo22: 
lH-NMR ( C D C I 3 ) :
13C-NMR (CDCI3):
MS (El) m/z:
IR (KBr) v/cm: 
Microanalysis (C,H,N):
R/0.45 (cyclohexane/ethyl acetate 1:1);
210-211°C;
-75.1 (c 0.7, chloroform);
Sh 1.44 (3H, d, J=  6.7Hz, tetrahydroisoquinoline CHC/Tj),
1.50 (3H, d, J=  6.9Hz, PhCHC//3), 2.67-2.73 (1H, m, 
AtGHaHbCHz), 2.79-2.87 (1H, m, ArCHAtfBCH2), 3.23-3.30 
(1H, m, CH2C/yAHBN), 3.83 (3H, s, ArOC/73), 3.84 (3H, s, 
ArOCtf3), 3.91-3.97 (1H, m, CH2CHAtfBN), 4.73 (1H, d, 
J=  7.1Hz, NH), 4.99-5.09 (2H, m, overlapping
tetrahydroisoquinoline CHCH3 and PhC/fCH3), 6.58 (1H, s, 
Ar/7-8), 6.59 (1H, s, Ar/7-5), 7.21-7.26 (1H, m, Phff-4’),
7.30-7.36 (4H, m, Phtf-2’, -3’, -5’, -6 ’);
5c 22.09 (tetrahydroisoquinoline CHCH3), 22.63 (PhCHCH3),
28.41 (ArCH2CH2), 37.85 (CH2CH2N), 50.05 
(tetrahydroisoquinoline CHCH3), 50.17 (PhCHCH3), 55.93,
56.03 (2 x ArOCH3), 109.85 (C^H-8 ), 111.36 (C^H-5),
126.12 (C^H-2’, CatH-6 ’), 126.16 ( C ^ a ) ,  127.05 (CArH- 
4’), 128.58 (CatH-3’, C^H-5’), 130.71 (C^-Sa), 144.70 ( C a t -  
1’), 147.64 (C^OMe), 147.70 (C^OMe), 156.14 (C=0);
M +  354(27), [ M - C H 3 ] +  339(32), 
[ M - ( C 6H 5 C H ( C H 3 ) N H C 0 + C H 3 ) ] + 192(100);
3422 (NH), 1643 (C=0), 1519 (CAr-CAr), 1253 (Cat-OMc); 
Calculated for C2 iH26N20 3: 71.16, 7.39, 7.90;
Found: 71.13, 7.18, 7.92.
(»S)-6,7-Dimethoxy-l-methyl-1,2,3,4-tetrahydroisoquinoline 
(42 S)
hydrochloride444
NH
HCI
A 2.0M solution of sodium n-butoxide in butan-l-ol was prepared by dissolving 
sodium spheres (1.15g, 0.05mol) in dry butan-l-ol (25mL) in a flame-dried round-
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bottomed flask under argon. 76(15',ctR) (3.54g, O.Olmol) was added to the sodium 
butoxide solution, and the resultant mixture was stirred at reflux; after three hours the 
reaction, now a clear solution, was allowed to cool to room temperature, before 
quenching the reaction by pouring into 2.0M aqueous hydrochloric acid (300mL). 
The solution was washed with ether (lOOmL); the ether layer was washed with fresh 
2.0M aqueous hydrochloric acid (lOOmL) then discarded. The aqueous layers were 
combined, basified by the addition of 5.0M aqueous sodium hydroxide (80mL), and 
the desired product was extracted into dichloromethane (2 x lOOmL). The combined 
dichloromethane extractions were washed with brine (50mL), and dried over dried 
magnesium sulfate, filtration and removal of solvent under reduced pressure gave a 
colourless syrup. The syrup was dissolved in dioxan (lOmL); the addition of 4.0M 
hydrogen chloride in dioxan (5mL, 2.0equivalents) to the stirred solution gave a 
dense colourless precipitate. The suspension was heated to boiling, and the minimum 
amount of methanol to dissolve the precipitate was added. The solution was allowed 
to cool to room temperature; filtration gave a colourless crystalline solid (1.07g, 
44%). Refrigeration gave a further crop of colourless crystals (600mg, 25%; total 
1.67g. 69%):
Characterisation:
TLC:
Melting point: 
Optical rotation [a]D 
'H-NMR(D20):
20.
13C-NMR (D20):
MS (El) m/z: 
IR (KBr) v/cm:
R f 0.23 (dichloromethane/ methanol/ 32% AcOH(aq.) 90:9:1); 
237-238°C (lit. 238-240°C444);
-26.6 (c 2.1, H20) (lit. -25.6 (c 2.1, H2O444);
6h 1.75 (3H, d, J=  6 .8 Hz, CHCJft), 3.04-3.17 (2H, m, 
ArC//2CH2), 3.43-3.50 (1H, m, CH2CffAHBN), 3.61-3.68 
(CH2CHaHbN), 3.87-3.89 (6 H, 2 x s overlapping,
2 x A1OC//3), 4.64 (1H, quartet, J  = 6 .8 Hz, GffCH3), 6.92 
(2H, s, AiH-5, ArH-S);
Sc 21.74 (CHCH3), 27.33 (ArCH2CH2), 41.99 (CH2 CH2N),
53.89 (CHCHj), 58.55 (ArOCH3), 58.67 (ArOCH3), 112.02 
(CatH-8), 114.53 (CatH-5), 126.73 (C ^ a ) ,  128.06 (CV83), 
150.18 (CArOMe-7), 150.69 (CArOMe-6);
M4" 207(18), [M-CH3]+ 192(100);
1516 (Cat-Cat), 1226 (CAr-OMe);
Microanalysis (C,H,N): Calculated for C12H18NO2CI: 59.14, 7.44, 5.75;
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Found: 58.92, 7.30, 5.87.
(J?)-6,7-Dimethoxy-l -methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride444 
(421?)
Five equivalents of a 2.0M solution of sodium butoxide in butan-l-ol were prepared 
by dissolving sodium spheres (1.27g, 0.055mol) in dry butan-l-ol (27.5mL) in a 
flame-dried 100ml round-bottomed flask under an atmosphere of argon. 76(11?,aS) 
(3.86g, 0.01 lmol) was added to the solution, and the resulting suspension was stirred 
at reflux (oil bath temperature of 130°C), with the last of the solid entering solution 
after 90 minutes. After a further two hours, the solution was cooled to room 
temperature, and quenched by pouring into 2.0M aqueous hydrochloric acid 
(lOOmL). Neutral species were extracted into diethyl ether (lOOmL); this extraction 
was washed with 2.0M aqueous hydrochloric acid (lOOmL), then discarded. The 
combined aqueous phases were basified with 5.0M aqueous sodium hydroxide, and 
the desired product was extracted into dichloromethane (2 x lOOmL). The combined 
dichloromethane extractions were washed with brine (50mL), and dried over dried 
magnesium sulfate. Filtration and removal of the solvent under reduced pressure 
gave a colourless oil, which was dissolved in dioxan (15mL). 4.0M Hydrogen 
chloride in dioxan (5.5mL, 2 equivalents) was added to the solution; the resulting 
suspension was heated to boiling, and methanol was added dropwise until the 
precipitate dissolved. The solution was hot filtered, and left to cool to room 
temperature overnight. Filtration, washing with ether and drying at 125°C under 
vacuum, gave a colourless crystalline solid (1.1 Og, 41%):
Characterisation:
TLC: /?/0.23 (dichloromethane/ methanol/ 32% AcOH(aq.) 90:9:1);
Melting point: 239-240°C (lit. 240-242°C444);
Optical rotation [a]D22: +26.6 (c 2 .1 , H20) (lit. +24.1 (c 1.8 , H2O444);
'H-NMR (D20): dH 1.75 (3H, d, J=6.8Hz, CHC//3), 3.05-3.17 (2H, m,
AiC//2CH2), 3.43-3.50 (1H, m, CH2C//AHBN), 3.62-3.68 
(CH2CHa//bN), 3.87-3.90 (6 H, 2 x s overlapping,
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2 x ArOCf/3), 4.64 (1H, quartet, 7=6.8Hz, C#CH3), 6.91 
(2H, s, ArH-5, Ar/T-8);
C-NMR (D20): 8 c 21.74 (CHCH3), 27.35 (ArCH2CH2), 42.00 (CH2CH2N),
53.90 (CHCH3), 58.51 (ArOCH3), 58.62 (ArOCH3), 111.94 
(CatH-8), 114.46 (CatH-5), 126.70 (CAr-4a), 128.29 (CAr-8a), 
150.14 (CArOMe-7), 150.64 (CArOMe-6);
MS (ESI-positive) m/z: MH+208(100);
I R  (KBr) v/cm: 1516 ( C a t - C a t ) ,  1267 ( C A r - O M e ) ;
Microanalysis (C,H,N): Calculated for Ci2H18N 02C1: 59.14, 7.44, 5.75;
Found 58.83, 7.27,5.91.
(5)-6,7-Dihydroxy-l-methyl-l,2,3,4-tetrahydroisoquinoline hydrobromide 
(335):
4 3 5
NH
HO
HO v  v  HBr
The hydrochloride salt of 425 (900mg, 0.0037mol) was dissolved in 48% aqueous 
hydrobromic acid (lOmL), and stirred at reflux for eighteen hours. The solvent was 
removed under reduced pressure to give a beige solid; trituration with a hot 1:1 
mixture of diethyl ether and propan-2-ol, followed by sonication, refrigeration and 
filtration, gave the pure catechol as a colourless powdered crystalline solid (570mg,
181-182°C (lit. 174-5°C435);
-32.0 (c 1.02, methanol) (lit. [ajo = -30.9 (methanol)435)
5h 1.65 (3H, d, J=  6.8Hz, CHCJT3), 2.93-3.06 (2H, m, 
ArCH2 CH2), 3.37-3.44 (1H, m, CH2C ^AHBN), 3.54-3.61 
(1H, m, CH2CHa/7bN), 4.53 (1H, quartet, J=6.8Hz, 
C^CH3), 6.75 (1H, s, Ar^-8), 6.79 (1H, s, Ar/T-5);
6C 21.60 (CHCH3), 27.05 (ArCH2CH2), 42.25 (CH2CH2N),
53.79 (CHCH3), 116.10 (CatH-8), 118.56 (CatH-5), 126.33 
(CAr-4a), 128.03 (CAr-8a), 145.98 (CArOMe), 146.69
(CArOMe);
Characterisation:
Melting point:
Optical rotation [a]B : 
'H-NMR (D2O):
13C-NMR (D20):
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MS (El) m/z: M+ 179(12), [M-CH3]+ 164(100);
IR (KBr) |//cm: 3296 (OH str.), 1528 (CAr-CAr), 1184 (Ar-OH);
Microanalysis (C,H,N): Calculated for CioHi4N0 2 Br: 46.17, 5.42, 5.38
Found: 45.96, 5.17, 5.47.
(/?)-6,7-Dihydroxy-l -methyl-1,2,3,4-tetrahydroisoquinoline hydrobromide 
(331?):
435
HBr
The hydrochloride salt of 42J? (550mg, 0.0023mol) was dissolved in 48% aqueous 
hydrobromic acid (lOmL), and stirred at reflux for eighteen hours. Removal of 
solvent from an aliquot under reduced pressure and analysis by ^-N M R confirmed 
the reaction to be complete, by the absence of the peaks at 5h 3.87-3.90. The solvent 
was removed from the reaction under reduced pressure to give an off-white solid; 
sonication in diethyl ether (7.5mL) formed the solid into a finely divided colourless 
precipitate, which was filtered, wash with fresh diethyl ether and dried under reduced 
pressure at 100°C for eighteen hours, to give the pure catechol as a colourless 
powdered solid (600mg, quantitative yield):
Characterisation:
185-186°C (lit. 174-175°C435);
+32.0 (c 1.01, methanol) (lit. [a]o = +30.0 (methanol)435);
5h 1.63 (3H, d, J=  6 .8 Hz, CHGf/3), 2.90-3.05 (2 H, m, 
A1 CH2 CH2), 3.35-3.43 ( 1 H, m, CH2GHaHbN), 3.52-3.59 
(1H, m, CH2CHAtfBN), 4.53 (1H, quartet, J = 6 .8 Hz, 
C//CH3), 6.76 (1H, s, Ar/7-8), 6.79 (1H, s, ArH-5);
5C 21.60 ( C H C H 3 ) ,  27.05 ( A r C H 2 C H 2 ) ,  42.25 ( C H 2 C H 2 N ) ,
53.79 ( C H C H 3 ) ,  116.11 (CatH-8), 118.57 (CatH-5), 126.34 
(CAr-4a), 128.04 (CAr-8a), 145.99 (CArOMe), 146.70
(CArOMe);
MH+ 180(100);
3296 (OH str.), 1527 ( C Ar- C A r ) ,  1184 (Ar-OH);
Melting point:
Optical rotation [a]o21: 
^-NM R (D20):
13C-NMR (D20):
MS (ESI-positive) m/z: 
IR (KBr) v/cm:
Microanalysis (C,H,N): Calculated for CioHi4N0 2Br: 46.17, 5.42, 5.38
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Found: 45.94, 5.30, 5.64.
2-(4-Chlorophenyl)ethyl isothiocyanate (32):
N  S
Thiophosgene 41 (15mL, 22.6g, 0.197mol) was dissolved in dry dichloromethane 
(200mL) with stirring under an atmosphere of nitrogen on ice; a solution of 2-(4- 
chlorophenyl)ethylamine 40 (30.0g, 0.193mol) and triethylamine (55mL, 40g, 
0.395mol) in dry dichloromethane (200mL) was added slowly over 15 minutes. The 
reaction was stirred for eighteen hours, poured into a 1L separatory funnel and 
washed consecutively with 0.5M aqueous hydrochloric acid (2 x 200mL) and brine 
(lOOmL). The organic phase was dried over dried magnesium sulfate, filtered, and 
the solvent removed under reduced pressure, to give a red oil. Purification by flash 
column chromatography (silica, cyclohexane/ ethyl acetate 30:1) gave an orange oil 
(36.4g, 95%):
Characterisation:
TLC:
'H-NMR (CDCb):
13C-NMR (CDCI3):
MS (El) m/z: 
IR (neat) v/cm: 
HRMS
R f 0.55 (cyclohexane/ethyl acetate 20:1);
SH 2.95 (2H, t, J=  6 .8 Hz, ArC//2CH2), 3.71 (2H, t, 
J=  6 .8 Hz, CH2Gff2NCS), 7.15 (2H, dm (AA’ of an AA’BB’ 
system), J ortho = 8.3Hz, Ar/f-2, ArH-6 ), 7.31 (2H, dm (BB’ of 
an AA’BB’ system), J ortho — 8.3Hz, ArH-3, ArH-5);
5C 35.81 (ArCH2CH2), 46.19 (CH2 CH2NCS), 128.94 (CatH- 
3, CatH-5); 130.16 (CatH-2, CatH-6), 131.16 (br, NCS), 
133.08 (Cat-4), 135.45 (Cat-1);
197(67), [M -(C H 2N C S ) ] + 125(100);
2095 ( N = C = S ) ,  1493 (C Ar-CAr);
no result by ESI-ionisation; HRMS not possible
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(5)-/V-(4-Chlorophenethylthiocarbamoyl)-6,7-dihydroxy-l-methyl-l,2,3,4-tetra- 
hydroisoquinoline (295):
HO.
HO
The hydrobromide salt of 33S  (420mg, 1.6mmol) was dissolved in dry 
tetrahydrofuran (15mL), with triethylamine (250pL, 180mg, 1.78mmol). 32 (320mg, 
1.6mmol) was added in dry tetrahydrofuran (lOmL), and the reaction was stirred for 
twenty four hours. The reaction was diluted in ethyl acetate (lOOmL) and washed 
consecutively with dilute aqueous hydrochloric acid (50mL), water (50mL) and brine 
(25mL), before drying over dried magnesium sulfate. Filtration and removal of 
solvent under reduced pressure, followed by purification by flash column 
chromatography (Biotage 40S, cyclohexane/ethyl acetate 1:1) gave a colourless 
foamed solid (480mg, 80%), which rapidly discoloured to a pale pink/orange, 
although the !H-NMR remained unchanged:
Characterisation:
TLC:
Melting point:
Optical rotation [a]o24:
’H-NMR (CDC13):
13C-NMR (CDC13):
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R f  0.19 (cyclohexane/ethyl acetate 1:1); 
amorphous solid;;
+122.7 (c 1.0, chloroform);
SH 1.36 (3H, d, J=  6 .8 Hz, CHGfiT3), 2.65 (2H, t, J=  6.0Hz, 
tetrahydroisoquinoline ArC/^CT^), 2.94 (2H, t, J=  7.0Hz, 
4 ’-chlorophenyl-C//2CH2), 3.34-3.41 (1H, m,
tetrahydroisoquinoline CH2C//aHbN), 3.86-4.01 (2H, m, 
C^C/feNH), 4.00-4.10 (1H, br, tetrahydroisoquinoline 
CH2CHAtfBN), 5.50-5.65 (1H, br, CtfCH3), 5.68 (1H, t, 
J=  5.1Hz, NH), 6.52, (1H, s, Artf-8 ), 6.55 (1H, s, Artf-5), 
7.13 (2H, dm (AA’ of an AA’BB’ system), J ortho = 8.4Hz, 
ArH-2\ Ar/f-6 ’), 7.24 (2H, dm (BB’ of an AA’BB’ system), 
Jortho = 8.4Hz, Artf-3’, Ar/f-5’);
5c 21.27 (CHCH3), 27.24 (tetrahydroisoquinoline 
ArCH2CH2), 34.70 (4’-chlorophenyl-CH2CH2), 42.48 
(tetrahydroisoquinoline CH2 CH2N), 46.83 (CH2CH2NH), 
54.72 (CHCH3), 113.40 (CmH-8), 114.85 (CatH-5), 125.91
(CAr-4a), 128.82 (CatH -3\ CatH-5’), 130.19 (CatH-2’, CatH- 
6’), 130.26 (CAr-8a), 132.44 (CatCI-4’), 137.28 (CAr- l ’),
142.50 (CatOH), 142.82 (CatOH), 179.72 (C=S);
MS (ESI-negative) m/z: [M-H]' 375.2(100);
IR (KBr) p/cm: 3408(OH str.), 1522 ( C a t - C a t ) ;
Microanalysis (C ,H ,N ):  Calculated for C 19H 21N 2 O 2 SC I: 60.55, 5.62, 7.43;
Found 60.23, 5.72, 7.35;
HRMS (negative) m/z: Calculated for [M-H] C 19H 20N 2 O 2 SC I: 375.0934;
Found 375.0931.
(f?)-AL(4-Chlorophenethylthiocarbamoyl)-6,7-dihydroxy-l-methyl-l,2,3,4-tetra- 
hydroisoquinoiine (29/?):
The hydrobromide salt of 33R  (l.Olg, 3.9mmol) was dissolved in dry 
tetrahydrofuran (25mL), with triethylamine (820jiL, 590mg, 5.8mmol). 32 (770mg, 
3.9mmol) was added in dry tetrahydrofuran (5mL), and the reaction was stirred for 
forty hours at room temperature. The tetrahydrofuran was removed under reduced 
pressure; the residue was dissolved in ethyl acetate (lOOmL) and washed 
consecutively with dilute aqueous hydrochloric acid (50mL), water (50mL) and brine 
(25mL), before drying over dried magnesium sulfate. The filtration and removal of 
solvent under reduced pressure followed by flash column chromatography (Biotage 
40S, cyclohexane/ethyl acetate 1:1) gave a colourless foamed solid (1.3 lg, 89%). 
This foam discoloured rapidly to a pale peach, although the *H-NMR remained 
unchanged. While all other characterisation was possible with the foamed solid, it 
was not possible to obtain a satisfactory microanalysis. However, precipitation of a 
sample of the foam (250mg) by dissolving in chloroform (4mL) and adding dropwise 
to a quantity of vigorously stirred cyclohexane (30mL), gave a colourless amorphous 
solid; this gave a satisfactory microanalysis (C,H,N), and was used for 
characterisation purposes:
Characterisation:
TLC: R f0.\9  (cyclohexane/ethyl acetate 1:1);
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Melting point:
Optical rotation [a]o24: 
^-NM R (CDCI3):
13C-NMR (C D C I 3):
MS (ESI-positive) m/z: 
IR (KBr) p/cm: 
Microanalysis (C,H,N):
HRMS (positive) m/z:
amorphous solid;
-124.8 (c 1.0, chloroform);
6 h 1.43 (3H, d, J=  6 .8 Hz, CHCif3), 2.76 (2H, t, J=  6 .0 Hz, 
tetrahydroisoquinoline A1CH2CK2), 2.96 (2 H, t, J=  6.9Hz, 
4 ’-chlorophenyl-C^2CH2), 3.40-3.47 (1 H, m,
tetrahydroisoquinoline CH2C//aHbN), 3.87-4.03 (2H, m, 
CH2C//2NH), 4.04-4.20 (1H, br, tetrahydroisoquinoline 
CH2CHA/yBN), 5.45 (1H, t, J=  5.1Hz, Ntf), 5.50-5.70 (1H, 
br, C/7CH3), 6.60, (1H, s, A r^-8 ), 6.62 (1H, s, ArH-5), 7.16 
(2H, dm (AA’ of an AA’BB’ system), Jorth0 = 8.3Hz, Ar/7-2’, 
ArflT-6 ’), 7.28 (2H, dm (BB’ of an AA’BB’ system), 
Jortho ~ 8.3Hz, Arif-3’, Arif-5’);
5c 21.24 (CHCH3), 27.26 (tetrahydroisoquinoline 
ArCH2CH2), 34.68 (4’-chlorophenyl-CH2CH2), 42.46 
(tetrahydroisoquinoline CH2 CH2N), 46.85 (CH2CH2NH),
54.75 (CHCH3), 113.37 (CatH-8), 114.84 (CatH-5), 125.87 
(CAr-4a), 128.80 (CatH-3’, CatH-5’), 130.17 (CatH-2’, CatH- 
6 ’, Cat -8a), 132.39 (CatCI-4’), 137.22 (Cat-1’), 142.43 
(CatOH), 142.75 (CatOH), 179.49 (C=S);
MH+ 377(100);
3404 (OH str.), 1523 ( C Ar - C Ar);
Calculated for C 19H 21N 2 O 2 SC I: 60.55, 5.62, 7.43;
Found 60.39, 5.75, 7.53;
Calculated for [M+H] C19H22N2O2SCI: 377.10905;
Found 377.10942.
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Enantiomers of /V-(4-chlorophenethylthiocarbamoyl)-6,7-dihydroxy-3-methyl-
1,2,3,4-tetrahydroisoquinoline analogues (30/? and 305)
Resolution of the enantiomers of 2-(3,4-dimethoxy-phenyl)-l-methyl ethylamine 
(38/? and 385)
l-(3,4-dimethoxy-phenyl)-propan-2-one O-methyl-oxime (37)
3,4-Dimethoxyphenylacetone 36 (5.0g, 25.8mmol), methoxylamine hydrochloride 
(2.37g, 28.3mmol) and anhydrous sodium acetate (2.32g, 28.3mmol) were combined 
in dry methanol (25mL), and stirred under an atmosphere of nitrogen for 18 hours, 
when the reaction was determined to be complete by TLC (cyclohexane/ethyl acetate 
4:1). The mixture was diluted to 200mL with ethyl acetate, and washed with water 
(2 x lOOmL) and brine (50mL), before drying over magnesium sulfate. Filtration, and 
removal of the solvent under reduced pressure, gave a red oil; purification by flash 
column chromatography (Biotage 40M cartridge; cyclohexane/ethyl acetate 10:1) 
gave a mixture of trans and cis isomers (-5:2 major:minor by !H-NMR) as a 
colourless oil (5.3g, 92%):
Characterisation:
R f0.55  (cyclohexane/ethyl acetate 4:1);
<5h 1.74 (2.2H, s, C C / / 3  major), 1.78 (0.8H, s, C C / / 3  minor), 
3.40 (1.47H, s, A1CH2C major), 3.61 (0.53H, s, Ai CH2C 
minor), 3.86 (3H, s, A r O C / f 3 ) ,  3.87 (3H, s, A1OCH3), 3.89 
(3H, s, N O C / / 3 ) ,  6.72-6.82 (3H, m, 3 x A r / / ) ;
6C 13.46 (CCH3, major), 19.65 (CCH3, minor), 34.93 
(ArCH2CH, minor), 41.71 (ArCH2CH, major), 55.83 (1 x 
ArOCH3 minor), 55.91 (1 x ArOCH3 major and 1 x 
ArOCH3), 61.22 (NOCH3), 111.30 (CatH major), 111.33 
(CatH minor), 112.08 (CatH, major), 112.35 (CatH, minor),
121.11 (Cai-H), 129.16 (Cat-1, minor), 129.46 ( C a t - 1 ,  major),
147.56 (CArOMe-4, minor), 147.98 (CArOMe-4, major), 
149.07 (CArOMe-3), 156.42 (C=N, minor), 156.77 (C=N,
TLC:
'H-NMR (CDCI3):
13C-NMR (CDCl3):
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major);
MS (ESI-positive) m/z: MH+ 224(100);
IR (film) v/cm: 1515 (Cat-Cat), 1263 (Ar-0CH3);
HRMS (positive) m/z: Calculated for [M+H] Ci2Hi8N 03 224.1287;
Found 224.1287.
2-(3,4-Dimethoxy-phenyI)-l-methylethylamine hydrochloride (3SRS)
37 (4.8g, 22mmol) was dissolved in 1.0M borane-THF complex in THF, and 
refluxed under an atmosphere of argon for 24 hours, until TLC (cyclohexane/ethyl 
acetate 4:1) confirmed that none of the oxime remained. The solution allowed to cool 
to room temperature, before being chilled on an ice-water bath. 2.0M Aqueous 
sodium hydroxide (50mL) was cautiously added, followed by methanol (50mL). The 
reaction was refluxed for a further 24 hours, until none of the borane complexes 
remained by TLC (cyclohexane/ethyl acetate 4:1; developed in iodoplatinate dip, 
where borane complexes show up white). The reaction was poured into water 
(500mL), and products were extracted into diethyl ether (2 x 200mL). The combined 
ether extractions were washed with fresh water (200mL) and brine (50mL), then 
dried over magnesium sulfate. Filtration, and the removal of ether under reduced 
pressure gave a yellow oil, which was dissolved in 50mL 1.0M HC1 in dioxan. The 
solvent was removed under reduced pressure; the residue was suspended in boiling 
ethyl acetate (200mL); methanol was added until a hazy solution remained; this was 
hot filtered, then left to cool to room temperature overnight. Filtration gave a 
colourless crystalline solid, which was washed with ether and dried at O.lmmHg and 
100°C for 24 hours (2.15g, 42%):
Characterisation:
TLC: RfO. 18 (dichloromethane/ methanol/ 32% AcOH(aq.) 90:9:1);
Melting point: 149-150°C (lit. 149-151°C510);
'H-NMR (D20): 5h 1.36 (3H, d, J=  6.6Hz, CHCff3), 2.92 (2H, d, J=  7.2Hz,
ArC/ftCH), 3.62-3.69 (1H, m, CH2C//CH3), 3.86-3.89 (6H,
2 x s overlapping, 2 x ArOC//3), 6.90 (1H, dd, J ortho = 8.2Hz,
Jmeta ~ 1.8Hz, Ar//-6), 6.95 (1H, d, Jmeta= \ m z ,  ArJ5f-2),
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13,C-NMR (D20):
'H -N M R  (D M S O -d 6):
13C-NMR(DMSO-d6):
MS (ESI-positive) m/r. 
IR (KBr) p/cm: 
Microanalysis (C,H,N):
7.00 (1H, d, Jortho = 8.2Hz, Artf-5);
b c  2 0 .3 4  (C H 3), 4 2 .5 1  (C H 2), 5 2 .0 1  (C H ), 5 8 .4 9
( 2  x A r O C H 3) , 1 1 4 .8 1  (CatH-5), 1 1 5 .5 8  (CatH-2), 1 2 4 .8 6  
(CatH-6), 1 3 1 .9 3  (CatCH2-1), 1 5 0 .1 0  (C A rO M e-4), 1 5 1 .0 6  
(C A rO M e-3);
6 h 1.13 (3H, d, J =  6.5Hz, CHCtf3), 2.62 (1H, dd, J  = 8 .6 , 
13.4Hz, ArCtfAHBCH), 2.93 (1H, dd, J  = 5.5, 13.4Hz, 
AtCHa^ bCH), 3.37 (1H, m, ArCH2CtfCH3), 3.73 (3H, s, 
ArOCHi), 3.75 (3H, s, ArOCtf3), 6.74 (1H, dd, J  = 1.9, 
8.1Hz, ArH-6 ), 6.85 (1H, d,J =  1.9Hz, AiH-2% 6.89 (1H, d, 
J =8.1Hz, Ar//-5), 8.06 (3H, br^  R
bc 1 7 .4 6  (CHCH3), 3 9 .5 3  (CH2, coincident with D M S O  and 
revealed by D E P T  experiment), 4 8 .1 1  (CH), 5 5 .3 7
(ArOCH3), 5 5 .4 0  (ArOCH3), 1 1 1 .7 7  (CatH-5), 1 1 2 .8 4  (CatH-
2 ) ,  1 2 1 .1 5  (CatH-6), 1 2 9 .1 8  (CAr-l), 1 4 7 .5 3  (C A rO M e-4), 
1 4 8 .6 3  (C A rO M e-3 );M H + 1 9 6 (1 5 ) ,  [M -N H 2]+ 1 7 9 (1 0 0 );
MH+ 196(15), [M-NH2]+ 179(100);
1518 (Cat-C at), 1269 (Cat-O ), 1235 (Cat-O);
Calculated for ChHi7N 0 2 .HC1: 57.02, 7.83, 6.04;
Found 5 6 .6 9 ,  7 .5 7 ,  6 .4 2 .
Protocol for the reaction of 38 and A-cif-(2,4-dinitro-5-fluorophenyl)-L- 
alaninamide (Marfey’s reagent, 1045)460
Following the method of Marfey460, O.Olmmol of the amine 38 was dissolved in 
400pL of a 1% solution of N-a-(2,4-dinitro-5-fluorophenyl)-L-alaninamide 1045 in 
acetone, with 80pL l.M aqueous sodium bicarbonate, and the mixture was stirred at 
40°C for exactly 1 hour, at which time the reaction was neutralised by the addition of 
40pL 2.0M HCl(aq). A lOpL aliquot was diluted to l.QmL in acetonitrile, and the 
diastereomeric ratio was established by reverse phase analytical HPLC, using either 
system 3 or system 4.
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(5)-2-(3,4-dimethoxy-phenyl)-l-methylethylammonium-(/?)-mandelate
(385+103/?)
38RS  (47.0g, 0.241mol) was dissolved in boiling propan-2-ol (1L) with (R)-(-)- 
mandelic acid 103/? (36.7g, 0.241mol). The solution was allowed to cool slowly to 
room temperature overnight, and a colourless crystalline solid was filtered out 
(70. lg, 0.202mol, 84%, [«]d26 -51.5° (c 1.0, water)). A sample of the diastereomeric 
salt mixture was converted to the free amine by dissolving in water, basifying with 
5M aqueous sodium hydroxide, and extracting into dichloromethane. Reaction with 
1045460 and analysis by reverse phase analytical HPLC (system 3) confirmed the 
amine as racemic.
65.Og of the diastereomeric salt mixture 3SRS+103R was dissolved in boiling ethyl 
acetate/methanol 2:1 (1.5L), then left to cool to room temperature. Filtration after 3 
hours gave a colourless crystalline solid (24.lg, crop 1). A second filtration after 20 
hours gave a second crop of a colourless crystalline solid (11.7g, crop 2). Removal of 
the solvent from the mother liquor gave a final batch of colourless crystalline 
material (29.6g). The enantiomeric ratio for each of these crystalline solids was 
established by the method of Marfey460, using reverse phase analytical HPLC 
(system 3); while crop 1 and the mother liquor both appeared to have slight excess of 
one enantiomer (1 0 % e.e.) and were subsequently combined, crop 2  was seen to be 
much enriched in the opposite enantiomer (80% e.e.). Recrystallisation of crop 2 
from 450mL ethyl acetate/methanol 2:1, from boiling to room temperature, gave 
6.17g of a colourless crystalline solid (crop 2A); the reaction of a freebased sample 
of this solid with Marfey’s reagent confirmed the amine as almost entirely one 
enantiomer (>97% e.e.). A further 24 hours at room temperature yielded a second 
crop (crop 2B) of 1.65g with a similar e.e. (overall yield 18%). Subsequent 
comparison of the rotation of the free base of the amine with literature precedent455 
identified this as the (5)-enantiomer of 38:
Characterisation:
Melting point: 172-173°C;
Optical rotation [ « ] d 26‘ -35.1 ( c  1 .0 , water);
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'H-NMR (D2O):
13C-NMR (D20):
MS (ESI-positive) m/z: 
MS (ESI-negative) m/z: 
IR (KBr) p/cm: 
Microanalysis (C,H,N):
Ammonium ion: 6 h 1.31 (3H, d, .7=6.6Hz, CHC//3), 2.90 
(2H, d, J=  7.2Hz, ArC/72CH), 3.61 (1H, m, CH2C^CH3),
3.86-3.88 (6 H, 2 x s overlapping, 2 x ArOC//3), 6.90 (1H, d, 
Jortho = 8.2Hz, Ar/7-6), 6.97 (1H, s, Artf-2), 7.05 (1H, d, 
Jortho = 8 .2 Hz, Ar/T-5);
Mandelate ion: 5H 4.99 (1H, s, ArCtfOH), 7.37-7.46 (5H, m, 
5 x PhH) \
Ammonium ion: 8 C 20.30 (CH3), 42.50 (CH2), 51.94 (CH),
58.43 (ArOCH3), 58.46 (ArOCH3), 114.77 (CatH-5), 115.53 
(CatH-2), 124.87 (CatH-6), 131.96 (Cat-1), 150.09 (CArOMe-
4), 151.04 (CArOMe-3);
Mandelate ion: 5C 77.84 (CH), 129.86 (2 x CatH-2, -6 ), 
130.99 (Cai-H-4), 131.59 (2 x CatH-3, -5) 143.37 (CatI), 
182.21 (C02H);
MET 196(24), [MH-NH3]+ 179(100);
[M-H]“ 151(100);
1558 (COO, 1516 (Ca^ C at), 1385 (C021 , 1236 (C-O); 
Calculated for C^H^NOs: 65.67, 7.25,4.03;
Found 65.62, 7.24,4.16;
(.S)-2-(3,4-dimethoxy-phenyl)-l ^ -methylethylamine (38S)
385+103J? (lg, 2.88mmol) was dissolved in water (75mL); the pH was adjusted to 
alkalinity by the addition of 5M aqueous sodium hydroxide (3mL, ~5 equivalents). 
The free base of the amine was extracted into dichloromethane (3 x 50mL). The 
combined extractions were washed with brine (20mL) and dried over dried 
magnesium sulfate. Filtration and removal of solvent under reduced pressure gave a 
colourless crystalline solid (540mg, quantitative). Recrystallisation from n-pentane 
gave colourless needles (250mg, 46%); reverse phase analytical HPLC (system 4) of 
the reaction of these needles with Marfey’s reagent confirmed them to have an e.e. in 
excess of 99%. Comparison of the optical rotation with the published data455 
confirmed the amine to be the («S)-enantiomer:
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Characterisation:
Melting point:
Optical rotation [ oc] d 22: 
'H-NMR (C D C I 3):
13C-NMR (CDCI3):
MS (ESI-positive) m/z: 
IR (KBr) v/cm: 
Microanalysis (C,H,N):
67-8°C (literature 39-40°C{Schrecker 1957 16 /id});
+32.5 (c 4.02, EtOH) (lit. [a] D21 +32.1 (c 3.98, EtOH)455);
5h 1.13 (3H, d, J =  6.3Hz, CHC//3), 1.37 (2H, br, Nff2), 2.44 
(1H, ddABx, J a b  = 13.4Hz, A x = 8.3Hz, ArC//AHBCH), 2.67 
(1H, ddBAx, J b a  = 13.4Hz, J BX = 5.1Hz, ArCHA/ / BCH), 3.14 
(1H, m, AtCHaHbC7/CH3), 3.86-3.88 (6 H, 2xs ,
2 x ArOC//3), 6.71-6.75 (2H, m, ArH-2, -6 ), 6.81 (1H, d, 
Jortho = 7.9Hz, Ar//-5);
b e  2 3 .5 8  (CH3), 4 6 .2 0  (CH2), 4 8 .5 3  (CH), 5 5 .8 3  (ArOCH3),
5 5 .9 0  (ArOCH3), 1 1 1 .1 8  (CatH-5), 1 1 2 .3 5  (CatH-2), 1 2 1 .1 3  
(CArH-6 ), 1 3 2 .3 4  (Cat-1), 1 4 7 .4 3  (C A rO M e-4), 1 4 8 .7 9  
(C A rO M e-3 );
MH+ 196(100), [M-NH2]+ 179(11);
1518 (Cat-C at), 1265 (Cat-O ), 1238 (Cat-O);
Calculated for CnHi7N 02: 67.66, 8.78, 7.17;
Found 6 7 .4 3 ,  8 .5 3 ,  7 .1 4 .
(i?)-2-(3,4-dimethoxyphenyl)-l-methylethylammonium-(5)-mandelate
(38K+1035)
OH
The combined crop 1 crystals and mother liquor (53.7g, 0.152mol) from the 
resolution of 385 were dissolved in water (1L); the solution was basified by the 
addition of aqueous sodium hydroxide, and the neutral amine was extracted into 
dichloromethane (2x500mL). The dichloromethane extractions were combined, and 
dried initially with a brine wash (200mL), then over dried magnesium sulfate. 
Filtration, and removal of the solvent under reduced pressure, gave a colourless 
syrup (~30g, 100%), which was dissolved in boiling propan-2-ol with (£)-(+)- 
mandelic acid 1035 (23.5g, 0155mol). The solution was allowed to cool slowly to 
room temperature overnight, whereupon filtration gave a colourless crystalline solid 
(50.0g, 0.142mol) [ oc] d 26 +49.0 (c 1.0, water). Resolution was achieved by two 
further recrystallisations from ethyl acetate/methanol (2:1), which gave 38R+1035 as
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Melting point:
Optical rotation [a]D25: 
1H-NMR(D20):
a colourless crystalline solid (yield 8.50g, 20%). The enantiomeric excess of 381? 
was established as >96% e.e. by the method of Marfey460, using reverse phase 
analytical HPLC (system 3):
Characterisation:
172-173°C;
+37.8 (c 1.0, water);
Ammonium ion: 8 U 1.31 (3H, d, J = 6 .6Hz, CHCtfj), 2.89 
(2H, d, J=  7.2Hz, A1CIT2CH), 3.61 (1H, m, CH2C//CH3),
3.86-3.88 (6H, 2 x s overlapping, 2 x ArOC/f3), 6.90 (1H, d, 
Jortho = 8.2Hz, Ar/f-6), 6.96 (1H, s, ArH-2), 7.04 (1H, d, 
Jortho = 8.2Hz, Ar//-5);
Mandelate ion: SH 4.99 (1H, s, ArCtfOH), 7.37-7.46 (5H, m, 
5 x Ph//);
Ammonium ion: 8 C 20.26 (CH3), 42.48 (CH2), 51.91 (CH), 
58.47 (ArOCH3), 58.50 (ArOCH3), 114.84 (CatH-5), 115.61 
(CatH-2), 124.86 (CatH-6), 131.96 (CatI), 150.12 (CArOMe-
4), 151.07 (CArOMe-3);
Mandelate ion: 8 C 77.81 (CH), 129.83 (2 x CatH-2, -6), 
130.93 (CatH-4), 131.36 (2 x CatH-3, -5) 143.42 ( C a t I ) ,
182.11 (C02H);
MS (ESI-positive) m/z: MH+ 196(9), [MH-NH3]+ 179(100);
MS (ESI-negative) m/z: [M-H]" 151(100);
IR (KBr) p/cm: 1558 (C02 ), 1516 (Cat-C at), 1384 (C02"), 1236 (C-O);
Microanalysis Calculated for CicH^NOs: 65.69, 7.25,4.03,23.03;
(C,H,N,0): Found 65.43, 7.30, 4.20, 22.73.
13C-NMR (D20):
(l?)-2-(3,4-dimethoxy-phenyl)-l-methylethylamme (38R)
NH,
(381?+103iS) (1.2g, 3.46mmol) was dissolved in water (lOOmL); the solution was 
basified by the addition of 5M aqueous sodium hydroxide (3mL, ~5 equivalents), 
and the free base of the amine was extracted into dichloromethane (3 x 50mL). The 
combined extractions were washed with brine (20mL) and dried over dried
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magnesium sulfate. Filtration and removal of solvent under reduced pressure gave a 
colourless crystalline solid (625mg, 93% yield). Recrystallisation from n-pentane 
gave colourless needles (360mg, 53%); despite clean NMR spectra and three 
attempts, a correct elemental analysis was not realised for this enantiomer: 
Characterisation:
Melting point:
Optical rotation [a] d22: 
^-N M R (CDCI3):
13C-NMR (CDCI3):
MS (El) m/z:
IR (KBr) v/cm: 
HRMS (positive) m/z:
softened 30-32°C, melted 62-4°C (literature 37-40°C455); 
-32.8 (c 4.00, EtOH) (lit. [a] D 2 2  -32.1 (c 4.00, EtOH)455);
5h 1.12 (3H, d, J =  6.3Hz, CHCtfj), 1.20 (2H, br, NJ5T2), 2.44 
(1H, d d A B X ,  J ab  = 13.4Hz, A x = 8.3Hz, ArCtfAHBCH), 2.67 
(1H, ddBAx, J ba = 13.4Hz, A x = 5.1Hz, ArCHAtfBCH), 3.15 
( 1 H, m, AtCHaHbCI/CHs), 3.86-3.88 (6 H, 2  x s,
2xA rO C //3), 6.71-6.75 (2H, m, Artf-2, -6 ), 6.81 (1H, d, 
Jortho = 7.9Hz, Ar//-5);
5C 23.58 (CH3), 46.20 (CH2), 48.53 (CH), 55.83 (ArOCH3),
55.90 (ArOCH3), 111.18 (CArH -5), 112.35 (C a tH -2 ), 121.13 
(C a tH -6 ) , 132.34 (C a t -1 ) , 147.43 (CArOMe-4), 148.79 
(CArOMe-3);
M+ 195(8), [MH-CH3CHNH2]+ 152(100);
1519 (C a t-C a t), 1265 (C a t-O ), 1239 (C at-O );
Calculated for [M+H] CnH18N 02: 196.13375;
Found 196.13342.
(S)-6,7-Dimethoxy-3-methyl-l ,2,3,4-tetrahydroisoquinoline (43 S)
NH
3 8 5  (l.Og, 5.1mmol) and paraformaldehyde (155mg, 5.1mmol) were dissolved in 
glacial acetic acid (5mL), and stirred at 40°C for 24 hours. The reaction was poured 
into water (200mL) and the solution was basified by the addition of 5M aqueous 
sodium hydroxide (25mL). The product was extracted into dichloromethane 
(3 x lOOmL). The combined dichloromethane extractions were washed with brine 
(50mL), and dried over dried magnesium sulfate. Filtration, and subsequent removal 
of solvent under reduced pressure gave a yellow syrup. Purification by flash column 
chromatography (Biotage 40S, ethyl acetate/methanol/ammonium hydroxide
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TLC:
Melting point:
Optical rotation [a]D21: 
^ - N M R  (C D C I 3):
100:10:1) gave a pale yellow solid (950mg, 90%). Recrystallisation from n-hexane 
gave a cream coloured crystalline solid (565mg, 53%):
Characterisation:
R f  0.25 (dichloromethane/ methanol/ 32% AcOH(aq.) 90:9:1);
70-71°C;
+141.2 (c 1.01, dichloromethane);
5h 1.23 (3H, d, J = 6.3Hz, CHC/T3), 1.44 (1H, br, NH), 2.42 
(1H, ddABx, J a b  = 16.0Hz, /ax  = 10.5Hz, ArCJTAHBCH), 2.68 
(1H, ddBAx, Jba = 16.0Hz, JBX = 3.8Hz, ArCHAtfBCH), 2.95-
3.00 (1H, m, ArCHAHBC//CH3), 3.83/3.84 (6 H, 2 x s  
(overlapping), 2 x ArOC//3), 3.94 (1H, dAB, J =  15.6Hz, 
ArC/rAHBN), 4.04 (1H, dBA, / =  15.6Hz, ArCHAJETBN), 6.52 
(1H, m, Ar/7-8), 6.55 (1H, m, Ar/T-5);
8 c 22.50 (CH3), 36.80 (ArCH2CH), 48.31 (ArCH2NH), 49.30 
(CH), 55.92 (2 x ArOCH3), 108.95 (C atH -8), 111.88 (C atH -
5), 126.77 (CAr-4a), 127.37 (C^-Sa), 147.27/147.42
( 2  x CArOMe);
MH+ 208.1(100), [2M+HT] 415.3(9);
3250 (NH), 1515 (Cat-C at), 1246 (Cat-OCH3), 1223 (CAr-  
OCH3);
Microanalysis (C,H,N): Calculated for Ci2Hi7N 02: 69.54, 8.27,6.76;
Found 69.29, 8.11,6.79.
13C-NMR (CDC13):
MS (ESI-positive) m/z: 
IR (KBr) p/cm:
(/?)-6,7-Dimethoxy-3-methy 1-1,2,3,4-tetr ahydroisoquinoline (43R)
38R (1.5g, 7.7mmol) and paraformaldehyde (240mg, 8.0mmol) were dissolved in 
glacial acetic acid (15mL), and stirred at 40°C for 24 hours. The reaction was poured 
into 2M aqueous sodium hydroxide (200mL), and the product was extracted into 
dichloromethane (2 x lOOmL). The combined dichloromethane extractions were 
washed consecutively with water (lOOmL) and brine (25mL), before drying over 
dried magnesium sulfate. Filtration, and subsequent removal of solvent under 
reduced pressure gave the desired product as a virtually pure beige solid (1.50g,
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94%). Recrystallisation from n-hexane gave a cream coloured crystalline solid
(1.10g, 69%): 
Characterisation:
TLC:
Melting point:
Optical rotation [of]o21: 
lH-NMR (CDCI3):
13C-NMR (C D C I 3):
MS (El) m/z:
IR (KBr) y/cm:
Microanalysis (C,H,N):
R f 0.25 (dichloromethane/ methanol/ 32% AcOH(aq.) 90:9:1);
71-72°C;
-138.8 (c 1.00, dichloromethane);
6 H 1.24 (3H, d, J=  6.3Hz, CHCf73), 1.60 (1 H, br, NH), 2.44 
(1H, ddABx, J a b  = 16.0Hz, A x = 10.6Hz, ArC^AHBCH), 2.69 
(1H, ddBAx, Jb a  = 16.0Hz, A x = 3.7Hz, ArCHAtfBCH), 2.97-
3.02 (1H, m, ArCHAHBC//xH3), 3.83/3.84 (6 H, 2 x s  
(overlapping), 2 x A1O C //3), 3.96 (1H, dAB, J =  15.6Hz, 
ArC/7AHBN), 4.06 (1H, dBA, J=  15.6Hz, ArCHA^ BN), 6.53 
(1H, m, Ar/7-8), 6.56 (1H, m, ArH-5);
6 C 22.47 (CH3), 36.77 (ArCH2CH), 48.27 (ArCH2NH), 49.31 
(CH), 55.92 (2 x ArOCH3), 108.95 (C atH -8), 111.87 (C atH -
5), 126.74 (CAr-4a), 127.29 (CAr-8 a), 147.28/147.43
( 2  x CArOMe);
M+ 207(30), [M-(NHCHCH3)]+ 164(100);
3250 (NH), 1516 (CAr-C Ar), 1246 (C A r-O C H 3), 1223 (CAr~ 
O C H 3 );
Calculated for Ci2HnN 02: 69.54, 8.27,6.76;
Found 69.52, 8.21,6.85.
Establishing the enantiomeric purity of 425 and 42R
2.5mg of each of 421? and 425 were combined and dissolved in 0.75mL C D C I3 
(+0.03% v/v TMS), and the *H-NMR spectrum recorded. The chiral solvating agent 
(5)-(+)-l-(9-anthryl)-2,2,2-trifluoroethanol463;464 ((5)-TFAE, 1065, 6.7mg, 1
equivalent) was added to the NMR sample, and the *H-NMR spectrum recorded. A 
second equivalent of 1065 was added, and the !H-NMR spectrum recorded. Two 
equivalents of 1065 was seen to be sufficient to achieve baseline separation of the 
signals corresponding to the methyl group of the stereogenic carbon, and the adjacent 
methylene protons. The experiment was repeated for separate samples of 421? and 
425; 5 mg of each were dissolved in 0.75mL C D C I 3 (+0.03% v/v TMS), and the !H- 
NMR spectrum recorded; 1065 (13.4mg, 2 equivalents) was added to each sample,
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and the ]H-NMR spectrum recorded. These spectra confirmed the samples of 42R 
and 425 to be enantiomerically pure, to the limits of analytical detection: 
Characterisation:
^-N M R (CDCI3): 42RS
8 h  1.24 (3H, d, J =  6.3Hz, CHCtf3), 1.83 (1H, br, N//), 2.44 
(1H, ddAsx, A b  = 16.0Hz, A x = 10.5Hz, ArC/AHBCH), 2.69 
(1H, ddBAx, J b a = 16.0Hz, J BX = 3.8Hz, ArCHA/ACH), 2.96-
3.02 ( 1 H, m, ArCHAHBCiyCH3), 3.83/3.84 (6 H, 2 x s 
(overlapping), 2  x ArOC/^), 3.95 (1H, dAB, J =  15.6Hz, 
ArC/yAHBN), 4.05 (1H, dBA, J =  15.6Hz, ArCHAtfBN), 6.52 
(1H, m, Ar/f-8 ), 6.56 (1H, m, Artf-5);
!H-NMR (CDCI3): 42RS  + 2 equivalents of 1065:
dH 1.07 (1.5H, d, J — 6.3Hz, CHCH3), 1.15 (1.5H, d, 
J =  6.3Hz, CHC//3), 2.13 (0.5H, ddAsx, A b = 16 .0H z, 
A x  = 10.5Hz, A tC ^ aHbCH), 2.34 (0.5H, ddABx,
A b = 16.0H z, A x  = 10.5H z, ArCfirAHBCH), 2.43 (0.5H, 
ddBAx, A a = 16.0Hz, A x  = 3.8H z, ArCHA/ / BCH), 2.55 
(0.5H, ddBAx, A a = 16.0Hz, A x  = 3.8Hz, ArCHAtfBCH), 
2.77-2.88 (1H, m, ArCHAHBC/fCH3), 3.46 (0.5H, dAB, 
J =  15.6Hz, A tC /A H bN ), 3.70-3.84 (-9.5H, overlapping 
4 x s, 3 x d and 1 x br s, 2 x A1 OCH3 , 0.5 x AtC /A H bN, 
1 x ArCHA/yBN and 2 x OH (TFAE)), 6.12 (0.5H, s, ArH), 
6.26 (0.5H, s, ArH), 6.21 (1H, s, ArH), 6.38 (0.5H, s, AiH),
6.52 (2H, quartet, J =  8.2Hz, ArC/7(OH)CF3), 7.43-7.53 (8 H, 
m, 4 x ArH  (TFAE)), 7.90-8.00 (6 H, m, 3 x ArH (TFAE)),
8.48 (2H, s, ArH), 9.02 (2H, br, ArH).
]H-NMR (CDCI3) 42R + 2 equivalents of 1065:
5h 1.15 (3H, d, J =  6.3Hz, CHC//3), 2.34 (1 H, ddABx, 
A b  = 16.0Hz, A x  = 10.5Hz, A tC //a H b C H ), 2.55 (1H, ddsAX? 
A a  = 16.0Hz, A x = 3.8Hz, AiCUaHbCH), 2.81-2.87 (1H, m, 
ArCHAHBC^CH3), 3.47 (1H, dAB, J =  15.6Hz, ArCfAHBN), 
3.70-3.85 (~9H, 2 x s, 1 x d and 1 x br s, 2 x A1OC/Z3, 
1 x ArCHAfA N  and 2 x OH (TFAE)), 6.12 (1H, s, ArH),
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6.38 (1H, s, ArH), 6.54 (2H, quartet, /=8.2Hz,
ArCtf(OH)CF3), 7.44-7.54 (8 H, m, 4 x ArH), 7.90-8.00 (6 H, 
m, 3 x ArH), 8.49 (2H, s, ArH), 9.01 (2H, br, ArH).
]H-NMR (CDCI3) 425 + 2 equivalents of 1065:
5h 1.06 (3H, d, J=  6.3Hz, CHC//3), 2.12 (1H, dd^x, 
J a b  = 16.0Hz, A x = 10.5Hz, ArCtfAHBCH), 2.42 (1H, ddBAx, 
JBa = 16.0Hz, JBX = 3.8Hz, ArCHAtfBCH), 2.78-2.84 (1H, m, 
ArCHAHB07C H 3), 3.67-3.83 (1H, d ^ ,  J=  15.6Hz,), 3.70-
3.85 (~10H, 2xs ,  2 x d  and l x b r s ,  2xA rO Cl/3, 
1 x ArCJ7AHBN, 1 x ArCHAtfBN and 2 x OH (TFAE)), 6.24 
(1H, s, ArH), 6.26 (1H, s, ArH), 6.53 (2H, quartet, J=  8.2Hz, 
ArCtf(OH)CF3), 7.44-7.54 (8 H, m, 4 x ArH), 7.90-8.00 (6 H, 
m, 3 x ArH), 8.49 (2H, s, ArH), 9.02(2H, br, Artf).
(5)-6,7-Dihydroxy-3-methyl-l ,2,3,4-tetrahydroisoquinoline hydrobromide (345)
425 (675mg, 3.3nmiol) was dissolved in 48% hydrobromic acid (lOmL), and stirred 
at reflux for eighteen hours; an aliquot was removed from the reaction, the solvent 
was removed under reduced pressure, and analysis by !H-NMR in D2O confirmed 
that the reaction was complete, by the absence of signals corresponding to aromatic 
methoxy groups. The reaction was cooled to room temperature, and the solvent was 
removed under reduced pressure, to leave a beige foam (850mg, quantitative) that 
was pure by ]H-NMR. Recrystallisation from methanol/ ethyl acetate (1:1 20mL) 
gave a beige crystalline solid (135mg, 16% yield), which was used for 
characterisation:
Characterisation:
Melting point: Softened from 240°C; melted 252-254°C;
Optical rotation [a]o25: +64.4 (c 1.03, water);
]H-NMR (D2O): (containing 0.75% 3 -(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d4  acid)
5h 1.46 (3H, d, / =  6.4Hz, CHC/Tj), 2.79 (1H, dd^x, 
J a b  = 17.2Hz, A x = 1 0 .6 Hz, ArC/AHBCH), 3.03 ( 1H, ddBAX,
J b a  = 17.2Hz, A x  = 4.6Hz, ArCHA/ / BCH), 3.56-3.65 (1H, m,
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A tC H a H b C ^ x C H 3) ,  4.26 (2 H, s ,  ArC/^N), 6.73 (1 H, m ,  
Ar/f-8 ), 6.75 (1H, m, Artf-5);
13C-NMR (D2O): (containing 0.75% 3 -(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d4  acid)
6C 20.70 (CH3), 34.69 (ArCH2CH), 46.73 (ArCH2NH), 52.94 
(CH), 116.28 (CatH-8), 118.57 (CatH-5), 121.95 (CAr-4a),
126.43 (C A r-8 a ) , 145.90/146.75 (2 x CatOH);
MS (ESI-negative) m/z: [M-H]~ 178.0(10), Br“ 80.9(100);
MS (ESI-positive) m/z: MH+ 180.0(100);
JR (KBr) v/cm: 3168 (OH str.), 1534 ( C at- C at) ,  1234 ( C at- O H ) ;
Microanalysis (C ,H ,N ):  Calculated for C io H i4N 0 2B r: 46.17, 5.42, 5.38;
Found 45.58/45.57, 5.16/5.17, i.46/5.47;
Recalculated + 0.17 equivalents of water: 45.70, 5.38, 5.33.
(i?)-6,7-Dlhydroxy-3-methyl-l ,2,3,4-tetrahydroisoquinoline hydrobromide (341?)
42R  (1.10g, 5.3mmol) was dissolved in 48% hydrobromic acid (lOmL), and stirred at 
reflux for twenty-four hours; an aliquot was removed from the reaction, the solvent 
was removed under reduced pressure, and analysis by !H-NMR in D20  confirmed 
that the reaction was complete, by the absence of signals corresponding to aromatic 
methoxy groups. The reaction was cooled to room temperature, and the solvent was 
removed under reduced pressure, to leave a beige foam (1.38g, quantitative). lH- 
NMR in D20  confirmed the foam as pure. Recrystallisation from methanol/ ethyl 
acetate (1:1 20mL) eventually gave a beige microcrystalline solid (55mg, 4% yield), 
which was used for characterisation:
Characterisation:
Melting point: 242-252°C;
Optical rotation [a]D22: -62.9 (c 1.00, water);
'H-NMR (D20): (containing 0.75% 3 -(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d4 acid)
6 h 1.48 (3H, d, J=  6.4Hz, CHCtf3), 2.79 (1H, ddAsx, 
J a b  = 17.2Hz, JAX = 10.6Hz, ArCf/AHBCH), 3.01 (1H, ddBAx, 
Jba = 17.2Hz, 7bx = 4.6Hz, ArCHA# BCH), 3.54-3.63 (1H, m, 
ArCHAHBCJ/xCH3), 4.26 (2H, s, ArC/T2N), 6.72 (1H, m,
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Ar/7-8), 6.74 (1H, m, ArJ/-5);
13C-NMR (D20): (containing 0.75% 3 -(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d4 acid)
5C 20.68 (CH3), 34.68 (ArCH2CH), 46.70 (ArCH2NH), 52.92 
(CH), 116.31 (CatH-8), 118.60 (CatH-5), 121.98 (Cat**),
126.44 (CAr-8a), 145.93/146.78 (2 x CatOH);
MS (ESI-negative) m/z: [M-H]~ 178.0(10), Br” 80.9(100);
MS (ESI-positive) m/z: MH+ 180.0(100);
IR (KBr) p/cm: 3168 (OH str.), 1534 (Cat-Cat), 1234 (Cat-OH);
Microanalysis (C,H,N): Calculated for CioHi4N0 2Br: 46.17, 5.42, 5.38;
Found 46.02, 5.18, 5.37.
(*S)-/V-(4-Chlorophenethylthiocarbamoyl)-6,7-dihydroxy-3-methyl-l,2,3,4-tetra- 
hydroisoquinoline (305):
345 (750mg, 2.88mmol) was suspended in dry dichloromethane (lOmL) with 
triethylamine (400pL, 291mg, 2.88mmol). Isothiocyanate 32 (570mg, 2.88mmol) 
was dissolved in dry dichloromethane (5mL) and added to the reaction mixture, 
which was stirred at room temperature under an atmosphere of argon for eighteen 
hours. The reaction was diluted to lOOmL with dichloromethane and washed 
consecutively with dilute aqueous hydrochloric acid (2 x 75mL), water (50mL) and 
brine (25mL), before drying over dried magnesium sulfate. Filtration, and removal of 
solvent under reduced pressure gave a bright yellow foam; purification by flash 
column chromatography (Biotage 40S, cyclohexane/ ethyl acetate 2:1) gave a yellow 
foam, which was dissolved in chloroform (lOmL) and precipitated from cyclohexane 
(50mL), to give a bright yellow amorphous solid. Drying under reduced pressure at 
55°C to constant weight gave the product as a finely divided powder, containing 
~0.05 equivalents of residual cyclohexane (690mg, 64%):
Characterisation:
Melting point: amorphous solid;
Optical rotation [o:]d25- - 1 14.5 (c 1.04, chloroform);
H-NMR (CDC13): SH 0.93 (3H, d, J=  6 .6 Hz, CHC/y3), 1.42 (0.6H, s, residual
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I3C-NMR (CDCU):
MS (ESI-negative) m/z: 
MS (ESI-positive) m/z:
IR (KBr) Wcm: 
Microanalysis (C,H,N):
HRMS (positive) m/z:
cyclohexane504), 2.40 (1H, d d A B x , Jab  = 15.5Hz, Jax  = 2 . 2 H z ,  
ArC//AHBCH), 2.87 (1H, ddBAx, Jba  = 15.5Hz, J BX = 4.9Hz, 
A t C H a ^ b C H ) ,  2.93 (2H, t, J=  7.1Hz, 4’-chlorophenyl- 
CH2 CH2), 3.84-4.00 (2 H, m, 4’-chlorophenyl-CH2Ciy2NH),
4.30 (1 H, br dAB, Jab «15Hz, ArCtfAHBN), 4.69 (1 H, br dAB, 
J ab ®15Hz, ArCHAtfBN), 4.9-5.1 (1H, br,
ArCHAHBC^xCH3), 5.69 (1H, t, J=  5.1Hz, NH), 5.85-6.15 
(2H, br, 2 x ArOtf), 6.58 (1H, m, Artf-8 ), 6.62 (1H, m, ArH- 
5), 7.12 (2H, dm (AA’ of an AA’BB’ system), J ortho = 8.4Hz, 
AiH-T, Artf-6 ’), 7.23 (2H, dm (BB’ of an AA’BB’ system), 
Jortho = 8.4Hz, Artf-3’, ArH-5');
8 q 17.56 (CH3), 26.92 (CH2, residual cyclohexane504), 34.44 
(tetrahydroisoquinoline ArCH2CH), 34.66 (4’-chlorophenyl- 
CH2CH2), 46.61 (ArCH2NH), 46.84 (4’-chlorophenyl- 
CH2CH2NH), 49.95 (CH), 113.15 (CatH-8), 115.64 (CArH-5),
123.49 (br, CAr-8 a), 125.19 (CAr-4a), 128.80 (CArH-3’, CatH- 
5’), 130.17 (CatH-2’, CatH-6’), 132.41 (CAr-Cl), 137.25 (Cat- 
1’), 142.55 (CatOH-7), 143.30 (CatOH-6), 179.85 (C=S); 
[M-H]” 375.2(100)/377.2(41);
MH+ 377.2(23)/379.2(8),
[M^C1C6H4CH2CH2NHC=S)]+ 178.1 (100);
3361 (OH str.), 1524 ( C Ar-C A r );
Calculated for Ci9H2 iN20 2SCl + 0.05 equivalents of 
cyclohexane: 60.81, 5.72, 7.35;
Found 60.56, 5.67, 7.38;
Calculated for [M+H] Ci9H22N20 2SC1: 377.1091;
Found 377.1097.
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(/?)-Ar-(4-Chlorophenethylthiocarbamoyl)-6,7-dihydroxy-3-methyl-l,2,3,4-tetra- 
hydroisoquinoline (30/2*):
HO.
HO
341? (1.15g, 4.4mmol) was dissolved in dry N,N-DM¥ (lOmL) with triethylamine 
(680pL, 495mg, 4.9mmol, 1.1 equivalents). The reaction was stirred under argon; 
after five minutes 32 (875mg, 4.4mmol) was dissolved in dry A^V-DMF (5mL) and 
added to the reaction mixture. The reaction was stirred at room temperature under an 
atmosphere of argon for eighteen hours. The reaction was diluted to 250mL with
i
ethyl acetate and washed consecutively with 2M aqueous hydrochloric acid 
(2 x lOOmL), water (lOOmL) and brine (50mL), before drying over dried magnesium 
sulfate. Filtration, and removal of solvent under reduced pressure gave an orange 
syrup; purification by flash column chromatography (Biotage 40M, cyclohexane/ 
ethyl acetate 2:1) gave a pale yellow foam. The foam was dissolved in chloroform 
(20mL) and precipitated from 200mL of vigorously stirring cyclohexane (200mL), to 
give a bright yellow amorphous solid. Drying under reduced pressure at 55°C to 
constant weight (5 days) gave the product as a finely divided powder, containing 
-0.05 equivalents of residual cyclohexane (955mg, 58%):
Characterisation:
Melting point: amorphous solid;
Optical rotation [a]D25: +113.0 (c 1.05, CHCI3);
!H-NMR (CDCI3): dH 0.94 (3H, d, J =  6 .6 Hz, CHC//3), 1.42 (-0.6H, s, residual
cyclohexane504), 2.42 (1H, d d A B x , J a b  = 15.5Hz, J a x  = 2.6Hz, 
A tC IT a H b C H ) ,  2.86-2.96 (3H overlapping signals,
comprising: 2.89 (1H, ddsAx, Jba = 15.5Hz, JBX = 5.0Hz, 
A tC H a ^ b C H ) ,  2.93 (2H, t, J =  7.1Hz, 4’-chlorophenyl- 
CH2 CH2))t 3.88-3.98 (2H, m, 4’-chlorophenyl-CH2Gfir2NH), 
4.32 (1H, br dAB, J a b  ®15Hz, ArC/yAHBN), 4.69 (1H, br dAB, 
J a b  ~15H z, A tC H a H b N ) ,  4.93-5.07 (1H, br,
ArCHAHBC//xCH3), 5.65 ( 1 H, t, J=5.2Hz, NH), 5.7-6.0 
(2H, br, 2 x ArO^), 6.59 (1H, m, Ari5f-8), 6.63 (1H, m, AiH-
5), 7.13 (2H, dm (AA’ of an AA’BB’ system), J ortho = 8.4Hz,
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13C-NMR (CDCI3):
MS (ESI-negative) m/z: 
MS (ESI-positive) m/z: 
IR (KBr) p/cm: 
Microanalysis (C,H,N):
HRMS (positive) m/z:
ArH-2\ Ar//-6 ’), 7.23 (2H, dm (BB* of an AA’BB’ system),
«Jortho ~ 8.4Hz, AiH-V, ArH-5’);
&c 17-57 (CH3), 26.92 (CH2, residual cyclohexane504), 34.47 
(tetrahydroisoquinoline ArCH2CH), 34.65 (4’-chlorophenyl- 
CH2CH2), 46.64 (ArCH2NH), 46.82 (4’-chlorophenyl- 
CH2 CH2NH), 49.93 (CH), 113.13 (CatH-8 ), 115.61 (CArH-5), 
123.53 (br, CAr-8 a), 125.23 (CAr-4a), 128.82 (C^H-3’, CatH- 
5’), 130.18 (CatH-2’, CatH-6 ’), 132.44 (Cat-CI), 137.25 (Cat- 
1’), 142.51 (CatOH-7), 143.28 (CatOH-6 ), 179.92 (CHS); 
[M -H r 375.2 (100);
M H + 377.1 (100); '
3 3 7 3  (O H  str.), 1 5 2 4  (C Ar-C A r);
Calculated for C 19H 21N 2 O 2 S C I + 0.05 equivalents of 
cyclohexane: 60.81, 5.72, 7.35;
Found 60.43, 5.69, 7.40;
Calculated for [M+H] C19H22N2Q2SCI: 377.1085;
Found 377.1084.
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Enantiomers of the fra/is-diastereomers of N-(4-chlorophenethylthio- 
carbamoyl)-6,7-dihydroxy-l,3-dimethyl-l,2,3,4-tetrahydroisoquinoline 
analogues (31(11?,3/?) and 31(15,35))
(5)-J/V-Benzyl-2-(3,4-dimethoxyphenyl)-l-methylethylamine (1555)
385 (lO.Og, 0.0513mol) was dissolved in dry methanol (200mL), and chilled to 0°C 
by stirring on ice under an atmosphere of argon. Benzaldehyde (5.21mL, 5.44g, 
0.0513mol) was added in one portion, and the reaction was stirred for 24 hours. 
TLC (dichloromethane/ methanol/ 32% AcOH(aq.) 90:9:1) confirmed no amine 
remained. The solution was cooled to -15°C on a salt/ice bath, sodium borohydride 
(2.9 lg, 0.077mol, 1.5 equivalents) was added portionwise over fifteen minutes, with 
accompanying effervescence, and the mixture was left to come to room temperature 
with stirring for 18 hours. The reaction was poured into 1.0M aqueous sodium 
hydroxide (500mL), and the product extracted into ethyl acetate (2 x 250mL). The 
combined extractions were washed with water (200mL) and brine (lOOmL), then 
dried over dried magnesium sulfate. Filtration and removal of solvent under reduced 
pressure, followed by purification by flash column chromatography (Biotage 40M 
cartridge; cyclohexane/ethyl acetate 1:4) gave a colourless oil (13.4g, 92%): 
Characterisation:
TLC: R f 0.50 (dichloromethane/methanol/32% aqueous acetic acid
90:9:1);
Optical rotation [a]o21: +38.4 (c 0.88, dichloromethane);
!H-NMR (CDCI3): 5 h  1.11 (3H, d, J =  6.2Hz, CHC173), 2.58-2.69 (2H, m,
ArC//2CH), 2.87-2.93 (1H, m, CH2C/yCH3), 3.72 (1H, d ^ , 
Jab = 13.4Hz, PhC/yAHBNH), 3.82 (3H, s, ArOC^-3), 3.85 
(1H, dBA, Jab = 13.4Hz, PhCHA/fBNH), 3.86 (3H, s, 
ArOC//3-4), 6.65 (1H, d, J meta = 1.8Hz, ArH-2), 6.70 (1H, dd, 
Jortho = 8.1Hz, J meta = 1.8Hz, ArlT-6 ), 6.79 (1H, d,
Jortho ~ 8.1Hz, ArflT-5), 7.17-7.23 (3H, m, AiH -2\ A iH  -4’, 
A r/f-6 ’), 7.24-7.29 (2H, m, ArH-3’, Ar/f-5’);
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13C-NMR (CDCI3): 6 C 20.24 (CHCH3), 43.27 (ArCH2CH), 51.25 (PhCH2N),
53.49 (CH2 CH(NH)CH3), 55.75 (ArOCH3-3), 55.93
(ArOCH3-4), 111.22 (C atH -5 ) ,  112.37 (C atH -2 ) ,  121.26 
(CArH-6 ), 126.81 (C atH - 4 ’) , 127.98, 128.35 (C atH - 3 ’, C atH -  
5’ and CArH-2\ CMH-6 ’), 132.00 (C^-l), 140.53 (C at- 1 ’) ,
147.50 (CArOMe-4), 148.86 (CArOMe-3);
TLC:
Melting point:
Optical rotation [a]o20: 
!H-NMR (CDCI3):
A sample of the oil (500mg, 1.75mmol) was dissolved in dioxan (lOmL); to the 
stirred solution 5.0 equivalents of hydrogen chloride was added, as 4.0M HC1 in 
dioxan (2.2mL). The dense white precipitate formed was filtered and washed with 
diethyl ether; this precipitate was dissolved in a boiling mixture of propan-2-ol 
(12mL) and methanol (5mL), hot-filtered, and cooled to room temperature overnight. 
Filtration gave a colourless crystalline solid (457mg, 82%):
Characterisation:
R f 0.50 (dichloromethane/ methanol/ 32% AcOH(aqj  90:9:1); 
204°C (sublimed);
+20.7 (c 0.45, ethanol);
6h 1.34 (3H, d, / =  6.5Hz, CHCtf3), 2.77 (1H, dd^x, 
Ab = 13.1Hz, A x = 10.7Hz, ArC/yAHBCH), 3.10-3.20 (1H, 
br m, CH2C//CH3), 3.42 (1H, ddBAX, A a = 1  3.1Hz, 
A x = 3.8Hz, ArCHA^ BCH), 3.81 (3H, s, ArOC//3-3), 3.84 
(3H, s, A1OC//3-4 ), 4.01-4.11 (2H, m, PhCtf2N), 6.60 (1H, d, 
Jmeta = 1.8Hz, ArH-2 ), 6.65 (1H, dd, J ortho = 8.2Hz,
J m e ta  = 1.8Hz, Ar/7-6), 6.76 (1H, d, J ortho = 8.2Hz, Artf-5),
7.31 (1H, t, Jortho = 7.4Hz, Ar/y-4’), 7.36-7.41 (2H, m, AxH- 
3’, Arfif-5’) 7.66 (2H, J ortho = 7.1Hz, Artf-2’, Artf-6’), 10.00 
(2H, b r , ^ ) ;
6C 15.85 (CHCH3), 38.72 (ArCH2CH), 47.92 (PhCH2N),
54.09 (CH2CHCH3), 55.87 (ArOCH3), 55.93 (ArOCH3),
111.25 (CatH-5), 112.35 (CatH-2), 121.37 (CArH-6), 128.81 
(Cat-1), 129.08 (CatH -3’, CatH -5 ’), 129.38 (CatH-4’), 
130.11 (Cat- I ’X 130.51 (CatH-2’, CArH-6’), 147.97
(CArOMe-4), 148.97 (CArOMe-3);
13C-NMR (CDC13):
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MS (ESI-positive) m/z: MH+ 286(100), [M-BnNH]+ 179(53);
IR (KBr) v/cm: 1518 (C at- C at) , 1268 (Ar-OCH3), 1 0 2 1  (ArO-CH3);
Microanalysis (C,H,N): Calculated for C16H24NO2CI: 67.17, 7.52, 4.35;
Found 67.12, 7.23,4.26.
(R)-ALBenzyl-2-(3,4-dimethoxyphenyl)-l-methylethylamine (155R)
38R  (4.00g, 0.0205mol) was dissolved in dry methanol (80mL), then cooled to 
-10°C on a salt/ice bath, with stirring under an atmosphere of nitrogen. 
Benzaldehyde (2.1mL, 2.18g, 0.0205mol) was added, and the reaction was left to stir 
for 62 hours, over which time the reaction temperature returned to ambient. The 
reaction temperature was returned to -10°C, and sodium borohydride (1.16g,
' 0.0308mol, 1.5 equivalents) was added portionwise over five minutes; the mixture
was stirred for four hours. An aliquot of the reaction was partitioned between ethyl 
acetate and 1 M aqueous sodium hydroxide; analysis of the organic phase against the 
starting primary amine by TLC (dichloromethane/methanol 10:1) confirmed the 
reaction to be complete. The reaction was poured into 1M aqueous sodium hydroxide 
(500mL) and the product was extracted into ethyl acetate (2x250mL). The combined 
organic extractions were washed with water (lOOmL) and brine (50mL), then dried 
over dried magnesium sulfate. Filtration, and removal of the solvent under reduced 
pressure, gave a colourless oil (5.83g, 98%).
Characterisation:
TLC: R f 0.50 (dichloromethane/ methanol/ 32% AcOH(aq.) 90:9:1);
Optical rotation [a]o21: -39.5 (c 0.84, dichloromethane);
^-N M R (CDC13): 5h 1.11 (3H, d, /=6.2H z, CHCri3), 2.58-2.70 (2H, m,
A1C //2CH), 2.87-2.93 (1H, m, CH2GffCH3), 3.72 (1H, dAB, 
Jab = 13.4Hz, PhCriAHBNH), 3.82 (3H, s, ArOCtf3-3), 3.85 
(1H, dBA, Jab = 1 3 .4 H z , PhCHAJTBNH), 3.86 (3H, s, 
ArOC//3-4), 6.65 (1H, d, Jmeta = 1.9Hz, Arif-2), 6.70 (1H, dd, 
Jortho = 8.1Hz, Jmeta=  1.9Hz, Arif-6 ), 6.79 (1H, d,
Joriho = 8.1Hz, Arif-5), 7.17-7.24 (3H, m, Arri-2’, A r i f -4’, 
A r i f -6 ’), 7.24-7.30 (2 H, m, AriT-3’, Arri-5’);
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13C-NMR (CDCI3): Sc 20.23 (CHCHs), 43.27 (ArCH2CH), 51.25 (PhCH2N),
53.49 (CH2 CH(NH)CH3), 55.80 (ArOCH3-3), 55.93
(ArOCH3-4), 111.22 (CatH-5), 112.38 (CatH-2), 121.26 
(CatH-6), 126.81 (CatH-4’), 127.98, 128.35 (CatH-3’, CArH- 
5’ and Ca,H -2 \ CArH-6 ’), 131.99 (CAr-l), 140.53 (Cat-1’).
147.50 (CArOMe-4), 148.86 (CArOMe-3);
TLC:
Melting point:
Optical rotation [q :]d 20: 
'H-NMR (CDC13):
A sample of the oil (430mg, 2.21 mmol) was dissolved in dioxan (5mL); to the stirred 
solution was added 5.0 equivalents of hydrogen chloride as 4.0M HC1 in dioxan 
(1.9mL), forming a dense colourless precipitate. The suspension was heated to 
boiling, and methanol was added dropwise until the precipitate dissolved (~2.5mL); 
the solution was left to cool to room temperature overnight. Filtration gave a 
colourless crystalline solid (336mg, 69%):
Characterisation:
R f 0.54 (dichloromethane/ methanol 10:1);
205°C (sublimed);
-20.8 (c 0.41, ethanol);
5H 1.34 (3H, d, J=  6.5Hz, CHCtf3), 2.77 (1H, ddABx, 
Jab =  13.2Hz, Ja x =  10.7Hz, ArCtfAHBCH), 3.10-3.20 (1H, 
br m, CH2CtfCH3), 3.42 (1H, ddBAx, JBA=13.2Hz, 
JBX = 3.8Hz, ArCHA^ BCH), 3.81 (3H, s, ArOCtf3-3), 3.84 
(3H, s, ArOCfiT3-4), 4.01-4.11 (2H, m, PhCJT2N), 6.60 (1H, d, 
Jmeta= 1.7Hz, AlH-2), 6.65 (1H, dd, Jortho= 8.2Hz,
Jmeta = 1.7Hz, Ar/7-6), 6.76 (1H, d, Jortho = 8.2Hz, Ar//-5),
7.31 (1H, t, Jortho = 7.4Hz, Ar/f-4’), 7.36-7.40 (2H, m, ArH- 
3’, ArZf-5’) 7.66 (2H, Jortho = 7.3Hz, ArH-T, ArH-6 ' \  10.03
(2H,br,N+J5T2);
5C 15.90 (CHCH3), 38.77 (ArCH2CH), 47.94 (PhCH2N),
54.10 (CH2CHCH3), 55.91 (ArOCH3), 55.97 (ArOCH3), 
111.38 (CatH-5), 112.47 (CatH-2), 121.47 (CatH-6), 128.87 
(Cm-1), 129.09 (CatH-3’, CmH-5’), 129.39 (CArH-4’), 130.15 
(CatI*), 130.53 ( 2  x CatH-2 ’, CmH-6 ’), 148.07 (C^OMe^),
149.07 (CArOMe-3);
13C-NMR (CDC13):
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MS (ESI-positive) m/z: MH+ 286(45), [M-PhCH2NH]+ 179(100);
IR (KBr) ('/cm: 1518 (Cat-Cat), 1268 (Ar-0CH3), 1021 (A1O-CH3);
Microanalysis (C,H,N): Calculated for C16H24NO2CI: 67.17,7.52,4.35;
Found 66.90,7.40,4.52.
Ethynyl-4-tolylsulfone (150)483
— H
Ethynyl-4-tolylsulfone 150 was synthesised according to the method of Waykole and 
Paquette483. Aluminium chloride (29.4g, 0.22mol) was suspended in dry 
dichloromethane (200mL), and stirred under an atmosphere of nitrogen. Toluene-4- 
sulfonyl chloride (41.9g, 0.22mol) was added, and the mixture was stirred for one 
hour, to give a hazy brown solution. A solution of bis(trimethylsilyl)acetylene 
(34.0g, 0.20mol) in dry dichloromethane (200mL) was stirred under an atmosphere 
of nitrogen, and cooled on an ice/water bath; the solution containing the tosyl 
chloride-aluminium chloride complex was added dropwise, over one hour, to give an 
orange solution, which was stirred at room temperature for eighteen hours. The now 
dark brown reaction mixture was poured into a mixture of 2.0M hydrochloric acid 
(200mL) and ice/water (200mL), stirred for ten minutes, then separated. The organic 
phase was washed consecutively with water (2 x 250mL), and brine (100mL), before 
drying over dried magnesium sulfate. Filtration and subsequent solvent removal 
under reduced pressure gave a brown crystalline solid; purification by flash column 
chromatography (silica, cyclohexane/ethyl acetate 10:1, to 4:1) and subsequent 
recrystallisation from ethyl acetate/cyclohexane, gave a beige crystalline solid (yield 
24.5g, 6 8 %):
Characterisation:
TLC: R f 0.34 (cyclohexane/ethyl acetate 4:1);
Melting point: 71-72°C (lit. 75°C)483;
‘H-NMR (CDCb): 6 h 2.48 (3H, s, ArCH3), 3.52 (1H, s, C^CH), 7.40 (2H, dm
(AA’ of an AA’BB’ system), J ortho = 8.2Hz, Ar/f-3 , Ar/f-5), 
7.89 (2H, dm (BB’ of an AA’BB’ system), ./ortho = 8.2Hz,
Ar/7-2, Ar/T-6 );
(lit. (CDC13) 8  2.47 (s, 3H), 3.52 (s, 1H), 7.38 (dd, 2H,
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13C-NMR (CDCI3):
MS (El) m/z:
IR (KBr) v/cm:
Microanalysis (C,H):
J=  8.5,0.6), 7.88 (d, 2H, J=  8.5)483);
6 C 21.77 (ArCHj), 80.28 (C^CH), 81.35 (CsCS02), 127.67 
(CatH-2, CatH-6), 130.13 (CArH-3, CatH-5), 137.75 
(CArS02), 146.09 (CArCH3);
M4  180(100);
3231 (*C-H), 2063 (Cs€), 1337 (S02), 1155 (S02)
(lit. (cm-1): 3235,2013, 1337, 1156483);
Calculated for C9H8SO2 : 59.98,4.47;
Found 60.06/60.09, 4.43/4.57.
/V-Benzyl-[(5)-2-(3,4-dimethoxyphenyl)-l-methyIethyl]-./V-[(ii)-2-(toluene-4- 
sulfonyl) vinyl] amine (1575)
\
150 (7.9g, 0.044mol) was dissolved in dry dichloromethane (lOOmL), and added to a 
chilled (0°C, ice bath) solution of 385 (12.5g, 0.044mol) in dry dichloromethane 
(250mL) with stirring, under an atmosphere of nitrogen. The resulting solution was 
stirred for 18 hours. The solvent was removed under reduced pressure, and the 
residue was dissolved in boiling ethyl acetate (350mL), hot filtered, then cooled to 
room temperature. Filtration after two hours gave a colourless crystalline solid 
(16.06g, 78%); a sample of these crystals was sent for X-ray crystallographic 
analysis. Removal of solvent from the mother liquor under reduced pressure, and 
purification by flash column chromatography (Biotage 40M, cyclohexane/ ethyl 
acetate 2 :1 ) gave a further crop of colourless crystalline solid (2 .2 g, 1 1 %): 
Characterisation:
R f  0.33 (cyclohexane/ ethyl acetate 2:1)
142°C;
+117.3 (c 0.55, dichloromethane);
dH 1.26 (3H, br d, CHCtf3), 2.39 (3H, s, ArCH3), 2.70-2.75 
(1H, br, AtC/TaHbCH), 2.83 (1H, ddBAx, Jba=13.9H z,
TLC:
Melting point:
Optical rotation [«]d22: 
'H-NMR (CDCI3):
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,3C-NMR (CDCI3):
MS (ESI-positive) m/z: 
IR (KBr) v/cm: 
Microanalysis (C,H,N)-
Jbx = 8.3Hz, AtCHa^bCH), 3.56-3.63 (1H, m,
ArCH2C/fCH3), 3.75 (3H, s, ArOCtf3-3), 3.87 (3H, s, 
ArOCJf3-4), 3.95-4.00 (1H, br d, PhCiyAHBN), 4.20 (1H, 
dAB, Ja b =  16.2Hz, PhCHAtfBN), 4.88-4.92 (1H, br d, 
S0 2Ci/=CHN), 6.55 (1H, d, Jmeta = 1.9Hz, Ar/f-2), 6.63 (1H, 
dd, Jmeta = 1.9Hz, Jortho = 8.1Hz, Artf-6 ), 6.76 (1H, d, 
Jortho = 8.1Hz, Artf-5), 7.00 (2H, br, Ph#-2\ -6 ’), 7.21-7.25 
(5H, m, PhfiT-3’, Phtf-4’, Ph/y-5’, tosyl Artf-3”, tosyl Artf- 
5” (a to CH3)), 7.54 (1H, d, Jtrans = 12.7Hz, S02CH=C#N), 
7.60 (2H, d, Jortho = 8.0Hz, tosyl Artf-2”, tosyl Ar/7-6” 
(a to sulfoxide));
5c 19.99 (br, CHCH3), 21.44 (ArCH3), 41.97 (br, ArCH2CH),
52.12 (br, PhCH2N), 55.79 (ArOCH3), 55.86 (ArOCH3),
61.91 (br, CH2 CHCH3), 94.06 (S02 CH=CHN), 111.26 
(CatH-5), 112.08 (CatH-2), 121.09 (CatH-6), 126.05
(tosyl CatH-2”, tosyl CArH-6 ” (a to sulfoxide)), 126.81 (br, 
phenyl CatH -2’, phenyl CatH-6’), 127.51 (phenyl CatH-4’),
128.68 (phenyl CatH-3’, phenyl CArH-5’), 129.35
(tosyl CatH-3”, tosyl CatH-5” (atoCH 3)), 130.18 
(vanillyl Cat-1), 135.33 (br, phenyl Cat 1’), 142.06, 142.12 
(tosyl CatCH3-4”, tosyl CArS02- l”), 147.61 (br,
S0 2CH=CHN), 147.78 (CArOMe-4), 148.93 (CArOMe-3); 
[M+Na]+ 488(100), [2M+Na]+ 953(14);
1610 (C=C), 1518 (Cat-Cat), 1258 (CAr-OMe), 1129 (S0 2); 
Calculated for C27H31N04 S: 69.65, 6.71, 3.01;
Found 69.66, 6.78, 3.07.
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/V-Benzyl-[(/?)-2-(3,4-dimethoxyphenyl)-l-methylethyl]-AL[(/s)-2-(toluene-4- 
sulfonyl)vinyl] amine (157/?)
\
o- "'o,
150 (3.7g, 0.0205mol) was dissolved in dry dichloromethane (lOOmL), and added to 
a solution of 381? (5.83g, 0.0205mol) in dry dichloromethane (lOOmL) with stirring, 
under an atmosphere of nitrogen; the resultant solution was stirred for 2 hours, at 
which time TLC (dichloromethane/methanol 10:1) confirmed the reaction to be 
complete. The solvent was removed under reduced pressure, and the residue was 
dissolved in boiling ethyl acetate (200mL), hot filtered, then left to cool to room 
temperature over the weekend. Filtration gave a colourless crystalline solid (7.15g, 
75%). Removal of solvent from the mother liquor under reduced pressure gave a 
brown residue; purification by flash column chromatography (Biotage 40S, 
cyclohexane/ ethyl acetate 2:1) gave a beige solid; recrystallisation gave a colourless 
crystalline solid (1.31,14%):
Characterisation:
R f  0.33 (cyclohexane/ ethyl acetate 2:1);
143°C;
-125.0 (c 0.52, dichloromethane);
6h 1.26 (3H, br d, CHC//3), 2.39 (3H, s, ArCtf3), 2.70-2.75 
(1H, br, ArC/yAHBCH), 2.83 (1H, ddBAX, «/BA=13.9Hz, 
J bx  = 8.3Hz, ArCHA/fBCH), 3.56-3.63 (1H, m,
ArCH2C//CH3), 3.75 (3H, s, ArOCtf3-3), 3.87 (3H, s, 
ArOCfiT3-4), 3.95-4.00 (1H, br d, PhC/7AHBN), 4.20 (1H, 
d ^ ,  Jab = 16.2Hz, PhCHAtfBN), 4.88-4.92 (1H, br d, 
S02C//=CHN), 6.55 (1H, d, J meta = 1.9Hz, Ar/7-2), 6.63 (1H, 
dd, J meta = 1.9Hz, J ortho = 8.1Hz, Ar/y-6), 6.76 (1H, d, 
J ortho = 8.1Hz, Arff-5), 7.00 (2H, br, Ph//-2\ Ph^-6’), 7.21-
7.25 (5H, m, Ph//-3\ Ph^-4’, Ph^-5’, tosyl Ar^-3”, 
tosyl Ar/T-5” (a to CH3)), 7.54 (1H, d, J trans = 12.7Hz,
TLC:
Melting point: 
Optical rotation [a]o 
'H-NMR (CDCU):
2 1 .
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S0 2CH=C//N), 7.60 (2H, d, Jortho = 8.0Hz, tosyl ArH-T\ 
tosyl Ar//-6 ” (a to sulfoxide));
13C-NMR (CDCI3): dc 19.99 (br, CHCH3), 2 1 .44 (ArCH3), 41.97 (br, ArCTfeCH),
52.12 (br, PhCH2N), 55.79 (ArOCH3), 55.86 (ArOCH3),
61.91 (br, CH2CHCH3), 94.06 (S02CH=CHN), 111.26 
(CatH-5), 112.08 (CArH-2), 121.09 (CatH-6), 126.05
(tosyl CatH-2 ”, tosyl CArH-6 ” (a to sulfoxide)), 126.81 (br, 
phenyl CatH -2’, phenyl CatH-6’), 127.51 (phenyl CatH-4’),
128.68 (phenyl CArH-3’, phenyl CArH-5’), 129.35
(tosyl CArH-3”, tosyl CatH-5” (atoCH 3)), 130.18 
(vanillyl C^-l), 135.33 (br, phenyl CAr- l ’), 142.06, 142.12 
(tosyl CATCH3-4 ”, tosyl CArS02- l”), 147.61 (br,
S0 2CH=CHN), 147.78 (CArOMe-4), 148.93 (CArOMe-3);
MS (El) m/z: M+ 465(11), [M-(3,4-dimethoxybenzyl)]+ 314(100);
IR (KBr) v/cm: 1610 (C=C), 1518 (Cat-Cat), 1258 (Ar-OCH3), 1128 (S02);
Microanalysis (C,H,N): Calculated for C27H3 iN0 4 S: 69.65, 6.71, 3.01;
Found 69.71, 6.62, 2.87.
(l/?,35)-2-Benzyl-6,7-dimethoxy-3-methyl-l-(toliieiie-4-siilfoiiylmethyl)-l,2,3,4- 
tetrahydroisoquinoline (158(1/?,35))
1575 (18.0g, 0.0387mol) was dissolved in dry dichloromethane (250mL), and cooled 
with stirring under an atmosphere of nitrogen on a salt/ice bath to -15°C. 
Trifluoroacetic acid (200mL, 296g, 2.65mol, 6 8  equivalents) was similarly cooled, 
then poured into the solution in one portion. The solution immediately changed 
colour, from colourless to bright yellow. After three hours, the reaction retained a 
slight yellow colouration. An aliquot (50pL) was neutralised in saturated aqueous 
sodium bicarbonate (500pL), and products were extracted into diethyl ether. TLC 
(cyclohexane/ ethyl acetate 2:1) showed no starting material remaining. The reaction 
was poured into water (1L), and made slightly alkaline (pH ~8 ) by the cautious,
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portionwise addition of solid sodium carbonate (~250g) over thirty minutes. The pH 
was further basified by the addition of 5.0M aqueous sodium hydroxide (500mL); 
neutral organic compounds were extracted into dichloromethane (3 x 250mL). The 
combined extractions were washed consecutively with saturated aqueous sodium 
bicarbonate (200mL), water (200mL) and brine (lOOmL), then dried over dried 
magnesium sulfate. Filtration, and removal of the solvent under reduced pressure 
gave a peach coloured foam; purification by flash column chromatography (3 x 
Biotage 40M; cyclohexane/ ethyl acetate 4:1) gave a colourless foam (16.4g, 91%): 
Characterisation:
TLC: R f 0.31 (cyclohexane/ ethyl acetate 2:1);
Melting point: amorphous solid;
Optical rotation [a]D21: -8.5 (c 1.02, ethanol);
'H-NMR (CD2C12): (no TMS) SH 1.01 (3H, d, J=  6 .6 Hz, CHCff3), 2.42 (3H, s,
ArC/fj), 2.46-2.58 (2H, m, ArCJftCH), 3.12-3.19 (2H, dAB 
and m overlapping, J ab  = 13.4Hz, P1iC//aHbN and 
CH2 CHCH3), 3.24 (1H, ddABx, J ab  = 14.9Hz, /ax = 4.2Hz, 
tosyl-C/TAHBCH), 3.67-3.73 (4H, m (overlapping ddfiAx 
( /b a  = 15.0Hz, / B x  = 7.5H z) and s, tosyl-CHA//BCH and 
ArOC/Tj), 3.74-3.78 (4H, m (overlapping dAe and s), 
PhCHA/TBN and ArOG//3), 4.19 (1H, ddxAB, / x a  = 4.2Hz, 
J x b  = 7.4Hz, tosyl-CH2GH), 6.48 (1H, s, Artf-8 ), 6.54 (1H, s, 
Ar/f-5), 7.22-7.31 (7H, m, Phtf-2, Ph^-3, Ph^-4, Ph/7-5, 
PhH-6 , tosyl ArH-3”, tosyl Ar//-5” (a to CH3)), 7.56 (2H, 
dm (BB’ of an AA’BB’ system), J ortho = 8.2Hz, tosyl AiH-2”, 
tosyl AiH-6 ” (a to sulfoxide));
13C-NMR (CD2C12): (no TMS) 5C 18.96 (CHCH3), 21.70 (ArCH3), 30.60
(ArCH2CH), 47.54 (CH2 CHCH3), 50.09 (PhCH2N), 56.14 
(2 x ArOCH3), 56.25 (tosyl-CH2CH), 62.77 (tosy-lCH2CH),
111.06 (CajH-8), 112.16 (CatH-5), 127.03 (br, CV^a or 
CAr8 a), 127.20 (phenyl CArH-4’ + CAr-4a or CAr8 a (peak size 
reduced in DEPT, with respect to adjacent signals), 128.27, 
128.35 (CArH-3\ CatH -5’ and tosyl CatH-2”, CatH-6”), 
129.87, 130.00 (phenyl CatH-2’, CatH-6 ’ and tosyl CatH-3”,
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CatH -5”), 138.04 (tosyl CAr-S02- l ”), 139.84 (phenyl CAr- 1’),
144.66 (tosyl CatCH3-4”), 148.32 (CArOMe), 148.55 
(CArOMe);
MS (ESI-positive) m/z: MH+ 466(100);
IR (KBr) iVcm: 1517 ( C at- C at) ,  1249 (Ar-OCH3), 1145cm*1 (S02);
Microanalysis (C,H,N): Calculated for C27H3 iN04S: 69.65, 6.71, 3.01;
Found 69.31, 6.71, 3.05.
(IS, 3/?)-2-Benzyl-6,7-dimethoxy-3-methyl-l-(toluene-4-sulfonylmethyl)-l, 2,3,4- 
tetrahydroisoquinoline (158(1*9,3/?))
157/? (8.25g, 0.0177mol) was dissolved in dry dichloromethane (75mL), and cooled 
with stirring under an atmosphere of nitrogen on a salt/ice bath to -15°C. 
Trifluoroacetic acid (lOOmL, 148g, 1.325mol, 75 equivalents) was similarly cooled, 
then poured into the solution in one portion. An immediate colour change, from 
colourless to bright yellow, was observed. After two hours, the reaction was poured 
into water (750mL), and made slightly alkaline (pH ~8 ) by the cautious, portionwise 
addition of solid sodium carbonate (~160g) over thirty minutes. Dichloromethane 
(250mL) was added; the biphasic solution was stirred vigorously for fifteen minutes, 
then separated. The aqueous phase was extracted with fresh dichloromethane 
(250mL), the combined dichloromethane extractions were consecutively washed 
with saturated aqueous sodium hydrogencarbonate (250mL) and saturated aqueous 
sodium chloride (lOOmL), then dried over dried magnesium sulfate. Filtration, and 
removal of the solvent under reduced pressure gave a colourless foam; purification 
by flash column chromatography (2 x Biotage 40M, cyclohexane/ethyl acetate 4:1) 
gave a colourless foam (7.57g, 92%):
Characterisation:
TLC: R f  0.31 (cyclohexane/ ethyl acetate 2:1);
Melting point: amorphous solid;
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Optical rotation [ck]d19: 
‘H-NMR (CD2C12):
13C-NMR (CD2C12):
MS (ESI-positive) m/z: 
IR (KBr) p/cm: 
Microanalysis (C,H,N):
-8.5 (c 1.00, ethanol);
(no TMS) 5h 1.02 (3H, d, J = 6 .6 Hz, CHCtfs), 2.42 (3H, s, 
ArC/73), 2.45-2.58 (2H, m, ArC//2CH), 3.13-3.19 (2H, dAB 
and m overlapping, Jab = 13.4Hz, P1iC//aHbN and 
CH2CHCH3), 3.25 (1H, d d A B x ,  / a b  = 14.9Hz, J a x  =  4.2Hz, 
tosyl-C//AHBCH), 3.67-3.73 (4H, m (overlapping ddBAx 
(J b a  = 15.0Hz, J BX = 7.5Hz) and s, tosyl-CHAftC H  and 
ArOC/73), 3.74-3.78 (4H, m (overlapping dAB and s), 
PhCHAtfBN and ArOCf73), 4.20 (1H, ddxAB, J x a = 4.2Hz, 
J xb  = 7.4Hz, tosylCH2GH), 6.48 (1H, s, Artf-8 ), 6.54 (1H, s, 
AiH-5), 7.23-7.31 (7H, m, Ph/T-2, Phtf-3, PhfiT-4, Phtf-5, 
PlifiT-6 , tosyl Ar/7-3”, tosyl Ar/f-5” (2 x tosyl ArH are a  to 
methyl)), 7.56 (2H, dm (BB’ of an AA’BB’ system), 
Jortho= 8.2Hz, tosyl ArH-T\ tosyl Ar//-6 ” (both a  to 
sulfoxide));
(no TMS) 5C 18.96 (CHCH3), 21.71 (ArCH3), 30.60 
(ArCH2CH), 47.56 (CH2 CHCH3), 50.10 (PhCH2N), 56.15 
(2 x ArOCH3), 56.25 (tosyl-CH2 CH), 62.77 (tosyl-CH2CH),
111.07 (CArH-8 ), 112.17 (CatH-5), 127.02 (br, C ^ a  or 8 a), 
127.20 (phenyl CatH-4’ and tetrahydroisoquinoline CAr-4a or 
CAr-8 a (peak size reduced in DEPT, with respect to adjacent 
signals), 128.28, 128.36 (phenyl CArH-3’, phenyl CatH-5’, 
tosyl CatH-2”, tosyl CatH-6”), 129.87, 130.00 (phenyl CatH- 
2’, phenyl CArH -6 ’, tosyl CVH-3”, tosyl CatH-5”), 138.04 
(CAr-S02), 139.81 (phenyl Cat-1’), 144.66 (C^-Me), 148.33 
(CArOMe), 148.56 (CArOMe);
MH* 466(100);
1517 ( C a t - C a t ) ,  1249 (Ar-OCH3), 1145cm'1 (S02); 
Calculated for C27H31NO4S: 69.65,6.71,3.01;
Found 69.81, 6.81, 3.05.
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(l/?,35)-6,7-dimethoxy-3-methyl-l-(toluene-4-sulfonylmethyl)-l,2,3,4-tetra- 
hydroisoquinoline (159(11?,35))
NH
158(11?,35) (1.26g, 2.7mmol) was dissolved in methanol (75mL) and stirred. After 
evacuation and purging with nitrogen (x 2), 270mg of 10% palladium on carbon 
(~0.27mmol) was added. The mixture was evacuated and left under reduced pressure 
for five minutes, before an atmosphere of hydrogen was introduced. The reaction 
was stirred for two hours, after which time TLC confirmed the reaction to be 
complete. The reaction was evacuated once more, and purged with nitrogen, before 
filtering through Celite and removing the volatile components under reduced 
pressure, to give the crude product in quantitative yield, as a colourless crystalline 
solid. Recrystallisation was achieved by suspending the residue in boiling n-hexane, 
and gradually adding small amounts of ethyl acetate until a solution was obtained. 
This was hot-filtered into a little n-hexane, and left to cool overnight. The product 
crystallised as fine needles (550mg, 54% yield), and these were used for 
characterisation. A small sample of the compound was crystallised slowly from 
ethanol, and larger crystals, suitable for X-ray crystallographic analysis, were 
obtained.
Characterisation:
TLC:
Melting point:
Optical rotation [a]D29: 
^-NM R (CDC13):
R f  0.25 (cyclohexane/ ethyl acetate 1:1);
151-152°C;
+49.6 (c 0.98, ethanol);
dH 1.11 (3H, d, J=  6.1Hz, CHCtf3), 2.05-2.35 (1H, br, NH), 
2.40 (1H, ddABx, Tab = 16.0Hz, JAx=10.7Hz,
AtC^aHbCHx), 2.47 (3H, s, ArCtf3), 2.60 ( 1H, ddBAx, 
Jba= 16.0Hz, Jbx= 10.7Hz, AtCHa1TbCHx), 3.02-3.07 (1H, 
m, CH2CJT(NH)CH3), 3.20 (1H, ddA’B’X’, Jaw  = 14.6Hz, 
A*x’ = 2.0Hz, S0 2C/Ta’Hb’CH), 3.68 (1H, ddA’B’x’,
Jb’A’ = 14.6Hz, /b ’x’ = 1 0 .2 Hz, SO2CHa^ b ’CHx0, 3.76 (3H,
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s, ArOC//3-7), 3.81 (3H, s, ArOC//3-6 ), 4.61 (1H, br d, 
CH2C//(NH)Ar), 6.31 (1H, s, Arfl-8 ), 6.51 ( 1 H, s, AiH-5),
7.39 (2H, d, Jor,Ho = 8 .2 Hz, Ar/7-3’and Arff-5’), 7.87 (2H, d, 
Jor,ho = 8.2Hz, AiH-2’ and ArH-6 ’);
13C-NMR (C D C I 3): Sc 21.65 (ArCH3), 22.00 (CHCH3), 36.78 (ArCH2CH), 42.61
(CH2 CHCH3), 51.58 (S02CH2 CH), 55.86 (ArOCH3), 56.10
(ArOCH3), 60.57 (S02 CH2CH), 109.35 (CatH-8), 111.69 
(CatH-5), 127.05 (CAr8 a), 127.63 {C*Aa), 128.01 (C atH -2\ 
CatH-6’), 130.03 (CatH-3’, CatH-5’), 136.92 (CatSOj-I’), 
144.86 (CatCHj-4’), 147.56 (CArOMe-7), 148.20 (CArOMe- 
6);
M S  (El) m/z: M + 375(20), [ M - C H 2 S 0 2 C 6H 4 C H 3]+ 206(100);
1R (KBr) r/cm: 3330 (NH), 1522 ( C a t C a t ) ,  1370 (S02), 1152 (S02);
Microanalysis (C ,H ,N ):  Calculated for C 20H 25N O 4 S: 63.98, 6.71, 3.73;
Found 64.03, 6.77,3.91.
(15,35)-2-Benzyl-6,7-dimethoxy-l,3-dimethyl-l,2,3,4-tetrahydroisoquinoline
(167(15,35))
A 1.0M solution of lithium napthalenide was prepared by dissolving naphthalene 
(12.8g, O.lmol) in dry THF (lOOmL), with stirring, under an atmosphere of argon. 
Lithium wire (2.08g, 0.3mol, 3 equivalents) was added in ~0.5cm pieces, and the 
mixture was stirred for two hours; the solution changed from colourless to a very 
dark green within a few minutes of the addition of the lithium wire.
158(11?,35) (7.6g, 0.0163mol) was dissolved in dry THF (360mL), and, whilst 
stirring under an atmosphere of argon, the solution was cooled on a carbon dioxide/ 
acetone bath to -70°C. The lithium naphthalenide solution was slowly added by 
syringe (36mL, -2.2 equivalents) over 10 minutes. During the addition the sulfone 
solution changed colour, from colourless, via a deepening orange, to dark green. 
After stirring for one hour, the reaction mixture was poured into 0.5M aqueous 
hydrochloric acid (400mL) to quench, and the neutral material was extracted into 
diethyl ether (2 x lOOmL). The aqueous layer was basified by the addition of 5.0M
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aqueous sodium hydroxide (50mL), and the now neutral amine products were 
extracted into diethyl ether (3 x 150mL). The second round of ether extractions were 
combined, washed with brine (lOOmL) and dried over dried magnesium sulfate. 
Filtration and removal of solvent under reduced pressure gave a brown oil; 
purification by flash column chromatography (Biotage 40M cartridge, cyclohexane/ 
diethyl ether 4:1) gave a colourless syrup (2.80g, 57%).
Characterisation:
TLC: R f 0.30 (cyclohexane/ ethyl acetate 4:1);
Optical rotation [a]D22: -43.8 (c 1.21, dichloromethane);
*H-NMR (CDC13): 5h 1.24 (3H, d, J =  6.7Hz, 3-CH 3%  1.35 (3H, d, J =  6.9Hz, 1-
C //3), 2.57-2.60 (2H, m, ArC^CH), 3.39-3.46 (2H, d^i and 
m overlapping, Jab = 14.1 Hz, PhC//AHBN and CH2C//CH3),
3.71 (1H, quartet, J=6.9Hz, ArCtfCH3), 3.80-3.85 (7H, m 
(overlapping dBA and 2 x s), PhCHA/fBN and 2 x ArOC//3),
6.47 (1H, s, Artf-8 ), 6.56 (1H, s, Artf-5), 7.23 (1H, t, 
Jo r th o  = 7.2Hz, Ph/y-4’), 7.28-7.33 (2H, m, Ph/T-3’, Ph/7-5’),
7.39 (2H, d, Jortho = 7.3Hz, Phtf-2\ Phtf-6 ’);
13C-NMR (CDC13): 6 c 18.46 (3-CH3), 22.52 (1-CH3), 32.12 (ArCH2CH), 46.36
(CH2 CHCH3), 50.27 (PhCH2N), 55.08 (ArCHCH3), 55.80, 
(ArOCH3), 55.85 (ArOCH3), 110.63 (CatH-8), 111.33 (CatH- 
5), 126.27 (C A r-4a), 126.51 (CatH-4’), 128.13 (CatH-3’, 
CatH-5’), 128.41 (CatH-2’, CatH-6’), 131.14 (CAr-8a), 141.01 
(Cat-1’), 147.13 (CArOMe), 147.24 (CArOMe);
MS (ESI-positive) m/z: MH+ 312(100);
H R M S  (positive) m/z: Calculated for [M + H ] C 2oH 2s N 0 2: 312.1964;
Found312.1964.
(li?,3R)-2-Benzyl-6,7-dimethoxy-l,3-dimethyl-l,2,3,4-tetrahydroisoquinolme 
(167(11?,3R))
A 1.0M solution of lithium napthalenide in tetrahydrofuran was prepared by 
dissolving naphthalene (6.4 lg, 0.05mol) in dry tetrahydrofuran (total volume of
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50mL), with stirring, under an atmosphere of argon, in a flame-dried round-bottomed 
flask. Lithium wire (1.04g, 0.15mol, 3 equivalents) was added portionwise over 
fifteen minutes, and the mixture was stirred for two hours; the solution changed from 
colourless to a very dark green within a few minutes of the addition of the lithium 
wire.
158(15,31?) (6.1g, 0.013lmol) was dissolved in dry tetrahydrofuran (290mL), with 
stirring under an atmosphere of argon; the solution was cooled on a carbon dioxide/ 
acetone bath to -70°C. The lithium naphthalenide solution was slowly added by 
syringe (30mL, ~2.2 equivalents) over 10 minutes; during the addition the sulfone 
solution changed colour, from colourless, via a deep orange, to dark green. After 
stirring for one hour, the reaction mixture (still dark green), was poured into 0.5M 
aqueous hydrochloric acid (400mL) to quench; neutral material was extracted into 
diethyl ether (2 x lOOmL). The aqueous layer was basified by the addition of 5.0M 
aqueous sodium hydroxide (50mL), and the now neutral amine products were 
extracted into diethyl ether (2 x 200mL). The second round of ether extractions were 
combined, washed consecutively with water (lOOmL) and brine (50mL), before 
drying over dried magnesium sulfate. Filtration and removal of solvent under 
reduced pressure gave a brown syrup; purification by flash column chromatography 
(Biotage 40M cartridge, cyclohexane/ diethyl ether 4:1) gave a colourless syrup 
(1.85g, 45%).
Characterisation:
TLC:
Optical rotation [ gc] d  
'H-NMR (CDC13):
22 .
13 C-NMR (CDCI3):
R f 0.30 (cyclohexane/ ethyl acetate 4:1);
+46.1 (c 1.35, dichloromethane);
5H 1.23 (3H, d, J=  6 .6 Hz, 3-C//3), 1.35 (3H, d, J =  6 .8 Hz, 1- 
C //3), 2.57-2.60 (2H, m, ArC//2CH), 3.40-3.46 (2H, d ^  and 
m overlapping, Jab = 14.2Hz, P1iC/7aHbN and CH2C//CH3),
3.71 (1H, quartet, J = 6 .8 Hz, ArC/7CH3), 3.80-3.84 (7H, m 
(overlapping dBA and 2 x s), P1iCHa//bN and 2 x A1 OCH3),
6.47 (1H, s, Ar/7-8), 6.56 (1H, s, AzH-5), 7.22 (1H, t, 
Jortho ~ 7.2Hz, Ph/7-4’), 7.28-7.32 (2H, m, Ph/7-3’, Ph/7-5’), 
7.38 (2H, d, Jortho = 7.3Hz, Ph/7-2’, Ph/7-6’);
5C 18.40 (3-CH3), 22.51 ( I - C H 3) ,  32.22 (ArCH2CH), 46.41 
(CH2 CHCH3), 50.36 (PhCH2N), 55.12 (ArCHCH3), 55.84,
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(ArOCH3), 55.90 (ArOCH3), 110.75 (CatH-8), 111.46 (CatH- 
5), 126.33 (CAr-4a), 126.51 (CArH -4’), 128.14 (CatH-3’, 
CatH-5’), 128.40 (CatH-2’, CatH-6’), 131.24 (CAr-8a), 141.07 
(Cat-1’), 147.22 (CArOMe), 147.32 (CArOMe);
MS (ESI-positive) ro/z: MH+ 312.2(100);
IR (neat) vlcm: 1515 (Cat-Cat), 1253 (CAr-OMe);
HRMS (positive) m/z\ Calculated for [M+H] C20H26NO2 : 312.1964;
Found 312.1964.
(15,35)-6,7-Dimethoxy-l ,3-dimethyl-1,2,3,4-tetrahydroisoquinoline (44(15', 35))
167(15,35) (2.65g, 8.52mmol) was dissolved in dry methanol (lOOmL); the stirred 
reaction was evacuated, purged with argon, and 10% palladium on activated carbon 
(170mg, 0.17mmol, ~2mol%) was added. The stirred suspension was evacuated, 
stirred for five minutes to thoroughly degas the solution, and placed under an 
atmosphere of hydrogen. The reaction was left to stir at room temperature for 18 
hours. After evacuation, and purging with argon, the reaction mixture was filtered 
through Celite, and the solvent removed under reduced pressure to give a pale yellow 
syrup (1.90g, -quantitative).
Characterisation:
Optical rotation [a]D20: +50.6 (c 1.22, methanol);
^-N M R (CDC13): 6h 1.31 (3H, d, J=  6.3Hz, 3-Ctf3), 1.52 (3H, d, J=  6.9Hz, 1-
CH3), 2.53 (1H, ddABx, Jab = 16.2Hz, ./ax = 9.9Hz,
AtCZTaHbCH), 2.76 (1H, ddBAx, Jba = 16.2Hz, J=4.2Hz, 
AtCHa^bCH), 3.30-3.40 (1H, m, CH2C/TCH3), 3.84 (6H, 
2 x s  overlapping, 2 x ArOCH3), 4.26 (1H, q, J=  6.9Hz, 
ArC^CH3), 6.54 (1H, s, Ar/f-5), 6.56 (1H, s, Artf-8); 
13C-NMR (CDC13): 5q 21.32 (3-CH3), 23.37 (1-CH3), 36.22 (ArCH2CH), 43.41
' (CH2CHCH3), 50.46 (ArCHCH3), 55.89 (ArOCH3), 56.02 
(ArOCH3), 109.54 (CatH-8), 111.60 (CatH-5), 125.53 (Cat- 
4a), 130.41 (CAr-8a), 147.51 (CatOCH3), 147.73 (CatOCH3);
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Melting point:
Optical rotation [a]D20:
'H-NMR (DMSO-d6):
For full characterisation, the residue was dissolved in dioxan (15mL), and 4.0M 
hydrogen chloride in dioxan (lOmL) was added, with stirring. The resultant 
suspension was heated to boiling, and sufficient methanol added to leave a hazy 
solution (~10mL); this was hot filtered, then left to cool to room temperature. 
Filtration gave a colourless crystalline solid (1.60g, 73%):
Characterisation:
268°C (sublimed);
+25.3 (c 1.08, dichloromethane);
+29.0 (c 1.02, water);
5h 1.39 (3H, d, J = 6.4Hz, 3-Ctf3), 1.59 (3H, d, J = 6.9Hz, 1- 
CH3), 2.72 (1H, ddABx, Jab = 16.8Hz, /ax = 10.1Hz, 
ArC//AHBCH), 2.95 (1H, ddBAx, /b a= 16 .8H z, /= 4 .9 H z , 
AtCHa/TbCH), 3.62-3.68 (1H, m, CH2C/7CH3), 3.73-3.74 
(6 H, 2 x overlapping s, 2 x A rCO /3), 4.46 (1H, q, / =  6.9Hz, 
ArC//CH3), 6.73 (1H, s, AiH-5), 6.83 (1H, s, Ar/7-8), 9.50-
9.85 (2 H, br, IsfH 2)\
bc 17.74 (3-CH3), 20.02 (1-CH3), 32.33 (ArCH2CH), 43.71 
(CH2 CHCH3), 48.88 (ArCHCH3), 55.44 (ArOCH3), 55.58 
(ArOCH3), 109.68 (CatH-8), 111.49 (CatH-5), 122.87 (C at 
4a), 125.54 (CAr-8a), 147.62 (CatOCH3), 148.09 (CatOCH3); 
MS (ESI-positive) m/z: MH+ 222(100);
IR (KBr) v/cm: 1590 (Cat-Cat), 1525 (CAr-C Ar), 1228 (Ar-OCH3);
Microanalysis (C,H,N): Calculated for Ci3H20NO2C1: 60.58, 7.82, 5.43;
Found 60.41, 7.72, 5.52.
13C-NMR(DMSO-d6):
(H?,3J?)-6,7-Dimethoxy-l ,3-dimethyl-l ,2,3,4-tetrahydroisoquinoline (44(1R,3R))
167(1/?,3/?) (1.85g, 5.95mmol) was dissolved in dry methanol (75mL); the stirred 
reaction was evacuated, purged with argon, and 1 0 % palladium on activated carbon 
(120mg, 1.2mmol, ~20mol%) was added. The stirred suspension was evacuated, 
before being placed under an atmosphere of hydrogen, and left to stir at room 
temperature for 18 hours. After evacuation, and purging with argon, the reaction
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Optical rotation [ a ] D 20: 
'H-NMR (CDCI3):
13C-NMR (CDCI3):
mixture was analysed by TLC, and, in the absence of starting material, was filtered 
through Celite, and the solvent removed under reduced pressure to give a pale yellow 
syrup (1.33g, ~quantitative):
Characterisation:
-50.7 (c 1.39, methanol);
8 n 1.25 (3H, d, J=  6.3Hz, 3-C//3), 1.47 (3H, d, J=  6.9Hz, 1- 
CH3), 2.45 (1H, ddABx, Jab= 16.2Hz, / a x  = 9.9Hz,
AtC^aHbCH), 2.73 (1H, ddBAx, /b a= 16 .2H z, J= 4 .2H z, 
ArCHAftCH), 3.05 (1H, br, N/Z), 3.26-3.34 (1H, m,
CH2Gf7CH3), 3.84 (6 H, 2 x s overlapping, 2  x ArOCZ/3), 4.20
(1H, q, J = 6.9Hz, ArC//CH3), 6.54 (1H, s, Ar/Z-5), 6.56 (1H, 
s, Ar/Z-8 );
dc 21.87 (3-CH3), 23.78 (1-CH3), 36.72 (ArCH2CH), 43.09 
(CH2 CHCH3), 50.58 (ArCHCH3), 55.87 (ArOCH3), 56.00 
(ArOCH3), 109.63 (CatH-8), 111.63 (CatH-5), 125.99 (C at 
4a), 131.31 (C A r-8 a ) , 147.36 (CatOCH3), 147.54 (CatOCH3); 
For full characterisation, the residue was dissolved in dioxan (20mL), and 4.0M
hydrogen chloride in dioxan (5mL) was added, with stirring. The resultant
suspension was heated to boiling, and sufficient methanol added to dissolve the 
precipitate; the solution was hot filtered into boiling dioxan, then left to cool to room 
temperature. Filtration gave a colourless crystalline solid (1.14g, 74%): 
Characterisation:
264-5°C (sublimed);
-24.3 (c 1.05, dichloromethane);
-28.2 (c 1 .0 2 , water);
SH 1.38 (3H, d, / =  6.4Hz, 3-Ctf3), 1.58 (3H, d, J = 6.9Hz, 1- 
CH 3), 2.71 (1H, ddABx, /ab = 16.9Hz, Vax = 10.0Hz, 
AtGJTaHbCH), 2.95 (1H, ddBAx, Jba=16.9H z, y=4.6Hz, 
AtCHa^bCH), 3.60-3.70 (1H, m, CH2CtfCH3), 3.73-3.74 
(6 H, 2 x overlapping s, 2 x ArOC/f3), 4.47 (1H, q, J=  6.9Hz, 
ArCl/CH3), 6.73 (1H, s, Ar^-5), 6.82 (1H, s, A r^-8 ), 9.45- 
9.65 (2H, br, bT/fc);
'H-NMR (D2O): (containing 0.75% 3-(trimcthylsilyl)propionic-2,2,.i,
Melting point:
Optical rotation [«]d20:
!H-NMR (DMSO-d6):
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sodium salt) SH 1.47 (3H, d, J=  6.5Hz, 3-CH3), 1.66 (3H, d, J  
= 6.9Hz, l-Cfla), 2.82 (1H, ddABx, J ab  = 17.4Hz, Ax = 
10.1Hz, AtC^aHbCH), 3.13 (1H, ddBAx, A a = 17 .4H z, 
J=  4.9Hz, ArCHA/7BCH), 3.81-3.87 (7H, m + 2 x s  
overlapping, CH2CtfCH3 + 2 x ArOC#3), 4.66 (1H, q, 
J=  6.9Hz, ArC#CH3), 6.89-6.90 (2H, 2 x s, Artf-5, Artf-8);
13C-NMR(DMSO-d6): 8 C 17.68 (3-CH3), 20.05 (1-CH3), 32.31 (ArCH2CH), 43.85
(CH2CHCH3), 48.91 (ArCHCH3), 55.47 (ArOCH3), 55.61 
(ArOCH3), 109.68 (CatH-8), 111.50 (CatH-5), 122.92 (C at 
4a), 125.58 (CAr-8a), 147.61 (CatOCH3), 148.06 (CatOCH3);
13C-NMR (D20): (containing 0.75% 3-(trimethyl silyl)propionic-2,2,3,3 -d4 ,
sodium salt) 8 C 20.46 (3-CH3), 22.59 (1-CH3), 35.15 
(ArCH2CH), 47.81 (CH2CHCH3), 53.06 (ArCHCH3), 58.58 
(ArOCH3), 58.68 (ArOCH3), 112.25 (CatH-8), 114.52 (CatH- 
5), 126.22 (CAr-4a), 128.15 (CAr-8a), 150.23 (CatOCH3), 
150.74 (CatOCH3);
MS (ESI-positive) m/z: MH+ 222(100);
IR (KBr) v/cm: 1523 (CAr-C Ar), 1256 (Cat-OCH3), 1228 (CAr-OCH3);
Microanalysis (C,H,N): Calculated for Ci3H2oN 02C1: 60.58, 7.82, 5.43;
Found 60.40, 7.62, 5.59.
(15,3iS)-6,7-Dihydroxy-l,3-dimethyl-l,2,3,4-tetrahydroisoquinoline 
hydrobromide (35(15,35))
44(15,35) (765mg, 3.0mmol) was dissolved in 48% hydrobromic acid (lOmL) and 
stirred at reflux for 5 hours. !H-NMR of an aliquot confirmed the reaction was 
complete; the reaction was cooled to room temperature, and the solvent was removed 
under reduced pressure. The foam was dissolved in a boiling mixture of propan-2-ol/ 
ethyl acetate 2:1, hot filtered, and cooled to room temperature. Filtration, and drying 
for 18 hours at 100°C and O.lmmHg gave a colourless microcrystalline solid 
(410mg, 50%):
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Characterisation:
Melting point:
Optical rotation [ck ]d 2 2 : 
‘H-NMR (DMSO-ds):
13C-NMR (DMSO-ds):
MS (ESI-positive) m/z:
IR (KBr) j'/cm:
Microanalysis (C,H,N): Calculated for CnHi6N02Br: 48.19, 5.88, 5.11;
Found 48.02, 5.71, 5.51.
(l/?,3/?)-6,7-Dihydroxy-l,3-dimethyl-l,2,3,4-tetrahydroisoquinoline 
hydrobromide (35(1/?,31?))
IH
'/,//  HBr
44(1/?,3/?) (280mg, 1.09mmol) was dissolved in 48% aqueous hydrobromic acid 
(5mL), and stirred at reflux for six hours. Removal of solvent under reduced pressure 
and analysis by 1 H-NMR confirmed the reaction to be complete (no signals 
corresponding to the methoxy substituents apparent in the spectrum). The reaction 
was cooled to room temperature, and the solvent removed under reduced pressure, to 
give a pale brown foam. The foam was suspended in hot ethyl acetate; methanol was 
added, with heating, until the foam dissolved; the solution was allowed to cool to 
room temperature, before refrigeration for 24 hours. At this time there had been no 
crystallisation, so diethyl ether was added until the solution became hazy; the
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209-210°C;
+16.0 (c 0.51, water);
5h 1.35 (3H, d ,  J = 6.4Hz, 3-CHi), 1.51 (3H, d ,  J = 6.8Hz, 1- 
cm\ 2.61 (1H, d d A B X , 7ab= 16.8Hz, yAx=10.0Hz,
A tC//aH bCH), 2.86 (1H, d d BAx ,  Jba = 16.8Hz, J b x  = 4.5Hz, 
ArCHA# BCH), 3.60-3.72 (1H, br m, CH2C/yCH3), 4.42-4.52 
(1H, br m, ArC#CH3), 6.52 (1H, s, Ar/7-5), 6.59 (1H, s, 
Arff-8), 8.94 (1H, s, ArCtfy-7), 8.95-9.05 (1H, br, N ^ aHb), 
9.06 (1H, s, ArOJy-6), 9.10-9.25 (1H, br, N ^ a^ b);
5C 17.83 (3-CH3), 20.23 (1-CH3), 32.06 (ArCH2CH), 43.97 
(CH2CHCH3), 48.86 (ArCHCHj), 112.91 (CatH-8), 114.79 
(CatH-5), 121.09 (CAr-4a), 123.85 (CA,-8a), 144.20 (CatOH- 
6), 144.90 (CArOH-7);
MS (ESI) m/z MH+ 194(100);
M il* 194(100);
3172 (OH) 1594 (CAr-CAr), 1533 (CAr-C Ar), 1241 (CAr-OH);
Melting point:
Optical rotation [a]o21: 
'H-NMR (DMSO-d6>:
solution was refrigerated for a further 24 hours. Filtration gave a colourless 
crystalline solid (165mg, 55%):
Characterisation:
220-221°C;
-16.1 (c 0.49, water);
8h 1.35 (3H, d, J=  6.4Hz, 3-Cff3), 1.51 (3H, d, J=  6.8Hz, 1- 
CHi), 2.60 (1H, ddABX, Jab = 16.8Hz, Jax=10.0H z, 
ArC//AHBCH), 2.86 (1H, ddBAx, Jba = 16.8Hz, JBX = 4.5Hz, 
AtCHaAbCH), 3.60-3.72 (1H, br m, CH2C/fCH3), 4.42-4.52 
(1H, br m, ArCflCH3), 6.52 (1H, s, kxH-5), 6.59 (1H, s, 
Artf-8), 8.94 (1H, s, ArOtf-7), 8.95-9.05 (1H, br, N+ZTaHb),
9.06 (1H, s, ArOtf-6), 9.10-9.25 (1H, br, N ^ a^ r);
5c 17.83 (3-CH3), 20.23 (1-CH3), 32.06 (ArCH2CH), 43.97 
(CH2CHCH3), 48.86 (ArCHCH2), 112.90 (CatH-8), 114.79 
(CatH-5), 121.09 (CAr-4a), 123.85 (CAr-8a), 144.20 (CatOH- 
6), 144.90 (CajOH-7);
MH+ 194(100);
3171 (OH) 1594 (Cat-Cat), 1533 (Cat-Cat), 1241 (Cat-OH); 
Microanalysis (C,H,N): Calculated for Ci iHi6N 02Br: 48.19, 5.88, 5.11;
Found 47.84, 5.73, 5.09.
13C-NMR (DMSO-d6):
MS (ESI-positive) m/z: 
IR (KBr) v!cm\
(l.S,,3*S)-AL(4-Chlorophenethylthiocarbamoyl)-6,7-dihydroxy-l,3-dimethyl- 
1,2,3,4-tetrahydroisoquinoline (31 (15,35))
HO.
HO
35(15,35) (1.07g, 3.90mmol) was dissolved in dry A^V-DMF (lOmL) with 
triethylamine (600pL, 437mg, 4.30mmol, 1.1 equivalents). 32 (800mg, 4.10mmol, 
1.05 equivalents) was dissolved in dry A i^V-DMF (5mL) and added to the solution. 
The resulting solution was stirred at room temperature under an atmosphere of argon 
for eighteen hours. The reaction was diluted to 150mL with ethyl acetate, and 
washed consecutively with 2M hydrochloric acid (2x50mL), water (lOOmL) and 
brine (50mL), before drying over dried magnesium sulfate. Filtration, and removal of
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TLC:
Melting point:
Optical rotation [a]D21: 
1 H-NMR (CDCI3):
solvent under reduced pressure gave a pale brown syrup. Purification by flash 
column chromatography (Biotage 40M cartridge; cyclohexane/ethyl acetate 3:1) 
gave a colourless foamed solid (1.32g, 87%). The foam was dissolved in chloroform 
(5mL) and precipitated from cyclohexane (lOOmL), to give a colourless powdered 
solid; drying at high vacuum at room temperature for seven days (to constant weight) 
gave 1.18g of material, containing 0.25 equivalents of cyclohexane (effective 
molecular weight 411.97, yield 73%):
Characterisation:
RfOA9 (cyclohexane/ ethyl acetate 1:1); 
amorphous solid;
-114.4 (c 0.52, dichloromethane);
6 H 0.77 (3H, d, J=  6.3Hz, 3-Ctf3), 1-34 (3H, d, J=  6.5Hz, 1- 
CH3), 2.42 (1H, ddABx, Jab = 15.1Hz, Jax=  1.7Hz,
tetrahydroisoquinoline AtC//aH bCH), 2.90-3.02 (2H, m, 4’- 
chlorophenyl-C//2CH2), 3.15 (1H, d d B A x ,  J b a  = 15.1Hz, 
J b x  = 4.7Hz, tetrahydroisoquinoline AtCHa/ZbCH), 3.86- 
3.94 (1H, m, 4’chlorophenyl-CH2CtfAHBNH), 3.99-4.07 (1H, 
m, 4’-chlorophenyl-CH2CHA/7BNH), 4.40-4.55 (1H, br, 
CH2Ctf(N)CH3), 5.35-5.50 (1H, br, ArCtf(N)CH3), 5.57 (1H, 
br t, J=  5.0Hz, NH), 6.20-6.40 (2H, br, 2 x ArOH), 6.69 (1H, 
s, Ar/f-5), 6.71 (1H, s, Artf-8 ), 7.16 (2H, dm (AA’ of an 
AA’BB’ system), J ortho = 8.4Hz, krH -2\ -6 ’), 7.26 (2H, dm 
(BB’ of an AA’BB’ system), J orth0 = 8.4Hz, AxH-V and -5 ’); 
6 C 18.43 (3-CH3), 23.32 (1-CH3), 34.20 (ArCH2CH), 34.52 
(4’-chlorophenyl-CH2CH2), 46.87 (4’-chlorophenyl- 
CH2 CH2NH), 50.63 (br, CH2CH(N)CH3), 55.45 (br, 
ArCH(N)CH3), 113.44 (CatH-5), 115.86 (CatH-8), 124.95 
(CAr-4a), 128.88 (2xC Ar-2’, -6 ’), 130.14 (2xCArH-3’, -5’),
130.66 (CAr-8 a), 132.50 (CatCI), 137.22 (Cat-H), 142.52 
(CatOH), 143.15 (CatOH), 178.78 (C=S);
MS (ESI-positive) m/z: MH+ 391(100), 393(37);
IR (KBr) ('/cm: 3419 (OH) 1517 (CAr-CAr), 1128 (CA-OH);
HRMS (positive) m/z: Calculated for C22H24N20 2SC1 [M+H]: 391.1247;
13C-NMR (CDC13):
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HPLC
Found 391.1251.
System 1 : retention time = 4.88 minutes; 
System 2: retention time = 7.46 minutes.
(ll?,31?)-/V-(4-Chlorophenetliylthiocarbamoyl)-6,7-diliydroxy-l,3-dimethyI- 
1,2,3,4-tetrahydroisoquinoline (31(1J?,3J?»
35(11?,31?) (1.07g, 3.9mmol) was dissolved in dry A/A-DMF (lOmL). Triethylamine 
(600pL, 437mg, 4.3mmol) was added to the stirred solution, followed by a solution 
of 32 (800mg, 4.1 mmol) in dry N,N-DMF (5mL). The reaction was stirred at room 
temperature under argon for 48 hours, then diluted with ethyl acetate (200mL) and 
washed consecutively with 0.1M hydrochloric acid (2 x lOOmL), water (50mL) and 
brine (20mL), before drying over dried magnesium sulfate. Filtration and removal of 
solvent under reduced pressure gave a colourless foam; the foam was dissolved in 
chloroform (15mL) and precipitated from vigorously stirred cyclohexane (200mL), 
to give a finely divided colourless amorphous solid (1.25g, 82% yield). Although 
initially pure by 1 H-NMR, the successful removal of residual solvent by prolonged 
drying at 70°C and O.lmmHg introduced a trace impurity, visible in the 1 H-NMR as 
doublets at 8 h 1.31 and 1.48, and a triplet at 8 h 3.71. Comparison with 1 H-NMR of 
35(1/?,3/S) confirmed the impurity was not a diastereomer, and the impurity was not 
apparent in the either analytical HPLC trace.
Characterisation:
TLC: R f 0.50 (cyclohexane/ ethyl acetate 1:1);
Melting point: amorphous solid;
Optical rotation [a]o21: +114.1 (c 0.54, dichloromethane);
H-NMR (CDCI3): 5h 0.79 (3H, d, J=  6.3Hz, 3-CH3\  1.36 (3H, d, J=  6 .6 Hz, 1-
CH3), 2.44 (1H, d d A B x ,  J a b  = 15.1Hz, . / a x  = 2.0Hz,
tetrahydroisoquinoline ArC//AHBCH), 2.93-3.02 (2H, m, 4’- 
chlorophenyl-C//2CH2), 3.18 (1H, d d B A x ,  J b a = 1  5.1Hz, 
J bx = 4.8Hz, tetrahydroisoquinoline ArCHA/ / BCH), 3.89- 
3.96 (1H, m, 4,chlorophenyl-CH2C ^AHBNH), 3.99-4.06 (1H,
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13C-NMR (CDCI3):
MS (APCI) m/z:
IR (KBr) Wcm: 
HRMS (positive) m/z:
HPLC
m, 4’-chlorophenyl-CH2CHAtfBNH), 4.38-4.58 (1H, br, 
CH2C/f(N)CH3), 5.20-5.55 (4H, broad overlapping signals 
(including t, J=  5.0Hz), NH, ArC//(N)CH3, 2 x AiOH), 6 . 6 8  
(1H, s, Ar/Z-5), 6.70 (1H, s, Artf-8 ), 7.17 (2H, dm (AA’ of 
an AA’BB’ system), J 0rtho~  8.4Hz, Ar//-2’, -6 ’), 7.28 (2H, 
dm (BB’ of an AA’BB’ system), J ortho = 8.4Hz, AxH-T and -
5’);
6 C 18.43 (3-CH3), 23.37 (1-CH3), 34.27 (ArCH2CH), 34.54 
(4’-chlorophenyl-CH2CH2), 46.84 (4’-chlorophenyl- 
CH2 CH2NH), 50.53 (br, CH2CH(N)CH3), 55.44 (br, 
ArCH(N)CH3), 113.44 (CatH-5), 115.79 (CArH-8 ), 125.05 
(CAr-4a), 128.91 (2 x Cat-2’, -6’), 130.16 ( 2 x ^ - 3 ’, -5’),
130.85 (C^-Sa), 132.55 (C^Cl), 137.30 (C ^-l’), 142.42 
(CatOH), 143.11 (CatOH), 179.05 (C=S);
MH+391.0 (100);
3386 (OH + NH) 1518 (Cat-Cat), 1127 (Cat-OH);
Calculated for C20H24N2O2SCl [M+H]: 391.1242;
Found 391.1241.
System 1: retention time = 4.90 minutes;
System 2: retention time = 7.49 minutes
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Enantiomers of the cis-diastereomers of N-(4-chlorophenethylthio-carbamoyl)-
6 ,7-dihydroxy-1,3-dimethy 1-1,2,3,4-tetrahydroisoquinoline analogues (31(11?,35) 
and 31(15,31?))
(15,35)-6,7-dimethoxy-3-methyl-l-(toluene-4-sulfonylmethyl)-l,2,3,4-tetra- 
hydroisoquinoline hydrochloride (159(15,35))
NH
HCI
385 (1.12g, 5.7mmol) was dissolved in dry dichloromethane (lOmL), and stirred on 
an ice/water bath under an atmosphere of dry argon. 150 (1.033g, 5.7mmol) was 
dissolved in dry dichloromethane (5mL), and added to the amine solution. After 30 
minutes, thin layer chromatography confirmed the absence of starting materials. The 
reaction solution was cooled to -10°C on a salt/ice bath, and cold (~10°C) 
trifluoroacetic acid (18mL, ~40 equivalents) was added in one portion. After two 
hours at -10°C, the reaction was poured into 400mL of a 1:1 mixture of 
dichloromethane and water. The TFA was neutralised by the cautious, portionwise 
addition of solid sodium hydrogen carbonate (30g, 0.357mol). The phases were 
separated, and the aqueous phase was washed with fresh dichloromethane (lOOmL). 
The combined organic extractions were washed consecutively with water (lOOmL) 
and brine (50mL), before drying over dried magnesium sulfate. Filtration, and the 
removal of volatile components under reduced pressure gave a beige foam. Two 
chromatographic purifications (Biotage40M, cyclohexane/ ethyl acetate 1:2, then 
Biotage 40S, cyclohexane/ ethyl acetate 1:2 of the impure fractions) gave the desired 
compound as a colourless glass (950mg, 44% yield), which resisted all attempts at 
crystallisation. Some of the colourless glass (370mg) was dissolved in methanol 
(5mL), precipitated by the addition of excess 4.0M hydrogen chloride in dioxan 
(500pL), filtered and dried, to give a colourless powdered solid. This was dried 
under high vacuum (O.lmmHg) at 100°C for four hours, to give 350mg. 
Characterisation:
TLC: free base RfO.21 (cyclohexane/ ethyl acetate 1:4);
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Melting point:
Optical rotation [a]D29: 
‘H-NMR (DMSO-d<s):
13C-NMR (DMSO-ck):
MS (El) m/z:
IR (KBr) v/cm: 
Microanalysis (C,H,N):
238-239°C;
+25.4 (c 0.5, water);
(no TMS; referenced to DMSO at 2.50ppm)
5h 1.47 (3H, d, J =  6.3Hz, CHCtf3), 2.43 (3H, s, ArCtf3), 
2.81 (1H, d d A s x ,  J ab = 16.6Hz, J a x  =  3.6Hz, ArCtfAHBCHx), 
3.03 (1H, ddBAx, J b a =  16.6Hz, Jbx = 11.9Hz,
AtCHa^bCHx), 3.41-3.55 (1H, br, CH2C//(NH)CH3), 3.65 
(3H, s, ArOC/T3-7), 3.73 (3H, s, ArOC/73-6), 4.14 (1H, 
ddA-B’X’, «/a’b* = 15.1Hz, / A’X’ = 4.1Hz, S02CtfA>HB’CH), 4.36 
(1H, ddA’B’x’, Jwa’ = 15.1Hz, JB’x’ = 6.4Hz, 
S0 2CHaJ7B’CHX’), 4.96-5.04 (1 H, br, CH2Ctf(NH)Ar), 6.75- 
6.76 (2H, 2 x s overlapping, ArH-5 and ArH-S), 7.49 (2H, d,
J  ortho 8.2Hz, Artf-3’ and Artf-5’), 7.95 (2H, d,
J  ortho 8.2Hz, AiH-2’ and Artf-6 ’);
(no TMS; referenced to DMSO at39.52)
5c 18.39 (CHCH3), 21.10 (ArCH3), 32.23 (ArCH2CH), 50.30 
(CH2 CHCH3), 50.64 (S02CH2CH), 55.52/55.56
(2 x ArOCH3), 58.25 (S02 CH2CH), 109.58 (CatH-8 ), 111.55 
(CatH-5), 121.23 (CAr8 a), 125.25 (C ^a), 128.03 (CatH-2’, 
CatH-6 ’), 129.94 (CatH-3’, CatH-5’), 136.05 (CatSCVI’),
145.12 (CArCHs-4’), 147.76 (CArOMe-7), 148.40 (CArOMe- 
6);
M 4- 375(21), [ M - C H 2 S 0 2 C 6H 4C H 3]+ 206(100);
2992 (NH2+), 1525 (Cat-Cat), 1229 (Cat-OMc), 1152 (S02); 
Calculated for C20H25NO4S.HCl: 58.31, 6.36, 3.40;
Found 58.31, 6.33, 3.59.
ALAcetyl-2-(3,4-dimethoxy-phenyl)-l-methyl ethylamine (170RS)
o
-o . ^  A
HN ^
38RS  (2.5g, 0.0108mol) was dissolved in dry dichloromethane (50mL) under an 
atmosphere of dry argon, by the addition of triethylamine (3.32mL, 2.42g, 0.024mol, 
2.2 equivalents) in one portion. The solution was cooled on an ice bath, before the
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TLC:
Melting point: 
‘H-NMR (CDCI3):
dropwise addition of a solution of acetyl bromide (800pL, 1.33g, 0.0108mol) in dry 
dichloromethane (5mL) over ten minutes. The reaction was stirred for forty-eight 
hours.
The reaction was diluted to 250mL with dichloromethane, and washed consecutively 
with dilute aqueous hydrochloric acid (2x200mL), water (200mL) and brine 
(50mL), before drying over dried magnesium sulfate. Filtration and removal of 
solvent under reduced pressure gave a colourless crystalline solid; recrystallisation 
from ethyl acetate/ n-hexane gave fine colourless needles (1.75g, 6 8 %): 
Characterisation:
R f 0.7 (dichloromethane/ methanol 10:1);
89°C;
5H 1.11 (3H, d, J=  6 .6 Hz, CHCtf3), 1.93 (3H, s, C(=0)CJJ3), 
2.64 (1H, ddABx, J a b  = 13.6Hz, J a x  = 7.8Hz, ArCJyAHBCH),
2.79 (1H, ddBAx, J b a  = 13.6Hz, J BX = 5.6Hz, ArCHA/ / BCH),
3.86-3.87 (6 H, 2 x s overlapping, ArOCH^-4 (Sh 3.86), 
ArOGfiT3-3 (6 h 3.87)), 4.18-4.28 (1H, m, CH2Ctf(NH)CH3), 
6.68-6.71 (2H, m, 2 x AiH-2, -6 ), 6.80 (1H, d, Jortho = 8.1Hz, 
AiH-5);
8 C 19.97 (CHCH3), 23.53 (C(=0)CH3), 42.04 (ArCH2CH),
46.17 (CH), 55.91 (2xArOCH3), 111.19 (C^H-5), 112.58 
(CatH-2), 121.44 (CArH-6 ), 130.58 (CV l), 147.71 (CArOMe-
4), 148.89 (C^OMe-3), 169.27 (C=0);
MS (ESI-positive) m/z: MH+ 238.1(10), [M+Na]+ 260.1(100);
IR (KBr) ('/cm: 3315 (NH), 1639 (C(=0)NH), 1264 (CAr-OMe);
Microanalysis (C,H,N): Calculated for C13H19NO3 : 65.80,8.07,5.90;
Found 65.68/65.73,7.87/8.03,5.86/5.88.
13C-NMR (CDCI3):
6,7-Dimethoxy-l ,3-dimethyl-3,4-dihydroisoquinolme (11\RS)
\10RS (1.75g, 0.0074mol) was dissolved in warm toluene (20mL); phosphorous 
oxychloride (1.75mL, 2.89g, 0.0189mol, -2.5 equivalents) was added, and the 
solution was refluxed for five hours with stirring under an atmosphere of argon. The
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TLC:
Melting point: 
'H - N M R  (C D C I 3):
solution was cooled, and poured into a vigorously stirring 0.5M aqueous solution of 
sodium hydroxide (250mL). The product was extracted into diethyl ether (200mL); 
the ether phase was washed consecutively with water (200mL) and brine (20mL), 
and dried over dried magnesium sulfate. Filtration and removal of solvent under 
reduced pressure gave a beige crystalline solid. Initial purification by flash column 
chromatography (Biotage 40M, dichloromethane/ methanol 50:1 to 25:1) gave a 
colourless crystalline solid (l.Og, 62%). For characterisation purposes this solid was 
dissolved in boiling n-hexane (20mL); subsequent cooling to room temperature 
yielded an off-white crystalline solid (550mg, 34%):
Characterisation:
R f 0.3 (dichloromethane/methanol 10:1);
78-79°C;
5h 1.37 (3H, d, J=  6 .8 Hz, CHCtf3), 2.37 (3H, d, J=  1.9Hz, 
CCtf3), 2.42 (1H, ddABx, Jab = 15.6Hz, JAX= l2 JRz f 
ArC/yAHBCH), 2.66 (1H, ddBAx, Jba = 15.6Hz, JBX = 5.3Hz, 
ArCHAtfBCH), 3.48-3.54 (1H, m, CH2CtfCH3), 3.90-3.92 
(6 H, 2 x s overlapping, 2 x ArOC/J3), 6.67 (1H, s, Ar//-5),
7.00 (1H, s, Arif-8 );
Sc 22.05 (C H C H 3) , 23.46 (C C H 3), 33.19 (C H 2), 52.05 
(C H 2 C H C H 3) , 55.97 (O C H 3) , 56.26 (O C H 3), 109.09 (CatH- 
8), 110.44 (CatH-5), 122.31 (CAr-8a), 131.00 (CAr-4a), 147.46 
(CArOMe-7), 150.90 (CArOMe-6), 162.66 (C ArC (C H 3)= N );  
MS (ESI-positive) m/z: M H + 220.1(100);
IR (KBr) I'/cm: 1604 ( C = N ) ,  1512 ( C Ar- C Ar), 1216 (CAr~OMe);
Microanalysis (C ,H ,N ):  Calculated for C i3H n N 0 2: 71.21, 7.81, 6.39;
Found 71.10, 7.79, 6.37.
13C-NMR (CDC13):
Product ratio of the diastereomers of 44, as synthesised from 38RS by the Pictet- 
Spengler tetrahydroisoquinoline synthesis with acetaldehyde
♦ ;ccx'O' ^  ^  ^ 'o' ^  ^  o
38RS  (500mg, 2.15mmol) was dissolved in water (lOmL); acetaldehyde (l.lmL, 
946mg, 21.5mmol, 10 equivalents) was added, followed by 37% aqueous
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hydrochloric acid (2.15mL). The solution was stirred at reflux for eighteen hours. 
Analysis by 1 H-NMR in DMSO-d6 confirmed the reaction to be approximately 50% 
completed. A further 1.1 mL of acetaldehyde and 2.15mL of 37% hydrochloric acid 
were added, and the reaction was stirred at reflux for a further twenty four hours. The 
reaction was again analysed by 1 H-NMR, and found to be complete. The excess 
reagents and solvent were removed under reduced pressure, to leave a greyish black 
solid. 1 H-NMR spectroscopy in DMSO-d6 showed a 3:1 mixture of diastereomers. 
Comparison with the !H-NMRs in DMSO-cU of the hydrochloride salts of the cis- 
diastereomer 44(1 J?,35) and the fra/w-diastereomer 44(11?,31?) confirmed the product 
mixture to be an approximately 3:1 cis'.trans mixture of the anticipated 
tetrahydroisoquinolines.
Product ratio of the diastereomers of 44, as synthesised by the reduction of 
1711?5 with sodium borohydride
NaBH.
O
\1 \R S  (125mg, 0.57mmol) was dissolved in dry methanol (5mL). Sodium 
borohydride (87mg, 2.3mmol, 4.0 equivalents) was added in one portion, and the 
reaction was stirred for eighteen hours at room temperature. The reaction was 
quenched with 0.5M aqueous sodium hydroxide; the products were extracted into 
dichloromethane (2 x 25mL). The combined dichloromethane extractions were 
washed consecutively with water (20mL) and brine (5mL), before drying over dried 
magnesium sulfate. Filtration and solvent removal under reduced pressure gave an 
off white crystalline solid. The residue was dissolved in dioxan (5mL); 4.0M 
hydrogen chloride in dioxan was added (0.5mL, 2.0mmol, ~4 equivalents) to give a 
dense precipitate. The precipitate was dissolved by the addition of methanol (lmL); 
the solvents and excess hydrogen chloride were removed under reduced pressure to 
leave an ochre solid (~150mg, quantitative). Analysis of the solid by 1 H-NMR in 
DMSO-d6 confirmed an approximate 6:1 ratio of products. Eventual comparison with 
the 'H-NMRs in DMSO-c^ of the hydrochloride salts of the c/s-diastereomer 
44(1/?,35) and the /raws-diastereomer 44(1/?,3/?) confirmed the product mixture to 
be an approximately 6:1 cis'.trans mixture of the anticipated tetrahydroisoquinolines.
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(iS)-Af-Acetyl-2-(3,4-dimethoxy-phenyI)-l-methyl ethylamine (170*S)
A
385 (5.08g, 0.0261mol) was dissolved in dichloromethane (75mL) with 
triethylamine (4.0mL, 2.90g, 0.0287mol), and stirred under argon. The solution was 
cooled to -15°C on a salt/ice bath; acetyl bromide (1.93mL, 3.21g, 0.0261mol) in dry 
dichloromethane (25mL) was added dropwise over 15 minutes, and the reaction was 
left to stir for 1 hour. TLC (dichloromethane/methanol/32% aqueous acetic acid 
90:9:1) showed no starting amine remaining. The reaction was diluted to 300mL with 
dichloromethane, and washed consecutively with 0.5M aqueous hydrochloric acid 
(lOOmL), water (lOOmL) and brine (50mL), then dried over dried magnesium 
sulfate. Filtration, and removal of the solvent under reduced pressure gave a 
colourless crystalline solid (5.95g, 96%). Recrystallisation from n-hexane/ethyl 
acetate (275mL/200mL; boiling to room temperature) gave a colourless fibrous solid 
(3.75g, 61%), and refrigeration gave a second crop of fibres (850mg, 14%). The 
removal of solvent under reduced pressure gave a colourless crystalline solid (1.30g, 
21%). Characterisation is for crop 1:
Characterisation:
R f 0.55 (dichloromethane/ methanol/ 32% AcOH(aq) 90:9:1); 
109°C;
-4.4 (c 0.55, ethanol)
SH 1.11 (3H, d, J =  6 .6 Hz, CHCtf3), 1.93 (3H, s, C(=0)C#3),
2.63 (1H, ddABx, J a b  = 13.6Hz, A x = 7.4Hz, ArCtfAHBCH),
2.80 (1H, ddBAx, Jba = 13.6Hz, Ax = 5.6Hz, ArCHAftC H ),
3.86 (6 H, 2 x s overlapping, 2 x ArOC/T3), 4.19-4.26 (1H, m, 
CH2C/f(NH)CH3), 7.72 (1H, br, NH), 6.69-6.71 (2H, d + s 
overlapping, AiH-2 , -6 ), 6.80 (1H, d, J ortho = 8 .6 Hz, Arff-5); 
6 C 19.97 (CHCH3), 23.52 (C(=0)CH3), 42.04 (ArCH2CH),
46.17 (CH), 55.91 (2xArOCH3), 111.19 (C^H-5), 112.58 
(CatH-2), 121.44 (CatH-6), 130.59 (C^-l), 147.71 (C^OMe- 
3), 148.89 (CArOMe-4), 169.28 (C=0);
MS (El) m/z: M4- 237(24), 178(100);
TLC:
Melting point:
Optical rotation [ oc] d 21: 
!H-NMR (CDC13):
13C-NMR (CDC13):
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IR(KBr)jVcm: 3315 (NH), 1635 (C(=0)NH), 1520 ( C a t - C a , ) ,  1263 (CAr-
OMe)
Microanalysis (C,H,N): Calculated for C13H19NO3 : 65.80, 8.07, 5.90;
Found 65.89, 8.15, 5.79.
(i?)-Ar-Acetyl-2-(3,4-dimethoxy-phenyl)-l-methylethylamine (1701?)
o
,0
HNA
'" * /
381? (2.50g, 0.0128mol) was dissolved in dichloromethane (50mL) with 
triethylamine (2.0mL, 1.46g, 0.0144mol), and stirred under argon. The solution was 
cooled to -15°C on a salt/ice bath; acetyl bromide (950^L, 1.58g, 0.0128mol) in dry 
dichloromethane (lOmL) was added dropwise over 10 minutes, and the reaction was 
left to stir for 2 hours. TLC (dichloromethane/methanol 10:1) showed no starting 
amine remaining. The reaction was diluted to 200mL with dichloromethane, and 
washed consecutively with 0.5M aqueous hydrochloric acid (50mL), water (50mL) 
and brine (25mL), then dried over dried magnesium sulfate. Filtration, and removal 
of the solvent under reduced pressure gave a colourless crystalline solid (2.92g, 
96%). Recrystallisation from n-hexane/ethyl acetate (275mL/200mL; boiling to room 
temperature) gave a colourless fibrous solid (crop 1 ,1.25g, 41%); refrigeration of the 
supernatant gave a further crop of colourless fibres (crop 2, 540mg, 18%); removal 
of solvent from the supernatant gave a colourless crystalline solid (1.07g, 35%). 1H- 
NMR revealed crop 1 and the supernatant residue to contain trace impurities; crop 2 
was dried at 100°C/ O.lmmHg under reduced pressure for 18 hours to characterise: 
Characterisation:
TLC: R f 0.44 (dichloromethane/methanol 10:1);
Melting point: 109°C;
Optical rotation [a]o21: +4.4 (c 0.54, ethanol);
!H-NMR (CDCI3): 5h 1.11 (3H, d, J = 6 .6 Hz, CHCtf3), 1.93 (3H, s, C(=0)CH3 ) 9
2.63 (1H, ddABx, Jab = 13.6Hz, A x = 7.4Hz, ArCtfAHBCH),
2.80 (1H, ddfiAx, Jba = 13.6Hz, JBX = 5.6Hz, ArCHAtfBCH),
3.86 (6 H, 2 x s overlapping, 2 x A1O C//3), 4.19-4.26 (1H, m, 
CH2C/T(NH)CH3), 7.72 (1H, br, NH), 6.69-6.71 (2H, d + s
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overlapping, AxH-2, -6 ), 6.80 (1H, d, J ortho = 8 .6 Hz, ArH-5); 
UC-NMR (CDCIs): Sc 19.97 (CHCHa), 23.52 (C(=0)CH3), 42.04 (ArCH2CH),
46 .17  (CH), 55.91 (2xArOCH3), 111.19 (CatH-5), 112.58 
(CatH -2), 121.44 (CatH-6), 130.59 (Cat- 1), 147.71 (CArOMe- 
3), 148.89 (CArOMe-4), 169.28 (C O );
MS (El) m/z: M+ 237(20), 178(100);
IR ( K B r )  * m :  3315 (NH), 1636 (C(0)NH), 1520 ( C a t - C at) ,  1263 ( C Ar-
OMe);
Microanalysis (C,H,N): Calculated for C13H19NO3 : 65.80, 8.07, 5.90;
Found 65.60/65.65, 7.88/7.83, 5.63/5.79.
(S)-6,7-Dimethoxy-l ,3-dimethyl-3,4-dihydroisoquinoline (1715)
1705 (5.6g, 0.0236mol) was dissolved in dry toluene (lOOmL) with phosphorous 
oxychloride (5.62mL, 9.24g, 0.060mol) and refluxed under an atmosphere of 
nitrogen for three hours. An aliquot was partitioned between 1M aqueous sodium 
hydroxide and ethyl acetate, and TLC of the ethyl acetate layer 
(dichloromethane/methanol 10:1) showed the reaction to be complete. The oil bath 
was removed, and the reaction was allowed to cool to room temperature before 
pouring into 1.0M aqueous sodium hydroxide (500mL). The product was extracted 
into ethyl acetate (2 x 250mL); the combined organic extractions were washed with 
water (200mL) and brine (50mL), then dried over dried magnesium sulfate. Filtration 
and removal of solvent under reduced pressure gave a brown solid; flash column 
chromatography (Biotage 40M cartridge, dichloromethane/methanol 50:1) gave an 
orange crystalline solid (4.40g, 85%); recrystallisation of this solid from boiling n- 
hexane (120mL) with a few drops of ethyl acetate after refrigeration gave a pale pink 
crystalline solid (3.64g, 70%):
Characterisation:
TLC: R f 0.40 (dichloromethane/methanol 50:1);
Melting point: 98°C;
Optical rotation [ofo20: -11 *8 (c 0.56, dichloromethane);
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'H-NMR (CDCI3):
13C-NMR (C D C I 3):
MS (El) m/z:
IR (KBr) v/cm: 
Microanalysis (C,H,N):
SH 1.37 (3H, d, J=  6 .8 Hz, C H G H 3) ,  2.37 (3H, s, CCHi), 2.42 
(1H, ddABx, Jab = 15.6Hz, JAX = 12.7Hz, ArC//AHBCH), 2 . 6 6  
(1H, ddBAx, Jba = 15.6Hz, JBX = 5.3Hz, AtCHaHbCH), 3.45- 
3.58 (1H, m, C H 2 C //C H 3) ,  3.91-3.92 (6 H, 2 x s overlapping, 
2 x ArOC//3), 6.67 (1H, s, Arff-5), 7.00 (1H, s, Arff-8 );
5c 22.06 (CHCH3), 23.48 (CCH3), 33.19 (CH2), 52.06 
(CH2 CHCH3), 55.98 (OCH3), 56.27 (OCH3), 109.09 (CVH- 
8 ), 110.44 ( C atH - 5 ) ,  122.32 (CVSa), 131.01 (CAr-4a), 147.46 
(CArOMe-7), 150.90 (C^OMe-6 ), 162.67 (CAiC(CH3)=N);
M+ 219(100), [M-CH3]+ 204(73);
1604 (C=N), 1512 (Cat-C ap) , 1216 (CAr-OCH3);
Calculated for C13H17NO2 : 71.21,7.81,6.39;
Found 71.09, 7.73,6.41.
(/?)-6,7-Dimethoxy-l ,3-dimethy 1-3,4-dihydroisoquinoline (171 J?)
170i? (2.65g, 0.0112mol) was dissolved in warm toluene (20mL); phosphorous 
oxychloride (2.65mL, 4.37g, 0.0286mol) was added, and the solution was refluxed 
for four hours with stirring under an atmosphere of nitrogen. A lOOpL aliquot was 
partitioned between ethyl acetate and 1.0M aqueous sodium hydroxide (lmL of 
each); analysis of the organic phase by TLC (dichloromethane/methanol 10:1) 
revealed the reaction to be complete. The solution was cooled, and poured into a 
vigorously stirring 1.0M aqueous solution of sodium hydroxide. The product was 
extracted into ethyl acetate (2 x 250mL); the combined organic phase were washed 
with water (lOOmL), then brine (50mL), and dried over dried magnesium sulfate. 
Filtration and removal of solvent under reduced pressure gave a dark orange 
crystalline solid; this solid was dissolved in boiling n-hexane (50mL) containing 
ethyl acetate (3mL), hot filtered and refrigerated to give a beige crystalline solid 
(1.75g, 71%):
Characterisation:
TLC: Rf 0.3 (dichloromethane/methanol 10:1);
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Melting point: 97-98°C;
Optical rotation [a]D21: +12.5 (c 0.53, dichloromethane);
'H-NMR (CDCla): 6h 1.37 (3H, d, J=  6 .8 Hz, CHGHj), 2.37 (3H, s, CCff3), 2.42
(1H, ddABx, Tab = 15.6Hz, Ax = 12.7Hz, AtCAaHbCH), 2.66 
(1H, ddBAx, Jba = 15.6Hz, Ax = 5.3Hz, AtCHaHbCH), 3.49- 
3.53 (1H, m, CH2C//CH3), 3.90-3.92 (6 H, 2x  s overlapping, 
2 x ArOCH}), 6.67 (1H, s, Arfl-5), 7.00 (1H, s, Arfl-8 );
13C-NMR (CDCI3): 6 C 22.06 (CHCH3), 23.48 (CCH3), 33.19 (CH2), 52.06
OMe);
Microanalysis (C,H,N): Calculated for C13H17NO2 : 71.21, 7.81, 6.39;
Found 70.88/71.09, 7.56/7.75, 6.22/6.16.
(l/?,35)-6,7-Dimethoxy-l,3-dimethyl-l,2,3,4-tetrahydroisoqumoline 
hydrochloride (44(11?,35))
The procedure was adapted from a literature protocol, for the reductive animation of 
aldehydes and ketones with sodium triacetoxyborohydride503. 1715 (4.0g, 
0.0183mol) was dissolved in 1,2-dichloroethane (50mL) with acetic acid (1.06mL,
1.1 Og, 0.0183mol). Sodium triacetoxyborohydride (95%, 6.12g, 0.0274mol, 1.5 
equivalents) was added in one portion, and the mixture was stirred under nitrogen for 
18 hours. An aliquot was worked up by partitioning between 0.5mL each of diethyl 
ether and 1.0M aqueous sodium hydroxide; removal of solvent from the organic 
phase under reduced pressure and subsequent analysis by 1 H-NMR showed there to 
be no 1715 remaining, and the reaction was assumed to be complete. The reaction 
was poured into 1.0M aqueous sodium hydroxide (500mL), and the product was 
extracted into diethyl ether (2 x 250mL). The combined ether extractions were 
washed with water (100mL) and brine (50mL), then dried over dried magnesium
(C H 2 C H C H 3) ,  55.98 (O C H 3) , 56.27 (O C H 3), 109.08 (CatH- 
8), 110.44 (CatH-5), 122.32 (CAr-8a), 131.01 (CAr-4a), 147.46 
(CArOMe-7), 150.90 (CArOMe-6), 162.67 (C ArC (C H 3)= N );
MS (El) m/z: 
IR (KBr) p/cm:
M+ 219(100), [M-CH3]+ 204(75);
1570 (C=N), 1512 (Cat-Cat), 1216 (CAr-OMe), 1061 (Cat-
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sulfate. Filtration, and removal of the solvent under reduced pressure gave a brown 
syrup; this syrup was dissolved in dioxan (50mL), and stirred while 4.0M HC1 in 
dioxan was added. After stirring for fifteen minutes, the solvent was removed from 
the suspension, and the resulting colourless solid was analysed by 1 H-NMR. The 
product was confirmed as predominantly one diastereomer (90% d.e.). The solid was 
dissolved in boiling methanol (50mL), and hot 1,4-dioxan was added portionwise 
until hazy (~50mL). Methanol was added in lmL portions until the haziness was 
gone. The solution was hot filtered, and left to cool to room temperature. Filtration 
after 18 hours gave a colourless crystalline solid (cropl, 2.28g); a second crop of 
colourless crystal was also collected (crop 2, 950mg). 1 H-NMR confirmed these 
crops to be diastereomerically pure, and they were combined (3.23g, 69% yield): 
Characterisation:
Melting point: 274-275°C (sublimed);
Optical rotation [a]o19: +96.9 (c 0.51, water);
1 H-NMR (D2O): (containing 0.75% 3 -(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d4 acid,
sodium salt) 5h 1.58 (3H, d, J=  6.5Hz, 3-CH/), 1.78 (3H, d, 
J -  6 .8 Hz, I-C//3), 2.94-3.08 (2H, m (2xdd overlapping), 
ArCtf2CH), 3.51-3.58 (1H, m, CH2GHCH3), 3.87-3.89 (6 H, 
2 x s, 2 x A1O C //3), 4.58 (1H, quartet, J=  6 .8 Hz, ArC//CH3),
6.87 (1H, s, AxH-5), 6.91 (1H, s, AiH-S);
13C-NMR (D20): (containing 0.75% 3 -(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d4 acid, 
sodium salt) 8 C 21.12, 21.16 (1-, 3-CH3), 35.79 (ArCH2CH), 
53.24 (CH2 CHCH3), 55.41 (ArCHCH3), 58.49 (ArOCH3),
58.63 (ArOCH3), 111.33 (CatH-8), 114.27 (CatH-5), 127.19 
(CAr-4a), 127.73 (CAr-8a), 150.17 (CAr-OMe), 150.65 (CAr- 
OMe);
MS (El) m/z: 
IR (KBr) v/cm:
M+ 221(15), [M-CH3]+ 206(100);
1524 ( C at- C at) ,  1254 (CAr-OMe), 1226 (CAr-OMe);
Microanalysis (C,H,N): Calculated for Ci3H2oN02C1: 60.58, 7.82, 5.43;
Found 60.47, 7.57, 5.49.
290
(15,3/?)-6,7-Dimethoxy-l,3-dimethyl-l,2,3,4-tetrahydroisoqumoline 
hydrochloride (44(15,3i?»
‘NH 
—  '0  HCI
1711? (5.0g, 22.8mmol) was dissolved in 1,2-dichloroethane (60mL) with acetic acid 
(1.32mL, 1.37g, 22.8mmol). Sodium triacetoxyborohydride503 (95%, 7.26g, 
34.2mmol, 1.5 equivalents) was added, and the mixture was stirred under a nitrogen 
atmosphere for 18 hours. An aliquot was partitioned between 0.5mL each of ethyl 
acetate and 1 .OM aqueous sodium hydroxide, and the organic phase was analysed by 
TLC to confirm that the reaction was complete.
The reaction mixture was poured into 1.0M aqueous sodium hydroxide (500mL), and 
the product was extracted into diethyl ether (2 x 250mL). The combined ether 
extractions were washed with fresh water (250mL) and brine (50mL), then dried over 
dried magnesium sulfate. Filtration, and subsequent removal of solvent under 
reduced pressure gave an off-white crystalline solid. The residue was dissolved in 
dioxan (50mL), and 4.0M HCI in dioxan (lOmL) was added to the vigorously stirring 
solution. The solvent was removed from the resultant suspension, to give a colourless 
solid. Analysis by 1 H-NMR showed a diastereomeric ratio of 20:1
44(15,3R):44(lR,3i?). Recrystallisation from methanol/dioxan (x2) gave pure
44(15,31?) as a colourless crystalline solid (2.65g, 45% isolated yield): 
Characterisation:
Melting point: 275-276°C (sublimed);
Optical rotation [a]D22 -95.2(c 0.50, water);
1 H-NMR (D2O): (containing 0.75% 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid,
sodium salt) SH 1.55 (3H, d, J=  6.5Hz, 3-CH3\  1.75 (3H, d, 
J=  6.8Hz, I-C//3), 2.96 (1H, d d A B x , « /ab  = 17.2Hz,
J ax  = 11.7Hz, ArC/yAHBCH), 3.05 (1H, ddBAx, Jba = 17.2Hz, 
JBX = 4.7Hz, A t C H a ^ b C H ) ,  3.52-3.58 (1H, m, CH2OyCH3),
3.87-3.88 (6H, 2 x s, 2 x ArOC/f3), 4.58 (1H, quartet,
J=  6.8Hz, ArC//CH3), 6.88 (1H, s, ArlT-5), 6.91 (1H, s,
ArlT-8);
13C-NMR (D20): (containing 0.75% 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid,
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sodium salt) 8 C 21.08, 21.16 (1-, 3-CH3), 35.79 (ArCH2CH), 
53.23 (CH2 CHCH3), 55.40 (ArCHCH3), 58.48 (ArOCH3), 
58.61 (ArOCH3), 111.33 (CatH-8), 114.27 (CatH-5), 127.22 
(CAr-4a), 127.76 (CAr-8a), 150.14 (CAr-OMe), 150.62 (CAr- 
OMe);
MS (ESI positive) m/z: MH+ 222(100);
IR (KBr) p/cm: 1524 (Cat-C at), 1254 (CAr-OMe), 1226 (CAr-OMe);
Microanalysis (C,H,N): Calculated for Ci3Hi9N 0 2 .HC1: 60.58, 7.82, 5.43;
Found 60.44, 7.73, 5.49.
(l/?,35)-6,7-Dihydroxy-l,3-dimethyl-l,2,3,4-tetrahydroisoquinolme 
hydrobromide (35(l/?,35))
44(1/?,35) (l.OOg, 3.9mmol) was dissolved in 48% hydrobromic acid (15mL) and 
stirred at reflux for eighteen hours. The solution was cooled to room temperature, 
and the solvent removed from a 50pL aliquot under reduced pressure for analysis by 
1 H-NMR in CD3OD, to confirm the absence of starting material. The solvent was 
removed from the reaction under reduced pressure, and the pale brown foam was 
recrystallised from propan-2-ol to give, after drying under high vacuum at 150°C to 
constant weight, a colourless crystalline solid (885mg, 84% yield), which 1 H-NMR 
revealed to still contain a trace amount of propan-2-ol (~0.35 mol%, 0.08% by 
mass):
Characterisation:
Melting point: 213-4°C;
Optical rotation [a\o3: +77.9 (c 1.00, ethanol);
1H-NMR(DMSO-d6): (no TMS) 5H 1.36 (3H, d, /=6.4H z, 3-Ctf3), 1.54 (3H, d,
J=  6.7Hz, l-C/73), 2.72 (1H, d d A s x ,  J a b  = 16.8Hz,
/ax  = 11.8Hz, ArC/yAHBCH), 2.81 (1H, ddBAx, Jba = 16.8Hz, 
JBX = 4.5Hz, ArCHA/7BCH), 3.44-3.50 (1H, m, 3-//), 4.43 
(1H, q, / =  6.7Hz, 1 -//), 6.53 (1H, s, ArH-5), 6 . 6 6  (1H, s,
Ar/T-8 ), 8.65 (1H, vbr s, N+H), 8.89 (1H, br s, ArOZT-7), 9.04
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(1H, br s, ArO/T-6 ), 9.19 (1H, vbr s, N^fl); 
l3C-NMR (DMSO-d<s): (no TMS) 8 C 18.37, 18.53 (1-CH3, 3-CH3), 32.68 (CH2),
49.42 (CH-3), 51.45 (CH-1), 112.15 (CatH-8), 114.75 (CArH-
5), 122.08 (CAr-4a), 123.57 (CAr-8a), 144.28 (CatOH-6), 
144.83 (CatOH-7);
MS (E l) m/z: M+ 193(10), [M-CH3]+ 178(100);
IR (KBr) r/cm: 3398 (Cat-OH), 3293 (Cat-OH), 1526 (Cat-Ca,-);
M icroanalysis (C,H,N): Calculated forCiiHi6N 0 2Br: 4 8 .1 9 ,5 .8 8 ,5 .1 1 ;
Found 48.08,5.73,5.27.
(1,S’,3/?)-6,7-Dihydroxy-1,3-dimethyl-1,2,3,4-tetrahvdroisoquinoline 
hydrobromide (35(1^, 3R))
HO
HO
NH
44(15,31?) (1.10g, 4.3mmol) was dissolved in 48% hydrobromic acid (lOmL) and 
stirred at reflux. The reaction was followed by removing the solvent from a 50pL 
aliquot of the reaction under reduced pressure and dissolving the residue in CD3OD, 
to monitor the loss of the signals corresponding to A1OCH3 by 1 H-NMR. After five 
hours, the reaction was complete. The reaction was cooled, and the solvent was 
removed under reduced pressure, to give a brown glass. Recrystallisation from 
propan-2-ol gave a colourless crystalline solid (840mg, 72%):
Characterisation:
214-5°C
-81.0 (c 0.99, ethanol);
(+ TMS) 5h 1.34 (3H, d, J=6.4Hz, 3-C#3), 1.55 (3H, d, 
J=  6.7Hz, l-C/y3), 2.74 (1 H, ddAsx, / a b = 1 6 . 8 z ,
Jax = 11.8Hz, ArCHARBCH), 2.83 (1H, ddBAx, Jba = 16.8Hz, 
JBX = 4.5Hz, AtCHaHbCH), 3.43-3.53 (1H, br, 3-H), 4.38- 
4.44 (1H, br, 1 -H), 6.53 (1H, s, ArH-5\ 6.65 (1H, s, Ar^-8 ), 
8.45-8.65 (1H, v br, 1NTH), 8.90 (1H, br s, ArOlT-7), 8.95- 
9.10 (1H, v br, N*H) overlapping 9.06 (1H, br s, ArOH-6 );
C-NMR (DMSO-d6): (+ TMS) 8 C 18.39, 18.51 (1-CH3, 3-CH3), 32.69 (CH2), 49.48
Melting point:
Optical rotation [ajo21: 
!H-NMR (DMSO-d6):
13
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MS (El) m/z: 
IR (KBr) c/cm:
(CH-3), 51.48 (CH-1), 112.18 (CatH-8), 114.79 (CArH-5),
122.13 (CA,-4a), 123.60 (CAr-8a), 144.28 (CatOH-6), 144.83 
(CatOH-7);
M* 193(18), [M-H]+ 192(28), [M-CH3]+ 178(100);
3399 (Cat-O H ), 3291 (Cat-OH), 1525 (Cat-Cat);
Microanalysis (C,H,N): Calculated for CnHieNQiBr: 48.19,5.88,5.11;
Found 48.44, 5.83,4.98.
(l/?,3*S)-AL(4-Chlorophenethylthiocarbamoyl)-6,7-dihydroxy-l,3-dimethyl-
1,2,3,4-tetrahydroisoquinoline (31(11?,35))
35(11?,35) (650mg, 2.4mmol) was dissolved in dry A^V-DMF (20mL) with 
triethylamine (370pL, 270mg, 2.7mol). 32 (490mg, 2.5mmol) was added to the 
reaction in dry NJf-DMF (5mL), and the reaction was stirred at ambient temperature 
under argon for eighteen hours. The reaction was diluted to 200mL with ethyl 
acetate, and washed consecutively with 2M HCl(aq) (2 x 50mL), water (50mL) and 
brine (20mL), before drying over dried magnesium sulfate. Filtration and under 
reduced pressure solvent removal gave a beige foam. Purification by flash column 
chromatography (Biotage 40M, cyclohexane/ ethyl acetate 5:2) gave a pale yellow 
foam. Precipitation in cyclohexane (lOOmL) from chloroform (5mL) and drying to 
constant weight under high vacuum (O.lmmHg) at room temperature gave a pale 
yellow powdered amorphous solid (660mg, 70%), which 1 H-NMR revealed to still 
contain a trace amount of cyclohexane (-0.15 equivalents, 3.1% by mass): 
Characterisation:
TLC: R f 0.45 (cyclohexane/ethyl acetate 1:1);
Melting point: amorphous solid;
Optical rotation [ck]d23: -6 8 .2  (c 1.00, dichloromethane);
H-NMR (CDC13): 6 h 1.14 (3H, d, J=  6.7Hz, 3-CH3), 1.38 (3H, d, J=  7.0Hz, 1-
C //3), 1.43 (1.85H, s, -0.15eq. cyclohexane), 2.55 (1H, 
d d A B x , J ab = 15.8Hz, A x = 5.0Hz, ArC17AHBCH), 2.81 (1H, 
ddBAx, Jba = 15.8Hz, A x  = 6.2Hz, ArCHA# BCH), 2.96 (2H,
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t, J=  7.0Hz, 4’-chlorophenyl-C7y2CH2), 3.94-4.00 (2H, m, 
4 ,chlorophenyl-CH2Ctf2NH), 4.85-4.95 (1H, br,
CH2C//(N)CH3), 5.20-6.00 (4H, comprising overlapping 
signals: 5.20-6.00 (2H, 2 x v  br, 2x  ArOTT), 5.50-5.60 (1H, 
br, ArC7T(N)CH3), 5.65 (1H, br t, J=  5.1Hz, Nfl)), 6.55 (1H, 
s, ArTT-5), 6.57 (1H, s, Artf-8), 7.15 (2H, dm (AA’ of an 
AA’BB’ system), Jortho = 8.4Hz, Aiff-2*, -6’), 7.26 (2H, dm 
(BB’ of an AA’BB’ system), J0rth0  = 8.4Hz, Ar/7-3’ and -5’); 
6C 20.37 (3-CH3), 21.65 (1-CH3), 26.93 (cyclohexane), 34.29 
(ArCH2CH), 34.55 (4’-chlorophenyl-CH2CH2), 47.00 
(CH2CH2NH), 49.27 (CH2CH(N)CH3), 53.52 
(br, ArCH(N)CH3), 112.97 ( C atH - 8 ) ,  115.12 ( C atH - 5 ) ,  
124.14 ( C A r - 4 a ) ,  128.87 ( C at- 3 ’ ,  C at- 5 ’) ,  129.32 (br, C A r - 8 a ) ,  
130.18 ( C at- 2 ’ ,  CAr-6’), 132.50 ( C atC I - 4 ’) ,  137.25 ( C at- 1 ’) ,  
142.54 ( C atO H ) ,  143.01 ( C atO H ) ,  179.70 (C= S);
3308 ( C a t - O H ) ,  1524 ( C Ar - C Ar), 1273 ( C a t - O ) ;
Calculated for C20H24N2O2SCl [M+H]: 391.1241;
Found 391.1242;
Calculated for C20H23N2O2SClNa [M+Na]: 413.1061;
Found 413.1061;
System 1: retention time = 5.95 minutes;
System 2: retention time = 8.20 minutes.
(15,3/?)-Ar-(4-Chlorophenethylthiocarbamoyl)-6,7-dihydroxy-l,3-dimethyl-
1,2,3,4-tetrahydroisoquinoline (31(15,37?)):
HO.
HO
35(15,37?) (500mg, 1.8mmol) was dissolved in dry A^V-DMF (lOmL). Triethylamine 
(280pL, 203mg, 2.0mmol) was added to the reaction, followed by 32 (395mg, 
2.0mmol) in dry A^V-DMF (5mL). The reaction was stirred at ambient temperature 
under argon for eighteen hours. The reaction was diluted to 150mL with ethyl 
acetate, and washed consecutively with 2M HCl(aq) (2 x 50mL), water (50mL) and
13C-NMR (CDCh):
IR (KBr) p/cm: 
HRMS (positive) m/z:
HPLC
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W'
TLC:
Melting point:
Optical rotation [o :]d 23: 
1 H-NMR (C D C I 3 ):
brine (lOmL), before drying over dried magnesium sulfate. Filtration and the 
removal of solvent under reduced pressure gave a beige foam. Purification by flash 
column chromatography (Biotage 40M, cyclohexane/ ethyl acetate 2:1) gave a pale 
colourless foam, which was dissolved in chloroform (4mL), and precipitated by 
dropwise addition to vigorously stirring cyclohexane (75mL). Drying to constant 
weight under high vacuum (O.lmmHg) at room temperature gave a pale yellow 
powdered amorphous solid (570mg, 80%), which 1 H-NMR revealed to still contain 
~0.5 equivalents of cyclohexane (10% by mass, effective MW 433.02, 72% yield): 
Characterisation:
Rf0A5  (cyclohexane/ ethyl acetate 1:1); 
amorphous solid;
+60.5 (c 1.01, dichloromethane);
5h 1.15 (3H, d, J =  6.7Hz, 3 -0 *3), 1.39 (3H, d, J =  7.0Hz, 1- 
C //3), 1.43 (6 H, s, 0.5eq. cyclohexane), 2.56 (1H, ddABx, 
Jab = 15.8Hz, JAx = 5.0Hz, ArC//AHBCH), 2.83 (1H, ddBAX, 
JBA= 15.8Hz, JBX = 6.2Hz, ArCHA/*BCH), 2.96 (2H, t, 
J =  7.0Hz, 4’-chlorophenyl-0/2CH2), 3.94-4.00 (2H, m, 
4’chlorophenyl-CH2C/*2NH), 4.85-4.95 (1H, br,
CH2C//(N)CH3), 5.20-6.00 (4H, comprising overlapping 
signals: 5.20-6.00 (2H, 2 x v br, 2 x ArOH), 5.55-5.65 (1H, 
br, ArO*(N)CH3), 5.62 (1H, br t, J =  5.1Hz, Ntf)), 6.55 (1H, 
s, Ar/f-5), 6.58 (1H, s, Ar/*-8 ), 7.15 (2H, dm (AA’ of an 
AA’BB’ system), J ortho = 8.4Hz, ArJ*-2’, -6 ’), 7.26 (2H, dm 
(BB’ of an AA’BB’ system), Jortho = 8.4Hz, KxH-V and -5’); 
6 C 20.37 (3-CH3), 21.66 (I-CH3), 26.93 (cyclohexane), 34.30 
(ArCH2CH), 34.54 (4’-chlorophenyl-CH2CH2), 46.99 
(CH2 CH2NH), 49.26 (CH2 CH(N)CH3), 53.51 
(br, ArCH(N)CH3), 112.96 ( C atH - 8 ) ,  115.09 ( C atH - 5 ) ,  
124.18 (CAr-4a), 128.88 ( C at- 3 ’ ,  ^ - 5 ’), 129.35 (br, C ^ a ) ,
130.17 ( C at- 2 ’ , CAr-6 ’), 132.51 ( C atC I - 4 ’ ) ,  137.24 ( ^ - 1 ’), 
142.46 ( C atO H ) ,  142.95 ( C atO H ) ,  179.74 (C=S);
MS (ESI-negative) m/z: [M-H]- 389.1 (100), 391.2(46) Cl isotope pattern;
IR (KBr) j'/cm: 3308 (NH, OH), 1524 (thioamide), 1273 (Cat-O);
13C-NMR (C D C I 3 ):
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HRMS (positive) m/z: 
HPLC
Calculated for C20H24N2O2SCI [M+H]: 391.1247; 
Found 391.1247;
System 1: retention time = 5.94 minutes;
System 2: retention time = 8.07 minutes.
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Biology -  in vitro assays 
Materials:
The culture medium was prepared from minimum essential medium alpha (MEM- 
a) without ribonucleosides and deoxyribonucleosides and supplemented with 1 0 % 
foetal bovine serum (FBS), plus geneticin selective antibiotic (G418) at 0 .5 mg/mL 
final concentration, penicillin at lOOunits/mL final concentration and streptomycin at 
lOOpg/mL final concentration. All components of the cell culture medium were ex- 
Invitrogen.
HEPES-buffered HBSS was Hank’s balanced salt solution (HBSS, ex-Invitrogen), 
buffered to pH 7.4 by the addition of 4-(2-hydroxyethyl)-l-piperazineethanesulfonic 
acid (HEPES) at a lOmM concentration.
The loading buffer for the agonist assay was a solution of fluo-4-AM (ex- 
Cambridge Bioscience, 50pg in 20mL) and 0.01% pluronic F-127 (ex-Cambridge 
Bioscience) in HEPES-buffered HBSS.
The loading buffer for the antagonist assay was a 2pM solution of fura-2/AM (ex- 
Molecular Probes) and 0.01% pluronic F-127 (ex-Cambridge Bioscience) in HEPES- 
buffered HBSS.
Methods - General
Preparation of cells:
40,000 Chinese hamster ovary cells (CHO) per well, expressing either the human or 
rat orthologue of TRPV1, were seeded overnight in lOOpL cell culture medium. The 
medium was removed and the cells were washed with lOOpL of HBSS, before 50pL 
of the loading buffer was added to each well. After 60 minutes, the loading buffer 
was removed and the cells in each well were washed with IOOjiL HBSS.
Methods -  Agonist Assay 
Preparation of test compound solutions:
From an original lOmM DMSO stock solution, test compounds were diluted to 
2mM, with further serial dilutions in DMSO being made using a Biomek 2000 on 
plates holding micronics tubes, to give final concentrations of 3.0, 1.0, 0.3, 0.1, 0.03, 
0.01, 0.003, 0.001, 0.0003 and O.OOOlmM respectively. 24pL of each DMSO stock 
solution, and, for control purposes, 24pL of DMSO, was diluted with 376pL of 
HBSS, to give final concentrations of 180, 60, 18.0, 6.0, 1.8, 0.6, 0.18, 0.6, 0.018,
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and 0.006pM (plus control), with a DMSO concentration of 6 %. A control solution 
of 6 % DMSO in HBSS was also prepared.
Agonist Assay
lOOpL of HBSS was added to each well. The plates with loaded cells were placed in 
a Molecular Devices Flexstation, and stimulated by light at 485 nm. Emissions were 
measured at 535 nm measured (with a 530 nm cut off), with the fluorescence 
measured at 5 second intervals over 60 seconds (13 readings). After 17 seconds (four 
basal readings) the agonist activity of the test compounds was determined by the 
addition of 20pL of each of the 6 % DMSO stock solutions to wells containing the 
loaded cells, to give final concentrations on the assay plate of 30, 10, 3.0, 1.0, 0.3, 
0.1, 0.03, 0.01, 0.003 and 0.001 pM, and a final DMSO concentration of 1%.
Methods - Antagonist Assay 
Preparation of test compound solutions:
From an original lOmM DMSO stock solution, test compounds were diluted to 
2mM, with further serial dilutions in DMSO being made using a Biomek 2000 on 
plates holding micronics tubes, to give final concentrations of 2.0, 0.667, 0.2, 0.0667,
0.02,0.00667, 0.002, 0.000667, 0.0002 and 0.0000667mM respectively.
1 2 pL of each DMSO stock solution was diluted with 388pL of HBSS, to give 
concentrations of 60, 20, 6.0, 2.0, 0.6, 0.2, 0.06, 0.02, 0.006 and 0.002pM, with a 
DMSO concentration of 3%. A control solution of 3% DMSO in HBSS was also 
prepared.
Antagonist Assay
50pL of HBSS was added to each well, followed by 50pL of the test compound 
solutions, to give final concentrations on the assay plate of 30, 10, 3.0, 1.0, 0.3, 0.1,
0.03, 0.01, 0.003 and 0.001 pM, and a final DMSO concentration of 1.5%. Low and 
high control wells, containing 50pL of HBSS plus 50pL of the control solution of 
3% DMSO in HBSS, were prepared. The plates were light stimulated at 340nm and 
380nm and emissions at 520nm measured at 5 second intervals over 60 seconds (13 
readings). 
vs. capsaicin
At 17 seconds (after four basal readings), 20pL of 0.3pM capsaicin in HEPES- 
buffered HBSS (plus 1.67% DMSO) was injected onto the cells (0.05pM final 
concentration). For the low control wells, just 1.67% DMSO in HEPES-buffered 
HBSS was added.
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vs. low pH
At 17 seconds (after four basal readings), 20pL of 60mM 2 -(A-morpholino)ethane 
sulfonic acid (MES) in HBSS was injected onto the cells (lOmM MES final 
concentration, 5.75 final pH). For the low control wells 20 pL of HEPES-buffered 
HBSS at pH 7.4 was added.
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APPENDIX 1: X-ray crystal 
co-ordinate data
339
(i?)-2-((5)-l-phenyIethyl)carbamoyl-6,7-dimethoxy-l-methyM, 2,3,4- 
tetrahydroisoquinoline, 71(1J?,olS)
Table 1. Bond Lengths (A) end Angies (°)
0(1)-C(15) 1.231(2) 0(2)-C(ll) 1.374(2)
0(2)-C(25) 1.418(2) O(3)-C(10) 1.371(2)
0(3)-C(26) 1.422(2) N(4)-C(15) 1.362(2)
N(4>C(6) 1.461(2) N(4)-C(14) 1.460(2)
N(5)-C(15) 1.368(2) N(5)-C(16) 1.455(2)
C(6)-C(7) 1.504(2) C(7)-C(8) 1.517(2)
C(8)-C(13) 1.384(2) C(8>C(9) 1.398(2)
C(9)-C(10) 1.378(2) G(10)-C(ll) 1.406(2)
C(ll)-C(12) 1.379(2) C(12)-C(13) % 1.406(2)
C(13)-C(14) 1.526(2) C(14)-C(23) 1.528(2)
C(16)-C(17) 1.519(2) C(16)-C(24) 1.529(2)
C(17)-C(18) 1.381(2) C(17)-C(22) 1.397(2)
C(18)-C(19) 1.390(2) C(19)-C(20) 1.374(3)
C(20)-C(21) 1.372(3) C(21)-q22) 1.386(3)
\
C(1 l)-0(2)-C(25) 116.5(1) C(10)-O(3)-C(26) 116.3(1)
C(15)-N(4)-C(6) 118.8(1) C(15)-N(4)-C(14) 126.6(1)
C(6>N(4)-C(14) 114.5(1) C(15)-N(5)-C(16) 120.3(1)
N(4)-C(6)-C(7) 109.6(1) C(6)-C(7)-C(8) 110.4(1)
C(13)-C(8)-C(9) 119.1(1) C(13)-C(8)-C(7) 121.3(1)
C(9)-C(8)-C(7) 119.5(1) C(10)-C(9)-C(8) 121.5(1)
O(3)-qi0)-C(9) 124.6(1) O(3)-C(10)-C(ll) 116.0(1)
C(9)-C(10)-C(ll) 119.4(1) 0(2)-C(ll)-C(12) 124.9(1)
O(2)-C(ll)-C(10) 115.9(1) C(12)-C(ll)-C(10) 119.2(1)
C(11>C(12)-C(13) 121.2(1) C(8)-C(13)-C(12) 119.4(1)
C(8)-C(13)-C(14) 122.4(1) C(12)-C(13)-C(14) 118.2(1)
N(4)-C(14)-C(13) 110.0(1) N(4)-C(14)-C(23) 111.0(1)
C( 13)-C(l 4)-C(23) 112.2(1) 0(1>-C(15>N(4) 121.7(1)
0(1)-C(15)-N(5) 120.6(1) N(4)-C(15)-N(5) 117.7(1)
N(5>C(16)-C(17) 113.8(1) N(5)-C(16)-C(24) 108.5(1)
C(17)-C(16)-C(24) 111.1(1) C( 18)-C( 17)-C(22) 117.7(1)
C(18)-C(17)-C(16) 123.4(1) C(22)-C( 17)-C( 16) 118.9(1)
C(17)-C(18)-C(19) 121.2(2) C(20)-C( 19)-C( 18) 120.3(2)
C( 19)-C(20)-C(21) 119.4(2) C(22)-C(21)-C(20) 120.6(2)
C(21>C(22)-C(i7) 120.8(2)
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Table 2. Atomic Coordinates
atom X y z U(eq)
0(1) .0035(2) .4612(1) .78491(5) .0611(3)
0(2) .0156(2) 1.0006(1) 1.04133(4) .0581(3)
0(3) .3054(2) 1.0726(1) .98911(5) .0616(3)
N(4) -.0564(2) .6268(1) .84364(5) .0493(3)
N(5) -.1233(2) .4145(1) .86822(5) .0510(3)
0 ( 6 ) .0177(2) .7194(2) .80386(6) .0508(3)
C(7) .1788(2) .7841(2) .82910(6) .0521(3)
C(8) .1355(2) .8333(1) .88730(5) ' .0445(3)
0(9) .2455(2) .9264(2) .91180(6) .0482(3)
0(10) .2061(2) .9789(1) .96330(6) .0471(3)
0(11) .0512(2) .9384(1) .99186(6) .0468(3)
C(12) -.0537(2) .8430(1) .96883(6) .0464(3)
0(13) -.0123(2) .7890(1) .91649(5) .0424(3)
0(14) -.1357(2) .6845(1) .89350(6) .0450(3)
0(15) -.0569(2) .4996(1) .82980(6) .0434(3)
0(16) -.1278(2) .2775(1) .85585(7) .0482(3)
0(17) -.3024(2) .2329(1) .82952(6) .0443(3)
C(18) -.4504(2) .3113(2) .82328(7) .0541(3)
0(19) -.6091(2) .2646(2) .8006(1) .0661(4)
C(20) -.6211(3) .1388(2) .78333(8) .0692(5)
C(21) -.4742(3) .0602(2) .78795(8) .0655(4)
C(22) -.3159(2) .1059(2) .81082(7) .0545(3)
C(23) -.3239(2) .7352(2) .88127(8) .0615(4)
0(24) -.0885(3) .2034(2) .9097(1) .0676(5)
C(25) -.1610(3) .9884(2) 1.06259(8) .0705(5)
C(26) .4509(3) 1.1240(3) .9578(1) .0783(6)
U(eq) is defined as 1/3 the trace o f the Uij tensor.
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2. (li?,3iSr)-6,7-dimethoxy-3-methyl-l-(toIuene-4-suIfonylmethyl)-l,2,3,4- 
tetrahydroisoquinoline hydrochloride 159(11?,35),
Table 1. Bond lengths (A)
molecule A molecule B
S(l)-0(2) 1.426(3) S(31)-0(32) 1.430(3)
S(l)-0(3) 1.430(4) S(31)-0(33) 1.440(3)
S(l)-C(17) 1.766(3) S(31)-C(47) 1.770(3)
S(l)-C(16) 1.774(3) S(31>C(46) 1.785(3)
CK4HX12) 1.367(4) 0(34)-C(42) 1.363(5)
0(4)-C(23) 1.420(4) 0(34)-C(53) 1.417(6)
0(5)-C(ll) 1.366(4) 0(35)-C(41) 1.369(4)
0(5)-C(24) 1.411(5) 0(35)-C(54) 1.404(6)
N(6)-C(15) 1.453(4) N(36)-C(45) 1.455(4)
W >CO) 1.487(5) N(36)-C(37) 1.478(5)
C(7)-C(25) 1.510(5) C(37)-C(55) 1.503(5)
C(7)-C(8) 1.511(5) C(37)-C(38) 1.519(5)
C(8)-C(9) 1.504(4) C(38)-C(39) 1.511(5)
C(9>C(i4) 1.377(4) C(39>C(44) 1.384(4)
C(9)-C(10) 1.415(4) C(39>C(40) 1.399(5)
C(10)-C(ll) 1.371(4) C(40)-C(41) 1.356(6)
C(ll)-C(12) 1.405(4) C(41)-C(42) 1.403(5)
C(12)-C(13) 1.383(4) C(42>C(43) 1.382(5)
C(13)-C(i4) 1.402(4) C(43)-C(44) 1.392(5)
C(14)-C(15) 1.523(4) C(44)-C(45) 1.526(4)
C(15)-C(16) 1.555(4) C(45)-C(46) 1.553(4)
C(17)-C(18) 1.372(6) C(47)-C(48) 1.370(4)
C(17)-C(22) 1.383(4) C(47KX52) 1.383(4)
C(18)-C(19) 1.365(7) C(48)-C(49) 1.384(5)
C(19>C(20) 1.386(6) C(49>C(50) 1.378(6)
C(20)-C(21) 1.373(6) C(50>C(51) 1.394(6)
C(20)-C(26) 1.507(6) C(50>-C(56) 1.505(6)
C(21)-C(22) 1.374(5) C(51>€(52) 1.384(5)
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TaWt 2. Atomic coordinates (U(cq) is (te&wd as 1/3 tb« trace of the Uij tensor)
mm X y X U(«q)
S<!) .1006(1) .23002(4) .54114(3)
om .3392(5) .2355(2) .5174(2) .100(1)
0(3) .0296(7) .2820(1) .5970(2) .095(1)
0(4) -.2153(4) .1775(1) .1138(2) .0079(5)
0(5) -.5818(4) .2399(1) .0678(2) .0753(0)
m ) -.1062(6) .3478(1) .4235(2) .0075(7)
cm -.3050(7) 3581(2) .4250(2) .0700(8)
cm -.4058(7) .3651(1) .3318(2) .0670(7)
cm -.3930(5) 3148(1) .2761(2) .0551(5)
C(i0) -.5285(5) .3010(1) .1975(2) .0590(6)
c a n -.4032(5) .2502(1) .1447(2) * .0577(6)
c(m -.2017(5) .2221(1) .1090(2) .0555(6)
0(13) -.1285(5) .2355(1) .2402(2) .0552(5)
0(14) -.1950(5) .2814(1) .2999(2) .0530(5)
C(15) -.0509(5) 3910(1) 3863(2) .0570(0)
0(16) -.0928(5) .2367(1) .4447(2) .0580(0)
0(17) .0417(0) .1670(2) .5879(2) .0607(6)
0(18) .1928(8) .1208(2) .5765(4) .093(1)
0(19) .151(1) .0680(2) .6148(5) .106(2)
0 (2 0 ) -.0448(8) .0590(2) .0618(3) .076(1)
0 (2 1 ) -.1918(7) .1062(2) .6723(2) .0710(8)
0 (2 2 ) -.1521(0) .1004(2) .6364(2) .0657(7)
0(23) -.0174(6) .1409(2) .1385(3) .0718(8)
0(24) -.7627(8) .2778(2) .0327(3) .086(1)
0(25) -.408(1) .4117(2) .4797(3) .105(2)
0 (2 0 ) -.085(1) .0003(2) .7041(4) .110(2)
S(3l) .5879(1) .08375(3) .90786(4) .0546(2)
0(32) .8353(4) .0771(1) .9333(2) .0743(6)
0(33) .4830(5) .0451(1) .8413(2) .0758(0)
0(34) .3445(7) .0833(2) 13465(2) .102(1)
0(35) .0131(7) .0071(2) 13577(2) .100(1)
MC34&> .4534(5) -.0370(1) .9973(2) .0070(6)
0(37) .1984(6) -.0496(1) .9772(2) .0676(7)
0(38) .1018(6) -.0688(1) 1.0618(3) .0702(8)
0(39) .1751(5) -.0274(1) 1.1360(2) .0614(6)
0(40) .0575(6) -.0297(2) 1.2123(2) .0706(8)
€(41) .1185(7) .0002(2) 1.2808(2) .075(1)
0(42) 3010(6) .0475(2) 1.275902) .0707(8)
0(43) .4207(0) .0496(2) 1.2012(2) .0637(7)
0(44) .3590(5) .0124(1) 1.1312(2) .0559(0)
0(45) .4936(5) .0161(1) 1.0495(2) .0573(0)
0(40) .4285(5) .0751(1) 1.0023(2) .0516(5)
0(47) .5402(5) .1574(1) .8727(2) .0540(5)
0(48) .7133(6) .1987(2) .8921(2) .0685(7)
0(49) .6821(8) .2554(2) .8001(3) .083(1)
0(50) .4811(8) .2708(2) .8085(3) .081(1)
0(51) 3008(7) .2281(2) .7903(2) .077(1)
0(52) 3341(0) .1712(2) .8223(2) .0002(7)
0(53) .529(1) .1255(3) 1.3448(4) .125(3)
0(54) -.161(1) -.0355(3) 13695(4) .117(2)
0(55) .160(1) -.0960(2) .9077(3) .094(1)
0(50) .451(2) .3320(2) .7714(5) .133(3)
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3. Benzyl-[(5>-2-(3,4-dimethoxy-phenyl)-l-methyIethyl]-[(£)-2-(toluene-4-
sulfonyl)-vinyl]-amine 151 S:
Table 1. Bond Lengths (A) and angles (°)
S(1KK2) 1.437(4) SOKX3) 1.445(4)
S(l)-C(13) 1.725(5) S(1K(7) 1.777(5)
0(4)-C(27) 1.359(6) O(4)-C(30) 1.437(7)
0(5)-C(26) 1.375(7) (X5K(31) 1.404(7)
N(6)-C(14) 1.331(6) N(6)-C(15) 1.455(6)
N(6)-C(22) 1.477(6) C(7)-C(12) 1.385(7)
C(7>-C(8) 1.371(7) C(8)-C(9) 1.369(8)
C(9)-C(10) 1.400(9) cxio h x h ) 1.372(8)
C(10)-C(32) 1.496(9) c (n )-c (i2) 1.371(7)
C(13)-C(14) 1.344(6) C(15)-C(16) 1.511(7)
C(ld)-C(21) 1.368(8) C(16)-C(17) 1.376(7)
C(17)-g(18) 1.374(9) C(18)-C(19) 1.353(9)
C(19KX20) 1.37(1) C(20)-C(21) 1.382(9)
CX22HX23) 1.530(7) C(22HX33) 1.526(7)
C(23)-C(24) 1.496(7) C(24)-C(29) 1.374(7)
C(24HX25) 1.388(7) C(25)-C(26) 1.382(7)
C(26)-C(27) 1.404(7) C(27)-C(28) 1.388(8)
C(28)-C(29) 1,383(8)
0(2)-S(l)-0(3) 118.6(3) 0(2)-S(l)-C(13) 109.3(2)
0(3)-S(l)-C(13) 107.5(3) 0(2)-S{l)-C(7) 106.5(2)
0(3)-S(l)-C(7) 105.7(2) C(13>S(1)-C(7) 108.8(2)
C(27)-O(4)-C(30) 116.8(5) C(26)-0(5)-C(31) 117.4(4)
C(14)-N(6)-C(15) 119.9(4) C(14)-N(6)-C(22) 119.8(4)
C( 15)-N(6)-C(22) 118.6(4) C(12)-C(7)-C(8) 119.5(5)
C(12)-C(7>S(1) 119.5(4) C(8)-C(7)-S(l) 121.1(4)
C(7KX8)-C(9) 120.9(5) C(8)-C(9)-C(10) 120.8(5)
C(il)-C(10)-C(9) 117.0(5) C(ll)-C(10)-C(32) 122.6(6)
C(9)-C(10)-C(32) 120.4(6) C(10>C(11)-C(12) 123.0(5)
C(7)-C(12)-C(l 1) 118.9(5) C(14)-C(13)-S(l) 119.0(4)
C(13>C(14)-K(6) 127.7(5) H(6)-C(15)-C(16) 115.8(4)
C(21)-C(16)-C(17) 118.3(5) C(21)-C(16)-C(15) 122.9(5)
C(17)-C(16)-C(15) 118.7(5) C(16)-C(17)-C(18) 121.2(6)
C(19)-C(18)-C(17) 120.2(6) C(18)-C(19)-C(20) 119.6(6)
C(21 )-C(20)-C( 19) 120.3(7) C(16)-C(21)-C(20) 120.4(6)
N(6)-C(22)-C(23) 111.1(4) N(6)-C(22)-C(33) 111.5(4)
C(23)-C(22)-C(33) ' 113.1(4) C(24>C(23)-C(22) 113.8(4)
C(29)-C(24)-C(25) 117.8(5) C(29>*C(24)-C(23) 122.1(5)
C(25)-C(24)-C(23) 120.0(5) C(26)-C(25)-C(24) 121.8(5)
0(5)-C(26)-C(25) 124.2(5) 0(5)-C(26)-C(27) 115.9(5)
C(25)-C(26)-C(27) 119.9(5) 0(4)-C(27)-C(28) 125.8(5)
0(4)-C(27>C(26) 116.0(5) C(28)-C(27)-C(26) 118.1(5)
C(29)-C(28)-C(27) 120.8(5) C(24>C(29)-C(28) 121.6(5)
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Table 2. Atomic coordinates and equivalent isotropic displacement 
parameters (A3)
atom X y z U(eq)
S(l) -.0001(2) .2364(1) .24502(6) .0659(4)
0(2) .1071(4) .3197(3) .2592(2) .084(1)
0(3) .0541(6) .1687(3) .2018(2) .091(1)
0(4) -.2862(6) .2809(3) .4658(2) .079(1)
0(5) -.1014(6) .4318(3) .4338(2) .079(1)
N(6) -.3759(5) .4268(3) .2237(2) .052(1)
0(7) -.0186(6) .1615(4) .3055(2) * .058(1)
0(8) .010(1) .2015(4) .3569(2) .077(2)
0(9) .002(1) .1426(5) .4032(2) .087(2)
0(10) -.0376(8) .0403(5) .3993(2) .074(2)
0(11) -.0668(7) .0026(4) .3474(3) .071(1)
0(12) -.0586(7) .0605(4) .3006(2) .063(1)
0(13) -.1976(7) .2808(4) .2272(2) .062(1)
0(14) -.2356(6) .3775(3) .2374(2) .051(1)
0(15) -.5198(7) .3720(4) .2014(2) .055(1)
0(16) -.5077(7) .3436(3) .1411(2) .057(1)
0(17) -.6105(8) .2683(4) .1214(2) .075(2)
C(18) -.608(1) .2413(5) .0666(3) .100(2)
0(19) -.507(1) .2909(6) .0306(3) .112(3)
C(20) -.406(1) .3669(7) .0492(3) .113(3)
0(21) -.403(1) .3919(5) .1047(2) .088(2)
C(22) -.4020(6) .5307(3) .2435(2) .058(1)
C(23) -.5204(8) .5329(4) .2934(2) .067(1)
C(24) -.4658(7) .4659(4) .3398(2) .057(1)
C(25) -.3126(7) .4829(4) .3661(2) .059(1)
C(26) -.2540(7) .4201(4) .4074(2) .059(1)
CX27) -.3517(8) .3376(4) .4243(2) .064(1)
C(28) -.5051(8) .3212(4) .3980(2) .070(1)
C(29) -.5592(7) .3839(4) .3560(2) .068(1)
C(30) -.370(1) .1873(5) .4775(3) .096(2)
0(31) .013(1) .5017(5) .4114(3) .091(2)
C(32) -.049(1) -.0232(6) .4502(3) .116(3)
C(33) -.459(1) .5999(4) .1968(2) .076(2)
U(eq) is defined as 1/3 the trace of the Uij tensor.
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APPENDIX 2 :1H-NMR spectra 
for the resolved stereoisomers of
29, 30 and 31
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APPENDIX 3 :13C-NMR spectra 
for the resolved stereoisomers of
29, 30 and 31
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